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AIMS OF THE THESIS 
 
Tumour cells have abnormal growth rates, which arise from malfunctions in the 
regulatory mechanisms that oversee the cells’ growth and development. This 
uncontrolled growth leads to a dramatic change in the physiology of the tumour itself. 
In particular, the development of hypoxic zones occurs as a result of a discrepancy 
between oxygen consumption and oxygen supply of the rapidly growing tumour. 
Hypoxia, in its turn, deeply modifies the metabolism and the behaviour of the tumour 
cells. Warburg effect, which is a shift from ATP generation through oxidative 
phosphorylation to ATP generation through glycolysis, even under normal oxygen 
concentrations, is the best characterized metabolic switch observed in hypoxic tumours. 
Hypoxia is also strongly associated with tumor progression and metastatic disease and 
this is likely because low oxygen tension is able to increase cell invasiveness. These 
pathological features make tumour hypoxia a poor prognostic factor in several kinds of 
malignancies. 
The goal of this PhD Thesis was to interfere with these two main peculiar features of 
hypoxic tumours, glycolytic metabolism and invasiveness, by focusing our attention on 
two key enzyme: lactate dehydrogenase A (LDH-A), which is essential for energy 
production in hypoxic conditions and lysyl oxidase (LOX), which is strictly involved in 
the metastasis formation deriving from hypoxic tumours. Specifically, this Thesis aimed 
at designing and synthesizing small organic molecules able to inhibit LDH-A, so to be 
developed as starvation agents against hypoxic tumours. The other aim of this Thesis 
was to develop hypoxia-activated prodrugs as LOX inhibitors, in order to selectively 
block this enzyme in hypoxic cancer cells and, consequently, reduce or even completely 
stop the invasiveness of hypoxic tumours. 
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PREFACE 
 
The first Chapter gives a broad overview of tumour hypoxia and the main 
pathological aspects of this condition, explaining why hypoxia is considered a poor 
prognostic factor in many cancers and introducing LDH-A and LOX in this context. 
Furthermore, the general strategies for attacking hypoxic tumours by inhibition of LDH-
A and LOX are presented in Chapter 1. 
Chapter 2 is focused on LOX, starting with the detailed description of this enzyme 
and previous research in this area, which support our choice to develop hypoxia-
activated prodrugs as LOX inhibitors. Synthesis and biological results for the 
synthesized molecules are reported. 
Chapter 3 deals with the main subject of this PhD Thesis, that is, LDH-A inhibition. 
Background of enzyme LDH-A is reported, including kinetic and structural features of 
human and Plasmodium falciparum enzyme isoforms, as well as inhibitors reported in 
the literature. A small overview of the most representative glycolytic inhibitors is also 
presented. The central part of this Chapter comprises the design and the synthesis of 
LDH-A inhibitors developed in my PhD project, which have been subdivided into 
structural classes and, for each group, enzymatic assays and molecular modeling studies 
are discussed. The last part of this Chapter is about cellular assays performed during the 
period spent at the University of Illinois at Urbana-Champaign (USA). 
Detailed experimental procedures for the synthesis and characterization of LOX and 
LDH-A inhibitors are described in Chapter 4. 
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“Introduction” 
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1.1. TUMOUR HYPOXIA 
 
1.1.1. The main pathological aspects of hypoxic tumours 
A distinctive feature of many solid tumours is the presence of hypoxic regions, 
which originate from an imbalance between blood supply and consumption of oxygen. 
This clinical consideration was made for the first time by Thomlinson and Gray about 
50 years ago and was then confirmed thanks to the subsequent introduction in the 1990s 
of an oxygen electrode, called the “Eppendorf” electrode, that made it possible to 
accurately measure the oxygen pressure in human tumours [1, 2]. In order to explain 
this pathological aspect, we have to take into account the fact that cancer cells possess 
an elevated rate of growth, so their metabolic requirements surpass the vasculature 
ability to provide oxygen and nutrients. This pathological condition results in areas 
characterized by low levels of oxygen pressure (pO2 < 5 mmHg corresponding to < 1% 
in the gas phase), and sometimes in necrotic regions, which have been detected in a 
wide range of cancers, such as brain, head and neck, cervix, breast tumours and soft 
tissues sarcomas. The development of this condition may be due to: a) temporary 
obstruction of microvessels or variable blood flow caused by structural and functional 
abnormalities of intratumoural vasculature (perfusion-limited or acute hypoxia); b) 
increased mean diffusion distances, about 100 μm or more, or adverse diffusion 
geometry caused by the irregular and fast tumour growth (diffusion-limited or chronic 
hypoxia) (Fig. 1.1) [3, 4]. 
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Figure 1.1. The vascular network of normal tissues (on the left) versus tumour tissues (on the right) [4]. 
Copyright©2004 Nature Publishing Group 
 
Hypoxia, in turn, acts as a promoter of tumour progression, because it provokes an 
overexpression of a great number of genes implicated in the cell survival, leading to 
many changes in tumour cellular behaviour and metabolism. In particular, the 
transcription factor HIF-1α (Hypoxia-Inducible Factor-1α), that is overexpressed in 
hypoxic tumours, starts a transcriptional program that provides many solutions to 
hypoxia by up-regulating a series of downstream target genes, such as Lactate 
Dehydrogenase A (LDH-A), Lysyl Oxidase (LOX), together with Glucose Transporter-
1 (GLUT-1), Carbonic Anhydrase IX (CA IX) and Vascular Endothelial Growth Factor 
(VEGF). In particular, the overexpression of two selected key enzymes, LDH-A and 
LOX at different oxygen concentrations and pH values in two tumour cells lines is 
shown in the graphs below (Fig. 1.2) [5, 6]. The x axis reports the oxygen concentration 
and the relative expression of these enzymes is displayed on the y axis: it is evident that, 
depending on the pH, the relative expression of the two enzymes is increased in both 
cell lines at 1% of oxygen compared with normoxia condition that is 21% of oxygen. 
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Figure 1.2. mRNA expression of LDH-A (top) and LOX (bottom) in SiHa (uterine cervix squamous cell 
carcinoma) and FaDuDD cells (pharyngeal squamous cell carcinoma) under different oxygen concentrations at 
various grades of acidosis. Cells were exposed to various oxygen levels at the different pH values for 24 h, 
then mRNA levels were determined, compared to untreated cells and plotted [5]. Copyright©2007 Elsevier B. 
V. 
 
The main function of these proteins, together with other factors, is to protect cells 
from the hostile hypoxic environment and to help them to proliferate and to survive in 
adverse conditions, constituting adaptive responses to hypoxia. Consequently, tumour 
cells become able to overcome the nutritive deprivation by increasing their 
vascularization through angiogenesis, enhancing the glucose uptake, and optimizing its 
sugar metabolism. Moreover, tumour cells acquire the ability of invading surrounding 
healthy tissues in order to escape from the adverse environment (Fig. 1.3). The 
overexpressed proteins mentioned above are considered among the main responsible 
factors contributing to the typical pathological alterations associated to tumours, 
although other molecular pathways that may be implied, such as oncogene activation 
and tumour suppressor loss, actively contribute to complete this process. Indeed, it is 
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recognized that the tumour microenvironment, involving several factors having both 
anti- and pro-tumour effects, makes the understanding of the tumour development and 
progression a very complex picture [7]. All these hypoxic tumour hallmarks result in the 
development of a more malignant and aggressive phenotype and provide a selective 
growth advantage over other competing cell populations. They also confer a higher 
survival ability to hypoxic tumour cells. As a consequence, a direct relationship between 
intratumoural hypoxia and poor patient prognosis has been observed [3, 8]. 
 
 
Figure 1.3. The biological relationships between the proteins up-regulated by HIF-1α in hypoxic conditions. 
ECM = extracellular matrix [9]. Copyright©2010 Bentham Science Publishers 
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One of the most important adaptive responses to hypoxia is the metabolic switch 
from oxidative to glycolytic pathway. Normally, cells produce most of the ATP from 
glucose through the oxidative phosphorylation (OXPHOS), but many cancer cells in 
hypoxic conditions obtain ATP by glycolysis and the final conversion of glucose to 
lactate, showing low levels of OXPHOS activity. This metabolic strategy is mainly 
permitted by the overexpression of LDH-A, a glycolytic enzyme which is a direct target 
of HIF-1α [10], although other enzymes belonging to the glycolytic pathway are also 
up-regulated. In fact, HIF-1α was proven to induce overexpression of glucose 
transporters GLUT-1 and GLUT-3, as well as of glycolytic enzymes hexokinase I and II 
(HK-I, HK-II), the liver isoform phosphofructokinase (PFK-L), aldolase A and C 
(ALD-A, ALD-C), phosphoglycerate kinase 1 (PGK-1), enolase α (ENO-α), pyruvate 
kinase M2 (PYK-M2), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
(PFKFB-3), and, of course, LDH-A [11]. As mentioned before, LDH-A converts 
pyruvate, the final product of glycolysis, to lactate, instead of undergoing the Krebs 
cycle in the mitochondria, due to the lack of oxygen that is the final electron acceptor in 
the electron transport chain. This reaction regenerates the cofactor NAD+ and, therefore, 
permits the continuation of glycolysis (Fig. 1.4). This kind of metabolism is maintained 
even when cells derived from hypoxic tumours are placed under normoxic conditions, 
confirming that the conversion of pyruvate into lactate, in order to obtain energy in 
conditions of low levels of oxygen, represents not only a simple adaptive mechanism to 
hypoxia, but above all a hallmark of hypoxic cancers involving epigenetic 
transformations that deeply affect some cellular pathways. A high rate of conversion of 
glucose into lactate with an elevated glucose uptake are the typical traits of the 
glycolytic phenotype and ensure adequate ATP levels and constant supply of 
intermediates essential for cell growth and division [12]. ATP generation via glycolysis 
is a less efficient energy production process (2 ATP molecules per glucose) than 
oxidative phosphorylation (36 ATP molecules per glucose). Hence, cancer cells 
consume more glucose than normal cells for maintaining an adequate ATP supply to 
proliferate. The fundamental role of this glycolytic phenotype is emphasized by studies 
demonstrating that increased glucose uptake coincides with the transition from pre-
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malignant lesions to invasive cancer, since the cancer cells’ dependence on glycolysis 
increases as malignant transformation increases [13, 14]. 
 
Figure 1.4. The glycolytic process and the two main metabolic pathways in which pyruvate is involved, 
depending on the presence of oxygen. The reaction catalyzed by LDH is highlighted (bottom-right) [9]. 
Copyright©2010 Bentham Science Publishers 
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The increased production of lactate by malignant cells even under aerobic conditions 
is called aerobic glycolysis or “Warburg effect” and it has been observed only in tumour 
tissues. This phenomenon was first reported by Otto Warburg in the 1920s, 
hypothesizing that this altered glucose metabolism derives from impaired mitochondrial 
activity [15]. Nowadays, the “Warburg hypothesis” has proven incorrect, but an 
increased dependence on glycolytic activity for ATP generation in tumours even in the 
presence of oxygen has often been confirmed. The metabolic switch from the 
energetically efficient Krebs cycle to the tumour glucose utilization in glycolysis is 
regulated by a very wide network of pathways involving both oncogenes and tumour 
suppressor genes, thus playing a central role in the altered catabolic and anabolic 
processes of several tumours [16]. 
The invasive and aggressive behaviour is another typical pathological feature found 
in hypoxic tumours. Since metastasis is considered the main cause of cancer death, the 
understanding of this very complex process is an extremely challenging goal for the 
treatment of cancer. Metastasis is a multistep process starting with the detachment of 
cells form the original tumour. In order to metastasize, a malignant cell must dissociate 
from the primary tumour and intravasate into the vascular or lymphatic systems by 
degrading and migrating through the basement membrane and extracellular matrix. 
Once in the lymph or in the blood streams, this cell must evade the host immune 
system, migrate to its target site, and finally extravasate out of the circulation to implant 
in a healthy tissue where proliferation gives rise to cancer metastases [7, 17, 18]. A 
complex network of proteins of the extracellular matrix were found to be involved in 
metastasis formation, such as Matrix Metalloproteinases (MMPs), integrins, Connective 
Tissue Growth Factor (CTGF), which favour dissemination of malignant cells from a 
primary tumour site to a secondary site by different mechanisms. Moreover, the tumour 
itself becomes able to secrete a large number of growth factors and proteases, which 
permit to modify the local microenvironment making it more permissive for cell 
motility and adhesion. Even the extracellular acidosis, caused by the increased lactate 
production operated by LDH-A, is a factor promoting the entry of tumour cells into the 
blood vessels, so leading to metastasis formation. In this picture, a key role is played by 
another direct target of HIF-1, that is LOX, an amine oxidase of the extracellular matrix, 
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whose catalytic function contributes to the formation and the reinforcement of the ECM. 
This enzyme was found to be directly involved in the metastatic process. Numerous 
studies demonstrate that its expression is directly correlated to the invasiveness of a 
large number of tumours, causing disease progression and poor overall survival [19]. 
 
1.1.2. Hypoxia as an obstacle to medical treatment of cancer 
Tissues possessing low levels of oxygen show resistance to radiotherapy and this is 
one of the principal clinical problems that compromises hypoxic cancer treatment 
documented as early as since 1953 [20]. The mechanism linking hypoxia to tumour 
radioresistance is generally known as the “oxygen enhancement effect” [21]. This 
phenomenon can be explained considering that DNA damage is usually provoked by 
direct ionization from ionizing radiations or is induced by oxygen radicals, such as 
hydroxyl radical, superoxide anion etc. In the presence of oxygen, DNA double-strand 
breaks cannot be repaired because O2 reacts with the broken DNA forming stable 
organic peroxides which are hardly repaired by the cell, leading to fatal chromosome 
aberrations. Basically, oxygen fixes the DNA damage, making it permanent. On the 
other hand, in the absence of oxygen, the damage is more easily repaired: the broken 
DNA can be restored to its original form, thanks to reparative processes based upon 
reductions by –SH containing intracellular components. This mechanism explains why 
tumours with low levels of oxygen show a reduced effect on response to radiotherapy, 
compared with normally oxygenated tissues [4, 21, 22]. 
Hypoxic cells are also resistant to conventional anticancer therapies and this is 
mainly due to their distance from blood vessels, so they are not sufficiently reached by 
most anticancer drugs. We can also mention other reasons that are behind chemotherapy 
resistance. For example, anticancer chemotherapy is usually more efficient against cells 
in rapid proliferation due to the mechanisms of actions commonly associated to most of 
the currently available treatment regimens, so it causes lower effects to hypoxic cells, 
which are characterized by slower rates of proliferation compared to normally 
oxygenated cancer cells. Furthermore, hypoxia selects cells that up-regulate genes 
encoding for proteins involved in drug resistance. It follows that, at present, there are 
not adequate anticancer drugs able to efficiently kill hypoxic cells [4, 23]. 
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In addition to radiotherapy and chemotherapy resistance, the higher malignant 
phenotype, typical of hypoxic cancer cells, is associated with a more metastatic and 
aggressive behaviour, consequently predisposing to the formation of metastases, that 
compromise curability of tumours by surgery [24]. 
Since hypoxic cells are resistant to standard therapies, it is clear that hypoxia has a 
negative impact on cancer treatment and prognosis. Nevertheless, the unique features of 
hypoxic tumours that do not occur in healthy tissues, such as the metabolic switch 
associated to the “Warburg effect”, could be exploited in cancer-selective therapy. 
 
 
1.2. LOX AND LDH-A: TWO KEY ENZYMES IN HYPOXIC 
INVASIVE TUMOURS 
 
Tumour cells become able to survive in conditions of low oxygen concentration, that 
is restrictive to normal cells, thanks to many pathological alterations in their metabolism 
and behaviour. In particular, the glucose uptake is increased and then the internalized 
sugar is processed through aerobic glycolysis in order to generate energy for 
continuously growing cells, even in the absence of oxygen. Moreover, hypoxia 
represents a stimulus for invasion and metastasis, because tumour cells, living in areas 
of nutrient and oxygen deprivation, need to invade new healthy tissues more permissive 
for their growth (Fig. 1.5). As a consequence, aerobic glycolysis and metastasis 
represents essential hallmarks of hypoxic cancer. In particular, in this PhD Thesis we 
focused our attention on two key enzymes, LOX and LDH-A, which play important 
roles in the metabolism and behaviour of tumour cells. LOX is deeply implicated in the 
progression of the tumour and in its spread in the surrounding tissues by metastasis 
formation; on the other hand, LDH-A supports the growth and the survival of hypoxic 
tumour cells, permitting the obtainment of ATP by glycolysis. Our interest is also 
justified by the almost total absence of suitable and selective inhibitors of these 
enzymes, so LOX and LDH-A can be considered innovative targets in the fight against 
invasive hypoxic tumours.  
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Figure 1.5. Tumour hypoxia-induced changes inside and outside the cancer cell. Increased glycolysis (in the 
cytoplasm) and increased invasive ability of tumour cells (in the extracellular environment) are schematically 
represented, together with the two key enzymes responsible for this altered behaviour, LDH-A and LOX. 
 
1.2.1. Targeting LOX for the treatment of invasive hypoxic tumours 
Metastasis constitutes an intricate process involving many tumours and stromal 
proteins necessary for the remodelling of the extracellular matrix and, of course, LOX 
represents one of the key ECM components involved in metastatic disease. The LOX 
involvement in metastatic disease is proved by numerous studies linking LOX to 
tumour development and metastasis formation [17]. LOX was found to be implicated in 
the promotion of the metastatic process in vivo and in vitro, being up-regulated by 
hypoxia-inducible factor-1 (HIF-1) in hypoxic tumour tissues [5, 6, 19]. An 
overexpression of LOX mRNA was identified principally in MDA-MB-231 cancer cell 
line, which is a highly invasive and metastatic breast cancer cell line, SiHa cervical 
cancer cells, and in head and neck cancers, but the same association was not found in 
the poorly invasive and non-metastatic human breast cancer phenotype MCF-7, 
demonstrating that this enzyme is required for the increased invasion in tumours and its 
expression seems to occur mainly in distant metastatic cancer tissues compared with 
primary tumours. Recently, LOX expression has been correlated to disease progression, 
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metastasis and poor overall survival also in oral cancers [25, 26]. LOX stimulates cell 
invasion through a mechanism mediated by hydrogen peroxide, a well-established LOX 
by-product [27-29].  
In vitro and in vivo invasion assays demonstrated that only catalytically active LOX, 
secreted in the extracellular matrix, is responsible for the increased invasion ability in 
hypoxic tumours. In fact, since LOX is a copper-dependent enzyme, the use of a copper 
chelator that cannot enter the cell, such as bathocuprione disulphonate (BCS), results in 
a reduction of invasiveness, thus confirming that extracellular LOX involvement is the 
responsible for such invasion ability. Furthermore, when LOX catalytic activity was 
compromised by using LOX short hairpin RNA cells (shRNA), treatment with LOX 
antibody or administration of a LOX irreversible inhibitor such as β-aminoproprionitrile 
(BAPN), the invasion ability of tumour cells was significantly decreased and the 
formation of metastases was considerably reduced or completely blocked. This confirms 
that LOX is actively involved in the invasion ability of hypoxic tumour cells. This 
behaviour is also confirmed by the cellular shape: in air, wild-type tumour cells show a 
branching morphogenesis typical of invasive human cancer cells grown on collagen, 
which was further enhanced by hypoxia. On the other hand, the LOX shRNA cells grew 
in a markedly different manner, remaining more rounded in spheroid-like cell clusters, 
showing little branching in air or hypoxia. These results definitively indicate a role for 
LOX in the development of an invasive phenotype of hypoxic human tumours. 
A recent study performed on a mouse model of mammary cancer proved the 
correlation among LOX activity, increased ECM stiffness due to collagen cross-linking, 
and progression to invasive disease. Pre-conditioning of mouse mammary fat pads with 
LOX-expressing fibroblasts promoted the growth and invasion of mammary cells and 
LOX inhibition with BAPN or LOX-specific antibody tempered tissues fibrosis, 
increased tumour latency, and decreased tumour incidence, suggesting that LOX-
mediated cross-linkages likely regulate tumour progression by modifying the tumour 
microenvironment [7, 30]. 
Furthermore, LOX seems to play a critical role in premetastatic niche formation. 
Upon modification of the extracellular matrix and recruitment of CD11b+ myeloid cells 
to premetastatic sites, LOX prepares the target organs for the subsequent arrival of 
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metastatic tumour cells and enhances the establishment and growth of metastases. It 
appears that LOX alters tumour microenvironment and is involved in tumour invasion 
at different stages of this process. These findings together support the high potentiality 
of this perspective therapeutic target [31].  
From a mechanistic point of view, the hypoxia-induced metastatic process starts 
with a series of adhesion and detachment interactions with the extracellular matrix by 
means of a cell pseudopode protrusion driven by actin polymerization. In particular, 
remarkable amounts of LOX are localized in proximity of the protrusion leading edge 
and on the many hair-like fibres sticking out from it. These events lead to invasion into 
the bloodstream and migration of the primary tumour cells, leaving behind a route of 
remodelled extracellular matrix that constitutes a sort of “highway” for the other cells, 
that can quite easily follow the first ones (Fig. 1.6 and 1.7). As a consequence, it is 
confirmed to LOX the role of an ECM remodelling enzyme during invasion that allows 
cell motility, but also during extravasation and colonization processes. According to 
these findings, LOX could be considered not only a potential marker for identifying 
highly invasive/metastatic and hypoxic tumours, but its inhibition could be exploited for 
the prevention and also the treatment of aggressive and metastatic tumours, so revealing 
a new good therapeutic target for several kinds of metastatic cancers [19]. 
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Figure 1.6. Metastasis early stage: ECM-remodeling and migration. 
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Figure 1.7. Metastasis later stage: extravasation and colonization of new tissues. 
 
The lack of suitable LOX inhibitors to be used in clinic makes lysyl oxidase 
inhibition a very challenging goal in the field of anti-tumour research and there are wide 
margins of research work to do because LOX inhibitors have been poorly studied so far. 
LOX involvement in metastasis opens a new research way that is potentially selective, 
LOX being a hypoxia-induced and extracellular target, and also innovative, due to very 
few treatment options for patients with metastases. For these reasons, we have 
developed molecules able to selectively inhibit LOX in hypoxic environments, and the 
results are reported in Chapter 2 of this Thesis. 
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1.2.2. Exploiting tumour hypoxia: LDH-A inhibition 
The much lower levels of oxygen in tumour cells compared to those in normal 
tissues constitute an useful opportunity to develop a selective anticancer therapy based 
on this peculiarity. At present, the most commonly and used strategies that have been 
attempted in this field are represented by hypoxia-activated pro-drugs [32] and by gene 
therapies based on the inhibition of HIF-1 in hypoxic conditions [33, 34]. 
Another way of taking advantage from the distinctive features of tumour cells is to 
consider their altered carbohydrate metabolism, that is the conversion of glucose to 
lactate even in the presence of normal oxygen pressure. The dependency of tumour cells 
on glucose metabolism constitutes the weak point of hypoxic cancers and it could be 
therapeutically exploited by interfering with LDH-A activity. Several attempts to inhibit 
the glycolytic enzymes, such as hexokinase (HK), up-regulated in hypoxic tumours and 
specially involved in malignancy progression have been realized. However, among the 
enzymatic checkpoints of the glycolytic pathway, LDH-A still remains one of the most 
attractive targets in this context [22, 35]. LDH-A is overexpressed in hypoxic tumour 
environment, whereas the other main isoform LDH-B is predominant in all living cells, 
both normal and malignant. The data reported in literature confirm that up-regulation of 
LDH-A ensures an efficient aerobic glycolysis in tumour cells, whereas this enzyme is 
not so necessary to healthy cells in normal conditions that generally use the aerobic 
oxidation pathway [5, 36-38]. 
It was discovered that when LDH-A levels are knocked down by means of shRNAs 
(short hairpin RNA) in tumour cell lines that show high glucose dependency and high 
LDH-A expression under both normal and hypoxic conditions, LDH-A activity is 
severely compromised and the ability of these cell populations to proliferate shows a 
remarkable reduction [39]. In particular, when the oxygen pressure is limited the effect 
is even more pronounced, because the proliferation was completely blocked and ATP 
levels were much lower. This suppression of aerobic production of lactate had also a 
great impact on OXPHOS activity and oxygen consumption, which were both 
significantly increased. Consistent with these observations, cancer cells with low levels 
of LDH-A possess a reduced ability to grow under hypoxic conditions and their 
tumorigenic potential is severely compromised. In order to determine if the growth 
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decrease is due to LDH-A knockdown and, as a consequence, to the inability of tumour 
cells to metabolize glucose to lactate, cDNA corresponding to human LDH-A was 
introduced into LDH-A-silenced cells. Ectopic expression of this enzyme restores the 
proliferation and reestablishes the glycolytic phenotype, thus confirming the specificity 
of LDH-A knockdown approach. Altogether, these data suggest that the A isoform of 
lactate dehydrogenase plays a fundamental role in tumour maintenance, because cancer 
cells rely on LDH-A activity for energy obtainment even when oxygen is not a limiting 
factor [39]. 
As regards possible side effects caused by this approach, humans suffering from a 
complete hereditary deficiency of LDH-A due to the lack of A subunit production have 
been studied. These individuals show myoglobinuria, that is, the presence of myoglobin 
in the urine usually associated with muscle damage, only after intense anaerobic 
exercise (exertional myoglobinuria), without displaying any symptoms under ordinary 
circumstances [40, 41]. 
All this evidence constitutes a good target validation for LDH-A. In fact, not only 
does the inhibition of LDH-A prevent the Warburg effect, by forcing hypoxic tumour 
cells to revert to OXPHOS metabolism from the glycolytic pathway, but it also 
attenuates cell proliferation, supporting the growing evidence that the glycolytic 
phenotype is responsible of tumorigenicity of hypoxic cancer cells. Up to now, unlike 
other glycolytic targets for which some suitable molecules as drug candidates have been 
found, only shRNAs have been used to selectively inhibit LDH-A in tumours, and there 
are not many small molecules able to selectively block LDH-A activity (Fig. 1.8). As a 
consequence, antagonizing LDH-A could be considered an interesting, innovative, 
selective and also potentially non-toxic strategy of interfering with hypoxic cancer 
growth. Therefore, we focused our efforts in an attempt to develop small molecules able 
to selectively inhibit LDH-A, and our results are reported in Chapter 3 of this Thesis. 
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Figure 1.8. Potential metabolic targets for the treatment of cancer with relative desired effects and 
compounds. For LDH-A inhibition (entry 4), only genetic techniques have been used [12]. Copyright©2008 
Elsevier Inc. 
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2.1. THE ENZYME LYSYL OXIDASE (LOX) 
 
2.1.1. Biological functions 
In the context of hypoxic tumours, the enzyme lysyl oxidase (LOX) plays a very 
important role, proving to be strictly involved in the tumour ability of invasion and 
metastasis, as already mentioned in Chapter 1. 
Lysyl oxidase is an extracellular copper-dependent amine oxidase, which is secreted 
in the ECM as a N-glycosylated pro-enzyme of 50 kDa (proLOX) and then the inactive 
pro-enzyme is cleaved by extracellular proteases, so releasing the active mature form of 
LOX (32 kDa). LOX, which was discovered in 1968 [1], belongs to a larger family 
consisting of five members, because there are four LOX-like enzymes (LOXLs) with 
various degrees of similarity to LOX, thus forming a isozyme family comprising LOX, 
LOXL1, LOXL2, LOXL3, LOXL4, nevertheless their exact distinct roles have not been 
clarified yet [2, 3]. In addition to being found extracellularly, mature LOX has also been 
localized into the cellular nucleus, suggesting a nuclear activity, in fact it interacts with 
basic nuclear proteins like histone H1 [4], so intranuclear LOX is involved in modifying 
gene expression, although the exact intracellular role of LOX still needs a more 
exhaustive characterization. 
The main biochemical function of LOX is to catalyze the covalent cross-linking of 
collagen and elastin molecules within the extracellular matrix (ECM), so stabilizing the 
fibrous deposits of these proteins in the ECM. These cross-links formed by the enzyme 
increase tensile strength and structural integrity necessary for normal connective tissue 
function, embryonic development, tissue remodeling and repair of diseased and aging 
connective tissues. In particular, it catalyzes the oxidation of the ε-amino group of 
peptidyl lysine to peptidyl aldehyde (α-aminoadipic-δ-semialdehyde, AAS) by 
consuming oxygen and water and producing ammonia and hydrogen peroxide (Fig. 
2.1). Then, the aldehyde group of AAS starts the formation of covalent cross-linkages, 
condensing either with a neighbouring ε-amino group of an unmodified lysine residue to 
form anhydrolysinonorleucine (deLNL) or with another peptidyl AAS to obtain an aldol 
condensation product (ACP) [5, 6]. 
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Figure 2.1. LOX-catalyzed reaction and spontaneous formation of crosslinkages from peptidyl AAS. 
 
Although the X-ray structure of human LOX has never been obtained yet, it has 
been possible to determine the presence of a copper (II) ion in the LOX catalytically 
active site, which is bound to three histidine residues (not been exactly identified as of 
yet), and also of a covalently bound organic cofactor lysine tyrosylquinone (LTQ, Fig. 
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2.2), which is peculiar since other known amine oxidases are associated to cofactor 
trihydroxyphenylalanine quinine (TPQ).  
 
 
Figure 2.2. Active site of LOX. Copper atom bound to histidine residues is highlighted in blue, LTQ cofactor 
in red. 
 
Probably, the cofactor LTQ is formed within the nascent enzyme, by an 
autocatalytical reaction between tyrosine 349 and lysine 314, in which Cu2+ catalyzes 
the oxidation of Tyr to quinone, followed by the covalent attack of the ε-amino group of 
lysine residue to the quinone ring, hence starting the formation of LTQ (Fig. 2.3) [7]. 
 
 
Figure 2.3. Autocatalytic formation of LTQ cofactor within LOX. 
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The catalytic cycle (Fig. 2.4) performed by LOX starts with the condensation of its 
cofactor with the amino group of the substrate peptidyl lysine, then subsequent 
rearrangements of the imino double bond, hydrolysis and reoxidation complete the cycle 
affording the aldehyde product and regenerating the initial form of LTQ. It is supposed 
that the copper is involved in the reoxidation of the cofactor, due also to the fact that 
deprivation of this element compromises the catalytic activity of the enzyme. 
 
 
Figure 2.4. LTQ role in the LOX catalytic cycle. 
 
The soluble precursors of collagen and elastin are not the only substrates of LOX, 
because it has been demonstrated that several basic proteins are oxidized in vitro by 
LOX. The selective preference for proteins with positive charges at physiological pH 
can be explained by the copious presence of anionic residues such as Asp and Glu in the 
catalytic active site (Fig. 2.5), furthermore this abundance of negatively charged sites 
could be exploited in the development of LOX inhibitors. 
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Arg307 Arg308 Glu311 Lys314 Glu320 Asp321 Asp325
Tyr349Asp347 Asp352 Asp354 Asp357
LTQ
 
Figure 2.5. Charged aminoacid residues adjacent the LTQ cofactor (red: anionic; blue: cationic). 
 
Beyond the deaminative oxidation of structural proteins of the ECM, LOX possesses 
other biological roles influencing cell behaviour, for example it has a potent 
chemoattractant activity for human peripheral blood monocytes and vascular smooth 
muscle cells, enhancing their migration with a mechanism mediated by hydrogen 
peroxide, a product of LOX catalytic activity [8, 9]. 
 
2.1.2. LOX inhibitors 
BAPN (2.1, Fig. 2.6) has been extensively used in assays devoted to demonstrate the 
role of LOX in metastasis formation, because it represents one of the very few known 
inhibitors of lysyl oxidase and so it constitutes the reference LOX inhibitor (IC50 = 10 
μM). In particular, BAPN irreversibly inhibits LOX by forming covalent bonds within 
the catalytically active site, probably by a condensation between BAPN pharmacophoric 
primary amino-group and the quinone group of LOX covalently bound cofactor lysine 
tyrosylquinone (LTQ) [10, 11]. Recently, the reduction of the metastatic colonization 
potential on MDA-MB-231 cells due to LOX inhibition by BAPN was proved in vivo 
by bioluminescence imaging and microcomputed tomography [12]. Unfortunately, 
BAPN itself cannot be developed as a drug because of its many unwanted side effects. 
In fact, the small and “simple” molecular structure of BAPN is able to cross many 
physiological barriers and interact with a variety of biological targets, thus causing 
many unwanted side effects. Besides, the toxicity of BAPN is ascribed also to its LOX 
inhibitory property, because it is considered the main responsible for a syndrome called 
Lathyrism [13], a pathological condition involving several body districts, observed in 
people and animals after excessive ingestion of sweet pea (Lathyrus odoratus), which 
contains remarkable amounts of BAPN. Usually, this syndrome manifests in intoxicated 
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children or weanling animals, for which a mature connective tissues has not yet been 
developed. 
 
NH2
N
2.1  
Figure 2.6. Structure of BAPN (2.1). 
 
In literature, there is a small number of LOX inhibitors, mainly because only few 
useful therapeutic uses had been envisaged so far. Most of them possesses primary 
amino group like BAPN itself, such as taurine 2.5 and compounds 2.6-2.14 [14-23] 
(Fig. 2.7) or they are hydrazine-derivatives, such as isoniazide 2.2, semicarbazide 2.3 
and thiosemicarbazide 2.4 [24], so they should interact with LTQ cofactor similarly to 
BAPN, whereas only a few most recent inhibitors show heterocyclic scaffolds 
(compounds 2.15-2.16). Besides, the presence of basic centers confirms the preference 
of LOX for cationic substrates. Unfortunately, most of these molecules not only are 
small and unspecific compounds, but they also have quite reactive structures and/or 
toxic functional groups, so they do not possess the proper “drug-like” requirements to 
be used as drugs, consequently they cannot be developed as anti-metastasis agents. Only 
the most recent LOX inhibitors such as benzazole 2.15 and pyridazinone 2.16, 
possessing different structures, have been patented for treating diseases as scleroderma 
and fibrosis, respectively. 
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DERIVATIVES 
 
  
Figure 2.7. Structures of known LOX inhibitors (2.2-2.16), divided in three different structural classes 
(hydrazino-, primary amino- and heterocyclic derivatives). 
 
At present, there are not small organic molecules able to selectively inhibit lysyl 
oxidase without provoking significant side effects in order to be used as anti-metastatic 
drugs, whereas there is a patent covering antibodies, polynucleotides, polypeptides and 
nucleic acids designed with the aim of blocking LOX activity in tumour tissues [25]. 
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2.2. BIOREDUCTIVELY ACTIVATED LOX INHIBITORS 
 
2.2.1. Hypoxia-activated cytotoxins: the nitroaromatic prodrugs 
The lack of selectivity towards tumour cells is the responsible of dose-limiting side 
effects and toxicity associated with conventional chemotherapeutic agents. One 
approach to improve the therapeutic index and decrease side effects is to deliver 
selectively the drugs to tumour sites. The design of targeted prodrugs for tumour site-
specific activation exploits the unique features associated with cancers, and in particular 
one of the well-known strategies exploits the low oxygen tension present in many solid 
tumours with the aim of developing prodrugs activated by hypoxia (hypoxia selective 
agents, HSA) [26].  
In a general sense, this hypoxia-selective mechanism is based on a reductive 
process, by which an inactive prodrug is activated to a cytotoxic drug upon reduction in 
a hypoxia-dependant manner, but the same reductive reaction could occur also in 
oxygenated tissues, because reducing enzymes may be also present in aerobic regions. 
Nevertheless, in this case the electron of the prodrug radical is rapidly transferred back 
to molecular oxygen, forming superoxide, which is scavenged by the enzyme 
superoxide dismutase to less toxic species (but it can contribute to some unwanted toxic 
side effects), and regenerating the initial prodrug (Fig. 2.8). This redox cycles is clearly 
advantageous, it ensures the cytotoxic action of the prodrug only in hypoxic areas, 
providing a selective treatment and minimizing the toxic side effects due to the 
activation of the drug in healthy oxygenated tissues. An ideal prodrug candidate has to 
meet some requirements to be developed as hypoxia-activated cytotoxin: it must be non 
toxic and stable and it must be able to diffuse efficiently through hypoxic tumour tissues 
but above all it must possess a reducible function, able to be converted to a potent 
cytotoxin when selectively activated by a specific enzyme or metabolic pathway present 
exclusively or predominantly in the targeted cancer cells, so exhibiting significantly 
greater toxicity to hypoxic compared to aerobic cells [27]. 
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Figure 2.8. Mechanism of action of hypoxia selective agents in oxygenated and hypoxic cells. PD = prodrug, 
D.¯ = prodrug radical. 
 
Hypoxia-activated prodrugs can be divided into four main classes on the basis of the 
structure of the group that undergoes the initial reductive process (usually called the 
“trigger group”): quinone, nitroaromatics, N-oxides and metal complexes. Nitroaromatic 
class comprises a very wide group of efficient prodrugs whose biotransformation leads 
to drug activation in hypoxic tumours, but albeit the interest in their utilization is great, 
no clinically useful compounds have been obtained yet. Nitroreductive activation is also 
of current interest, due to the recent possibility of introducing specific exogenous 
nitroreductases into tumours [28]. Hypoxia-targeted prodrugs using nitroaromatic 
moieties were initially developed from the nitroimidazole-based radiosensitizers 
Misonidazole 2.17 and etanidazole 2.18 (Fig. 2.9). They acts as mimetics of oxygen, 
causing fixation of radiation-induced damage to DNA or other biologically relevant 
biomolecules, when used in combination with radiation therapy, thus increasing the 
radiation sensitivity of hypoxic cells and, consequently, enhancing radiotherapeutic 
effect in vivo. Unluckily, they do not possess significant cytotoxicity or marked hypoxia 
selectivity. Moreover, they provoke neurotoxicity. Extensive studies and important 
progresses were made in the development of this class, starting from these first 
structures. 
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Figure 2.9. Structure of the radiosensitizers Misonidazole (2.17) and etanidazole (2.18). 
 
Nitroreductase enzymes catalyze the reduction of aromatic nitro groups and usually 
the major metabolic products of nitroreductase-catalyzed reductions are the four-
electron product hydroxylamine and the six-electron product amine, both of them 
passing by the first electron adduct of nitro group, the nitro radical anion. This first 
intermediate can be oxidized back by O2 to the parent nitro group, so limiting the 
activation reaction to hypoxic areas, where the nitro radical anion is further reduced 
stepwise by irreversible reactions to hydroxylamine or amine (Fig. 2.10). The reduction 
processes catalyzed by nitroreductases are particularly facilitated in cells characterized 
by total or partial absence of oxygen because they are rich in reduced cofactors. 
 
 
Figure 2.10. Reduction reactions of nitroaromatics and back-oxidation of nitro radical anion by oxygen. 
 
The electronic reduction represents a very significant electronic density change in 
the structure of a nitroaromatic compound, thus it can be exploited as an efficient 
“electronic switch” to release or generate the latent active drug [29]. Nitroaromatics 
have been extensively used as pro-moieties to release a large number of anticancer 
agents and various linking groups have been employed to attach the cytotoxic portion to 
the masking nitroaromatic group. However, the most investigated mechanism of 
activation and release of drug involves the bioreduction of the nitro group of a 
nitrobenzyl portion to a hydroxylamine intermediate, followed by double bond 
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rearrangements and consequent spontaneous 1,6-elimination to release the cytotoxic 
drug (Fig. 2.11). 
 
 
Figure 2.11. Activation and release of active drug from nitro-benzyl prodrug triggered by bioreduction and 
1,6-elimination. 
 
2.2.2. Pro-BAPNs as hypoxia-activated LOX inhibitors [30] 
During my PhD project, in order to selectively deliver the reference LOX inhibitor 
BAPN to hypoxic tumours and block LOX-induced metastasis, we used the well-known 
hypoxia-sensitive nitroaromatic group to mask the pharmacophoric primary amino-
group of BAPN. We developed a series of inactive nitroaryl pro-drugs of BAPN, that 
could be selectively activated to BAPN itself by bioreductive processes in the hypoxic 
environment of invasive tumours. Under hypoxic conditions, the masking nitro group is 
readily reduced to hydroxylamine or amine. Consequently, this transformation weakens 
the bond between the masking moiety and BAPN portion, promoting the spontaneous 
removal of the masking group and allowing the release of active BAPN selectively in 
hypoxic tumour cells (Fig. 2.12).  
 
O2N
aromatic
ring
HN
Bioreductive
activation
Hypoxic
tumour
environment
RHN aromaticring
HN
CN
R = H, OH
labile bond
Spontaneous
cleavage
electron-withdrawing electron-donating
Inactive pro-BAPN BAPN
H2N CN
CN
 
Figure 2.12. Activation mechanism of pro-BAPNs. 
 
Exploiting this strategy, we designed and synthesized new pro-LOX inhibitors, 
which are nitrobenzyl- (2.19 and 2.20), nitrobenzylcarbonyl- (2.21) [31] and 
nitrofuranmethyl- (2.22) [32] derivatives of BAPN (Fig. 2.13). In these preliminary 
series of prodrugs, the nitrogen of the pharmacophoric primary amino group of BAPN 
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was linked to nitroaromatic moieties by a methyl (2.19, 2.20 and 2.22) or a 
methoxycarbonyl (2.21) unit. 
 
 
Figure 2.13. Structures of pro-BAPNs (2.19-2.22). 
 
Synthesis of compounds 2.19-2.22 was accomplished as illustrated in Scheme 2.1. 
Compounds 2.19, 2.20 and 2.22 were prepared starting from the correspondent 
commercially available aldehyde precursors (2.23, 2.26 and 2.30), whose condensation 
with an excess of β-aminopropionitrile in anhydrous dichloromethane afforded imine 
derivatives 2.24, 2.27 and 2.31, respectively. Then, reduction of the imine double bond 
with sodium borohydride at 0 °C afforded compounds 2.25, 2.28 and 2.32, and final 
treatment with Et2O.HCl converted them into their corresponding water-soluble 
hydrochloride salts 2.19, 2.20 and 2.22 [33]. Carbamate derivative 2.21 was simply 
obtained by a single step involving p-nitrobenzylchloroformate 2.29 and BAPN in 
DCM. Nitrofurane analogue 2.22 required a very slow addition of NaBH4 to the 
intermediate 2.31 and strict control of the temperature to avoid the possible undesired 
reduction of the highly electron-deficient furan ring. 
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Scheme 2.1. a) β-aminopropionitrile, dry DCM, RT; b) NaBH4, dry MeOH, 0 °C.; c) Et2O.HCl, dry MeOH, 
RT. 
 
It has often been observed a direct association between the ease of activation of 
bioreductive prodrugs to their electrochemical reduction potential values [34, 35]: 
usually, a higher reductive potential value corresponds to a ready activation and, 
consequently, to a greater cytotoxicity in hypoxic cells. For this series of pro-BAPNs, 
cyclic voltammograms were recorded in iso-osmotic saline phosphate buffer solutions at 
pH 7.2, so measurements of their reduction potentials were obtained in order to evaluate 
their predicted ability to be reduced in the hypoxic environment (Table 2.1 and Fig. 
2.14). All the derivatives produced a single reduction peak when the potential was 
scanned from 0.0 to -1.8 V, which is the result of the reduction of their nitro group to 
the hydroxylamine product. Moreover, the voltammetry graph shows the irreversibility 
of the reductive process, missing a correspondent oxidation peak in the lower part of the 
curve. This indicates the irreversible transformation of the molecules (loss of the BAPN 
portion) following the NO2/NHOH conversion. Among these compounds, analogues 
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2.19-2.21 displayed similar reduction potentials, with E° values ranging from -0.75 V of 
the two para-nitro derivatives 2.19 and 2.21 to -0.77 V for the ortho-nitro analogue 
2.20; while it is evident that nitrofuranmethyl-derivative 2.22 showed the less negative 
reduction potential (E° = -0.61 V), as shown by the blue line in the voltammogram. This 
means that 2.22 is much more inclined to reduction and, as a consequence, it should be 
more readily activated in hypoxic tumours releasing BAPN.  
 
Table 2.1. Reduction potential values of compounds 2.19-2.22. Measurements were recorded, using 5.10-4 M 
solutions, at glassy carbon electrode in phosphate buffer (pH 7.2, 0.15 M NaCl), with a sweep rate of 0.1 V s–
1. 
Compound Structure Reduction Potential (E°)
2.19 –0.75 V 
2.20 –0.77 V 
2.21 –0.75 V 
2.22 –0.61 V 
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Figure 2.14. Cyclic voltammograms of compounds 2.19-2.22. Measurements were recorded, using 5.10-4 M 
solutions, at glassy carbon electrode in phosphate buffer (pH 7.2, 0.15 M NaCl), with a sweep rate of 0.1 V s–
1. Compound 2.22 in blue; 2.21 in red; 2.20 in yellow; 2.19 in green, in the graph. 
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2.3. BIOLOGICAL EVALUATION OF LOX INHIBITORS[30] 
 
Compounds 2.19-2.22, synthesized as pro-BAPNs molecules, were biologically 
assayed by the research group of Prof. Amato J. Giaccia at the University of Stanford 
(California, USA). Initially, their ability to inhibit LOX enzyme was tested, then they 
were submitted to in vitro invasion assays to measure their anti-invasive ability in 
tumour cells. 
The inhibition potency of this series of inhibitors was assayed by using a 
conditioned medium (CM) from the MDA-MB-231 breast tumour cell line, which was 
incubated with the reference inhibitor BAPN and with 200 μM LOX inhibitors 2.19-
2.22, both in hypoxic and normoxic conditions (Fig. 2.15). The LOX inhibition is 
related to the fluorescence development by a method previously described [36, 37]. This 
method consists in the reduction of the LOX by-product hydrogen peroxide by N-
acetyl-3,7-dihydroxyphenoxazine (Amplex Red), catalyzed by the enzyme horseradish 
peroxidase, and this redox reaction produces as product fluorescent resorufin. This 
fluorometric measurement of hydrogen peroxide has been extensively used for 
measuring LOX activity, correlating a diminished fluorescence with a great LOX 
inhibition. It is clear from the bar graph that compounds 2.19, 2.21 and 2.22 are much 
more active under hypoxia than in normoxia, consequently confirming their reduction 
and activation in conditions of low oxygen concentrations. On the other hand, the 
reference inhibitor BAPN does not show any significant difference in its activity 
between air and hypoxia, since it does not need any activation. In particular, compounds 
2.21 and 2.22 provided the best results, thanks to their much greater inhibitory activities 
under hypoxic conditions, whereas their activities in the presence of air are almost the 
same of control and DMSO, thus showing a very selective behaviour.  
ortho-Nitrobenzyl derivative 2.20 showed a very high fluorescence, if compared to 
the other derivatives and to control. This unpredictable result is likely generated by an 
interference with the fluorescence-based assay, possibly due to its high photo-
instability, so, currently, optimization of the assay conditions for this specific derivative 
is in progress. 
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Figure 2.15. LOX inhibition bar graph: fluorescence assay for LOX activity on CM from MDA-MB-231 cells 
incubated in air (white bars) or hypoxia (2% O2, purple bars) with 200 μM LOX inhibitors 2.19-2.22. 
 
Subsequently, the anti-invasion abilities of this series of compounds were 
determined. Cell invasion assays were performed in vitro on MDA-MB-231 breast 
cancer cells, following a method that has already been described [38]. Briefly, tumour 
cells were serum deprived and after 24 h seeded both on Matrigel-coated and uncoated 
inserts, then they were moved to chambers containing FBS as a chemo-attractant and 
incubated under normoxic or hypoxic conditions. The incubation with control or with 
the compounds was started 24 h before serum deprivation and continued for all the 
duration of the experiment. This tumour cell line is highly invasive and become even 
more aggressive when it is placed under oxygen deprivation, as shown by the control 
data in the graph (Fig. 2.16), where the percentage of invasion under hypoxia is about 
two-fold higher than that in air. It is interesting to note that, even in this case, the most 
promising compounds are 2.21 and 2.22. In fact, they possess not only enhanced 
activities in hypoxic conditions, but they also provoke a six-fold reduction of cell 
invasion under hypoxia, if compared to control experiments. In particular, the nitrofuran 
derivative 2.22 manifests the highest hypoxia-selectivity, since it maintains the same 
invasion level as control in normoxic conditions (30%), but it markedly reduces the 
level under air deprivation. The non-selective behaviour of the carbamate inhibitor 2.21 
suggests that it may produce anti-invasive effects by means of a non-LOX-mediated 
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mechanism, showing an anti-invasive action even under normoxic conditions, although 
further studies need to be done to explain this phenomenon. 
 
 
Figure 2.16. Cell invasion assay bar graph: transwell invasion assay to test ability of the synthesized 
compounds to inhibit in vitro invasion of MDA-MB-231 cells incubated in air (white bars) or hypoxia (2% 
O2, purple bars) with 200 μM LOX inhibitors 2.19-2.22. 
 
Observing the data form both LOX inhibition and anti-invasion assays, we can 
conclude that pro-drug 2.22 proved to be the most active and hypoxia-selective 
compound and this result nicely correlates with its higher reduction potential (E° = –
0.61 V) when compared to the other active members of the series of pro-BAPNs (2.19 
and 2.20, E° = –0.75 V). Indeed, its least negative potential is associated with an easier 
bioreduction and activation of the nitrofuran masking portion, if compared to the other 
nitroaryl derivative 2.19-2.21, and it is evident that this mechanism leads to more 
pronounced effects in hypoxia conditions in the performed biological assays.  
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2.4. CONCLUSIONS 
 
To the best of our knowledge, the use of nitroaromatic pro-drugs to selectively 
inhibit the recently discovered target LOX is a completely new method to reduce or 
block the invasiveness of hypoxic tumours. Hypoxia-activated LOX inhibitors represent 
a new and effective therapeutic approach against metastatic tumours and it could be 
useful not only for the prevention of future metastasis, but also for the treatment of 
established metastatic conditions.  
Pro-drug 2.22 showed a notable LOX inhibition activity and a marked anti-invasion 
ability in hypoxic conditions by selectively delivering LOX inhibitor BAPN to tumour 
tissues. Although the compound database is too small to demonstrate a definitive 
correlation, the hypoxia-enhanced activities of these prodrugs of BAPN appear to be 
strictly related to their electrochemical potential value, suggesting that the promising 
biological activities found with 2.22 are associated to the easier activation of its 
nitrofuran masking portion in hypoxic conditions, when compared to that of the other 
derivatives. 
The direct involvement of the masking portions in the biological activity of the 
nitrofuranmethyl and p-nitrobenzyl derivatives 2.22 and 2.21, which proved to be the 
most active compounds, are not to be excluded. In fact, the nitroaromatic groups, after 
detaching from BAPN under hypoxic conditions, might interact with LOX in a 
synergistic fashion with the active BAPN, even if attempts to demonstrate the 
involvement of chemical species derived from the masking portions have so far failed. 
This research line can be further developed and expanded by using different 
masking moieties to be linked to BAPN or even by introducing completely new LOX 
inhibitors in the place of BAPN itself. This last goal could be achieved, for example, 
with derivatives able to bind LTQ cofactor, such as primary amino-derivatives, or even 
with compounds containing chelating groups, which can coordinate to the copper ion 
present in the LOX active site. Moreover, since LOX is an extracellular target, it can be 
accessible even to drugs that do not efficiently cross the cell membranes and this 
constitutes a further advantage, because higher concentrations of drugs in the tumour 
stroma are more likely to be reached than inside the cancer cell. 
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3.1. GLYCOLYTIC ENZYMES: POTENTIAL TARGETS 
AGAINST HYPOXIC TUMOURS 
 
The peculiar tumour metabolism of hypoxic solid tumours has inspired the search 
for new therapeutic approaches able to selectively interfere with the Warburg effect. 
LDH inhibition is likely one of the most innovative way of attacking cancer of the past 
few years, but other drug candidates targeting glycolysis at different stages contribute to 
further demonstrate the central role of this metabolic pathway and the potential 
therapeutic selectivity of this kind of approach. In particular, glycolysis, the 
cytoplasmatic catabolic process responsible for ATP production in hypoxic cancers, 
starts with the internalization of glucose by means of specific transporters 
overexpressed in hypoxic tumours and comprises ten reactions, each catalyzed by 
specific enzymes, thus offering several possibilities for blocking the energy production 
in tumour cells (Fig. 3.1) [1]. 
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Figure 3.1. The glycolytic pathway: all the enzymes participating to glycolysis are indicated. Some of the 
most important glycolytic enzyme inhibitors are reported. HK = hexokinase, PGI = glucose 6-phosphate 
isomerase, PFK = phosphofructokinase, ALD = aldolase, TPI = triosephosphate isomerase, GAPDH = 
glyceraldehyde 3-phosphate dehydrogenase, PGK = phosphoglycerate kinase, PGM = phosphoglycerate 
mutase, ENO = enolase, PK = pyruvate kinase, PDH = pyruvate dehydrogenase, PDK = pyruvate kinase. 
 
Hexokinase (HK), which exists in four different isozymes (HK I, II, III and IV), 
represents the first enzyme of glycolysis, catalyzing the irreversible phosphorylation of 
glucose to glucose-6-phosphate. This reaction constitutes a very important control site 
of glycolysis, transforming glucose into an anionic molecule, so trapping it into the cell, 
where it is ready to be utilized.  
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The glucose analogue 2-deoxyglucose (2-DG) (3.1, Fig. 3.2) is one of the most 
important HK inhibitor, developed by Threshold Pharmaceuticals and now in phase I 
clinical trial [2, 3]. Phosphorylation of 2-DG by the enzyme HK leads to the 
accumulation of this molecule within the cell without being metabolized further, so 
blocking the next steps of glycolysis. However, the not entirely satisfactory action of 
this agent on hypoxic tumours and its toxic effects when used as a primary therapy limit 
the use of this molecule [4]. 
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Figure 3.2. Structure of 2-deoxyglucose (3.1).  
 
Lonidamine (3.2, Fig. 3.3), a derivative of indazole-3-carboxylic acid developed by 
Threshold Pharmaceuticals, is an orally administered anticancer and antispermatogenic 
drug. Its mechanism of action still needs to be completely understood, but the 
interference in the glycolytic pathway by HK inhibition is well established [5]. Now it 
has completed a phase 3 trial; however, pancreatic and hepatic toxicity have been 
detected [6]. 
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Figure 3.3. Structure of Lonidamine (3.2).  
 
3-Bromopyruvate (3-BrPA), another well-known HK inhibitor, is a synthetic 
derivative of pyruvic acid (3.3, Fig. 3.4). The supposed mechanism of inhibition is the 
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selective alkylation of sulfhydryl groups necessary for enzymatic function but not 
involved in glucose or ATP binding [7]. Preclincal studies on this compound showed 
promising results, but no clinical trials are yet available, probably due to its unspecific 
mode of action and also the low economical potential of this non-patentable structure 
[8]. 
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Figure 3.4. Structure of 3-bromopyruvate (3.3). 
 
Pyruvate dehydrogenase (PDH) possesses a central role in glucose metabolism, 
favouring the switch from glycolysis to oxidative phosphorylation (OXPHOS), that 
could be beneficial to hypoxic tumour cells. This enzyme converts pyruvate to acetyl-
CoA by pyruvate decarboxylation, so it directs the end product of glycolysis toward the 
Krebs cycle, promoting the restoration of normal OXPHOS to the detriment of aerobic 
glycolysis. PDH is inhibited by pyruvate dehydrogenase kinase (PDK) by means of a 
phosphorylation reaction requiring ATP as the phosphate source. Therefore, inhibition 
of PDK leads to reactivation of PDH and, indirectly, to the physiological demolition of 
pyruvate [9]. Dichloroacetate (3.4, Fig. 3.5), a molecule already known for the treatment 
of lactic acidosis and inherited mitochondrial diseases, is a PDK inhibitor under phase I 
clinical study thanks to its marked anticancer action. Some side effects such as 
peripheral nerve toxicity, anxiolytic and sedative effects have been reported and recent 
evidences outline the fact that PDK-knockout does not block proliferation of hypoxic 
tumour cells [10]. Besides, being a non-patentable compound, DCA has received a 
limited interest by pharmaceuticals companies.  
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Figure 3.5. Structure of dichloroacetate (3.4). 
 
The increased glucose uptake detected in hypoxic tumours was exploited by 
prodrugs like glufosfamide (3.5, Fig. 3.6), composed by an alkylating moiety 
conjugated to β-D-glucose [11]. This prodrug, developed by Threshold Pharmaceuticals, 
which has already been evaluated in clinical trials on several kind of cancers [12], takes 
advantage of the glucose transporters overexpressed in tumours to be internalized within 
the cells and then the linkage between the sugar moiety and the cytotoxic portion is 
cleaved in vivo, thus releasing the active drug that is the alkylating phosphoramide 
mustard.  
 
 
Figure 3.6. Structure of glufosfamide (3.5). 
 
Pyruvate kinase (PK) is the last glycolytic enzyme catalyzing the irreversible 
transformation of phosphoenolpyruvate to pyruvate, producing ATP. PK is under 
complex control, allowing the cell to sense the levels of anabolic precursors as well as 
its energy status. It is noteworthy that the human fetal isoform of pyruvate kinase (PK-
M2), a phosphotyrosine-binding protein, is overexpressed in hypoxic tumours. It 
switches from a tetrameric form with high affinity to its substrate phosphoenolpyruvate 
to a low affinity form and the balance between these two conformational states 
contributes to the control of glycolysis. Indeed, PK-M2 proved to be necessary for the 
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tumourigenicity, by promoting Warburg effect, even if its inhibition may lead also to 
controversial effects on cancer growth [13, 14]. For this reason, the search for PK-M2-
selective inhibitors, either peptidic or small organic molecules, for disrupting tumour 
glycolysis [15, 16] is joined by the recent development of N,N’-diarylsulfonamides as 
PK-M2 activators (3.6, Fig. 3.7), although these opposite effects on tumour cells still 
need to be verified [17]. 
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Figure 3.7. General structure of N,N’-diarylsulfonamide derivatives (3.6). 
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3.2.THE ENZYME LACTATE DEHYDROGENASE (LDH) 
 
3.2.1. Introduction 
Although the roles of lactate dehydrogenases (LDHs) in biology have been well-
established for many years, this enzyme is not commonly considered as a potential 
therapeutic target. However, its inhibition might be desirable in many pathologies, so 
different as cancer and malaria, where the modulation of the glucose metabolism may 
lead to clinically relevant effects. 
Lactate dehydrogenases (LDHs) are a family of 2-hydroxyacid oxidoreductases that 
are found in almost all animal tissues, in microorganisms, in yeasts and in plants. They 
catalyze the reversible transformation of pyruvate to lactate with the simultaneous 
interconversion of NADH to NAD+. LDH is one of the best characterized enzymes in 
the scientific literature because it is known since the early period of enzymology, with a 
well-studied kinetic mechanism and many crystal structures solved. As a matter of fact, 
LDH structures have been reported for dogfish [18], pig [19], Bacillus 
steareothermophilus [20], Bifidobacterium longum [21], Plasmodium Falciparum [22] 
and more recently also for the human enzymes M and H (isoforms typical of muscle and 
heart, respectively) [23].  
The great attention directed to LDH is due to the central role that this enzyme plays 
in several metabolic pathways. It exerts its action principally during energy production 
in anaerobic conditions, that occur when there is a sudden demand for energy and, at the 
same time, oxygen is absent or in short supply, like in working human skeletal muscle. 
In this situation LDH converts pyruvate, that is the end product of the glycolytic 
process, to lactate. As a consequence, LDH permits to overcome a momentary oxygen 
debt in the form of accumulated lactate to be later discharged by the reoxidation of 
lactate to pyruvate when oxygen becomes available. In fact, under aerobic conditions, 
pyruvate can be further oxidized to CO2 and H2O in mitochondria through the Krebs 
(citric acid) cycle, generating ATP and NAD+. However, when the Krebs cycle cannot 
start because of the lack of oxygen, the only source of ATP is glycolysis, so NAD+ 
needs to be regenerated, being an electron acceptor essential for glycolysis to continue 
(Fig. 3.8). The reduction of pyruvate to lactate, known as anaerobic homolactic 
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fermentation, represents an important mean of regenerating NAD+, thus enabling the 
achievement of energy even in anaerobic conditions. The product of this reaction is the 
L-isomer of lactate in most of the cases, but certain lower animals and some 
microorganisms catalyze the formation of D-lactate isomer from pyruvate [24]. 
 
 
Figure 3.8. Reaction catalyzed by LDH and regeneration of the cofactor NAD+, needed for the glycolytic 
process. 
 
LDH performs also the reverse reaction in gluconeogenesis during the Cori cycle, a 
metabolic pathway that takes place mainly in the liver, in order to produce glucose, and 
subsequently ATP, from non saccharidic precursors during intense muscle activity, 
when the level of blood glucose decreases. In this physiological situation, lactate 
produced in anaerobic conditions is converted to pyruvate in the cytosol by LDH and 
subsequently internalized in mitochondria, where it undergoes two consecutive 
metabolic transformations in order to be used in the gluconeogenetic pathway. In this 
way gluconeogenesis also prevents lactic acidosis, that is the production of significant 
amounts of lactate during muscle activity by LDH, which causes muscle pain and 
cramps because of ionization of lactic acid in the blood [25]. 
The catalytic activity of LDH was first discovered in cell-free muscle extracts [26] 
and the enzyme was purified in a crystalline form for the first time by Straub in 1940 
[27]. The accepted catalytic mechanism of LDH is rather simple and starts with the 
initial binding of NADH to the enzyme followed by binding of the pyruvate. Then, the 
LDH-NADH-pyruvate ternary complex undergoes a rate-limiting conformational 
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change, in which a substrate specificity loop closes to form a desolvated ternary 
complex, principally in order to bring the catalytical residue Arg109 into the active site 
where it polarizes the ketone functionality of pyruvate, thus promoting hydride and 
proton transfer to the substrate. Apart from the catalytic residues Arg109, Asp168, and 
His195, which are highly conserved in all LDHs, other amino acids are also involved in 
substrate discrimination and recognition, such as Gln102, Arg171, and Thr246, together 
with Arg109. For example, Gln102, Arg109 and Thr246 are implicated in pyruvate 
recognition by enclosing the methyl side chain of the native substrate, which is in fact 
oriented towards these residues (Fig. 3.9). The catalytic mechanism involves a direct 
and stereospecific transfer of a hydride ion (H–) from the C4 carbon of the 
dihydronicotinamide ring of NADH to the ketone group of the pyruvate, in conjunction 
with proton donation (H+) to the carbonyl oxygen of pyruvate from the catalytic diad 
Asp168/His195, finally producing lactate. The imidazole ring of His195 has the 
function of proton donor/acceptor in this reaction and it also orients the substrate in the 
proper position for its interaction with the C4 of NADH. The other aminoacid of the 
catalytic diad, Asp168, interacts with His195 by stabilizing the protonated/cationic form 
of its imidazole ring through an H-bond between the side chain carboxylic group of 
Asp168 and imidazole ring of His195. The function of the last catalytic residue Arg171 
is to fix the substrate through a strong two-point interaction between its side chain and 
the carboxylate of pyruvate. It is important to note that Ile250 with its hydrophobic side 
chain provides an environment suitable for the nicotinamide ring of NADH.  
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Figure 3.9. Schematic representation of the LDH catalysis mechanism. LDH active site bound to both 
substrate pyruvate and cofactor NADH; residues directly involved in catalytic interactions and 
substrate/cofactor recognition are reported. 
 
The particular interest for this enzyme also rises from its importance as a diagnostic 
marker. A sudden increase in LDH activity in serum is associated with acute diseases, 
which cause a rapid release of this enzyme into the blood flow. In particular, the highest 
levels of LDH were found in patients with megaloblastic anaemia and malignancy, but 
the determination of total serum LDH is also widely used for the diagnosis of 
myocardial infarct, liver, hematological and skeletal muscle diseases and other 
secondary diseases. The pathological presence of LDH into the circulation could be 
explained by considering that LDH release from cells is caused by a defect in the 
plasma membrane; hence, LDH is considered as a hallmark of general cell damage for 
several tissues and it is often exploited as a diagnostic tool in human diseases [28].  
LDH exists in several isozymic forms, for example in mammals the association of 
two principal types of subunits, which are genetically distinct, give rises to five 
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tetrameric isozymes. The two homotetramers and three heterotetramers are also present 
in all vertebrates with a characteristic tissue-specific expression relatively similar to the 
human case. Each species diverges in their physical-chemical properties, biological 
functions and developmental regulations [29]. 
Recent discoveries have made LDH a valid target for very different diseases, such as 
malaria and cancer. Isoforms expressed by the Plasmodium parasites, in particular 
Plasmodium LDHs (pLDHs) from Plasmodium falciparum (pfLDH), vivax (pvLDH), 
ovale (poLDH) and malariae (pmLDH), display high levels of similarity among them. 
The development of inhibitors of the parasite LDH isoforms has reached a potentially 
great therapeutic value. In fact, it is well established that lactate dehydrogenase from 
Plasmodium falciparum (pfLDH) is a key enzyme for the survival of the malarial 
parasite and, as a consequence, several small organic molecules have been designed and 
synthesized with the aim of attacking this antimalarial target [30-34]. 
On the other hand, the human isoform LDH-M, also referred to as LDH-A, is a 
relatively innovative anticancer target. The idea that the inhibition of this isoform could 
be useful to reduce tumour growth and invasiveness is very recent and nowadays LDH-
A has been blocked only by genetic techniques [35], although many pfLDH inhibitors 
are not very selective and act also on human isoforms, including LDH-A. 
 
3.2.2. hLDH isoforms 
Human LDHs (hLDHs) are a family of tetrameric isozymes [36], that is to say, 
enzymes coded by different genes but translated into proteins with a high degree of 
similarity in sequence and activities. Each isozyme shows distinct kinetic parameters or 
regulatory properties. In mammals, each tetramer is composed by two different kinds of 
subunits, the M- and the H-type. As a consequence, there are five possible combinations 
of these polypeptide chains, corresponding to five forms of LDH. This composition 
gives rise to two homotetramers LDH-1 (H4) and LDH-5 (M4), which are also simply 
called LDH-H (or LDH-B) and LDH-M (or LDH-A), respectively, and three hybrid 
tetramers, LDH-2 (M1H3), LDH-3 (M2H2) and LDH-4 (M3H1) (Fig. 3.10). 
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Figure 3.10. The two homotetramers (LDH-1 and LDH-5) and the three heterotetramers (LDH-2, LDH-3 and 
LDH-4) are schematically represented. A (or M) and B (or H) are the kinds of the subunits. 
 
The numbers were assigned according to the different electrophoretic mobility of the 
isozymes. For example LDH-5 shows the lowest mobility, whereas LDH-1 is the fastest 
moving enzyme in this family. Each subunit is coded by a different gene, that are ldh-a 
and ldh-b for M and H subunit, respectively. Therefore, the five isozymes are also 
named LDH-B4 or simply LDH-B (H4), LDH-A1B3 (M1H3), LDH-A2B2 (M2H2), LDH-
A3B1 (M3H1) and LDH-A4 or LDH-A (M4) (Fig. 3.10). A third less common isoform, 
LDH-X or LDH-C4, has been identified and corresponds to human ldh-c gene [37-39]. 
It should be noted that, although human LDH-C isoform seems to play a key role in 
male fertility, no evidences that this enzyme may be targeted by male contraceptive 
agents have been reported as of yet. 
Each subunit has a molecular weight of about 35 kDa in humans, differing in 
aminoacid compositions, but possessing an high level of homology not only among 
different types of human subunits but also among subunits of the same type in different 
species. The names of the two types of subunits LDH-H and -M derive from the tissues 
in which they are mainly expressed. In fact in humans there is a specific distribution 
pattern: LDH-5 (M4) and also LDH-4 (M3H1) are found especially in anaerobic tissues 
such as skeletal muscle (M stands for muscle), liver and neoplastic tissues; LDH-1 (H4) 
and also LDH-2 (M1H3) strongly predominate in tissues with a principal aerobic 
metabolism such as cardiac muscle (H stands for heart), spleen, kidney, brain and 
erythrocytes. The intermediate LDH, isoform LDH-3, which possesses two subunits of 
each type, is mainly present in lymphatic tissues, platelets and many malignant tissues. 
LDH-X (C4), the less known isoform of human LDHs and the most specialized of them 
all, was found only in testes and sperm, so its gene appears totally inactive in females. 
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Thus, the relative abundance of the five isoforms in each cell is completely dependent 
upon the numbers of subunits of each type available to combine. At the same time, the 
numbers of available subunits reflect the relative levels of activation of the 
corresponding genes. 
As for the intracellular distribution of the isozymes, isoform LDH-X has a wide 
cellular distribution in sperm; in fact, it has been found in the cytosol, in the 
mitochondrial matrix between the inner and the outer mitochondrial membranes and in 
the plasma membrane. In contrast, the other five isozymes are mainly localized in the 
cytosol of somatic cells, but they have also been observed in mitochondria. Recently, it 
has been hypothesized that LDH has a fundamental role in an “intracellular lactate 
shuttle”, a model that seems to be widely used in mammalian muscle and liver. In the 
intracellular lactate shuttle mechanism, cytosolic lactate from glycolysis is transported 
into the mitochondrial intermembrane space, oxidized to pyruvate by mitochondrial 
LDH and finally pyruvate is oxidized via the Krebs cycle that takes place exactly in 
mitochondria [40]. LDH isozyme distribution displays not only tissue specificity, but 
also differs between mitochondria and the surrounding cytosol in each tissue. For 
example, in the heart LDH-1 is mostly concentrated in the mitochondrial matrix, 
whereas LDH-5 in the skeletal muscle is equally present in cytosol and in mitochondria, 
but the same isoform in liver is more abundant in mitochondria. 
Although all these isoforms are able to catalyze the transformation of pyruvate into 
lactate, when the number of H over M chains increases, isozymes become more 
efficient in catalyzing the reaction in the opposite direction, that is oxidation of lactate 
to pyruvate. In other words, the muscle-specific form LDH-5, and to a lower extent 
LDH-4, favour lactate formation from pyruvate, whereas the heart-specific forms, LDH-
1 and LDH-2, promote the conversion of lactate to pyruvate, thus favouring its entrance 
into the Krebs cycle. This consideration is supported by the fact that LDH-1 shows a 
higher degree of affinity for lactate than LDH-5. In fact, LDH isoforms present in 
aerobic tissues (mainly LDH-1 and LDH-2) act as scavengers for lactate produced 
during glycolysis, either for resynthesis of glucose in the liver or for further production 
of pyruvate which is then degradated in the Krebs cycle in order to produce ATP [41]. 
This hypothesis follows the widely accepted theory by Kaplan and coworkers 
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concerning the differential physiological functions of the LDH isozymes, the so called 
“aerobic-anaerobic theory”, which hypothesizes that LDH-1 is suited to aerobic 
metabolism, whereas LDH-5 is well-suited to tissues frequently exposed to oxygen 
limitations [24]. 
However, this theory does not take into due consideration some exceptions to the 
classical distribution pattern, such as human erythrocytes, which perform exclusively 
glycolysis, but synthesize predominantly the B subunit. Moreover, there are also 
differences in isoform distribution between organs of the same type in different species, 
which may not be easily rationalized by the Kaplan’s theory [24]. 
 
3.2.3. Structural and kinetic features of hLDHs 
LDH-M and LDH-H enzymes possess about 75% amino acid sequence identity, 
differing in 81 out of 331/332 amino acid positions. In particular, the residues that form 
the cofactor/substrate binding pockets are well conserved between the two isoforms and 
the differences generate only slight changes in the overall structures. The 
homotetramers have essentially the same tertiary structure, possessing identical folding 
of the main chain and the same α-helices and β-pleated sheets. Both proteins show high 
degrees of similarity with isoforms from other species such as those of pig and mouse. 
Moreover, the hybrid tetramers LDH-M1H3, LDH-M2H2 and LDH-M3H1 display 
macroscopic structures very similar to LDH-M4 and H4. Human tetramers are composed 
of four 330-residue subunits. Each monomer has two domains: a) a larger domain that 
assumes a typical “Rossmann fold” formed by residues 20-162 and 248-266; the classic 
“Rossmann fold” is a structural motif shared with many dinucleotide binding proteins, 
which was discovered by Rossmann et al. in 1975 [42] and then refined thanks to 
further studies by Bellamicina in 1996 [43]; b) a smaller accompanying domain, which 
is a “mixed α/β substrate binding” domain, comprising residues 163-247 and 267-331. 
Despite the negligible structural diversity between LDH-M and -H, there are small 
but very significant dissimilarities in the kinetic properties of each form, that become 
even more pronounced when comparing them with LDH-X. The overall turnover rate is 
two-fold higher for LDH-M than -H, that is, LDH-M has higher Vmax, whereas the LDH-
H isoform shows about a three-fold increase in the ability to bind pyruvate compared 
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with the -M one, corresponding to a lower Km value for pyruvate. Moreover, LDH-H is 
more sensitive to inhibition by high pyruvate concentrations. It has been supposed that 
the different kinetic properties probably arise from the way of substrate binding 
accompanied by the closure of the active-site loop. LDH-X has kinetic properties very 
different from the five isoforms deriving from the association of M and H subunits and 
possesses also a broader substrate specificity than the other isozymes [23]. 
 
 
3.3. PLASMODIUM LDH (pfLDH) AS AN ANTIMALARIAL 
TARGET 
 
3.3.1. pfLDH role in the fight against malaria 
Malaria is one of the major diseases affecting mankind, which is widely reemerging 
in many tropical and subtropical areas of the world, constituting a huge public health 
problem. It provokes more than 300 million new infections annually, resulting in at least 
one million deaths among which many children. The causative agents are protozoan 
parasites from the genus Plasmodia. In particular the most virulent Plasmodium 
falciparum is the main responsible for the infection in humans. Development of strains 
resistant against almost all the existing anti-malarial drugs, especially against 
chloroquine, is rapidly growing and also the spread of vectors resistant to insecticides is 
rising. Moreover, useful vaccines are not yet available. These facts cause an increasing 
need to find new drug candidates, which are effective towards the causative parasite 
Plasmodium falciparum and, in particular, which hit different targets from those 
considered by currently used anti-malarial therapies. 
Plasmodial metabolic pathways that are either absent in humans, or at least very 
different, constitute good targets for selective anti-malarial therapies with a reduced risk 
of side effects. One of these approaches consists in exploiting the unusual dependence 
of Plasmodium on the glycolytic pathway, which is normally absent in human hosts. As 
a matter of fact, during its asexual erythrocytic cycle, that is, the portion of the parasite 
life cycle found in infected humans responsible for malarial symptoms, the parasite 
lacks a functional Krebs cycle. In this phase, its main source of ATP is the anaerobic 
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fermentation of glucose to lactate, consequently exhibiting levels of glucose 
consumption about 30-50-fold higher than that occurring in host human cells, producing 
high quantities of L-lactate [44, 45]. Hence, its lactate dehydrogenase isoform, (pfLDH) 
[46], which plays the essential role of regenerating NAD+ needed for the continuity of 
the glycolytic cycle, is considered as the key enzyme in the parasite energy supply, 
constituting a potential drug target. Inhibition of pfLDH is expected to block ATP 
production and, consequently, to cause parasite death. However, due to the almost 
complete dependence for ATP production from glucose metabolism, many enzymes of 
the entire glycolytic pathway are expressed at high levels in the parasite compared with 
the host cells, and could be then considered as additional potential drug targets. This 
approach against the Plasmodium provides a potentially innovative strategy in the field 
of anti-malarial drugs and several authors have already considered pfLDH inhibition as 
a new valuable way of causing mortality of the parasite. 
 
3.3.2. Unique features of pfLDH 
One of the well-known difficulties in the search for an ideal drug candidate able to 
block energy production in the Plasmodium is the selectivity for pfLDH compared with 
human LDHs (hLDHs). Fortunately, pfLDH has several structural features that 
distinguish it from the human homologues, so that such peculiarities may be used to 
selectively block the parasite cell cycle without damaging the host. pfLDH is a 316 
amino acid protein coded by a single gene on chromosome 13. Beyond the several 
features that the parasite and the human enzymes have in common, there are some 
significant differences between them. As regards the similarity, pfLDH has the same 
overall “Rossmann fold” topology observed in other mammalian LDHs. It also displays 
high similarity in the primary structure, and the essential catalytic residues Arg109, 
Asp168, Arg171 and His195, implicated in substrate and coenzyme binding, are well 
conserved [47]. However, overlapping the crystal structures of both pfLDH and hLDHs, 
two key differences were observed, involving both the cofactor and substrate sites. The 
positioning of the NADH cofactor is slightly different between these isoforms, because 
of changes in the amino acid sequence in the cofactor binding pocket. A 
superimposition of the two catalytic sites shows the displacement of the cofactor 
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nicotinamide ring by about 1.2 Å in pfLDH compared to human LDHs and other 
mammalian isoforms [22]. This shift can be explained by considering that human 
Ser163, a widely conserved residue among hLDH isoforms, is replaced by a leucine in 
pfLDH. Consequently, hydrogen bonding between the OH of serine and the amide 
group of nicotinamide is no longer possible in the parasite, and the more hydrophobic 
side chain of leucine in pfLDH is buried into the core of the protein, thus altering the 
conformation of this region.  
It was also observed that a change occurs both in the sequence and in the secondary 
structure of a mobile loop region, called the substrate specificity loop, which closes 
down on the active site during catalysis, helping to define the catalytic site. This loop 
includes residues from 98 to 110 in human H and M isoforms and possesses a quite 
highly conserved sequence in all other known LDHs, with the exception of pfLDH, 
where not only is the sequence different, but there is also a five residue insertion 
immediately in front of the conserved catalytic residue Arg109, from residues 104 to 
108 (104DKEWN108), which forms an extended specificity loop that bulges away from 
the protein surface, thus forming a distinctive cavity adjacent to the catalytic site 
possessing a cleft-shape (Fig. 3.11). These changes result in a larger volume of the 
active site in pfLDH relative to its human counterparts, which may constitute a further 
advantage when designing selective inhibitors for the parasite isoform. 
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Figure 3.11. Comparison between LDH-A (A, pdb code 1I10) and pfLDH (B, pdb code 1LDG). The substrate 
specificity loop (residues 98-110) is highlighted in black in both structures. Oxamate and NADH are reported 
as reference structures. 
 
Other differences are found in: a) the N-terminus, which turns out to be more 
extended in human LDH, and wraps around adjacent subunits; b) in the structure of the 
antigenic loop (residues 205-221). Furthermore, the most significant modifications of 
residues that are present in the binding site of all known LDHs, but are not conserved in 
pfLDH are: 1) a neutral Gln102, which contributes to define the active site, is replaced 
by a positively charged lysine; 2) Ile250, with its hydrophobic side chain stacking 
against the nicotinamide ring, is substituted by a proline; 3) Thr246, adjacent to both the 
nicotinamide group and the substrate site, is replaced again by a proline; 4) finally, an 
asparagine is present in the place of the conserved anionic Asp197 in the active site 
[22]. 
pfLDH possesses also unique kinetic properties when compared to other isoforms. 
For example, mammalian LDH is inhibited by the substrate pyruvate and by the tight 
complex formed by pyruvate and NAD+, whereas pfLDH is only weakly sensible to 
inhibition by the substrate and the pyruvate-NAD+ complex.  
Cofactor selectivity also reflects the changes in the pfLDH active site. For example, 
it is well established that a variety of NAD+ analogs with chemical modifications at the 
3-position of the pyridine ring can be used as cofactors by LDHs, with no relevant 
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differences between pfLDH and human isoforms in discriminating these cofactors. 
Nevertheless, the NADH analogue APADH (3-acetylpyridine adenine dinucleotide) 
displays some relevant differences between the parasite and the mammalian isoforms. In 
fact, when APAD+ replaces NAD+, pfLDH increases its Kcat and its catalytic efficiency 
is several hundred fold higher. Since loop closure is the rate-limiting step, this loop 
movement for pfLDH is faster when APAD+ is bound to the enzyme than when NAD+ 
is present. On the other hand, APAD+ proved to be a poor cofactor for the two human 
isoforms LDH-A and LDH-B. This may be due to the fact that the replacement of the 
carboxamide moiety of NADH with an acetyl group in APADH disrupts the hydrogen-
bonding network normally occurring with Ser163 present in human LDHs (Fig. 3.12). 
On the contrary, in the parasite this H bond is not present, and the remainder of the 
cofactor binding site adapts to favour binding of both NADH and APADH [48]. 
 
 
Figure 3.12. Differences in the interactions between human (hLDH) or plasmodial (pfLDH) LDH and the two 
cofactors NADH and APADH are schematically represented. a) the carboxamide group of NADH interacts 
only with hLDH through a hydrogen bond with the hydroxyl of Ser163; b) the methyl group of APADH is 
unable to establish this interaction.  
 
These structural diversities, as well as the kinetic differences, observed between the 
human and malarial LDH constitute the basis for a possible development of selective 
pfLDH inhibitors. In addition, the observation that LDHs from four Plasmodium species 
(pfLDH, pvLDH, poLDH, pmLDH) possess a high degree of structural similarity 
supports the idea that inhibitors which are effective against multiple parasite species is a 
real possibility [31, 49, 50]. 
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3.4. LDH INHIBITORS - BACKGROUND 
 
3.4.1. Perspective therapeutic applications [51] 
The roles of human LDH-A in cancer progression and that of pfLDH in Plasmodium 
survival discussed above confer a validation to these two enzymes as promising 
therapeutic targets in the treatment of hypoxic tumours and malaria, respectively. 
Nowadays, more progresses has been made on pfLDH as anti-malaria target, whereas 
LDH-A is a more innovative tumor target, since research efforts in this direction are still 
at an early stage. In fact, many small organic molecules have been synthesized in 
attempts to inhibit pfLDH and, consequently, causing Plasmodium Falciparum death 
[30-33]. On the contrary, until the discovery of the relationship between LDH-A activity 
and the “Warburg effect” by Leder et al. in 2006 [35], LDH-A had not been seen as a 
possible target in the treatment of cancer. At the moment, genetic inhibition of LDH-A 
through shRNA remains the most selective way of interfering with LDH-A catalytic 
activity and still no reports about small organic molecules able to reverse the “Warburg 
effect” by inhibiting LDH-A are present in the literature, to the best of our knowledge. 
A restricted number of examples of unspecific inhibitors of human isoforms, showed 
good levels of inhibition of LDH-X and, therefore, may be considered for the 
development of male contraceptive drugs [37]. 
In this chapter, we provide an overview of the most important class of inhibitors of 
pfLDH and LDH-A in an attempt to delineate the most important structural features 
needed to interact with this class of isozymes, and to find whether there are selective 
lead structures to be subsequently functionalized and developed. All the molecules 
herein reported were initially designed and synthesized in the search for antimalarial 
drugs, but also tested on other mammalian isoforms in order to detect their degree of 
selectivity. 
 
3.4.2. Gossypol and its derivatives 
Gossypol (“Gossyp” from its Gossypium origin, the cotton plant, and “ol” from its 
phenolic nature) is a polyphenolic binaphthyl disesquiterpene compound. It exists as 
two optically active forms generated by atropisomerism that originates from the reduced 
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rotation ability about the C2-C2’ binaphtalenic bond (3.7, Fig. 3.13). It is usually 
extracted from the cotton seeds belonging to the Gossypium species and the tropical tree 
Thespesia populnea, both of which are members of the Malvaceae family [52]. It was 
isolated for the first time in 1886 during cottonseed oil refinement as a mixture 
containing other molecules, but the chemical structure was unequivocally established 
only in 1938 as a consequence of its physical and chemical properties [53]. In the cotton 
plan, its biosynthesis occurs via dimerization of hemigossypol and plays the role of 
rendering the plant resistant to various kinds of pathogens and insects, acting as a 
natural insecticide together with other sesquiterpenoids present inside the plant [54]. 
 
 
Figure 3.13. Structure of gossypol (3.7). 
 
Gossypol has initially received a great deal of attention for its potential therapeutic 
application as a male antifertility agent, thanks to its spermicidal action [55, 56]. Later, 
further promising biological properties of gossypol were found, such as antitumour, 
antioxidant, antiviral, and antiparasitic activities [57]. In particular, among its numerous 
biological activities, the antiparasitic effect against the malarial parasite Plasmodium 
Falciparum is considered as one of the most interesting activities. The main problem 
that has stopped any further development is the gossypol general toxicity, leading to 
cardiac arrhythmias, hypokalemia, renal failure, muscle weakness, fatigue and, in some 
cases, even paralysis [58-60]. One of the structural reasons for the unspecific toxicity of 
gossypol may lie in the presence of two functional aldehyde groups. These groups can 
easily bind primary amino groups belonging to lysine residues of biological important 
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proteins, leading to the formation of stable Schiff’s bases and, consequently, affecting 
the activity of many enzymes [61]. 
Gossypol preferentially acts on redox reactions catalyzed by NAD+/NADH-based 
enzymes such as many dehydrogenases, which possess a common structural homology 
showing the typical dinucleotide “Rossmann fold”. This evidence is also confirmed by 
the fact that most of the biological activities of gossypol may result from inhibition of 
several of these dehydrogenases. For example, its antifertility action has been mainly 
attributed to inhibition of LDH-C4 [37, 62], its antitumour activity in some cell lines 
seems due to the action on LDH-A [63] and especially the antimalarial activity is 
provoked via the inhibition of pfLDH, which are all NAD+/NADH-linked enzymes. As 
a consequence, gossypol is generally considered a non-selective competitive inhibitor of 
LDH relative to NADH (Table 3.1) [61]. 
 
Table 3.1. Activity profile of gossypol (3.7). 
 
Cpd Ki (μM) pfLDH 
Ki (μM) 
LDH-A 
Ki (μM) 
LDH-B 
Ki (μM) 
LDH-C 
3.7 0.7a 1.9a 1.4a 4.2b 
 
a Data from ref. [48]; b data from ref. [37]. 
 
Unluckily, the above-mentioned toxicity of gossypol precludes its direct use as a 
therapeutic agent. For this reason, many derivatives or analogs of gossypol that do not 
retain the aldehyde functional groups were prepared in order to verify if the resulting 
compounds were able to maintain the beneficial biological activities of gossypol, with a 
reduction of its toxic side effects. However, the possibility of obtaining derivatives by 
direct modifications of gossypol aldehyde groups has been limited because of the 
presence of the phenolic hydroxyl groups in the 1 and 1’ (peri) positions, that 
complicate the chemistry of the CHO groups at the 8 and 8’ positions. As a 
consequence, in many derivatives obtained by synthetic transformations of gossypol the 
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1,1’-hydroxyl groups are absent [31, 37], acylated [30] or incorporated into the 
functional groups replacing the aldehydes [48]. 
Initially, some gossypol analogs were prepared and tested for other purposes, such 
as inhibition of aldose reductase [64] or anti-HIV activity [65, 66]. More recently, in 
most cases, gossypol derivatives were designed as new potential antimalarial drugs (Fig. 
3.14). However, the pfLDH inhibition is often accompanied by a comparable inhibitory 
action on other LDH isoforms, especially the human ones, because of their low 
selectivity [30, 31]. 
In the series of peri-acylated gossylic nitriles (compounds 3.8-3.11, Fig. 3.14, Table 
3.2), the aldehyde groups are converted into nitriles and also the peri (1 and 1’) 
hydroxyl groups are derivatized through acylation (R1 = acyl group) in order to stabilize 
the nitrile derivatives; free ortho and meta phenolic hydroxyls groups are instead 
present [30]. Compounds 3.8-3.11 were evaluated in enzymatic inhibition assays against 
pfLDH (Table 3.2). They were also evaluated in vitro for antimalarial activities against 
both chloroquine-sensitive and chloroquine-resistant strains of Plasmodium Falciparum 
(data not shown in the table). All the inhibition values show a particular pattern 
according to the length of the acyl-substituent: the activity substantially increases with 
the length of the peri-acyl group, with the propionylated derivative 3.11 displaying the 
lowest Ki (0.3 μM). All the experimental data are in agreement with the assumption that 
peri-acylated gossylic nitriles are competitive inhibitors of NADH binding to pfLDH. 
However, inhibition values do not show any significant improvements over gossypol 
(Table 3.1). 
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Figure 3.14. Structures of gossypol derivatives and analogs: peri-acylated gossylic nitriles (compounds 3.8-
3.11), derivatives of 8-deoxyhemigossylic acid (3.12-3.25), 1,1’-dideoxygossylic acid (3.26), gossylic 
lactones (3.27-3.28). 
 
Table 3.2. Peri-acylated gossylic nitriles (3.8-3.11).a 
Cpd R1 Ki (μM) pfLDH 
3.8 
 
0.8 
3.9 
 
1.1 
3.10 
 
0.6 
3.11 0.3 
 
 
a Data from ref. [30]. 
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Another group of gossypol analogs (compounds 3.13-3.25, Fig. 3.14, Table 3.3) is 
structurally related to the sesquiterpene 8-deoxyhemigossylic acid (2,3-dihydroxy-6-
methyl-4-(1-methylethyl)-1-naphtoic acid) 3.12 (Table 3.3) [31, 37]. The aim of the 
design of these substituted 2,3-dihydroxy-1-naphtoic acids was to test the role of the 
alkyl group in the 4-position (R2) of the 8-deoxyhemigossylic scaffold, replacing the 
isopropyl group with a methyl or a n-propyl substituent (3.13-3.18) and contemporarily 
to analyze the role of the substituent in the 7-position (R3), which is the coupling 
position in the formation of disesquiterpenes like gossypol itself (3.19-3.25). All these 
molecules compete with NADH cofactor for binding both to pfLDH and human LDHs. 
The reference compound 8-deoxyhemigossylic acid 3.12 is an equally potent inhibitor 
of pfLDH and LDH-A (Ki of 2 and 3 μM, respectively), but shows a 30-fold higher Ki 
value for LDH-B (91 μM), whereas its dimer 1,1’-dideoxygossylic acid 3.26 (Table 3.4) 
is non-selective in the inhibition of all these three isoforms with very similar Ki values 
in the low micromolar range. Thus, if the dimerization of 3.12 increases activity only on 
LDH-B and 3.12 and its dimer 3.26 show similar inhibitory abilities against LDH-A and 
pfLDH, it seems that only half of the gossypol backbone is necessary for the inhibition 
of LDH-A and pfLDH. For this reason, it was investigated if addition of groups at the 7-
position, the coupling position in the gossypol derivatives, has any effect on the 
inhibitory properties. It is interesting to note that the introduction of a benzyl group in 
the 7-position (compound 3.20) determined a strong inhibition of human isoforms A 
and B, but not of malarial enzyme, compared with the reference structure, whereas the 
introduction of a substituted benzyl group completely changed this pattern. For 
example, the p-(trifluoromethyl)benzyl derivative 3.21 is more active against pfLDH 
than human LDHs, showing selectivity for the malarial enzyme. As regards 
modification in the 4-position (R2), compounds 3.13-3.15 possessing a methyl group in 
this position are selective for pfLDH and LDH-A, with improvements in their inhibitory 
properties for all the three LDHs when a large group such as a benzyl is present in the 7-
position (compound 3.15). Among the 4-isopropyl-substituted derivatives 3.19-3.25, 
compound 3.24, substituted in the 7-position with a p-tolylbenzyl group, is the most 
active, showing a high activity and selectivity for LDH-A (Ki = 30 nM). In summary, 
substituents at both the 4- and the 7-position are important in determining potency and 
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selectivity for this class of inhibitors. The p-(trifluoromethyl)benzyl derivative 3.21 
shows that the development of selective pfLDH inhibitors is possible. Moreover, even a 
certain degree of selectivity for LDH-A over LDH-B is showed by many compounds 
belonging to the 2,3-dihydroxy-1-naphtoic acid family, such as derivatives 3.22-3.25, in 
spite of the high similarities of the two human isoforms. 
 
Table 3.3. 2,3-Dihydroxy-1-naphtoic acids (3.12-3.25). 
Cpd R2 R3 Ki (μM) pfLDH 
Ki (μM) 
LDH-A 
Ki (μM) 
LDH-B 
3.12a 
  
2 3 91 
3.13a   22 34 >250 
3.14a   13 4 190 
3.15a  
 
8 0.5 39 
3.16a   6 1 49 
3.17a   0.1 0.1 19 
3.18a   
0.3 0.05 1 
3.19a 
  
1 2 78 
3.20a 
  
0.7 0.2 7 
 
 
Chapter 3 
85 
 
3.21a 
 
0.2 13 81 
3.22b 
 
n.t.c 3 >125 
3.23b 
 
n.t. 0.2 34 
3.24b 
 
n.t. 0.03 8 
3.25b 
  
n.t. 1 8 
 
 
a Data from ref. [31]; b data from ref. [37]; c n.t. = not tested. 
 
Table 3.4. Activity profile of 1,1’-dideoxygossylic acid (3.26).a 
 
HO
HO
OHO
2
Cpd Ki (μM) pfLDH 
Ki (μM) 
LDH-A 
Ki (μM) 
LDH-B 
3.26 1.2 1.3 0.7 
 
a Data from ref. [48]. 
 
Subsequently, compound 3.18 (called FX11 by Le et al.) was further selected as a 
candidate small organic molecule LDH-A inhibitor of the dihydroxynaphtoic acid 
group, due to its ability to inhibit preferentially LDH-A as opposed to the malarial and 
B isoform (Table 3.3) [67]. It was retested on the purified human liver LDH-A showing 
a Ki values of 8 μM. Furthermore, it was demonstrated that FX11 affects cellular energy 
supply significantly, diminishing cellular production of lactate, by targeting LDH-A. 
FX11 proved to be the first compound up to now able to reduce tumour growth in 
tumour cells that are dependant on glycolysis and in xenograft models, supporting the 
essential role of LDH-A in tumorigenesis and tumour maintenance. Although these 
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encouraging results, the highly reactive cathecolic structure of FX11 could contribute to 
its biological activity by means of off-target effects, making this compound unsuitable 
as drug. 
Other two compounds that can be included in the gossypol-like series are lactone 
3.27 and iminolactone 3.28 (Fig. 3.14, Table 3.5). They were considered as antimalarial 
agents thanks to their good abilities to inhibit pfLDH [48, 68], although they were 
initially studied as anti-HIV agents [65, 66] or aldose reductase inhibitors [64]. 
Unfortunately, gossylic lactone 3.27 is completely non selective, whereas gossylic 
iminolactone 3.28, that differs from gossylic lactone 3.27 only for a nitrogen/oxygen 
atom exchange, is generally less active than 3.27 against pfLDH (40-fold reduction) and 
against LDH-B (230-fold reduction); it keeps a good activity on LDH-A with a Ki of 2.5 
μM and is more selective for LDH-A than its lactone analogue (Table 3.5). 
 
Table 3.5. Gossylic lactone and iminolactone (3.27-3.28).a 
Cpd X Ki (μM) pfLDH 
Ki (μM) 
LDH-A 
Ki (μM) 
LDH-B 
3.27  0.4 0.6 0.4 
3.28  16 2.5 92 
 
 
a Data from ref. [48]. 
 
The low selectivity of many gossypol derivatives and analogs in the inhibition of a 
particular LDH isoform is in agreement with the ability of these classes of compounds 
of inhibiting various kinds of dehydrogenases, that may contribute to a wide range of 
side effects. Nevertheless, in spite of the high homology between enzymes belonging to 
the dehydrogenase family, some of these dihydroxynaphtoic acids proved to be able to 
discriminate LDH-A, LDH-B and pfLDH. This observation enhances the chances of 
developing potent and selective LDH inhibitors structurally related to gossypol. 
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3.4.3. Naphthoic acids 
A further noteworthy class of LDH inhibitors is the naphthoic acid family, 
characterized by a simple naphthalene scaffold substituted by carboxylic acid or 
sulphonic acid groups [69]. As previously demonstrated, the pharmacophore core of 
gossypol is a naphthalene bicycle substituted in various positions with different 
functional groups (like hydroxyls, carboxyls). Consequently, starting from this 
consideration, some commercially available compounds containing the naphthalene 
moiety as central scaffold were selected (compounds 3.29-3.34, Table 3.6) in order to 
determine the inhibitory ability of molecules possessing this kind of scaffold on both 
pfLDH and human LDHs. Unfortunately, these compounds are very modest LDH 
inhibitors, showing IC50 values in the millimolar range. These biological data raise the 
question as to whether strong simplifications of gossypol structure can be detrimental 
for anti-LDH activity. However, some of these compounds inhibit preferentially pfLDH 
(compounds 3.33-3.34), whereas others (3.29-3.30) show some preference for hLDHs. 
The crystal structures of three enzyme-inhibitor complexes highlight two different 
binding modes for this naphtoic acids in the pfLDH active site. Compounds 3.30 (2,6-
naphtalene disulphonic acid, simply called NDSA) and 3.32 (3,7-dihydroxy 
naphthalene-2-carboxylic acid, DHNCA) lie vertically in the active site, in a manner 
similar to pyruvate: in this position, the sulphonate of 3.30 and the carboxylate of 3.32 
are able to establish charged hydrogen bonds with Arg171 and, possibly, a weak 
hydrogen bond with His195, while the two hydroxyls of 3.32 and the second sulphonate 
group of 3.30 interact with the backbone carbonyl group of Pro246, via a water-
mediated hydrogen bond. This positioning is reinforced through van der Waals contacts 
that the naphthalene moiety establishes in the hydrophobic groove that it occupies. The 
second type of binding mode is showed by the horizontal position assumed by 
compound 3.29 (2,6-naphtalenedicarboxylic acid, NDCA) in the active site, bridging the 
cofactor and the substrate binding sites. One carboxylate takes part in a charged 
hydrogen bond with His195 and two water-mediated contacts with Arg171, while the 
other carboxylate interacts with the backbone nitrogen of Ile31 via a hydrogen bond. In 
addition, Ser245 which is present only in pfLDH, permits the formation of several 
water-mediated interactions. The naphthalene ring is located in a hydrophobic pocket 
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that seems like a cleft, mainly delimited by residues unique to pfLDH, such as Pro246, 
Tyr247 and Pro250 (Thr, Ser and Ile respectively, in human).  
 
Table 3.6. Naphtoic acids (3.29-3.34).a 
Cpd R1 R2 R3 R4 R5 R6 
IC50 (mM) 
pfLDH 
IC50 (mM) 
hLDHb 
3.29      5.1 1.4 
3.30       21 9.8 
3.31 
 
     0.52 1.1 
3.32       2.4 5.0 
3.33       1.7 150 
3.34   Br     0.31 5.9 
 
 
a Data from ref. [68]; b unspecified human LDH isoform used. 
 
In this section it is worth mentioning 6,6’-dithiodinicotinic acid 3.35 (Table 3.7) 
[69], which is somewhat different from the naphtoic acid derivatives for two structural 
characteristics: a disulphur linker that separates the two aromatic rings and two pyridine 
rings in the place of a pair of fused phenyl rings. Compound 3.35 is non-selective in its 
inhibition of pfLDH and hLDH, showing comparably poor IC50 values in the millimolar 
range. 
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Table 3.7. Activity profile of 6,6’-dithiodinicotinic acid (3.35).a 
 
N
S
S
N OH
O
HO
O  
Cpd IC50 (mM) pfLDH 
IC50 (mM) 
hLDHa 
3.35 6.6 4.6 
 
a Data from ref. [68]; a unspecified human LDH isoform used. 
 
3.4.4. N-Substituted oxamic acids 
Oxamic acid (3.36, Fig. 3.15, Table 3.8), a structural isoster of pyruvic acid, 
represents a well-known substrate-like inhibitor of LDHs and, consequently, it is 
competitive with the pyruvate substrate binding. Both human LDH structures (LDH-A 
and LDH-B) [23] and pfLDH were crystallized as ternary complexes in the presence of 
the NADH cofactor and 3.36 [22]. Oxamate has attracted a great deal of attention thanks 
to its better inhibition properties against pfLDH than human LDHs, raising the question 
whether the development of selective inhibitors related to the oxamate moiety was 
possible. 
 
HO
NH2
O
O
3.36  
Figure 3.15. Structure of oxamic acid (3.36). 
 
A first series of N-substituted oxamic acids 3.37-3.45 (Table 3.8), which show a 
competitive inhibition with the pyruvate binding site, was synthesized and tested against 
human LDH-A, -B and -C [37]. The intent was to determine if structural modifications 
of the oxamic acid scaffold, such as the introduction of rather simple aryl and alkyl 
groups on the nitrogen of the oxamate amide group, allowed the development of 
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selective inhibitors. Unluckily, this class did not prove to be very promising on any of 
the human isoforms LDH-A/C since the Ki values of these compounds are in the 
millimolar range and are not even very selective (Table 3.8). On the other hand, 
excellent inhibition levels of pfLDH were found with some of these oxamate analogs. In 
particular, N-benzyl derivatives 3.38-3.40, and their higher homologues 3.41 and 3.44 
possessing a slightly longer aliphatic spacer between the nitrogen atom and the phenyl 
ring, all displayed IC50 values in the sub-micromolar range, thus resulting as highly 
selective inhibitors for the parasite isoform over the human subtypes. 
 
Table 3.8. Oxamic acid (3.36) and its derivatives (3.37-3.45) assayed on human, parasite and bovine LDH 
isoforms. 
Cpd R1 
Ki (mM) 
LDH-A 
Ki (mM) 
LDH-B 
Ki (mM) 
LDH-C 
IC50 
(μM) 
pfLDH 
IC50 
(μM) 
mLDHd 
3.36a  - - - 94.4 116 
3.37b 
 
>10 6 >10 - - 
3.38b 
 
0.4 0.4 2 0.08c - 
3.39b 
 
1 0.5 0.3 0.07c - 
3.40b 2 0.5 0.6 0.09c - 
3.41b 
 
7 3 5 0.10c - 
3.42b >10 2 >10 - - 
3.43b 0.8 9 >10 - - 
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3.44b 
 
0.9 0.7 0.7 0.035c - 
3.45b 2 3 0.6 41a 88a 
 
 
a Data from ref. [34]; b data from ref. [37]; c data from ref. [69]; d mLDH = mammalian LDH extracted from 
bovine heart. 
 
Choi and co-workers reported another series of mono- and di- N-substituted oxamic 
acids obtained by an automated synthetic strategy directed to find potential antimalarial 
drugs acting against pfLDH [34]. This library of molecules (compounds 3.46-3.66, 
Table 3.9) was also tested on mammalian LDH (mLDH), extracted from bovine heart, in 
order to see if these oxamic-based structures can be selective pfLDH inhibitors. Most 
oxamic acids show pfLDH selectivities and, in particular, compound 3.55 is the most 
active against pfLDH with an IC50 value of 14 μM, although the highest degree of 
selectivity for the plasmodial enzyme, about 5-fold, is obtained by compound 3.51. 
Some compounds inhibit only mLDH, for example compounds 3.59 and 3.61, showing 
a high selectivity for the mammalian isoform. Compound 3.52 is the most active 
inhibitor of mammalian dehydrogenase of this series with an IC50 value of 20 μM, 
although it also inhibit pfLDH (IC50 = 59 μM). Observing the inhibition values within 
this class, we can assert that oxamic acids that are disubstituted on the nitrogen atom 
with bulky groups (for example 3.47) are generally less active on both enzymes than the 
other compounds, maybe due to the steric hindrance that makes the entrance of these 
molecules in the active site difficult. This consideration is confirmed by the fact that the 
most active compounds 3.55 and 3.57 on both dehydrogenases have small groups on the 
oxamate nitrogen atom (R1 = H and R2 = small alkyl ethers). The binding mode of this 
class of compounds was supported by molecular docking studies on pfLDH showing 
that oxamic acid and its derivatives interact similarly with catalytical residues of the 
enzyme, with some differences caused by the presence of additional groups on the 
nitrogen atom. These substituents occupy part of the NADH binding site by establishing 
new interactions, that could explain why, for example, compound 3.55 is more active 
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than 3.57. In fact compound 3.55, which differs from 3.57 only by a methylene group 
less in the ether chain, reaches and establishes a hydrogen bond with Asn140, which is 
near the hydroxyl of NADH ribosyl moiety, whereas the longer ether side chain of 
compound 3.57 cannot interact with this residue in the same way. Compound 3.64 
positions its two phenyl rings near both the nicotinamide and ribosyl rings of the 
cofactor and Leu163, which is a residue unique to pfLDH (in human it is replaced by a 
serine). Usually, Leu163 establishes a H-bond between its amide oxygen atom and the 
amide group of the NADH nicotinamide moiety. As a consequence, the perspective 
introduction of a hydrogen bond donor on one of the two phenyl groups of compound 
3.64 is expected to improve pfLDH selectivity [34], supporting the idea that the 
exploitation of structural features exclusive of pfLDH is the best strategy to obtain 
selective inhibitors as anti-malarial drugs.  
 
Table 3.9. Oxamic acid derivatives (3.46-3.66) assayed on parasite and bovine LDH isoforms.a 
Cpd R1 R2 IC50 (μM) pfLDH 
IC50 (μM) 
mLDHb 
3.46 
CH3
97.9 107 
3.47 
  
>200 158 
3.48   160 >200 
3.49  
 
>200 150 
3.50  
 
>200 186 
3.51  43 >200 
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3.52  59 20 
3.53 169 46 
3.54 101 59 
3.55   14 25 
3.56   
47 133 
3.57   
43 31 
3.58   88 >200 
3.59 
 
>200 32 
3.60  
 
>200 168 
3.61 >200 43 
3.62  
 
157 >200 
3.63  188 >200 
3.64  35 90 
3.65  146 >200 
3.66  51 >200 
 
 
a Data from ref. [34] b mLDH = mammalian LDH extracted from bovine heart. 
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A series of larger oxamic acid derivatives containing a chromene portion (3.67-3.71, 
Table 3.10) was designed with the principal aim of inhibiting pfLDH, by means of 
compounds that mimic the shape of the bioactive conformation of the NADH cofactor, 
in an attempt to fill both the substrate and the cofactor binding sites and, consequently, 
to improve the inhibitory activities in comparison with the previous class of substituted 
oxamic acids [32]. The chromene group was considered as a suitable replacement of the 
diphosphate moiety of NADH, possessing a greater rigidity and hydrophobicity than the 
diphosphate group. This group was also chosen in view of its easy synthetic 
accessibility. The chromene moiety, connected covalently to the nitrogen of the 
oxamate portion through an aryl-alkyl linker, generally showed a binding mode similar 
to that of the NADH phosphate group, possessing hydrogen bonding acceptor portions 
(OH and C=O) comparable to oxygen atoms of the phosphate group. Moreover, the N-
aryl group directly linked to the oxamic acid is a good mimic of the nicotinamide ring 
of the cofactor. This observation suggests that the substituted oxamate moiety and the 
chromene group together may constitute a scaffold that can bind to almost the entire 
LDH active site. These compounds were tested against pfLDH, and also, for 
comparison, against mammalian LDH (mLDH) extracted from bovine heart. In addition, 
it was observed a certain degree of inhibition even on malate dehydrogenase (MDH) 
(data not shown in the table), a very important enzyme in glucose metabolism of 
Plasmodium Falciparum, which may substitute pfLDH when this enzyme is blocked. 
This dual enzyme inhibition might increase the ability of oxamic derivatives to block 
ATP production in the parasite. Similarly to simple oxamic acid 3.36, some of these 
derivatives show good levels of pfLDH selectivity over mLDH (Table 3.10). It is 
evident that the presence of a second COOH group on the chromene terminal moiety 
(3.67, 3.68) is detrimental for the inhibitory potency, whereas amide analogs (3.69-3.71) 
generally show very good inhibitory properties against pfLDH. Compound 3.71 is the 
most potent and selective, as well as its structurally related analogs 3.69 and 3.70. The 
ortho-substituent to the N-oxamic acid (R1) has a marked influence on the inhibition. In 
fact, the introduction of a methoxy group in that position causes an improvement of the 
inhibitory activity against pfLDH (compare 3.71 to 3.69), whereas a cyano group causes 
a slight decrease in inhibitory potency (3.70). This result can be explained by the 
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replacement of human Ser163 with plasmodial Leu163 and the consequence that this 
substitution provokes. The hydrogen bond between the hydroxyl of Ser163 present in 
human LDHs and the amide of the nicotinamide ring is impossible in pfLDH, where no 
H-bond takes place on Leu163. Ortho-substituents (R1) are positioned near to pfLeu163, 
in close proximity to the amide group of the cofactor nicotinamide ring. As a 
consequence, the introduction of groups able to act as H-bond acceptors, such as a 
methoxy, in the ortho position (3.71) improves the activity and the selectivity of this 
class of compounds for pfLDH. Molecular docking studies confirmed that compounds 
3.69 and 3.71 bind in the same way in both the cofactor and the substrate binding sites, 
establishing hydrogen bonds with catalytical residues and with amino acids delineating 
the cofactor binding site. 
 
Table 3.10. Chromene-based oxamic acids (3.67-3.71).a 
 
Cpd R1 R2 n IC50 (μM) pfLDH  
IC50 (μM) 
mLDHb 
3.67   1 87.3 >232 
3.68   2 191 >225 
3.69  
 
2 3.13 >187 
3.70  
 
2 8.25 >179 
3.71  
 
2 1.75 11.4 
 
 
a Data from ref. [32]; b mLDH = mammalian LDH extracted from bovine heart. 
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3.4.5. Azole-based compounds  
Another important class in the field of anti-LDH drugs is constituted by the azole-
based inhibitors (Fig. 3.16) [33]. They were identified in a high throughput enzymatic 
screening with the aim of finding antimalarial drugs, but, as it often happened for other 
classes of LDH inhibitors, they showed inhibitory properties against both pfLDH and 
hLDHs. However, some of them possess good levels of pfLDH selectivity, by inhibiting 
preferentially this isoform at low micromolar concentrations. The active compounds are 
mixed competitive inhibitors towards both NADH and pyruvate and are competitive 
against lactate. These compounds were also tested in vitro against drug-sensitive and 
drug-resistant strains of Plasmodium Falciparum, showing IC50 values in agreement 
with those obtained in enzymatic assays. In details, four parent kinds of azole-based 
compounds were identified with a common pharmacophoric portion: a hydroxyl and a 
carboxyl moieties in adjacent positions, that are 3 and 4 positions of the azole ring (Fig. 
3.16). 
 
 
Figure 3.16. General chemical structures of 1,2 or 1,5-isoxazole, 1,2,5-oxadiazole, 1,2,5-thiadiazole and 
triazole classes [33]. 
 
For each class, derivatives with various substituents in the pentacyclic ring were 
synthesized in order to explore structure-activity relationships of the azole class (Table 
3.11). From the IC50 values reported against both pfLDH and hLDH (human heart 
isoform LDH-B), it is evident that C3-hydroxyl and C4-carboxyl are essential for 
activity. Both 1,2- and 1,5-isoxazole scaffolds are active against the parasite isoform, 
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provided they maintain the “OH/COOH” pharmacophoric portion, as in compound 3.72 
and 3.73, respectively, although compound 3.72 showed higher levels of inhibition on 
both pfLDH and hLDH-B than its 1,5-regioisomer 3.73. The data confirmed that vicinal 
OH and COOH groups are fundamental for the inhibitory activity within this class. In 
fact, both methoxy-substituted derivative of 3.72 and its N-CH3 tautomer are inactive, as 
well as its ester analog; the introduction of a small methyl group in position 5 also 
causes a loss of activity on both isoforms (Fig. 3.17). A further confirmation of the strict 
requirement to keep the “OH/COOH” pharmacophoric portion is given by the 1,2,5-
oxadiazole class, since only compound 3.74 displayed inhibitory properties for both 
pfLDH (IC50 = 0.65 μM) and, to a much lesser extent, hLDH-B (IC50 = 72.05 μM). 
 
Table 3.11. Azole-based compounds 3.72-3.75.a 
Cpd Structure IC50 (μM) pfLDH  
IC50 (μM) 
hLDH-B 
3.72 1.1 54 
3.73 16 >100 
3.74 0.65 72.05 
3.75 0.14 10.27 
 
 
a Data from ref. [33]. 
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Figure 3.17. Structural modifications of active azoles (inner circle) leading to inactive inhibitors (outer 
circle). 
 
Similar results were obtained with 1,2,5-thiadiazole derivatives, where the 3-
hydroxy-4-carboxy-substituted derivative 3.75 exhibited an excellent inhibitory potency 
against pfLDH (IC50 = 0.14 μM) with a >70-fold selectivity over the human heart 
isoform. However, also in this case, the replacement of the 3-OH group, with either an 
amino or a methoxy group caused a complete loss of activity (Fig. 3.17). 
These data obtained within the azole classes show that changes of heteroatoms are 
sometimes useful; in fact replacement of the oxygen in position 1 (Y, Fig. 3.16) with a 
sulfur atom gives more potent, but also less selective, pfLDH-inhibitors (compare 3.75 
with 3.74 and 3.72), whereas the replacement of the same oxygen with a nitrogen atom, 
leading to triazoles, is detrimental for activity. In fact, the few examples of OH/COOH-
substituted triazoles reported (Fig. 3.17) did not show any relevant inhibition of pfLDH 
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and hLDH-B, in spite of the fact that the pharmacophoric portion is present in these 
compounds. 
These biological results can be explained by observing the complexes of pfLDH 
with the most active azole derivatives 3.72, 3.74 and 3.75 obtained by X-ray studies: in 
all the cases, the carboxylate group interacts with Arg109 and Arg171 in the active site 
through a bifurcated salt bridge like the substrate pyruvate and, at the same time, the 
hydroxy group establishes a hydrogen bond network with the side chains of Arg109, 
His195 and with the backbone of Leu140 (Fig. 3.18). 
 
HN N
N
H NH2
NH2
H
O
O
HN
H2N NH2
Z
YX
O O
O
CH3
H3C HN
OLeu140
Arg171
H
Arg109
His195
Asp168
 
Figure 3.18. Schematic illustration of the interactions between the “OH/COOH”-substituted azole scaffold 
and the pfLDH active site. Residues directly involved in the interactions are represented. 
 
Moreover, the crystal structures of the enzyme-inhibitor complexes explain the 
pfLDH-selectivity showed by the azole-based compounds. As a matter of fact, the azole 
rings bind in the active site of both LDHs, stacking parallel to the nicotinamide ring of 
the cofactor NADH. In the pfLDH structure complexed to 3.72, 3.74 and 3.75, the 
portion of the azole ring bearing the carboxylic moiety is in close proximity to Ser245 
and Pro246 and the hydroxyl group of Ser245 side chain is hydrogen bonded to the 
oxygen or the sulfur atom at position 1 of the azole ring of the inhibitor via a water 
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molecule. Differently, in the human isoform the oxygen or the sulfur of the azole ring of 
3.72, 3.74 or 3.75 is only bound to a water molecule, and they do not interact with the 
enzyme, because in this case the equivalent residue is a tyrosine (Tyr248) that projects 
away from the inhibitor molecule. The analysis of these complexes suggests that the H-
bond between Ser245 and the heterocyclic atom at position 1 is responsible for the 
selectivity for pfLDH and this hypothesis was also confirmed by site-directed 
mutagenesis studies, performed to change Ser245 to alanine. As a consequence, the 
disposition of the inhibitors in the LDH active site can also explain why even a simple 
methyl group introduced at 5 position of the ring (Fig. 3.17) causes a loss of activity; in 
fact, Pro246 (threonine in human LDH) is located next to the carboxylate function 
leaving very little space for the introduction of a group at position 5 of the ring. 
Initial toxicity and pharmacokinetic studies of these compounds highlight their low 
cytotoxicity and favorable drug-like properties, making them possible candidates as 
antimalarial drugs. However, because of the moderate potency levels displayed by these 
inhibitors, an improvement in their activity is necessary for considering them as 
possible candidates for clinical trials. Furthermore, their relatively small sizes preclude 
their use as selective therapeutic agents, as they may unspecifically interact with several 
biological targets. 
 
3.4.6. Other LDH inhibitors 
In addition to the LDH inhibitor classes reported in the previous sections, other 
examples of compounds endowed with a certain ability of LDH inhibition were 
reported.  
A series of pyridylpyruvates were designed as mimics of the substrate pyruvate. As 
a matter of fact, they contain a pyruvate-like moiety linked to the 4-position of a 
pyridine ring, resembling in part the transition state of the conversion of pyruvate into 
lactate with the involvement of NADH [70]. Among them, compounds 3.76 and 3.77 
resulted active against the muscle isoform of rabbit LDH, showing IC50 values in the 
range of 70-100 μM (Fig. 3.19). 
Chapter 3 
101 
 
 
Figure 3.19. Structures of ethyl 3-(3-cyano-4-pyridyl)pyruvate (3.76) and 3-(3-nitro-4-pyridyl)pyruvic acid 
(3.77). 
 
Spirolactone 3.78 (Fig. 3.20) proved to be a LDH inhibitor non-competitive with 
respect to pyruvate (Ki = 7.5 mM), but competitive with NADH (Ki = 0.3 mM, Ki values 
originated from enzymatic assays on the muscle isoform of rabbit LDH) [71]. This 
molecule was originally synthesized for the therapeutic treatment of lactacidosis, 
together with other aromatic β,γ-unsatured α-ketoacids. The spiro structure is 
completely new in the field of LDH inhibitors. However, this compound possesses a 
latent carboxylate function (lactone), confirming the fundamental role that this 
functional group has in the interaction process with the target enzyme. 
 
O
O
OH
3.78  
Figure 3.20. Structure of 3-hydroxy-2-oxo-1-oxaspiro[4.5]-dec-3-ene (3.78). 
 
Over the past few years, several metal complexes have been evaluated for their anti-
cancer properties. In particular, ruthenium complexes have already been investigated as 
cytotoxic agents [72]. However, their pharmacological mechanism of action remains 
unclear. Trigun et al. reported an example of a ruthenium (II) complex (3.79, Fig. 3.21) 
containing 4-carboxy-N-ethylbenzamide (CNEB) moieties as an inhibitor of hLDH-A 
and, in particular, the cytotoxicity of this complex was demonstrated in Dalton’s 
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lymphoma [73]. Complex 3.79 displays a non-competitive inhibition of LDH activity 
with a Ki value of 32 μM. It was suggested an allosteric inhibition for this complex, 
constituting the first example of a new alternative mechanism of LDH inhibition, never 
reported before for other compounds. 
 
 
Figure 3.21. Structure of CNEB and the empirical composition of Ru(II)-CNEB complex (3.79). 
 
The same authors also developed Cu and Zn-bipyridyl complexes (3.80 and 3.81 
respectively, Fig. 3.22) [74], exploiting the good biocompatibility of copper (Cu2+) and 
zinc (Zn2+), since these two metal ions are present in several proteins and take part to 
many physiological reactions. The evaluation of their interactions with all the five LDH 
isoforms in mouse tissues afforded average binding constants of 1 mM for Cu-bpy 
complex 3.80 and 7 μM for Zn-bpy 3.81. Although Cu-bpy 3.80 proved to be a weaker 
LDH inhibitor than its Zn-based analog 3.81, its inhibition of LDH activity was detected 
in all mouse tissues, unlike the Zn-analog which showed inhibition only in kidney, heart 
and liver. 
 
 
Figure 3.22. Structure of Cu-bpy (3.80) and Zn-bpy (3.81) complexes. bpy = 2,2' bipyridine. 
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3.4.7. Features and perspectives of LDH inhibitors 
The fundamental biological role of LDH in sugar metabolism has been extensively 
studied so far in humans. However, this enzyme has attracted a great deal of attention 
also thanks to its possible involvement as an innovative anti-malarial target. Moreover, 
quite recently, the possibility of a LDH involvement in hypoxic tumour maintenance 
has been confirmed, transforming human isoform-5 (LDH-A) in an even more attractive 
target in the oncology field. These two very interesting roles of hLDH-A and pfLDH 
have been differently exploited as of yet. As a matter of fact, the strategy of inhibiting 
LDH of Plasmodium falciparum in the search for an ideal antimalarial therapy, able to 
overtake the emerging resistance typical of several Plasmodium strains, has been 
followed and, nowadays, interest in pfLDH inhibitors in the field of antimalarial 
research is continuously growing. The risk/benefit ratio in this case depends on the 
selectivity that the inhibitors have for the parasite isoform of the enzyme, so that they do 
not interfere with any of the metabolic pathways of the patient. The synthesis of several 
small organic molecules in order to find a lead candidate against pfLDH shows that, 
unluckily, it is not an easy task to obtain molecules that selectively interact with the 
parasite isoform. Nevertheless, this low selectivity reveals the possibility of developing 
inhibitors of the human A isoform, opening a challenging research line for the discovery 
of new anticancer drugs. In fact, the activity of some compounds on the human A 
isoform was initially discovered as a side effect of pfLDH inhibition. To the best of our 
knowledge, the only application of LDH inhibitors in the anti-cancer treatment is 
represented by a recent patent [75], where well known natural products, such as 
flavonoids and other polyphenols, are reported to inhibit LDH-A. As a therapeutic 
perspective, the selective inhibition of the muscle isoform (LDH-A) overexpressed in 
tumors would guarantee a low toxicity to the patient. In fact, the blockage of this 
enzyme might lead to toxicity only if combined with an intense physical activity, 
otherwise it does not seem to cause any particular side effect in humans [76, 77]. 
The structural similarity shared by most of LDH inhibitors could be the starting 
point from which development of new inhibitors can begin. The features that the 
existing LDH inhibitors have in common are principally the presence in adjacent 
positions of an acidic group, such as carboxylate, lactone or sulphonate, and a hydroxyl 
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or carbonyl moiety. This observation is in agreement with the substrate structures, such 
as those of pyruvate and lactate that are α-ketoacid and α-kydroxyacid, respectively 
(Fig. 3.23), and finds its explanation in the structure of the active site, which is 
characterized by the presence of many polar and basic residues able to establish 
attractive interactions with these molecular portions. On this basis, LDH-inhibitors may 
be classified as lactate-like, if they present an hydroxy-acid motif, which resembles the 
polar portion of lactic acid, or as pyruvate-like, if they have a C=O group directly linked 
to the carboxylate, similarly to what happens in pyruvic acid (Fig. 3.23). 
 
OH
COOH
R
aryl
COOH
H3C
OH
COOH
H3C
O
COOH
N
O
R
HCOOH
O
R
lactate pyruvate
lactate-like inhibitors pyruvate-like inhibitors
 
Figure 3.23. Generic structural features for the two main classes (lactate-like and pyruvate-like) of LDH 
inhibitors. 
 
Moreover, most inhibitors reported so far possess a hydrophobic aromatic scaffold, 
mimicking the NADH cofactor. Hence, a valid strategy for obtaining more potent 
inhibitors could consist in combining substrate-like moieties, possessing a hydroxyl-
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carboxylic pattern, with various kinds of aromatic cycles, which resemble part of the 
cofactor structure. In fact, the most potent inhibitors so far developed occupy both the 
substrate and the cofactor binding sites. The isozyme selectivity may also be improved 
by exploiting the known structural characteristics that distinguish each LDH isoforms, 
although the data as of yet available are not sufficient to provide a valid rationale to 
support this purpose. 
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3.5. N-HYDROXYINDOLES AS LDH-A INHIBITORS 
 
3.5.1. The N-hydroxyindole nucleus in Medicinal Chemistry 
As highlighted in the previous section, all the existing LDH inhibitors have a very 
high similarity in their molecular structure, sharing a carboxylate-hydroxyl/carbonyl 
moiety supported on an aromatic scaffold, so partially mimicking the structures of the 
LDH substrates, lactate or pyruvate. The identification of these pharmacophoric groups 
was the starting point of our search for new LDH-A inhibitors, hence some series of 
OH-COOH substituted aromatic scaffolds were developed during my PhD research 
work. Most of the synthesized compounds possess a N-hydroxyindolic structure (NHI) 
with a carboxylic group in position 2 of the heterocycle (structure NHI, Fig. 3.24) [78]. 
This group of molecules retains the OH-COOH motif observed in the other LDH 
inhibitors, with the difference of the N-OH group that is slightly less acidic than the 
phenol group [79]. 
 
 
Figure 3.24. Structure of N-hydroxyindole-2-carboxylic acid derivatives (generally abbreviated NHI). 
 
N-hydroxyindoles are not only scarcely represented chemical entities in nature, but 
also a relatively new and unexplored class of heterocyclic compounds in the field of 
Medicinal Chemistry.  
Until 1996, there were not examples of N-hydroxyindoles isolated as natural 
products, although it was hypothesized the existence of 1-hydroxytryptophan 
derivatives in living organism, undergoing nucleophilic substitution reactions with 1-
OH as a leaving group for explaining the occurrence of biologically relevant indole-
based molecules such as serotonin, melatonin, trypthophan derivatives etc. (1-
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Hydroxindole Hypotheses) [80]. At last, in 1996, two peptides bearing a 1-
methoxytrypthophan residue in their structures were isolated as natural products: HUN-
7293 3.82, a cyclic heptadepsipeptide from fungal broth which is a potent inhibitor of 
cell adhesion molecule expression [81] and Apicidin 3.83, a cyclic tetrapeptide isolated 
from Fusarium pallidoroseum with antiprotozoal activity against Apicomplexan 
parasites [82, 83], demonstrating the existence in nature of NHI-like structures (Fig. 
3.25). 
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Figure 3.25. Structures of HUN-7293 (3.82) and Apicidin (3.83). 
 
More recently, other natural products containing the NHI unit were discovered such 
as Nocathiacins I, III and IV (3.84-3.86, Fig. 3.26) isolated from bacteria species 
Nocardia and the fungus Amicolaptosis [84-86], and Thiazomycin and Thiazomycin A 
(3.87-3.88, Fig. 3.26) isolated from Amycolatopsis fastidiosa [87], possessing a highly 
substituted NHI moiety within their structure. They all belong to the thiazolyl peptide 
class and they are among the most potent in vivo antibacterial agents known at the 
moment, although their clinical use has been limited by their poor physicochemical 
properties, in particular, by their low aqueous solubility. These discoveries in nature 
increased the interest toward the NHI motif, in particular for the potential application of 
this challenging heterocycle in Medicinal Chemistry. 
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Name R1 R2 R3 
3.84 
 
OH 
 
3.85 
 
OH H 
3.86 H OH 
 
3.87 
 
OH 
 
3.88 
 
OH 
 
  
Figure 3.26. Structures of Nocathiacins I, III and IV (3.84-3.86), Thiazomycin (3.87) and Thiazomycin A 
(3.88). 
 
The almost total absence of NHI structure in Medicinal Chemistry is mainly due to 
the lack of suitable methods for the assembly this scaffold, but also the presumed 
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instability of this organic framework might have contributed to neglect its use in the 
design of bio-relevant molecules. Somei [80, 88] and Acheson [89] were the first who 
showed interest in the synthesis of NHI molecules, succeeding in creating quite simple 
and efficient procedures for their synthesis. Briefly, the best methods discovered by 
Somei are: 1) conversion of 2-nitrotoluene I to enamine II by heating it with N,N-
dimethylformamide dimethylacetal (DMF/DMA) and 1,8-diazabicyclo[5.4.0]undec-7-
ene (DBU), followed by reductive cyclization of the intermediate nitroenamine II with 
titanium chloride or zinc and ammonium chloride to give N-hydroxyindole III; 2) 
oxidation of 2,3-dihydroindoles IV in methanol/water with H2O2 in the presence of a 
catalytic amount of sodium tungstate (Fig. 3.27).  
 
 
Figure 3.27. a) DMF/DMA, DBU; b) TiCl3 or Zn, NH4Cl, H2O/Et2O; c) H2O2 30%, Na2WO4.2H2O, 
H2O/MeOH.  
 
Nevertheless, the instability of the so obtained 1-hydroxyindoles still continued to be 
the main obstacle to their isolation. 1-Hydroxyindole is so reactive, that it has only been 
obtained in solution, polimeryzating to a green powder on attempted isolation. 
Substitutions of the indole nucleus with electron withdrawing or resonance stabilizing 
groups, methylation of the 1-OH group, insertion of bulky groups in position 3 or 
substituents in position 2 able to form hydrogen-bonds with the N-hydroxyl group, are 
all factors that contribute to the increase in stability of the molecule. For this reason, N-
hydroxyindole-2-carboxylic acids (Fig. 3.24) can be readily obtained and isolated, being 
relatively stable thanks to the hydrogen bond between the hydrogen atom of the 1-OH 
group as H-bond donor and the oxygen atom of the 2-carbonyl group as H-bond 
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acceptor or, in the case of its tautomer 3H-indole 1-oxide, which is less representative 
than its non-charged counterpart, between the H atom of the carboxylic group and the 
oxygen of N-O group (Fig. 3.28). 
 
 
Figure 3.28. Intramolecular hydrogen bonds in N-hydroxyindole-2-carboxylic acids. 
 
During the last decade, K.C. Nicolaou has directed his attention to the synthesis of 
substituted N-hydroxyindole-2-carboxylic acids, reporting a new synthetic procedure for 
their construction that was applied to the total synthesis of Nocathiacin I, whose 
structure contains a NHI domain [90-92]. The synthetic scheme adopted by Nicolaou is 
showed in Fig. 3.29. Commercially available nitrotoluene I is alkylated with sodium 
hydride and dimethyl oxalate. Treatment of ketoester II with Eschenmoser’s salt (N,N-
dimethyleneiminium chloride) in the presence of NaH lead to α,β-unsaturated nitroester 
III, which is cyclized using SnCl2 and, then, the so-obtained reactive nitrone IV is 
immediately subjected to 1,5-addition by a nucleophile to afford N-hydroxyindole V 
substituted at the 3-position. 
 
 
Figure 3.29. a) NaH, (COOMe)2, DMF; b) NaH, CH2=NMe2+Cl-, THF; c, d) SnCl2.2H2O, MS 4Å, NuH, 
DME. MS = molecular sieves; NuH = nucleophile; DME = 1,2-dimethoxyethane. 
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A recent paper by Penoni et al. [93] reports a completely new method for NHI 
construction, via a cylcoaddition of nitrosoarenes and alkynes. Anyway, at the present, 
the Nicolaou’s way of synthesis represents the most suitable method to generate N-
hydroxyindoles with a carboxylic group in position 2 of the nucleus. Consequently, we 
followed the Nicolaou’s procedure for the synthesis of our new NHI derivatives, 
making only minor adjustments when necessary. 
 
 
3.6. N-HYDROXYINDOLES SUBSTITUTED WITH SMALL 
GROUPS  
 
3.6.1. Synthesis 
We started to synthesize compounds belonging to NHI class, selecting a series of 
exploratory substituents in order to test if it was possible to obtain satisfactory levels of 
LDH-A inhibition using this scaffold. We chose several small substituents such as 
halogens, methyl, ethyl, cyano, trifluoromethyl and carboxy group and also small 
heterocycles such as tetrazole and oxadiazolone group, that are carboxylic acid isosters. 
Compounds 3.89a-p (Fig. 3.30) were synthesized according to the general synthetic 
procedure showed in Scheme 3.1. Some starting materials were commercially available 
(opportunely substituted o-nitrotoluenes 3.90a-l or 1-ethyl-2-nitrobenzene 3.90m and 1-
nitro-2-propylbenzene 3.90n) and others were appropriately synthesized (3.90o-p, see 
Scheme 3.2). These ortho-alkyl-nitroaryl precursors were alkylated with an excess of 
dimethyl oxalate and sodium hydride in dry DMF at –15 °C to room temperature [91], 
then the so obtained ketoesters 3.91a-n were subjected to a reductive cyclization 
process with stannous chloride dihydrate in the presence of 4Å molecular sieves in 
anhydrous DME to afford methyl ester N-hydroxyindoles 3.92a-n [92], which were 
finally hydrolyzed in the dark with a 2N aqueous solution of litium hydroxide in a 
MeOH/THF mixture, until the disappearance of the precursors on TLC, to give final 
products 3.89a-n [94]. 
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Cpd R1 R2 R3 R4 
3.89aa     
3.89ba     
3.89ca     
3.89da     
3.89ea     
3.89f     
3.89g     
3.89h     
3.89i     
3.89j     
3.89ka     
3.89la     
3.89ma     
3.89na     
3.89o    
3.89p    
  
Figure 3.30. First exploratory N-hydroxyindoles 3.89a-p; a compounds 3.89a-e and 3.89k-n were previously 
synthesized during experimental graduation thesis in the same research laboratory. 
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Scheme 3.1. a) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; b) for 3.91a-n: SnCl2·2H2O, dry DME, 4Å 
MS, 0 °C to RT; for 3.91o-p: H2PO2Na·H2O, Pd-C 10%, H2O/THF (1:1), RT; c) aqueous 2N LiOH, 
THF/MeOH (1:1), RT. 
 
Synthesized precursors 3.90o and 3.90p were submitted to the same synthetic steps 
as compounds 3.90a-n, with the exception of the reductive cyclization reaction (step b 
in Scheme 3.1). In these two cases, the chosen conditions (SnCl2 and DME) did not 
promote only the proper cyclization to build the NHI scaffold, but they also gave a 
mixture of N-hydroxyindole and the over-reduced side product indole. In fact, the over-
reduction of the nitro group to amine (path b, Fig. 3.31) leads to the formation of indole 
and this side reaction is contemporaneous with the reduction to hydroxylamine that 
produces NHI (path a, Fig. 3.31). These mixtures lowered the yields of the cyclization 
step and they were of difficult separation either by crystallization or column 
chromatography, due to the very similar Rf values of the formed products. Anyway, 
NHI and the corresponding indole can be easily detected on TLC, by the typical 
fluorescence of the indole stain visible at the wavelength of 254 nm and by staining the 
TLC with a solution of copper sulfate in a MeOH/water mixture: Cu2+ complexes with 
the N-OH group, resulting in a violet spot on TLC plate which clearly indicates the 
presence of the N-hydroxy compound. For these two substrates we decided to change 
conditions by using sodium hypophosphite monohydrate and catalytic palladium over 
charcoal in a mixture H2O/tetrahydrofuran: this reducing system had already been 
successfully utilized in the past for the selective reduction of nitro-groups to 
hydroxylamines, but it was not used for the preparation of N-hydroxyindole systems 
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like ours. Exploiting this reducing system, we successful got the desired NHI 3.92o-p 
and, in other cases, this method proved to be effective in reducing the amounts of the 
over-reduced side products, when compared to other conditions (see following schemes) 
[95, 96]. Although in most cases the separation of the desired NHI compound from the 
indole analogue, or the use of alternative reaction conditions were successful in 
obtaining the pure product, some compounds, such as for example compounds 3.89g 
and 3.89i, were obtained in mixture with a certain (low) percentage of the correspondent 
indole analogue. Besides, for the ketoester 3.91o-p formation, we doubled the 
equivalents of both sodium hydride and dimethyl oxalate (8 eq of NaH and 10 eq of 
(COOMe)2), due to the presence of the carboxylic acid bioisosters present on the 
molecules which can consume NaH in addition to that needed for the proper 
functionalization of the toluenic methyl groups. 
 
 
Figure 3.31. Mechanism of reductive cyclization (path a) and formation of the indolic by-product (path b). 
 
Chapter 3 
115 
 
As for compound 3.89o-p, precursors 3.90o and 3.90p were respectively prepared 
by a zinc-promoted addition of sodium azide to benzonitrile 3.90j in water [97] and by 
formation of amidoxime 3.93 from benzonitrile 3.90j with hydroxylamine 
hydrochloride and diisopropylethylamine (DIEA) and its subsequent cyclization with 
DBU and 1,1-carbonildiimidazolo (CDI) (Scheme 3.2) [98].While tetrazole is a 
common carboxylic acid bioisostere [99], 1,2,4-oxadiazol-5-one is a less commonly 
used acidic heterocycle, with physico-chemical properties that are slightly different 
from those of the carboxylic group, which may lead to an improved bioavailability of 
compounds bearing this moiety [100]. In spite of these small synthetic problems 
requiring optimizations, the introduction on the NHI nucleus of an additional carboxylic 
group (3.89g) as well as carboxylic acid bioisosteres (3.89o-p) was encouraged by the 
observation of the X-ray structure of the LDH-A active site (see docking sections 
below), which normally hosts the substrate pyruvate or lactate and the cofactor NADH, 
so this cavity is rich in cationic residues such as arginines, which may give rise to 
favourable attractive interactions with deprotonatable groups of perspective inhibitors.  
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Scheme 3.2. a) NaN3, ZnBr2, H2O, reflux; b) DIEA, NH2OH.HCl, abs. EtOH, reflux; c) DBU, CDI, 1,4-
dioxane, reflux. 
 
In the ketoester formation (step a, Scheme 3.1), the colour of the reaction mixture is 
indicative of the progress of the reaction. After a certain time, depending on the 
substrate, it is possible to observe the development of an intense colour, varying from 
Inhibitors of lactate dehydrogenase A 
116 
 
cherry red to violet-blue, due to the deprotonated enolic form of the ketoester III (Fig. 
3.32) that is present in the basic medium of the reaction, and to the possibility of 
delocalizing the negative charge on the substituted phenyl ring. Hence, the development 
of that colour suggests that the formation of the desired product is taking place. 
 
 
Figure 3.32. Mechanism of ketoester formation. 
 
3.6.2. Enzymatic assays 
Methods. All the synthesized compounds were assayed on human LDH-A (as LDH-
5, or LDH-A4) and LDH-B (as LDH-1, or LDH-B4) purified isoforms, by the research 
group of Prof. G. Giannaccini at the University of Pisa.  
A spectrophotometric assay was used to monitor the rate of the decrease of the 
absorbance of NADH to NAD+ at 340 nm, in the absence of interfering reactions, 
running the reaction in the forward direction (pyruvate → lactate). Assays were 
performed at 37 °C, with all reagents (the enzyme, the cofactor NADH, the substrate 
pyruvate and the candidate inhibitor) dissolved in 0.1 M sodium phosphate buffer 
solution (NaH2PO4 and Na2HPO4), at pH 7.4. Compounds, tested in concentration range 
= 25-100 μM, were initially dissolved in stock solutions of DMSO (concentrations of 
DMSO during the initial rate measurements did not exceed 0.5%).  
In the initial screening, using 25 μM NADH and 2 mM sodium pyruvate, we 
evaluated the percentual inhibition of the compounds, then additional kinetic studies 
were carried out only on compounds that showed a ≥ 50% inhibition. The LDH 
inhibitory activities of the compounds that resulted promising from the first “single 
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point” analysis were measured by standard enzyme kinetic experiments. Kinetic 
parameters for pyruvate and NADH were obtained, adding 0.005 units of LDH-A in 100 
mM sodium phosphate buffer, performing the assays in pyruvate-saturating conditions 
(2 mM sodium pyruvate and 6.25 μM to 150 μM NADH), in order to verify the 
competition with NADH, or in NADH-saturating conditions (200 μM NADH and 25 
μM to 2 mM sodium pyruvate), to check the ability of the compounds to compete with 
the natural enzyme substrate. Hence, Ki values for each single inhibitor were determined 
using double-reciprocal plots (Lineweaver-Burk plots). LDH-B enzyme activity was 
measured for compounds displaying significant inhibition properties on the desired A 
isoform, only in pyruvate-saturating conditions. 
Results and discussion. Enzymatic results derived from the simplest NHI derivatives 
substituted with a series of exploratory groups 3.89a-p (Section 3.6.1) are shown in 
Table 3.12. The smallest member of this group, the unsubstituted derivative 3.89a, 
showed a very modest but encouraging inhibition on both isoforms (16% on LDH-5 at 
250 μM, and 22% on LDH-1 at 125 μM), due to the wide possibility of further 
modifying and developing this scaffold. The introduction of halogens in various 
positions gave poor results (3.89c, d, h, k) or provoked the total loss of activity (3.89f), 
with the exception of the 4-bromosubstituted compound 3.89b, which almost reaches a 
50% inhibition, but the shift of the bromine atom to position 6 (3.89d) deeply decreases 
the inhibition value. Cyano, methyl, trifluoromethyl substitutions, as well as carboxylic 
group and COOH-mimicking heteroaryl portion did not significantly improve the 
inhibition on the A isoform, when compared to the unsubstituted analogue 3.89a. On 
the other hand, observing the inhibition percentages of the 3-susbtituted compounds 
3.89m and 3.89n, we can suppose that bulky groups in this position of the heterocycle 
are not well tolerated, due to the reduction in activity when the methyl group (3.89m) is 
replaced by the ethyl (3.89n), although small groups may be tolerated. As for the B 
isoform, compounds 3.89c, h and i showed a trend similar to compound 3.89a, 
displaying a modest activity also on this isoform, but most of the substituted derivatives 
completely lost the activity on LDH-1. The inhibition level (Ki = 275 μM) reached by 3-
CH3-substituted derivative 3.89m, is noteworthy, since it represents the first of our 
compounds to be slightly selective for LDH-1. 
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Table 3.12. Inhibition data on LDH-5 (LDH-A4) and LDH-1 (LDH-B4) for compounds 3.89a-p.  
Cpd Structure Inhibition values LDH-5a LDH-1b
3.89ad 
 
16% 22% 
3.89bd 
 
48% n.a. 
3.89cd 
 
17% 14% 
3.89dd 
 
22% n.a. 
3.89ed 
 
26% n.a. 
3.89f 
 
n.a. n.a. 
3.89g 
 
10% indolee 
6% n.a. 
3.89h 
 
13% 20% 
3.89i 
 
30% indolee 
8% 18% 
3.89j 
 
n.a. n.a. 
3.89kd 
 
5% n.a. 
3.89ld 
 
10% n.a. 
3.89md 
 
18% Ki = 275 μM (NADH) 
3.89nd 
 
13% n.a. 
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3.89o 15% n.a. 
3.89p 13%c n.t. 
 
 
a compounds tested at 250 μM, b compounds tested at 125 μM, c compounds tested at 100 μM, d compounds 
3.89a-e and 3.89k-n were previously synthesized by undergraduate students during experimental thesis in the 
same research laboratory, e compounds tested as a mixture with the reported percentage of indole. n.a. = not 
active, n.t. = not tested. 
 
 
3.7. N1-HYDROXYBENZIMIDAZOLES AND N1-
HYDROXYBENZIMIDAZOL-N3-OXIDES AS LDH-A 
INHIBITORS 
 
3.7.1. Synthesis 
After the synthesis of this first series of N-hydroxyindoles, we decided to explore 
different heterocycles with an high degree of similarity with NHI cycle. In particular, 
we decided to introduce a nitrogen atom in position 3 of the NHI heterocycle, so 
creating N1-hydroxybenzimidazoles (NHB) as new target molecules (Fig. 3.33). This 
kind of structure maintains the pharmacophoric carboxylic group in position 2 and the 
hydroxyl moiety linked to the heterocyclic nitrogen in adjacent position, as for the NHI 
class, but the introduction of a second nitrogen atom in the cycle opens up the way for 
new possible interactions, in particular hydrogen bonds, with residues present in the 
enzyme active site. 
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Figure 3.33. N1-hydroxybenzimidazole structure (generally abbreviated NHB, on the left). Its 1H-
benzimidazole 3-oxide tautomer is displayed (on the right). 
 
Such kind of structure had been previously reported for purposes that are completely 
different from our intents [101]. In my PhD Thesis, we synthesized the non substituted 
NHB 3.97 following a straightforward procedure previously reported for other amino-
substituted N1-hydroxybenzimidazoles (Scheme 3.3) [102]. Commercially available 1-
fluoro-2-nitrobenzene 3.94 was heated to reflux with glycine methyl ester hydrochloride 
in methanol in the presence of sodium bicarbonate to afford the N-arylglycinic 
derivative 3.95. The choice of using methanol instead of ethanol as the solvent derived 
from the results obtained in a previous attempt, when the same reaction performed in 
ethanol caused the formation of the ethyl ester product, derived from a 
transesterification side reaction. Intermediate 3.95 was treated with a freshly prepared 
solution of sodium methoxide in methanol to cyclize it to benzimidazole 3.96 [103]. 
Final hydrolysis of the methyl ester with an aqueous solution of lithium hydroxide 
yielded the desired product 3.97. 
 
 
Scheme 3.3. a) H3N+CH2COOMeCl-, NaHCO3, MeOH, reflux; b) NaOMe, MeOH, RT; c) aqueous 2N LiOH, 
THF/MeOH (1:1), RT. 
 
N1-hydroxybenzimidazol-N3-oxide (NHO) derivatives resemble the precedent NHB 
class, but the N-oxide functionality introduces a new polar moiety in the structure, 
which can lead to new potential binding interactions with the enzyme. Thanks to the 
availability of the commercial substrates and the easy synthetic routes, the reference non 
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substituted N1-hydroxybenzimidazol-N3-oxide 3.98, the 6-chloro and the 6-phenyl 
derivatives 3.99 and 3.100, respectively, were synthesized with the aim to explore the 
effect of substituents of this nucleus on the enzyme inhibitory properties (Fig. 3.34). 
 
 
Figure 3.34. N1-hydroxybenzimidazol-N3-oxide (NHO) derivatives 3.98-3.100. 
 
Benzofuroxan derivative 3.103 was prepared by cyclocondensation in boiling 
toluene of nitrophenyl azide 3.102, which could be easily obtained from 2-nitroaniline 
3.101 [104], whereas the precursor 5-chlorobenzofuran-3-oxide 3.104 was 
commercially available (Scheme 3.4). Benzofuroxans 3.103 and 3.104 were then 
transformed into the corresponding 2-methyl ester N1-hydroxybenzimidazol-N3-oxides 
by following two different procedures previously developed for similar compounds. 
Compound 3.103 was stirred at room temperature with methyl phenylsulfonlyacetate in 
a methanolic solution of potassium hydroxide to yield 3.105a [105]. Unfortunately, the 
same attempt with this reactant for 3.104 was fruitless, even after heating, so in this 
latter case we preferred to change conditions using methyl nitroacetate with 
diethylamine, and these conditions successfully afforded compound 3.105b [106]. Then, 
for both intermediates, alkaline hydrolysis of their ester groups produced final 
compounds 3.98 and 3.99. 
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Scheme 3.4. a) NaNO2, NaN3, aqueous HCl, H2O, -5/0 °C to RT.; b) toluene, reflux; c) for 3.103: 
PhSO2CH2COOMe, methanolic 8% KOH, MeOH, RT; for 3.104: CH3COOCH2NO2, Et2NH, THF, RT; d) 
aqueous 2N LiOH, THF/MeOH (1:1), RT. 
 
The last compound of this structural class, phenyl-substituted derivative 3.100, was 
prepared by reacting 5-chloro-2-nitroaniline 3.106 with benzeneboronic acid using the 
cross coupling conditions developed by Greg Fu [107], comprising 
tris(dibenzylideneacetone)dipalladium as the catalyst with tricyclohexylphosphine as 
the ligand, that are suitable for the less reactive aryl chlorides (Scheme 3.5). From this 
point, the phenyl nitroaniline 3.107 followed the same synthetic scheme described for 
compound 3.99, with the use of the opportunely substituted nitroalcane in diethylaniline 
for the formation of the cycle, although this final synthetic step was characteized by a 
considerably low efficiency. Previously, we had tried the insertion of the phenyl ring 
directly on the commercially available 5-chlorobenzofuran-3-oxide 3.104, to decrease 
the number of reactions steps and speed up the synthesis of the desired compound, but 
the chlorobenzofuroxan did not react properly under these conditions, so we decided to 
insert the phenyl ring on the simpler precursor, as shown in Scheme 3.5. 
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Scheme 3.5. a) C6H5B(OH)2, Cs2CO3, Pd2(dba)3, Pcy3, dry 1,4-dioxane, 80 °C; b) NaNO2, NaN3, aqueous 
HCl, H2O, -5/0 °C to RT.; c) toluene, reflux; d) CH3COOCH2NO2, Et2NH, THF, RT; e) aqueous 2N LiOH, 
THF/MeOH (1:1), RT. 
 
3.7.2. Enzymatic assays 
The preliminary exploration of new similar N-hydroxy-based heterocycles has so far 
proved to be fruitless, as shown by the results reported in Table 3.13. In particular, 
unsubstituted N1-hydroxybenzimidazole 3.97 and N1-hydroxybenzimidazol-N3-oxide 
3.98 were completely deprived of any inhibitory activity. Even the 6-phenyl N1-
hydroxybenzimidazol-N3-oxide 3.100 showed no detectable inhibition of LDH-A. 
Compound 3.99, bearing a chlorine atom in position 6, displayed an almost undetectable 
weak inhibition of the LDH-A isoform, which is barely above baseline (about 2% at 250 
μM), whereas it showed a certain inhibition of the heart isoform (17% at 125 μM). 
Overall, this preliminary screening did not show any promising results associated to 
the NHB and NHO derivatives herein reported. 
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Table 3.13. Inhibition data on LDH-5 (LDH-A4) and LDH-1 (LDH-B4) for compounds 3.97-3.100. 
Cpd Structure Inhibition values LDH-5a LDH-1
3.97 
 
n.a. - 
3.98 
 
n.a. - 
3.99 
N
N
OH
COOH
O
Cl
 
2% 17%b 
3.100 
 
n.a. - 
 
 
a compounds tested at 250 μM, b compounds tested at 125 μM. n.a. = not active 
 
 
3.8. ARYL-SUBSTITUTED N-HYDROXYINDOLES  
 
3.8.1. Synthesis 
The preliminary biological results obtained from N1-hydroxyindole, N1-
hydroxybenzimidazole and N1-hydroxybenzimidazol-N3-oxide classes (see Sections 3.6 
and 3.7) demonstrated that N-hydroxyindole derivatives proved to be the more 
promising structures to be developed as LDH-A inhibitors, so we decided to focus our 
attention on this class. After the introduction of small groups on the NHI nucleus, we 
further developed this scaffold by inserting non-substituted phenyl rings in different 
positions, so obtaining the first aryl-substituted compounds (mono-aryl derivatives 
3.111-3.113 and di-aryl derivative 3.114, Fig. 3.35). 3-Phenyl-substituted-N-
hydroxyindole was not synthesized because of synthetic difficulties and of a presumable 
low affinity for the LDH-A active site since this portion of the inhibitor is hosted by the 
substrate pocket (see below) which is rather small and, therefore, is not able to fit large 
phenyl ring. As for position 7, our attempts to introduce a phenyl ring did not afford the 
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desired product, due to its high instability, in fact during the last step of hydrolysis of 
the methyl ester the compound polymerized and it was impossible to get the final 
product. 
 
 
 
  
Figure 3.35. Aryl-substituted compounds 3.111-3.114; a compound 3.111 was previously synthesized during 
experimental graduation thesis in the same research laboratory. 
 
In the first step of the synthesis, halogenated precursors 3.90b, 3.90d and 3.115 were 
subjected to a cross-coupling reaction with phenylboronic acid using the classical 
thermal Suzuki conditions [108] to get phenyl-substituted nitrotoluenes 3.118a-c 
(Scheme 3.6). Compounds 3.117, which was obtained by nitration with potassium 
nitrate in concentrated sulfuric acid from the commercially available 3,4-
dichlorotoluene 3.116 [109], was subjected to slightly different cross-coupling 
conditions, using the phase transfer catalyst tetrabutylammonium bromide, potassium 
phosphate as the base, long reaction times (48 h) and higher temperatures (125 °C) 
[110], in order to obtain the double substitution, because previous attempts under milder 
reaction conditions (Suzuki) afforded a mixture of the inseparable mono- and di-phenyl 
substituted derivatives. For the reduction-promoted cyclization of compound 3.119c and 
3.119d, we exploited synthetic procedures different from those previously described 
(ipophosphite with palladium and stannous chloride in DME), because we experienced 
that the choice of the best reaction conditions strongly depends on the structure of the 
substrate we were going to cyclize. In fact, several attempts were necessary to find out 
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the most suitable reducing agent in each case. In particular, for 3.119c we used stannous 
chloride in the presence of tiophenol and triethylammine: PhSH and the basic 
conditions slightly decrease the reductive ability of bivalent tin, thus counteracting the 
exhaustive reduction of the nitro group to amine; this adjustment proved to reduce the 
indole formation and, therefore, properly promote the partial reduction/cyclization step 
which furnished the desired product [111]. In the same synthetic step run on 3.119d, we 
found out that metallic lead in the presence of a triethylammonium formate (TEAF) 
buffer solution in methanol permitted an optimal reaction outcome [112]. 
 
 
Scheme 3.6. a) KNO3, conc. H2SO4, 5 °C to RT; b) C6H5B(OH)2, Pd(OAc)2, PPh3, aqueous 2M Na2CO3, 
distilled toluene, abs. EtOH, 100 °C, 24 h; for 3.117: Pd(OAc)2, TBAB, K3PO4, H2O, 125 °C, 48 h; c) 
(COOMe)2, NaH 60%, dry DMF, –15 °C to RT; d) for 3.119a: SnCl2·2H2O, dry DME, 4Å MS, 0 °C to RT; 
for 3.119b: H2PO2Na·H2O, Pd-C 10%, H2O/THF (1:1), RT; for 3.119c: SnCl2·2H2O, C6H5SH, Et3N, CH3CN, 
RT; for 3.119d: Pb, TEAF, MeOH, 55 °C; e) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
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During precedent efforts for the cyclization of compound 3.119c, using SnCl2 and 
DME, predominant amounts of indoles were obtained (34:66 for 3.120c/3.121, Scheme 
3.7). In that case, we separated NHI 3.120c from its indole analogue 3.121 by column 
chromatography; they were separately hydrolyzed to get also the indole-carboxylic 
derivative 3.122 (Scheme 3.7). The methyl ester 3.120c and the indole derivative 3.122 
were used in biological assays as valuable tools to establish the importance of the 
pharmacophoric portions, COOH and OH respectively, needed for LDH-A inhibition. 
With the same aim, an example of O-methylated NHI (3.124) was also synthesized [95], 
to verify the importance of the free OH group in the enzyme inhibition assays. To this 
purpose, NHI 3.120c was treated with iodomethane and DBU in THF to give ester 
3.123, which was finally hydrolyzed to compound 3.124. 
 
 
Scheme 3.7. a) SnCl2·2H2O, dry DME, 4Å MS, 0 °C to RT; b) aqueous 2N LiOH, THF/MeOH (1:1), RT; c) 
CH3I, DBU, THF, RT. 
 
Afterwards, we were particularly attracted by the effects that could be generated by 
the insertion of variously substituted aryl rings. Hence, we began to introduce 
substituents on the phenyl rings, with a particular focus on 5- and 6-phenyl-substituted 
derivatives, encouraged by the promising biological results obtained with compounds 
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3.112-3.114 (see enzymatic assay Section below). We inserted various groups 
possessing different electronic and steric properties, such as halogens, methoxy, 
trifluoromethoxy, trifluoromethyl, carboxy (directly bound to the phenyl ring or with an 
ethylene chain linker) and methylsulfonyl groups, in meta and para positions of the 
phenyls, with the aim to increase the interactions of our inhibitors (3.125a-j, 3.126a-f, 
Fig. 3.36) with the LDH-A binding site.  
 
 
 
Cpd R1 R2 Cpd R1 R2 
3.125a   3.126a   
3.125b   3.126b   
3.125c   3.126c   
3.125d 
 
 3.126d   
3.125e   3.126e   
3.125f   3.126f   
3.125g   
 
3.125h   
3.125i   
3.125j   
 
 
Figure 3.36. Structures of 6- and 5-phenyl-substituted compounds 3.125a-j and 3.126a-f, respectively. 
 
The same synthetic scheme (ketoester formation, reduction-promoted cyclization 
and hydrolysis) was followed also in the synthesis of these two series of compounds, 
including 6-aryl-substituted compounds 3.125a-j (Scheme 3.8-3.9) and 5-aryl-
substituted compounds 3.126a-f (Scheme 3.10). All the halogenated precursors 3.90d, 
3.115 and the nitrotoluenic boronic acid 3.127 (“umpolung” reagent) were subjected to 
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cross-coupling reactions using classical conditions or the more advantageous 
microwave-assisted Suzuki coupling for the significantly reduction of the reaction time 
(classical method: 24 h, microwave-assisted coupling: 5 to 20 minutes) [113, 114]. For 
the synthesis of 3.125d (Scheme 3.9), coupling reaction with 4-(methylthio)-
benzeneboronic acid was followed by the ketoester 3.134 formation with NaH and 
(COOMe)2 and, subsequently, the oxidation of methylthio- to methyl-sulphonic group 
was performed by using oxone as oxidant in dioxane [115]. This sequence of steps was 
optimized after the unsuccessful attempt of converting the methyltio moiety before the 
alkylation step: in that case we obtained not only the proper formation of the ketoester 
chain, but also the alkylation of the methyl-sulfonyl group. We supposed that the 
presence of two S=O groups linked to the methyl group increases the acidity of the 
methyl protons, so promoting the removal of a proton by sodium hydride and the 
subsequent attack by dimethyl oxalate. 
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Scheme 3.8. a) for 3.129a-b-e: Pd(OAc)2, PPh3, aqueous 2M Na2CO3, distilled toluene, abs. EtOH, μW, 20 
min.; for 3.129c: Pd(OAc)2, PPh3, aqueous 2M Na2CO3, distilled toluene, abs.EtOH, 100 °C, 24 h; for 3.129h-
i: Pd(OAc)2, TBAB, K3PO4, H2O, 125 °C, 24 h; for 3.129j: Pd(OAc)2, TBAB, Na2CO3, H2O, μW, 5 min.; b) 
Pd(OAc)2, TBAB, Na2CO3, H2O, μW, 5 min.; c) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; d) for 
3.131a-b-e: SnCl2·2H2O, dry DME, 4Å MS, 0 °C to RT; for 3.131c: H2PO2Na·H2O, Pd-C 10%, H2O/THF 
(1:1), RT; for 3.131f-g-h-i-j: SnCl2·2H2O, C6H5SH, Et3N, CH3CN, RT; e) aqueous 2N LiOH, THF/MeOH 
(1:1), RT. 
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Scheme 3.9. a) 4-(methyltio)-benzene boronic acid, Pd(OAc)2, PPh3, aqueous 2M Na2CO3, distilled toluene, 
abs. EtOH, 100 °C, 24 h; b) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; c) Oxone® 50% w/w, 1,4-
dioxane, 0 °C to RT; d) SnCl2·2H2O, dry DME, 4Å MS, 0 °C to RT; e) aqueous 2N LiOH, THF/MeOH (1:1), 
RT. 
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Scheme 3.10. a) all the cross-coupling reactions were performed with appropriate substituted-phenylboronic 
acids; for: 3.135a-b: Pd(OAc)2, PPh3, aqueous 2M Na2CO3, distilled toluene, abs. EtOH, 100 °C, 24 h; for 
3.135c-d-e-f: Pd(OAc)2, TBAB, Na2CO3, H2O, μW, 5 min; b) (COOMe)2, NaH 60%, dry DMF, –15 °C to 
RT; c) for 3.136a-b: H2PO2Na·H2O, Pd-C 10%, H2O/THF (1:1), RT; for 3.136c: SnCl2·2H2O, dry DME, 4Å 
MS, 0 °C to RT; for 3.136d-e-f: SnCl2·2H2O, C6H5SH, Et3N, CH3CN, RT; d) aqueous 2N LiOH, THF/MeOH 
(1:1), RT. 
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Subsequently, we designed compounds bearing contemporarily halogenated groups 
(Cl, CF3) and a phenyl on the NHI scaffold, with the aim of further stabilizing the 
structure and, possibly, improving the inhibitory activity of one of the most active 
compounds obtained up to now, that is, compound 3.113 (Fig. 3.37), with electron-
withdrawing groups on the NHI nucleus. Moreover, the choice of the target molecules 
was also dictated by the synthetic accessibility of the desired products. Hence, we 
initially synthesized derivatives 3.138 and 3.139 (Fig. 3.37), both of them possessing a 
phenyl ring in position 6, together with either a trifluoromethyl in position 4, or a 
fluorine atom in position 5, respectively. Thanks to the very good results obtained in 
biological assays by compound 3.139 (see enzymatic assay Section below), we were 
attracted by the possibility to further develop this compound, by adding a phenyl in 
position 7, which was impossible to introduce on the unsubstituted NHI scaffold, due to 
the high instability of the structure itself, as previously explained, to afford compound 
3.140 (Fig. 3.37). Moreover, we wanted to combine in compound 3.141 (Fig. 3.37) both 
the structural features of compound 3.139 and the p-chloro-substitution of the derivative 
3.125j, which proved to be very promising for its high LDH-A inhibition ability. We 
completed our design of this series of 6-phenyl-substituted NHIs with a final structural 
modification: the introduction in the 6-phenyl group of an additional chlorine atom in 
the meta position with respect to the already present Cl atom (compound 3.142, Fig. 
3.37), in order to verify if the introduction of this atom could positively affect the 
affinity of these chloro-substituted molecules for the enzyme. 
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Figure 3.37. Compounds 3.138-3.142 deriving from structural development of compounds 3.113 and 3.125j; a 
compound 3.138 was previously synthesized during experimental graduation thesis in the same research 
laboratory. 
 
Compound 3.138 was synthesized by following the same synthetic scheme seen for 
the other phenyl-substituted derivatives (Scheme 3.11). Commercially available 4-
bromo-5-fluoro-2-nitrotoluene 3.143 was submitted to a cross-coupling reaction, where 
only the most reactive bromine could be replaced by the aryl group under classical 
Suzuki conditions using Pd(PPh3)4 as catalyst. Then the so obtain product 3.144 was 
alkylated with dimethyl oxalate, then cyclized with SnCl2 in DME and finally 
hydrolyzed with lithium hydroxide to get the free acid 3.138.  
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Scheme 3.11. a) C6H5B(OH)2, Pd(OAc)2, PPh3, aqueous 2M Na2CO3, distilled toluene, abs. EtOH, 100 °C, 24 
h; b) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; d) SnCl2·2H2O, dry DME, 4Å MS, 0 °C to RT; e) 
aqueous 2N LiOH, THF/MeOH (1:1), RT. 
 
For the synthesis of CF3-derivatives 3.139, 3.141 and 3.142 (Scheme 3.12), 
commercially available 2-methyl-3-nitrobenzotrifluoride 3.901 was iodinated with N-
iodosuccinimide (NIS) in concentrated sulfuric acid to give iodo-aryl derivative 3.147 
[116] in order to permit, in the next step, the exchange of the iodine with the appropriate 
aryl ring by a ligand-free cross-coupling in a microwave reactor, which afforded 
compounds 3.148a-b. For the synthesis of compound 3.148c, we preferred the milder 
thermal Suzuki reaction to the harsher ligand-free microwave conditions, in order to 
avoid the potential over-reaction of the chlorine atoms present in the aryl substituent.  
During the synthesis of the compounds bearing the 4-trifluoromethyl group, the 
previously described conditions in the ketoester formation (sodium hydride, DMF, 
dimethyl oxalate) gave very low yields of the desired intermediate, due to the formation 
of side products, whose interpretation by NMR signals was difficult. For such reason, 
we changed the base, using potassium tert-butoxide in the place of sodium hydride, in 
anhydrous diethyl ether and methanol, with dimethyl oxalate; under these conditions we 
obtained a reddish suspension where the potassium salt of the desired ketoester 
precipitates in the reaction mixture as soon as it forms [117]. The ketoseters 3.149a-c so 
obtained were then cyclized with stannous chloride in DME and finally hydrolyzed to 
get final products 3.139, 3.141 and 3.142.  
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Scheme 3.12. a) NIS, conc. H2SO4, 5-10 °C to RT; b) for 3.148a-b: appropriate substituted phenylboronic 
acids, Pd(OAc)2, TBAB, Na2CO3, H2O, μW, 5 min; for 3.148c: 2,4-dichlorobenzeneboronic acid, Pd(OAc)2, 
PPh3, aqueous 2M Na2CO3, distilled toluene, abs. EtOH, 80 °C, 24 h; c) (COOMe)2, tBuOK, dry Et2O-MeOH 
(10:1), 0 °C to RT; d) SnCl2·2H2O, dry DME, 4Å MS, 0 °C to RT; e) aqueous 2N LiOH, THF/MeOH (1:1), 
RT. 
 
For the double phenyl insertion on 3,4-dichloro-2-nitro-6-trifluoromethyltoluene 
3.151 (Scheme 3.13), a microwave-assisted Suzuki coupling with an excess of 
benzeneboronic acid (3 equivalents) and an increased reaction time (10 minutes) 
compared with standard conditions, was used and biphenyl-substituted nitrotoluene 
3.152 was successfully obtained. In this case the use of tert-butoxide gave almost no 
reaction, whereas sodium hydride afforded the proper ketoester 3.153.  
Several attempts were performed for the reduction-promoted cyclization of the 
ketoester, always obtaining mixtures of the NHI and the indole side product. The 
optimization of this step led us to finally use zinc dust, previously activated with iodine 
in tetrahydrofuran in refluxing conditions, in the presence of an aqueous solution of 
ammonium chloride, albeit also this method gave a certain percentage of indole, which 
was eliminated by chromatographic purification [92]. 
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Scheme 3.13. a) C6H5B(OH)2, Pd(OAc)2, TBAB, Na2CO3, H2O, μW, 10 min; b) (COOMe)2, NaH 60%, dry 
DMF, –15 °C to RT; c) Zn dust, I2, NH4Cl, dry THF, H2O, RT; d) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
 
All the 4-CF3-6-aryl-substituted derivatives showed very good results in the LDH-A 
inhibition assays, so the next step was to further substitute the NHI scaffold to probe the 
chemical space available for a better inhibition of the enzyme. We planned, as an 
additional structural modification, the introduction of a small group in position 3 such 
as a methyl, in order to see if that introduction was tolerated by the enzyme binding site. 
Therefore, we synthesized compounds 3.155 and 3.156 (Fig. 3.38).  
 
N
CH3
COOH
OH
CF3
N
CH3
COOH
OH
CF3
Cl3.155 3.156  
Figure 3.38. 3-Methyl-substituted compounds 3.155 and 3.156. 
 
We optimized the synthetic procedure for the introduction of the 3-methyl group. In 
Fig. 3.39, the main synthetic strategies we attempted in the search for the best method 
are reported. In the first two strategies (path I and II), ketoester was treated with 
potassium or lithium tert-butoxide in the presence of methyl iodide [118] with the aim 
to deprotonate the methylene moiety and insert the methyl group, but in both cases a 
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mixture of O- and C-methylated derivatives was obtained, whose separation by 
purification techniques was quite challenging. Moreover, the recovery of starting 
material by hydrolysis of the formed O-methylated side-product proved to be quite 
difficult. In the last case (path III), where we tried to introduce the methyl group already 
in the initial nitro-toluene precursor, hydroxymethylation with formaldehyde and 
potassium hydroxide [119], followed by OH/Br exchange with tetrabromomethane, 
triphenylphosphine in DCM [120], and subsequent reduction with sodium borohydride 
as the reducing agent and anhydrous 1-methyl-2-pyrrolidinone (NMP) as the solvent 
[121] gave a mixture of the desired ethyl-substituted derivative together with the 
unsaturated styrene by-product derived from an undesired elimination reaction. 
 
 
Figure 3.39. Synthetic strategies (path I, II and III) adopted for the insertion of the 3-methyl group are 
schematically represented. Reagents and conditions are briefly summarized on the arrows. 
 
In the light of these insufficient results, we decided to follow the Nicolaou’s method 
used for the insertion of several kinds of groups in position 3 of the NHI scaffold [92]. 
This approach consists in treating the potassium salts of ketoesters with Eschenmoser’s 
salt (N,N-dimethylmethilideneammonium chloride) in THF to give the corresponding 
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α,β-unsaturated ketoesters 3.157a-b and then carrying out the reductive cyclization in 
the presence of triethylsilane as the hydride donor to efficiently afford 3-methyl-N-
hydroxyindoles 3.158a-b (Scheme 3.14). 
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Scheme 3.14. a) NIS, conc. H2SO4, 5-10 °C to RT; b) appropriate substituted phenylboronic acids, Pd(OAc)2, 
TBAB, Na2CO3, H2O, μW, 5 min; c) (COOMe)2, tBuOK, dry Et2O-MeOH (10:1), 0 °C to RT; d) 
CH2=N+Me2Cl-, dry THF, 0 °C to RT; e) SnCl2·2H2O, trietyhlsilane, dry DME, 4Å MS, 0 °C to RT; f) 
aqueous 2N LiOH, THF/MeOH (1:1), RT. 
 
For completing the series of the aryl-substituted NHI, we envisaged the possibility 
of introducing heterocycles or other different aromatic moieties on the NHI nucleus in 
the place of the aryl rings present in the previously synthesized products, in order to 
enlarge the molecular diversity of the series of aryl-substituted N-hydroxyindoles. In 
particular, we focused our synthesis on the introduction of biphenyl, naphthalene, furan, 
1,3-benzodioxolane and 2,2-difluoro-1,3-benzodioxolane groups in position 6 
(compounds 3.159a-f, Fig. 3.40) and p-chlorophenoxy portion in position 5 (compound 
3.160, Fig. 3.40). The choice of these products was also dictated by the commercial 
availability of the precursors and on the synthetic accessibility of the resulting target 
molecules. 
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Figure 3.40. Structures of heterocyclic compounds 3.159a-f and 3.160. 
 
Nitrotoluenic precursors 3.162a-f were synthesized by a microwave-assisted Suzuki 
coupling starting from commercially available 4-bromo-2-nitrotoluene 3.90d, 4-
biphenyl or 1-/2-naphtalene-boronic acids (3.161a-c). Otherwise, the commercial 
availability of the “umpolung” reagent 4-methyl-3-nitrobenzeneboronic acid 3.127 
allowed us to run the cross-coupling reactions with bromo-substituted derivatives 
3.161d-f (Scheme 3.15). According to the same synthetic scheme previously described 
for the construction of the NHI scaffold, the so obtained compounds 3.162a-f were 
reacted with NaH and dimethyl oxalate to give ketoesters 3.163a-f, whose reductive 
cyclization was performed with SnCl2 in the presence of thiophenol, and finally methyl 
esters of 3.164a-f were hydrolyzed with lithium hydroxide. Similarly, the procedure 
adopted for the synthesis of compound 3.160 was accomplished as shown in Scheme 
3.16, where commercially available 5-fluoro-2-nitrotoluene 3.90f was treated with p-
chlorophenol in the presence of potassium carbonate in dimethylsulphoxide to yield 
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compound 3.165 [122], then the final steps were practically identical to those described 
in Scheme 3.15. 
 
 
Scheme 3.15. a) Pd(OAc)2, TBAB, Na2CO3, H2O, μW, 5 min; b) (COOMe)2, NaH 60%, dry DMF, –15 °C to 
RT; c) SnCl2·2H2O, C6H5SH, Et3N, CH3CN, RT; e) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
 
 
Scheme 3.16. a) 4-chlorophenol, K2CO3, DMSO, RT to 80 °C; b) (COOMe)2, NaH 60%, dry DMF, –15 °C to 
RT; d) SnCl2·2H2O, dry DME, 4Å MS, 0 °C to RT; e) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
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3.8.2. Enzymatic assays 
Following the first series of exploratory compounds, aryl-substituted derivatives 
were tested. Here again, we checked the activity on the B isoform only for those 
compounds that displayed relevant inhibition levels of the A isoform (Table 3.14). In 
spite of the poor results obtained with 4-phenyl-substituted compound 3.111, 
compounds 3.112 and 3.113, bearing a phenyl ring in positions 5 and 6, respectively, 
showed an evident increase in the inhibitory potency, with Ki values in a range of 10-20 
μM in pyruvate-saturating conditions. Moreover, they proved to be competitive also in 
NADH-saturating conditions, showing Ki values of 15.7 and 35.5 μM for 3.112 and 
3.113, respectively. A synergistic effect, generated by joining the substitutions present 
in compounds 3.112 and 3.113, was found in the di-phenyl derivative 3.114 which 
reached a Ki value of 5 μM. Moreover, compounds 3.112-3.114 did not show any 
appreciable activity on the other isoform, so demonstrating to be selective for LDH-A. 
The lack of activity of methyl ester 3.120c, indole 3.122 and O-methylated derivative 
3.124 (analogues of compound 3.113) constituted the proof that the OH-COOH motif 
represents the pharmacophoric group needed for LDH-A inhibition. In fact, when 
COOH or N-OH are methylated or the N-OH is substituted with N-H the inhibition 
activity is completely loss (3.120c and 3.124) or dramatically reduced (3.122). The 
indole derivative 3.122 proved to be a very modest non-selective LDH inhibitor, 
showing also a small inhibition percentage (8%) on the B isoform. An activity 
worsening was provoked by the introduction of methylsulfonic (3.125d) and methoxy 
groups (3.125e and 3.126c) in position 4 of the phenyl substituent, when compared to 
their corresponding unsubstituted analogues 3.113 and 3.112. The presence of a 
carboxylic group showed controversial effects: when the COOH moiety is directly 
linked to the phenyl ring, scarce results were obtained (compounds 3.125a and b), with 
the exception of the m-COOH-5-phenylsusbstituted derivative 3.126a (Ki = 19 μM for 
NADH). However, when the acid group is spaced by an ethylene chain linker (3.125c 
and 3.126b) the activity sensibly increases. Trifluoromethoxy-substituted NHIs 3.125f 
and 3.125g are among the most potent and selective compounds assayed up to now, as 
well as para-chloro derivatives 3.125j and 3.126f, reaching Ki values in the low micro 
molar range. On the contrary, the presence of the trifluoromethyl group and the fluorine 
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atom in para of the phenyl rings in both positions (5 for compounds 3.126d-e and 6 for 
compounds 3.125h-i) resulted to be detrimental for the activity on the enzyme. 
 
Table 3.14. Inhibition data on LDH-5 (LDH-A4) and LDH-1 (LDH-B4) for compounds 3.111-3.114, 3.120c, 
3.122, 3.124, 3.125a-j, 3.126a-f. 
Cpd Structure Inhibition values LDH-5a LDH-1
3.111e n.a. - 
3.112 
 
Ki = 10.4 μM (NADH) 
 15.7 μM (Pyr) n.a.
a 
3.113 
 
Ki = 19.8 μM (NADH) 
 35.5 μM (Pyr) n.a.
a 
3.114 Ki = 5.0 μM (NADH)  7.5 μM (Pyr) n.a.
b 
3.120c 
 
n.a. - 
3.122 
 
12% 8%a 
3.124 
 
n.a. - 
3.125a 
 
31% indolef 
3% - 
3.125b 
 
32%c - 
3.125c 
 
Ki = 117.6 μM (NADH) n.a.b 
3.125d 
 
17% - 
3.125e 
 
18% - 
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3.125f 
 
Ki = 8.5 μM (NADH) 
 33 μM (Pyr) n.a.
b 
3.125g 
 
10% indolef
Ki = 7.5 μM (NADH) 
 40 μM (Pyr) n.a.
b 
3.125h Ki = 42 μM (NADH)  25 μM (Pyr) n.a.
b 
3.125i Ki = 67 μM (NADH)  17 μM (Pyr) n.a.
b 
3.125j Ki = 5.0 μM (NADH)  56 μM (Pyr) n.a.
b 
3.126a Ki = 19.4 μM (NADH)  27.2 μM (Pyr) n.a.
b 
3.126b 
 
15% indolef 
55%c 27%c 
3.126c 25%c - 
3.126d 30%d - 
3.126e 5%d - 
3.126f Ki = 16 μM (NADH)  100 μM (Pyr) n.a.
b 
 
 
a compounds tested at 125 μM, b compounds tested at 100 μM, c compounds tested at 250 μM, d compounds 
tested at 50 μM, e compound 3.111 was previously synthesized by undergraduate students during experimental 
thesis in the same research laboratory,  f compounds tested as a mixture with the reported percentage of indole. 
n.a. = not active. 
 
The co-presence of halogenated substituents and aryl rings on the NHI scaffold 
provided very good results (Table 3.15). Initially, we found that 4-CF3-6-phenyl-
substituted compound 3.139 caused a 87% of inhibition of LDH-A at 125 μM, with a Ki 
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as low as 8.9 μM, together with a minimal activity (11%) on LDH-B. On the contrary, 
the insertion of a fluorine atom in position 5, as in compound 3.138, led to a total loss of 
activity. The other CF3-derivatives 3.140-3.142, close analogues of lead compound 
3.139, generally maintained a very high potency on the desired isoform, without 
showing any relevant activity on LDH-B, so slightly improving their biological profiles. 
In details, the additional presence of the 7-phenyl ring in compound 3.140 lowered the 
activity if compared to 3.139 (Ki = 17 μM instead of 8.9 μM), whereas the activity 
turned out to be sensibly improved upon insertion of a chlorine atom in para-position of 
the phenyl ring (3.141) and, even more, when two chlorine atoms were present in para- 
and ortho-positions. In fact, dichlorophenyl-substituted compound 3.142 proved to be 
the most active LDH-A inhibitor among all the so far synthesized N-hydroxyindole 
derivatives, in both pyruvate- (Ki = 1.5 μM) and cofactor-saturating conditions (Ki = 1.6 
μM), associated with a total selectivity for this isoform (0% inhibition on LDH-B at 100 
μM). 3-Methyl-substituted derivatives 3.155 and 3.156 maintained approximately the 
same activity of their corresponding non-methylated analogues 3.139 and 3.141, 
respectively, with the only peculiarity of a remarkable increase of the Ki value showed 
in NADH-saturating conditions for compound 3.155 (98 μM), when compared to that 
obtained by its analogue 3.139 (4.7 μM). 
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Table 3.15. Inhibition data on LDH-5 (LDH-A4) and LDH-1 (LDH-B4) for compounds 3.138-3.142, 3.155-
3.156. 
Cpd Structure Inhibition values 
LDH-5 LDH-1a 
3.138c N COOH
OH
F
 
n.a. - 
3.139 Ki = 8.9 μM (NADH)  4.7 μM (Pyr) 11%
b 
3.140 Ki = 17 μM (NADH)    14.3 μM (Pyr) n.a. 
3.141 Ki = 2.6 μM (NADH) 16 μM (Pyr) n.a. 
3.142 Ki = 1.5 μM (NADH)  1.6 μM (Pyr) n.a. 
3.155 Ki = 10 μM (NADH)  98 μM (Pyr) n.a. 
3.156 Ki = 10 μM (NADH) 6 μM (Pyr) n.a. 
 
 
a compounds tested at 100 μM, b compounds tested at 125 μM, c compound 3.138 was previously synthesized 
by undergraduate students during experimental thesis in the same research laboratory. n.a. = not active. 
 
In accordance with the previous results, most of the subsequently synthesized N-
hydroxyindoles, substituted with aromatic portions in position 6 of the central ring, 
resulted to be active (Table 3.16). Biphenyl derivative 3.159a showed a very high 
activity on LDH-A (Ki = 4.5 μM in pyruvate-saturating conditions), so confirming that 
the insertion of hydrophobic moieties in this position of the nucleus is favourable for the 
inhibition abilities of our compounds, although this molecule showed also an undesired 
20% inhibition on the B isoform. Naphthalene-substituted compounds 3.159b-c 
maintained a good activity (Ki values ranging from 10 to 15 μM), and they proved to be 
completely LDH-A selective. The insertion of a furan ring as in compound 3.159d 
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provoked a small decrease in the potency (Ki = 54 μM). The introduction of the 
benzodioxolane group (compound 3.159e), which produced a dramatic drop in the 
inhibitory activity, reaching only a 9% inhibition at 125 μM. This situation is reverted if 
two fluorine atoms are inserted in the methylene bridge linking the two benzodioxolane 
oxygen atoms (3.159f), restoring an acceptable Ki value (52 μM vs. NADH; 17 μM vs. 
Pyr). Unluckily, compound 3.160, possessing a p-chlorophenyl ring in position 5 spaced 
by an oxygen atom form the central nucleus, was not tested in enzymatic assays, due to 
its very low solubility even when relatively high concentrations of DMSO were used in 
the assay. 
 
Table 3.16. Inhibition data on LDH-5 (LDH-A4) and LDH-1 (LDH-B4) for compounds 3.159a-f, 3.160. 
Cpd Structure Inhibition values 
LDH-5 LDH-1
3.159aa 
 
10% indolee 
Ki = 4.5 μM (NADH) 
  13.5 μM (Pyr) 20%
b 
3.159b 
 
9% indolee 
Ki = 10 μM (NADH) 
7 μM (Pyr) n.a.
b 
3.159c 
 
13% indolee 
Ki = 15.3 μM (NADH) 
13 μM (Pyr) n.a.
b 
3.159d 
 
15% indolee 
Ki = 54 μM (NADH) 
 20 μM (Pyr) n.a.
c 
3.159e 
 
9%d - 
3.159f N
OH
COOH
O
OF
F
 
Ki = 52 μM (NADH) 
 17 μM (Pyr) n.a.
c 
3.160 N
O
Cl
OH
COOH
 
n.t - 
 
 
a compound 3.159a was tested using a 2% DMSO, for solubility problems, b compounds tested at 50 μM, c 
compounds tested at 100 μM, d compounds tested at 125 μM, e compounds tested as a mixture with the 
reported percentage of indole. n.a. = not active. n.t. = compound 3.160 was not tested for solubility problems. 
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As a summary of these fruitful enzyme kinetic studies, we can say that all the 
compounds that proved to be active in inhibiting LDH-A, with Ki values in the low 
micromolar range, were found to behave as competitive inhibitors with respect to both 
NADH and pyruvate in the conversion of pyruvate to lactate catalyzed by this enzyme, 
whereby NADH is converted to NAD+. This competitive behaviour is confirmed by the 
Lineweaver-Burk plots, where the lines obtained in the absence and presence of various 
concentrations of the inhibitor intersect on the ordinate. This would suggest that these 
compounds likely occupy both the cofactor and the substrate binding sites. A graphical 
representative example of the double-reciprocal plots obtained with compound 3.142, 
which is the most potent and selective LDH-A inhibitor obtained so far, in competition 
with both the cofactor NADH (top, Fig. 3.41) and the substrate pyruvate (bottom, Fig. 
3.41) is reported below. 
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Figure 3.41. Lineweaver-Burk plots determined from enzyme kinetic experiments human LDH-5 (LDH-A4) 
in the presence of inhibitor 3.142 at different concentrations in competition with NADH (top) and pyruvate 
(bottom). 
 
3.8.3. Molecular modeling studies 
Methods. In order to perform docking calculations, the X-ray structure of the human 
muscle L-LDH M chain complexed with NADH and Oxamate [23] (PDB code 1I10) 
was taken from the Protein Data Bank [123]. With the aim of obtaining an open loop 
conformation form of the protein, the loop structure from A96 to K118 was taken from 
the open conformation of the rabbit muscle L-LDH M chain (PDB code 3H3F) [124]. 
The structure was directly replaced since between the two loop sequences there is one 
hundred percent of identity. The so obtained structure was placed in a rectangular 
parallelepiped water box, an explicit solvent model for water, TIP3P, was used, and the 
complex was solvated with a 8 Å water cap. Chlorine ions were added as counterions to 
neutralize the system. Two steps of minimization were then carried out. In the first 
stage, we kept the complex fixed with a position restraint of 500 kcal/mol•Å2 and we 
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solely minimized the positions of the water molecules. In the second stage, we 
minimized the entire system through 5000 steps of steepest descent followed by 
conjugate gradient (CG) until a convergence of 0.05 kcal/mol•Å2 was attained. The 
ligands were built using Maestro 9.0 [125] and were minimized using the CG method 
until a convergence value of 0.05 kcal/mol•Å2 was reached. The minimizations were 
carried out in a water environment model (generalized-Born/surface-area model) using 
the MMFFs force field and a distance-dependent dielectric constant of 1.0. Automated 
docking was carried out by means of the GOLD program, version 4.1.1 [126]. The 
region of interest used by GOLD was defined in order to contain the residues within 10 
Å from the original position of NADH and oxamate in the X-ray structures. The “allow 
early termination” option was deactivated, the remaining GOLD default parameters 
were used, and the ligand was submitted to 30 genetic algorithm runs by applying the 
ChemScore fitness function. The best docked conformation was taken into account. The 
docking of the analysed compounds was carried out using the procedure described 
above and using as the target protein the structure extracted from the minimized average 
structure of the LDH-3.139 complex obtained from the MD simulations. 
All the molecular dynamics (MD) simulations were performed using AMBER 10 
[127]. MD simulations were carried out using the parm03 force field at 300 K. The 
complex was placed in a rectangular parallelepiped water box, an explicit solvent model 
for water, TIP3P, was used, and the complex was solvated with a 10 Å water cap. 
Chlorine ions were added as counterions to neutralize the system. Prior to MD 
simulations, two steps of minimization were carried out using the same procedure 
described above. Particle mesh Ewald (PME) electrostatics and periodic boundary 
conditions were used in the simulation [128]. The MD trajectory was run using the 
minimized structure as the starting conformation. The time step of the simulations was 
2.0 fs with a cutoff of 10 Å for the nonbonded interaction, and SHAKE was employed 
to keep all bonds involving hydrogen atoms rigid. Constant-volume periodic boundary 
MD was carried out for 400 ps, during which the temperature was raised from 0 to 300 
K. Then 9.6 ns of constant pressure periodic boundary MD was carried out at 300 K 
using the Langevin thermostat to maintain constant the temperature of our system. In 
the first 1.2 ns, all the α carbons of the protein were blocked with a harmonic force 
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constant, which decreased during these 1.2 ns from 10 to 1 kcal/mol•Å2, while in the 
last 7.8 ns, no constraints were applied. General Amber force field (GAFF) parameters 
were assigned to the ligand, while partial charges were calculated using the AM1-BCC 
method as implemented in the Antechamber suite of AMBER 10. The final structure of 
the complex was obtained as the average of the last 5.5 ns of MD minimized by the CG 
method until a convergence of 0.05 kcal/mol•Å. The average structure was obtained 
using the ptraj program implemented in AMBER 10. 
Results and discussion. In order to understand and characterize the interaction of 
the synthesized compounds with LDH-A active site, one of the most promising ligands, 
compound 3.139 (Section 3.8.1), was analyzed by docking modeling studies into an 
open loop conformation of the enzyme. The compound was docked into LDH-A using 
the GOLD program [126] and the best pose was used as starting geometry for 
molecular dynamics (MD) calculations. Ten nanoseconds of MD simulation with 
explicit water were carried out, in the first 1.2 ns all the α carbons of the protein were 
blocked with a harmonic force constant, which decreased during these 1.2 ns from 10 
to 1 kcal/mol•Å2, while in the last 7.8 ns no constraints were applied. The system 
reached an apparent equilibrium after about 0.5 ns of MD, since the total energy for the 
residual nanoseconds remained constant (see panel A in Fig. 3.42). Analyzing the root-
mean-square deviation (RMSD) from the initial model of the α carbons of the proteins, 
we observed that, after an initial increase, the RMSD remained approximately constant 
around the value of 1.5 Å during the last 5.5 ns (see panel B in Fig. 3.42). 
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Figure 3.42. Analysis of the MD simulation of the LDH-3.139 complex. Total energy (kcal/mol) of the 
system plotted vs time (A) and RMSD in angstrom of the α carbon of the protein from the starting model 
structure during the simulation vs time (B) are reported. 
 
Fig. 3.43 shows the minimized structures of the average of the last 5.5 ns of the MD 
simulation. In the proposed model the carboxylic group of compound 3.139 shows a 
strong interaction with R169 and T248 (see panel A in Fig. 3.43), whereas the N-
hydroxy group shows an H-bond interaction with the nitrogen backbone of T248 and a 
water molecule that mediates the interaction of 3.139 with the catalytic H193 (see 
panels A and B in Fig. 3.43).  
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Figure 3.43. MD simulation results for the complex of LDH with 3.139. Overall disposition of the ligand 
into LDH (A, residues 240-245 are hidden for a better visualization) and LDH-ligand interactions (B). 
 
An important role of residues R169, T248 and H193 for the ligand interaction has 
been already highlighted by the analysis of the X-ray structure of the LDH complexed 
with the natural substrate pyruvate and NADH (Fig. 3.44). In fact, this structure 
confirms the interactions between the pyruvate carboxylate group with the arginine and 
threonine residues of the enzyme, as well as that occurring between the carbonyl 
oxygen atom of the substrate and the above-mentioned histidine aminoacid (compare 
Figures 3.43 and 3.44). With regards to the 6-phenyl substituent, it shows lipophilic 
interactions with V32 and Y247. 
 
 
Figure 3.44. A representative example of a 1.80 Å resolution X-Ray structure of the complex of LDH with 
NADH (green) and pyruvate (purple): detailed view of the catalytically active site [PDB code: 3D4P]. 
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The H-bond analysis of the last 5.5 ns of the MD simulation seems to confirm the 
interactions described above. In particular, as shown in Table 3.17, it is interesting to 
note that the interaction between the water molecule (bound to H193) and the N-
hydroxy group is highly conserved during MD, confirming the important role of this N-
hydroxy substituent. Furthermore, the analysis of the X-ray structure of Plasmodium 
falciparum isoform of lactate dehydrogenase complexed with 3,7-dihydroxy-2-
naphthoic acid [69], revealed the presence of a water molecule able to mediate a H-
bond between an OH group of this ligand and the catalytic H193 of the enzyme, thus 
supporting the possible presence of this water molecule also in the human LDH-A 
form, as we have found with our calculations. As for the 4-(trifluoromethyl)indole 
central scaffold, it results to be placed in a cleft mainly delimited by H193, G194, 
A238, V241, I242, T248. Moreover, N138 is placed in close proximity to the 
trifluoromethyl substituent in our model. According to our calculations, the 6-phenyl 
group is directed towards the entrance of the binding site cavity and shows lipophilic 
interactions with I242 and Y247. Overall, this molecular portion seems to partially 
overlap with the region occupied by the cofactor NADH in the human LDH-A X-ray 
structure [23]. 
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Table 3.17. Hydrogen Bonds Analysis of the LDH-3.139 interactions during the last 5.5 ns of MD 
Simulation. 
 
donor acceptorh acceptor distance (Å) % occupied 
WAT@O LIG@H LIG@O3 2.6 99 
LIG@O1 T248@H1 T248@OG1 2.7 93 
LIG@O2 R169@H2 R169@NH2 2.8 88 
LIG@O1 R169@H1 R169@NH1 2.8 70 
LIG@O3 T248@H2 T248@N 2.9 51 
H193@NE2 WAT@H2 WAT@O 2.8 41 
H193@NE2 WAT@H1 WAT@O 2.8 37 
 
In order to analyze the interactions of other synthesized and tested compounds, two 
representative compounds belonging to the aryl-substituted N-hydroxyindole class, 
compounds 3.112 and 3.114, were docked in the minimized structure of the protein 
extracted from the complex with 3.139.  
Then the resulting protein-ligand complexes were energy minimized. Docking of 
compound 3.112 (Fig. 3.45) shows a binding mode very similar to that found for 3.139, 
with the carboxylic group of compound 3.112 showing a strong interaction with R169 
and T248 and the N-hydroxy group displaying an H-bond interaction with the nitrogen 
backbone of T248 and a water molecule that mediates the interaction of 3.112 with the 
catalytic H193. The shift of the 6-phenyl group to position 5 determines the loss of the 
interaction with V32 and Y247 and the presence of a lipophilic interaction with L110. 
Therefore, in agreement with the good activity of both 3.139 and 3.112, they show a 
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very similar binding disposition with the formation of the same hydrogen bonds and 
similar lipophilic interactions.  
 
 
Figure 3.45. Docking analysis of compound 3.112. Overall disposition of the ligand into LDH (A, residues 
240-245 are hidden for a better visualization) and LDH-ligand interactions (B). 
 
In agreement with the very high activity of compound 3.114, the docking analysis 
of this compound highlights the same H-bonds showed by compound 3.139 and 3.112, 
the lipophilic interactions of the 6-phenyl ring with V32 and Y247 and the interaction 
of the 5-phenyl ring with L110 (see Fig. 3.46). 
 
 
Fig. 3.46. Docking analysis of compound 3.114. Overall disposition of the ligand into LDH (A, residues 240-
245 are hidden for a better visualization) and LDH-ligand interactions (B). 
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3.9. TRIAZOLE-BASED DERIVATIVES 
 
3.9.1. Synthesis 
During my PhD work, we directed our attention to the design and the synthesis of 
triazole-based N-hydroxyindoles due to the synthetic accessibility of this kind of 
structure, obtained by Huisgen 1,3 dipolar cycloaddition, generally simply referred as 
Click Chemistry. Although this popular definition, the term Click Chemistry is used 
improperly for this reaction, because it was coined by K. Berry Sharpless referring to a 
more general concept of a chemistry able to generate substances quickly and safely, by 
joining small units together, giving high yields and inoffensive by-products, without the 
need of complex purification processes (such as chromatography, while distillation and 
crystallization are preferred) and without the use of toxic solvent, so usually preferring 
water-based reactions [129]. Certainly, one of the most famous reactions within the 
Click Chemistry philosophy is the Huisgen cycloaddition, consisting in a copper-
catalyzed triazole formation by a reaction between azides and terminal alkynes at room 
temperature in a mixture of water and tert-butanol, with no efforts to exclude oxygen 
from the reaction medium. However, even this simple reaction may require high 
temperature and it may results in the production of a mixture of the 1,4 and 1,5 
regioisomers, although the copper(I) catalyst strongly directs towards the 1,4-
regioselectivity, so affording 1,4-disubstituted 1,2,3-triazoles (Fig. 3.47). As for Cu(I) 
catalyst, the best sources proved to be Cu2+ salts, such as CuSO4.5H2O, which are 
reduced in situ by the reductant sodium ascorbate. 
 
 
Figure 3.47. Possible formation of the 1,4- and 1,5-regiosiomers from the Huisgen cycloaddition. 
 
The proposed mechanism for the catalytic cycle, which is still under study, is 
exemplified in Fig. 3.48. It starts with the formation of Cu(I) acetylide (step A, 
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supported also by the lack of reactivity shown by internal alkynes), then azide attack on 
the copper atom of this intermediate (step B), which subsequently leads to the formation 
of the triazole (step C) where the copper is still linked on the just formed heterocycle. 
Finally, the cycle ends with the detachment and the regeneration of the copper catalyst 
and the formation of the triazole (step D). 
 
 
Figure 3.48. Probable catalytic cycle leading to triazole formation in the Huisgen cycloaddition. 
 
Using this reliable and simple strategy, which shows a wide tolerance for both the 
alkyne and the azide substrates, we obtained a relatively numerous class of triazole-
bearing NHI derivatives. We then investigated the effect on LDH-A inhibition caused 
by presence of variously substituted triazoles in position 4, 5 and 6 of the NHI scaffold, 
as shown by synthesized compounds 3.168a-c, 3.169a-d and 3.170a-f, respectively 
(Fig. 3.49). In details, we introduced a series of lipophilic and hydrophilic exploratory 
groups on the triazole ring, which acts as a linker between them and the NHI 
heterocycle. Possibly, these substituents may be placed in the entrance groove of the 
LDH active site, which normally hosts the cofactor NADH, so they may potentially gain 
new interactions with the enzyme, some of which may be similar to those established 
with NADH itself. 
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Figure 3.49. Structural class of triazole derivatives 3.168a-c, 3.169a-d and 3.170a-f. Commercially available 
terminal alkynes, used in the cycloaddition reaction for triazole formation, are listed on the left column. 
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The azide precursors 3.174-3.176 were synthesized from the opportune 
commercially available methyl-nitro-substituted aniline 3.171-3.173, dissolved in 
aqueous hydrochloridric acid, in the presence of sodium nitrite and sodium azide 
(Scheme 3.17). Sodium nitrite is the source of the nitrosyl cation (NO+), which 
undergoes a nucleophilic attack by the primary amminic nitrogen of the aniline, 
resulting in the formation of a diazonium cation, which eliminates molecular nitrogen 
and reacts with sodium azide by incorporating the N3 moiety in the aromatic structure 
[130]. 
 
 
Scheme 3.17. a) NaNO2, NaN3, aqueous HCl, H2O, -5/0 °C to RT. 
 
Compounds 3.168a-c, possessing a triazole moiety in position 4 of the NHI 
heterocycle, were synthesized from azide 3.174 by “click” reactions with different 
terminal alkynes, such as, phenylacetylene 3.177, 1-hexyne 3.178 and 3-butyn-1-ol 
3.179, in the presence of catalytic amount of copper sulfate pentahydrate and sodium 
ascorbate in a mixture of water and tert-butanol, affording triazole derivatives 3.180a, 
3.180b and 3.180c, respectively (Scheme 3.18). In particular, only condensation of 
azide 3.174 and phenylacetylene 3.177 gave good yield at room temperature, whereas in 
the other two cases longer reaction times and higher temperatures (80 °C) were required 
to obtain the precipitation from the reaction mixture of the desired products [131, 132]. 
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The resultant triazoles were then subjected to the same synthetic pathway described 
before for the synthesis of other NHI derivatives, which comprises ketoester formation, 
cyclization with stannous chloride in DME and hydrolysis of the methyl esters.  
During previous attempts, we tried to treat the azide derivatives with sodium hydride 
and dimethyl oxalate to form the ketoester chain directly, in order to maintain the azide 
group up to the reductive cyclization step and then subject these common azide 
intermediates to the treatment with different alkynes, in an attempt to postpone as much 
as possible the diversification step. Unfortunately, azides are instable precursors and 
they polymerize under alkylating conditions, so we were forced to apply the synthetic 
strategy displayed in Scheme 3.18. 
 
N
N
N
R1
N
COOH
OH
N
N
N
R1
N
N
N
N
COOMe
OH
R1
N3
CH3
NO2
R1
N
N
N
R1
CH3
NO2 NO2
COOMe
O
3.174
3.177 R1=Ph;
3.178 R1=(CH2)3CH3;
3.179 R1=(CH2)2OH
3.177-3.179 3.180a-c 3.181a-c
3.182a-c 3.168a-c
3.180a R1=Ph;
3.180b R1=(CH2)3CH3;
3.180c R1=(CH2)2OH
3.168a R1=Ph;
3.168b R1=(CH2)3CH3;
3.168c R1=(CH2)2OH
a b c
d
 
Scheme 3.18. a) appropriate alkyne, CuSO4.5H2O, sodium ascorbate, H2O/tBuOH (1:1), RT; for 3.178 and 
3.179: 80 °C b) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; c) SnCl2·2H2O, dry DME, 4Å MS, 0 °C to 
RT; d) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
 
The same sequence of reactions shown in Scheme 3.18 was adopted for the 
preparation of compounds 3.169a-d (Scheme 3.19). During the synthesis of compound 
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3.184a, we observed the simultaneous formation of its 1,5-regioisomer, however we 
succeeded in the isolation from the reaction mixture of the desired 1,4-regioisomer, 
which was unambiguously identified in the NMR spectrum by the presence of the 
typical singlet over 8 ppm relative to the triazole proton. 
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OH
CH3
NO2
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CH3
NO2 NO2
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3.175
3.177 R1=Ph;
3.178 R1=(CH2)3CH3;
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3.177-3.179, 3.183 3.184a-d 3.185a-d
3.186a-d 3.169a-d
3.184a R1=Ph;
3.184b R1=(CH2)3CH3;
3.184c R1=(CH2)2OH;
3.184d R1=COOH
3.169a R1=Ph;
3.169b R1=(CH2)3CH3;
3.169c R1=(CH2)2OH;
3.169d R1=COOH
a b c
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N
N
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Scheme 3.19. a) appropriate alkyne, CuSO4.5H2O, sodium ascorbate, H2O/tBuOH (1:1), RT; for 3.179 and 
3.183: 80 °C b) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; c) SnCl2·2H2O, dry DME, 4Å MS, 0 °C to 
RT; d) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
 
Scheme 3.20 displays the synthesis of compounds 3.170a-e, bearing the triazole 
substituents in position 6. Even in this series, some substrates required heating in the 
cycloaddition step (step a) for an efficient completion of the reaction. In particular the 
condensation of 3.176 with 4-pentynoic acid 3.187 was particularly slow, so we 
increased the temperature up to 100 °C in a closed vessel; even in this case isolated 
yield of intermediate 3.190c remained rather low (39%). It is important to note that the 
same reaction with 5-hexynoic acid 3.188 led to the formation of a mixture of 1,4- and 
1,5-regioisomer triazoles 3.190d and 3.193 (Scheme 3.21), which were not separable by 
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chromatographic methods, so we pursued all the following steps on that regioisomeric 
mixture, until the reductive cyclization step when it was possible to separate the two 
isomers 3.192d and 3.195. From this point, we separately hydrolyzed also the 1,5-
isomer 3.195 to give the derivative 3.196. As for this series of 6-triazole-substituted 
NHI derivatives, the synthesis of the phenyl-triazole derivative (formed by reaction with 
phenylacetylene) could not be completed due to the formation of excessively high 
amounts of indole side-product in the reductive cyclization step of the corresponding 
ketoester, as well as to the degradation of the very small amounts of the NHI methyl 
ester during the hydrolysis step.  
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CH3
NO2 NO2
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O
3.176
3.179 R1=(CH2)2OH;
3.183 R1=COOH;
3.187 R1=(CH2)2COOH;
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3.187-3.189 3.190a-e 3.191a-e
3.192a-e 3.170a-e
3.170a R1=(CH2)2OH;
3.170b R1=COOH;
3.170c R1=(CH2)2COOH;
3.170d R1=(CH2)3COOH;
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3.190a R1=(CH2)2OH;
3.190b R1=COOH;
3.190c R1=(CH2)2COOH;
3.190d R1=(CH2)3COOH;
3.190e R1=C5H5N
 
Scheme 3.20. a) appropriate alkyne, CuSO4.5H2O, sodium ascorbate, H2O/tBuOH (1:1), RT; for 3.179: 80 °C; 
for 3.187: 100 °C; for 3.189: 45 °C; b) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; c) SnCl2·2H2O, dry 
DME, 4Å MS, 0 °C to RT; d) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
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Scheme 3.21. a) CuSO4.5H2O, sodium ascorbate, H2O/tBuOH (1:1), RT; b) (COOMe)2, NaH 60%, dry DMF, 
–15 °C to RT; c) SnCl2·2H2O, dry DME, 4Å MS, 0 °C to RT; d) chromatographic separation; e) aqueous 2N 
LiOH, THF/MeOH (1:1), RT. 
 
Later, we carried out the synthesis of “NHI-dimer” 3.170f, in which 2 N-
hydroxyindole portions are spaced by a 1,3-ditriazole-propylene chain. The synthesis 
was accomplished as illustrated in Scheme 3.22, starting from the cycloaddition of 2 
equivalent of azide 3.176 with 1 equivalent of 1,6-heptadiyne 3.197.  
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Scheme 3.22. a) CuSO4.5H2O, sodium ascorbate, H2O/tBuOH (1:1), RT; b) (COOMe)2, NaH 60%, dry DMF, 
–15 °C to RT; c) H2PO2Na·H2O, Pd-C 10%, H2O/THF (1:1), 40 °C; d) aqueous 2N LiOH, THF/MeOH (1:1), 
RT. 
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During biological evaluation of our triazole-based inhibitors (see enzymatic assay 
Section below), the phenyl-derivative 3.168a showed an appreciable inhibitory activity, 
and also COOH-containing triazole compounds, such as for example 3.169d, displayed 
some levels of inhibitions. Consequently, we applied our efforts in the synthesis of more 
challenging triazole derivatives, trying to combine the phenyl substitution and the 
presence of a carboxylic group. In this research line, compounds 3.201-3.205 (Fig. 
3.50), bearing carboxy-substituted phenyl groups (m- or p-COOH) in position 4 of the 
triazole rings, were prepared, with the same aim of enriching of polar moieties our 
inhibitors and so acquiring new possible interactions in the enzyme active site. 
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Figure 3.50. Triazole derivatives 3.201-3.205. 
 
For the synthesis of this series of compounds, the appropriate terminal alkynes 
3.210a and b were synthesized according to Scheme 3.23, by exploiting a reliable and 
simple common procedure for the preparation of both meta and para-ethynyl benzoic 
acids. Commercially available 3- and 4-bromobenzoic acids 3.206a and b were 
subjected to a Fischer esterification in methanol with a catalytic amount of sulfuric acid 
in refluxing conditions to give the corresponding methyl esters 3.207a and b. 
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Subsequently, these aryl bromides were reacted with the alkyne 2-methyl-3-butyn-2-ol 
(often abbreviated as MEBYNOL) in a Sonogashira coupling which is carried out with 
tetrakis(triphenylphosphine)palladium as the catalyst and copper iodide as the co-
catalyst, in the presence of triethylamine [133]. The supposed mechanism includes two 
catalytic cycles, one relative to the copper catalyst and another one relative to the 
palladium catalyst. Briefly, it starts with the formation of a π-complex between the 
alkyne and the copper atom, increasing the acidity of the terminal proton, so that a weak 
base as triethylamine can remove it. This intermediate then reacts with the palladium-
aryl bromide complex, affording the desired product and regenerating the catalyst. The 
protecting groups of alkynes 3.208a and b needed to be removed by treatment with 
sodium hydroxide and butanol in refluxing conditions [134], but the desired cleavage 
was accompanied by the simultaneous saponification of the methyl esters, so we 
decided to esterify again the benzoic acids 3.209a and b in order to facilitate the next 
synthetic steps and purifications. 
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R2
Br
R1
R2
R1
R2
R1
R2
R1
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CH3
CH3
3.206a-b 3.207a-b 3.208a-b
3.209a-b 3.210a-b
a b c
a
3.206a R1=COOH, R2=H;
3.206b R1=H, R2=COOH
3.207a R1=COOMe, R2=H;
3.207b R1=H, R2=COOMe
3.209a R1=COOH, R2=H;
3.209b R1=H, R2=COOH
3.210a R1=COOMe, R2=H;
3.210b R1=H, R2=COOMe  
Scheme 3.23. a) MeOH, conc. H2SO4, reflux; b) 2-methyl-3-butyn-2-ol, Pd(OAc)2, PPh3, CuI, Et3N, dry 
DMF, reflux; c) NaOH, n-BuOH, reflux. 
 
For the synthesis of compound 3.201 (Scheme 3.24), azide 3.174 and alkyne 3.210a 
were subjected to a Huisgen cycloaddtion in a microwave reactor at 300 W of power, 
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which permitted a favourable reduction of reaction times, albeit this harsh conditions 
favoured the simultaneous formation of the undesired 1,5-regioisomer together with the 
desired 1,4-adduct [135]. The chromatographic separation of the mixture of the two 
isomers afforded pure compound 3.211, which was then alkylated with sodium hydride 
and dimethyl oxalate, cyclized using ipophosphite and palladium over charcoal and at 
last hydrolyzed in the presence of increased (double) amounts of lithium hydroxide in 
order to efficiently saponify both the methyl esters present in the structure 3.213 to give 
compound 3.201. The corresponding product, bearing the carboxylic acid in position 
para of the phenyl ring, could not be synthesized, because of the unsuccessful formation 
of the ketoester intermediate, for reasons that we are not able to find as of yet. 
 
 
Scheme 3.24. a) CuSO4.5H2O, sodium ascorbate, H2O/tBuOH (1:1), μW, 15 min.; b) (COOMe)2, NaH 60%, 
dry DMF, –15 °C to RT; c) H2PO2Na·H2O, Pd-C 10%, H2O/THF (1:1), RT; d) aqueous 2N LiOH, 
THF/MeOH (1:1), RT. 
 
The synthetic procedure used for compound 3.201 (Scheme 3.24), was adopted also 
for the preparation of the similar derivatives 3.202, 3.204 and 3.203, 3.205 (Schemes 
3.25-3.26). In all the cases, microwave-assisted triazole formation was preferred to the 
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classical conditions for the abbreviation of the reaction time. The lower regioselectivity 
of this procedure was not an obstacle to the obtainment of the desired compounds, 
thanks to the successful chromatographic purifications. 
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Scheme 3.25. a) CuSO4.5H2O, sodium ascorbate, H2O/tBuOH (1:1), μW, 15 min.; b) (COOMe)2, NaH 60%, 
dry DMF, –15 °C to RT; c) SnCl2·2H2O, C6H5SH, Et3N, CH3CN, RT; d) aqueous 2N LiOH, THF/MeOH 
(1:1), RT. 
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Scheme 3.26. a) CuSO4.5H2O, sodium ascorbate, H2O/tBuOH (1:1), μW, 15 min.; b) (COOMe)2, NaH 60%, 
dry DMF, –15 °C to RT; c) for 3.218a: Pb, TEAF, MeOH, 55 °C; for 3.218b: SnCl2·2H2O, dry DME, 4Å MS, 
0 °C to RT; d) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
 
3.9.2. Enzymatic assays 
The series of triazole-based compounds (Table 3.18) generally revealed lower 
potencies on the enzyme, with only a few exceptions. The insertion of triazole group in 
position 4 of the central heterocycle led to the obtainment of active compounds only in 
the case of the phenyl-substituted derivative 3.168a, while the use of alkyl (3.168b) or 
hydroxyl-alkyl chains (3.168c) as substituents of the triazole ring did not produce active 
inhibitors. Compounds 3.169a-d, bearing the triazole motif in position 5, were mostly 
inactive (3.169a and 3.169c), or they were not tested for solubility problems in the assay 
conditions (3.169b); among them, compound 3.169d, possessing a carboxylic group 
directly linked to the triazole ring, showed a weak 33% of inhibition on the enzyme. A 
similar behaviour was observed in the series of derivatives bearing the triazole moiety 
in position 6 of the NHI scaffold. In this series, variable percentages of inhibition could 
only be found with those derivatives bearing a carboxylic group, either directly linked  
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to the triazole ring (3.170b), or spaced by an alkyl chain (3.170c, 3.170d and its 1,5-
regioisomer 3.196). Among these compounds the percentages of inhibition range from 
6-8% of the carboxy-propyl derivatives 3.170d and 3.196 to 27% of the carboxy-ethyl 
analogue 3.170c, whereas compound 3.170b possesses an intermediate potency, which 
is, by the way, lower than that of its 5-substituted analogue 3.169d. Among these 6-
triazole-substituted NHIs, the hydroxyethyl chain of compound 3.170a and the use of a 
pyridine cycle in compound 3.170e did not get any positive results: 3.170a was 
completely inactive and 3.170e was too insoluble in the assay conditions. We were 
initially encouraged by the biological data obtained with the carboxylic-substituted 
triazole derivatives, as well as by the promising Ki value of phenyl-triazole derivative 
3.168a, we planned to combine their structural features (COOH group and phenyl ring 
bound to the triazole moiety) and, therefore, we synthesized compounds 3.201-3.205. 
Unluckily, only the meta-carboxylic derivatives 3.201 (Ki = 57 μM vs. NADH and 86 
μM vs. Pyr) and 3.203 (Ki = 50 μM vs. NADH and 45 μM vs. Pyr) maintained an 
acceptable potency, albeit lower than non-carboxylic analogue 3.168a. Moreover, 
compound 3.201 showed a very similar inhibition potency also on the other isoform (Ki 
= 88 μM vs. NADH on LDH-B) and it represents the first compound of this class that 
does not show an isoform-selective inhibition. The other COOH-phenyl-substituted 
compounds of the triazole series (compounds 3.202, 3.204 and 3.205) displayed only 
modest activities (3.202 and 3.205) or they were totally inactive (3.204). Finally, the 
dimer 3.170f showed a very good inhibitory activity on LDH-A, but, unfortunately, it 
proved to possess a low level of isoform-selectivity because it also caused a notable 
32% inhibition on LDH-B. 
 
 
 
 
 
 
 
 
 
Inhibitors of lactate dehydrogenase A 
170 
 
Table 3.18. Inhibition data on LDH-5 (LDH-A4) and LDH-1 (LDH-B4) for compounds 3.168a-c, 3.169a-d, 
3.170a-f, 3.196, 3.201-3.205. 
Cpd Structure Inhibition values LDH-5a LDH-1b
3.168a 
 
Ki = 27.5 μM (NADH) 
 43.7 μM (Pyr) n.a. 
3.168b 
 
n.a. - 
3.168c 
 
5% - 
3.169a 
 
n.a. - 
3.169b 
 
n.t. - 
3.169c 
 
n.a. - 
3.169d 
 
37% indoled 
33% - 
3.170a NOH
COOH
N
N N
HO
 
19% indoled 
n.a. - 
3.170b  
26% indoled 
17% - 
3.170c  
31% indoled 
27% - 
3.170d N
COOH
OH
N
N N
HOOC
 
30% indoled 
6% - 
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3.196 
 
10% indoled
8% - 
3.170e NN
OH
COOH
N NN  
n.t. - 
3.170f 
 
Ki = 20.7 μM (NADH) 
 37.4 μM (Pyr) 32.6% 
3.201 Ki = 57 μM (NADH)  86 μM (Pyr) 
Ki = 88.7 μM 
(NADH) 
3.202 15%c - 
3.203 NN
OH
COOH
N N
HOOC
 
Ki = 50 μM (NADH) 
 45 μM (Pyr) n.a.
c 
3.204 n.a.b - 
3.205 NN OH
COOH
N N
HOOC
 
26% indoled 
27%c - 
 
 
a compounds tested at 250 μM, b compounds tested at 125 μM, c compounds tested at 100 μM, d compounds 
tested as a mixture with the reported percentage of indole. n.a. = not active. n.t. = compounds not tested for 
solubility problems. 
 
3.9.3. Molecular modeling studies 
Molecular modeling studies of one of the most active triazole derivatives, 3.168a, 
demonstrated that the presence of a triazole-phenyl group in position 4 allows the 
interaction of the compound with a different zone of the binding site. As shown in Fig. 
3.51, docking of compound 3.168a shows a binding mode of the central 1-hydroxy-H-
indole-2-carboxylic scaffold very similar to that found for the other analyzed 
compounds. The carboxylic group of compound 3.168a shows a strong interaction with 
R169 and T248 and the N-hydroxy group shows an H-bond interaction with the nitrogen 
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backbone of T248 and a water molecule that mediates the interaction of 3.168a with the 
catalytic H193. As shown in Fig. 3.51, the phenyl group linked to the triazole ring 
displays a favorable π- π interaction with Y239.  
 
 
Fig. 3.51. Docking analysis of compound 3.168a. Overall disposition of the ligand into LDH (A, residues 
240-245 are hidden for a better visualization) and LDH-ligand interactions (B). 
 
 
3.10. AMIDE AND SULFONAMIDE DERIVATIVES 
 
3.10.1. Synthesis 
Part of my PhD work concerned the synthesis of amide- and sulfonamide-substituted 
NHI derivatives. We initially planned to introduce amide groups in positions 5 and 6 of 
the NHI structure to explore if the presence of these kinds of groups could be beneficial 
for LDH-A inhibition activity. The first synthesized amides 3.220a-d and 3.221a-d are 
summarized in Fig. 3.52. The choice of the combinations of the various substituents on 
the amidic nitrogen was dictated by the availability of the precursors and also by the 
synthetic feasibility of both intermediates and target molecules. The use of the 
cyclopropane sulfonamide group, which is a versatile building block for many 
biologically active compounds, rises from our initial idea to introduce polar moieties on 
N-hydroxyindoles in order to gain new hydrophilic interactions in the LDH-A active 
site between the enzyme and our inhibitors. In particular, this group can be considered 
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as a bioisoster of a phosphate group, then it should be able to mimick the diphosphate 
portion present in the LDH-cofactor NADH.  
 
 
Cpd R1 R2 Cpd R1 R2 
3.220a   3.221a   
3.220b  3.221b  
3.220c   3.221c 
3.220d  3.221d  S
O O
 
 
Figure 3.52. Structures of 6- and 5-amido-substituted compounds 3.220a-d and 3.221a-d, respectively. 
 
The synthesis of N-unsubstituted amide derivatives 3.220a and 3.221a was 
accomplished as shown in Scheme 3.27. Commercially available benzamides 3.222 and 
3.223 were treated with sodium hydride and dimethyl oxalate for the synthesis of the 
respective ketoesters, but the proper formation of ketoester chains was accompanied by 
the alkylation of the primary amidic groups, thus producing compounds 3.224 and 
3.225. These labile immidic products were subsequently hydrolyzed by exploiting the 
slight acidity of silica gel in methanol to selectively remove the -COCOOMe moiety 
linked to the amidic nitrogen, whereas the more stable ketoester chain was not affected 
by these conditions. Then, desired ketoesters 3.226a-b were cyclized with stannous 
chloride by carefully maintaining the temperature at 0 °C for all the reaction time to 
prevent the formation of the over-reduced indole side-product; however, even under 
those conditions, 3.227a was not obtained as a pure compound, but it was isolated in a 
mixture containing a 50% of the corresponding indole. Finally hydrolysis yielded the 
desired products 3.220a (together with a 50% of its indole analogue) and pure 3.221a. 
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Scheme 3.27. a) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; b) SiO2, MeOH, RT; c) SnCl2·2H2O, dry 
DME, 4Å MS, 0 °C; e) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
 
Amides 3.220b and 3.221b were prepared starting from the acid chlorides 3.228 and 
3.229: 4-methyl-3-nitrobenzoylchloride 3.228 is commercially available, while 3.229 
was obtained by reaction of 3-methyl-4-nitrobenzoic acid 3.90g with oxalyl chloride in 
dichloromethane (Scheme 3.28). Then, acid chlorides 3.228 and 3.229 were reacted 
with an excess of N-methylaniline in DCM in a closed vessel, affording amides 3.230 
and 3.231, which, at this point, followed the same synthetic steps of alkylation, 
reductive cyclization and hydrolysis seen before for the synthesis of other NHI 
derivatives. It is interesting to note that only ketoester 3.232b was obtained with a low 
yield, due to the contemporaneous formation of a methyl ester side product, generated 
by a nucleophile attack of MeO-, formed in the reaction medium from dimethyl oxalate, 
to the amidic group, resulting in the formation of a di-ester side product, which could be 
easily separated from the desired intermediate by column chromatography. Compounds 
3.220c and 3.221c were achieved by means of a synthetic path similar to the one 
exemplified in Scheme 3.28; in this case we used dimethylamine and morpholine 
instead of N-methylaniline for the preparation of their amidic nitrotoluene intermediates 
3.234 and 3.235 (Scheme 3.29). 
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Scheme 3.28. a) (COCl)2, DCM, RT; b) N-methylaniline, DCM, RT; c) (COOMe)2, NaH 60%, dry DMF, –15 
°C to RT; d) SnCl2·2H2O, dry DME, 4Å MS , 0 °C; e) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
 
 
Scheme 3.29. a) (COCl)2, DCM, RT; b) for 3.234: dimethylamine, DCM, RT; for 3.235: morpholine, DCM, 
RT c) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; d) SnCl2·2H2O, dry DME, 4Å MS, 0 °C; e) aqueous 
2N LiOH, THF/MeOH (1:1), RT. 
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Cyclopropansulfonamide moiety was inserted in position 6 of the NHI nucleus by a 
reaction of commercially available cyclopropane sulfonamide (abbreviated CPS, in 
Scheme 3.30) with 4-methyl-3-nitrobenzoylchloride 3.228 using triethylamine as the 
base [136] and in position 5 by condensation with the synthesized benzoic derivative 
3.91g with CDI as the condensing agent and DBU as the base [137]. In both cases, the 
reactions proceeded with good yields (70-80%), so both the carboxylic acid and acid 
chloride proved to be equally efficient condensation substrates for CPS, pending the use 
of respectively appropriate reaction conditions. Then ipophosphite and palladium 
promoted the reductive cyclization of ketoesters 3.239 and 3.240 to compounds 3.241a 
and 3.241b, respectively, which were hydrolyzed to get the desired products 3.220d and 
3.221d.  
 
CH3
NO2
O
Cl
CH3
NO2
O
H
N
S
O O
NO2
O
H
N
S
O O
COOMe
O
CH3
NO2 NO2
COOMe
O
NO2
COOMe
O
O
N
H
S
O O
N
COOMe
OH
N
COOH
OH
b c
3.90g 3.91g 3.240
R1 R1
R2
a b
R2
d
e
3.228
HO
O
HO
O
3.238 3.239
3.241a-b
3.241a R1=H, R2=
O
N
H
S
OO
3.241b R1=
O
N
H
S
OO
R2=H,
3.220d R1=H, R2=
O
N
H
S
OO
3.221d R1=
O
N
H
S
OO
R2=H,
3.220d, 3.221d
 
Scheme 3.30. a) CPS, Et3N, DCM, 0 °C to RT; b) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; c) CPS, 
CDI, DBU, dry THF, RT; d) H2PO2Na·H2O, Pd-C 10%, H2O/THF (1:1), RT; e) aqueous 2N LiOH, 
THF/MeOH (1:1), RT. 
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Amide derivatives proved to be very weak LDH-A inhibitors (see enzymatic assay 
Section below), therefore we did not complete all the possible structural combinations 
of these substituents in the various positions of the NHI scaffold. We rather shifted our 
interest to the design of sulfonamide-substituted N-hydroxyindoles. We started this 
series with the synthesis of three representative compounds, to find the best position for 
the introduction of this kind of moiety, as well as, the most appropriate substituents of 
the sulfonamidic nitrogen atom for the development of this class. These compounds are: 
3.242, which bears a N,N-dimethyl sulfonamide in position 6; 3.243, possessing a N-
methyl-N-phenyl sulfonamide in the same position 6; 3.244, where the same N-methyl-
N-phenyl sulfonamide is shifted to position 5 (Fig. 3.53). 
 
 
Figure 3.53. Sulfonamide compounds 3.242-3.244. 
 
The preparation of compounds 3.242 and 3.243 proceeded following a synthetic 
pathway that is similar to that already described for the amide derivatives (Scheme 
3.31). 4-Methyl-3-nitrobenzenesulfonylchloride 3.245 was reacted with an excess of the 
appropriate amine, dimethylamine for 3.246a and N-methyalaniline for 3.246b, to get 
the relative sulfonamide products. Pure cyclized methyl ester 3.248a was obtained by 
simply treating 3.247a with stannous chloride. On the contrary, the same reaction 
conditions applied to 3.247b produced a relevant percentage of indole side product, 
whereas we were pleased to find that the use of sodium ipophosphite and catalytic 
palladium over charcoal gave the pure desired intermediate 3.248b. 
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Scheme 3.31. a) for  3.246a: dimethylamine, DCM, RT; for 3.246b: N-methylaniline, DCM, RT; b) 
(COOMe)2, NaH 60%, dry DMF, –15 °C to RT; c) for 3.247a: SnCl2·2H2O, dry DME, 4Å MS, 0 °C; for 
3.247b: H2PO2Na·H2O, Pd-C 10%, H2O/THF (1:1), RT; d) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
 
For the synthesis of compound 3.244 (Scheme 3.32), 3-methyl-4-
nitrobenzensulfonylchloride 3.251 was not commercially available, so 4-amino-3-
methylbenzenesulfonic acid 3.249 was first subjected to oxidation of the aniline NH2 
group with hydrogen peroxide in refluxing acetic acid [138]. The resulting nitro-
substituted sulfonic acid derivative 3.250 was converted into sulfonyl chloride 3.251 by 
using thionyl chloride as the chlorinating agent in the presence of some drops of DMF, 
that acts as the catalyst, at 100 °C in a closed vessel [139]. Then, the synthesis followed 
the same steps we used for the preparation of compound 3.243, with the exception of 
the SnCl2-promoted reductive cyclization of ketoester 3.253, which was carried out in 
the presence of thiophenol and triethylamine, because these additives proved to improve 
the efficiency of that step. 
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Scheme 3.32. a) H2O2 35%, CH3COOH, 75 °C; b) SOCl2, dry DMF, 100 °C; c) N-methylaniline, DCM, RT; 
d) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; e) SnCl2·2H2O, C6H5SH, Et3N, CH3CN, RT; f) aqueous 2N 
LiOH, THF/MeOH (1:1), RT. 
 
Among these first sulfonamide derivatives, only compound 3.243 showed a notable 
inhibition activity on the enzyme, so we planned to make some structural modifications 
on this molecule that could provide an improvement in its activity on LDH-A, such as: 
1) substitution of the N-methyl group with a bulkier and more lipophilic n-butyl group 
(compound 3.255, Fig. 3.54); 2) introduction of substituents in the para position of the 
sulfonamidic phenyl ring (compounds 3.256-3.259, Fig. 3.54); 3) introduction of a 
phenyl spacer between the NHI core and the sulfonamide groups (compounds 3.260-
3.261, Fig. 3.54). 
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Figure 3.54. Compounds 3.255-3.261 deriving from structural developments of compound 3.243. 
 
Compound 3.255 (Scheme 3.33) was obtained in the same manner as its N-methyl-
substituted analogue 3.243, with the only exceptions of the use of the appropriate N-
butylaniline for the sulfonamide formation (step a, Scheme 3.33) and of the reagents 
used for the cyclization step (stannous chloride with thiophenol/triethylamine, step d, 
Scheme 3.33). 
 
 
Scheme 3.33. a) N-buthylaniline, DCM, RT; b) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; c) 
SnCl2·2H2O, C6H5SH, Et3N, CH3CN, RT; d) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
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Inhibitors 3.256-3.259 were obtained as illustrated in Scheme 3.34. For the 
sulfonamide formation step, only 3.265a could be obtained in high yield by simple 
condensation of sulfonyl chloride 3.245 with an excess N-methyl-p-toluidine in 
dichloromethane, whereas in the other three cases (3.265b-d) the use of catalytic 4-
dimethylaminopyridine (DMAP) in pyridine was preferred, because these latter 
conditions proved to considerably reduce reaction times and increase the isolated yields. 
In the cyclization step of all the sulfonamido-substituted ketoesters 3.266a-d, the use of 
SnCl2 and PhSH/Et3N always produced the cyclized methyl esters 3.267a-d in complex 
product mixtures containing a certain amount of impurities. After an optimization study, 
we found out that the use of metallic lead in TEAF afforded purer cyclized products, 
similarly to what we experienced in the preparation of cyclized intermediate 3.120d 
previously described (Scheme 3.6). This method was, then, preferred for the reaction of 
these sulfonamido-substituted substrates producing intermediates 3.267a-d. 
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Scheme 3.34. a) for 3.265a: N-methyl-p-toluidine, DCM, RT; for 3.265b-c-d: appropriate p-substituted N-
methylaniline, pyridine, DMAP, dry DCM, 0 °C to RT; b) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; c) 
Pb, TEAF, MeOH, 55 °C; d) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
 
The subsequent structural evolution concerned the introduction of a phenyl in 
position 6 as a linker between the N-hydroxyindole cycle and the sulfonamide group 
Inhibitors of lactate dehydrogenase A 
182 
 
(compounds 3.260-3.261, Fig. 3.54). These compounds were inspired by the 
combination of the structural characteristics contained in 6-phenyl-substituted NHI 
3.113 and sulfonamides such as 3.243, which both proved to be active LDH-A 
inhibitors. Initially, we started our synthetic studies (Scheme 3.35) on the simpler N,N-
dimethyl-sulfonamide derivative by reacting 4-bromo-N,N-
dimethylbenzenesulfonamide 3.268 with 4-methyl-3-nitrobenezeneboronic acid 3.127 in 
a microwave-assisted Suzuki coupling. Then, the same procedure was applied to the 
synthesized bromo derivative 3.271, but with poorer results (only 40% yield), so this 
substrate was subjected to a Suzuki coupling in the classical thermal conditions, this 
time obtaining compound 3.272 in 70% yield. Subsequently, the two nitrotoluenic 
substrates 3.269 and 3.272 were treated with sodium hydride and dimethyl oxalate to 
give ketoesters 3.273a-b, then SnCl2-induced cyclization in the presence of 
thiophenol/triethylamine and hydrolysis with lithium hydroxide afforded final products 
3.260 and 3.261. 
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Scheme 3.35. a) N-methylaniline, DCM, RT; b) for 3.268: 4-methyl-3-nitrobenezeneboronic acid 3.127, 
Pd(OAc)2, TBAB, Na2CO3, H2O, μW, 5 min; for 3.271: 4-methyl-3-nitrobenezeneboronic acid 3.127, 
Pd(OAc)2, PPh3, aqueous 2M Na2CO3, distilled toluene, abs. EtOH, 100 °C, 24 h; c) (COOMe)2, NaH 60%, 
dry DMF, –15 °C to RT; d) SnCl2·2H2O, C6H5SH, Et3N, CH3CN, RT; e) aqueous 2N LiOH, THF/MeOH 
(1:1), RT. 
 
Compound 3.259, possessing a chlorine atom in para position of the phenyl ring, 
proved to be the best LDH-A inhibitor (see enzymatic assay Section below) generated 
from the structural modifications of compound 3.243. On this basis, we completed our 
SAR studies of this sulfonamide class, by changing the position of the chlorine atom. So 
we decided to shift it form the para to the meta and ortho positions of the phenyl 
substituent, thus producing compounds 3.275 and 3.276, respectively (Fig. 3.55). 
Inhibitors of lactate dehydrogenase A 
184 
 
N
OH
COOH
S
N
OO
CH3
Cl 3.259
N
OH
COOH
S
N
OO
CH3
3.275
N
OH
COOH
S
N
OO
CH3
3.276Cl
Cl  
Figure 3.55. Chloro-substituted compounds 3.275 and 3.276 deriving from structural modifications of 
compound 3.259. 
 
Sulfonamides 3.277a and 3.277b were synthesized from commercially available 4-
methyl-3-nitrobenzenesulfonylchloride 3.245 by respectively using different reaction 
conditions (Scheme 3.36). Solvent-free condensation of 3.245 with 3-chloro-N-
methylaniline in the presence of anhydrous sodium bicarbonate successfully afforded 
compound 3.277a [140]. Unfortunately, the same reaction conditions produced 
sulfonamide 3.277b in very low yields, so we switched back to the already used 
condensation conditions, comprising catalytic DMAP and pyridine, which demonstrated 
to be the most suitable for the synthesis of this compound. For the cyclization step, we 
initially tried the same Pb/TEAF conditions that were efficiently employed for para-
substituted ketoesters 3.266a-d: however, in this case these reagents did not afford the 
proper cyclized products 3.279a-b, whereas they promoted the retro-Claisen reaction, 
forming the nitrotoluenic derivatives 3.277a-b. On the contrary, we optimized the 
stannous chloride/thiophenol conditions for these substrates, by decreasing the 
equivalents of the tin salt (1 eq. instead of 1.5 eq) for compounds 3.278a-b. With this 
way we were able to limit the formation of the over-reduced indole side products.  
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Scheme 3.36. a) for 3.277a: 3-chloro-N-methylaniline, anhydrous NaHCO3, RT; for 3.277b: 2-chloro-N-
methylaniline, pyridine, DMAP, dry DCM, 0 °C to RT; b) (COOMe)2, NaH 60%, dry DMF, –15 °C to RT; c) 
SnCl2·2H2O (1eq.), C6H5SH, Et3N, CH3CN, RT; d) aqueous 2N LiOH, THF/MeOH (1:1), RT. 
 
3.10.2. Enzymatic assays 
Enzymatic results regarding amide derivatives are summarized in Table 3.19. 
Generally, amides did not show encouraging results, all of them possessing very low 
inhibition percentages. The simple 6-amide-susbtituted derivative 3.220a proved to be 
slightly more active on the enzyme when compared to its analogue substituted in 
position 5 3.221a, with a 8% inhibition on LDH-A. The insertion of two methyl groups 
on the amidic nitrogen, as in compound 3.220c, nearly preserved the same very modest 
activity of 3.220a (6%), whereas the replacement of one of the two N-methyl groups 
with a phenyl ring (3.220b) caused the complete loss of inhibition activity. On the 
contrary, the insertion of methyl and phenyl groups on the amidic nitrogen in position 5 
in compound 3.221b led to a slightly increased potency with respect to that of 
compound 3.221a, so displaying an opposite trend relative to the 6-amide derivatives. 
When the nitrogen atom was included in a morpholine cycle (3.221c), no significant 
activity could be detected. Compounds 3.220d and 3.221d, bearing a 
cyclopropanesulfonamide group on the amidic nitrogen in positions 6 and 5, 
respectively, were both active, but with low inhibition percentage. Anyway 3.221d, 
with a poor 11% of inhibition at 250 μM, proved to be the most active compound of this 
Inhibitors of lactate dehydrogenase A 
186 
 
unsuccessful amide series, together with the N-methyl-N-phenylamide derivative 
3.221b, confirming that insertion of amides in position 5 of the N-hydroxyindole 
scaffold is preferred to the same modification in position 6. 
 
Table 3.19. Inhibition data on LDH-5 (LDH-A4) and LDH-1 (LDH-B4) for compounds 3.220a-d, 3.221a-d. 
Cpd Structure Inhibition values LDH-5a LDH-1
3.220a 
 
50% indoleb 
8% - 
3.220b N
COOH
OH
N
O
CH3
 
10% indoleb 
n.a. - 
3.220c N
COOH
OHO
N
CH3
H3C
 
40% indoleb 
6% - 
3.220d 
 
6.5% - 
3.221a n.a. - 
3.221b N
OH
COOH
N
O
CH3
 
50% indoleb 
11% - 
3.221c N COOH
OH
O
N
O
 
15% indoleb 
n.a. - 
3.221d 11% - 
 
 
a compounds tested at 250 μM, b compounds tested as a mixture with the reported percentage of indole. n.a. = 
not active. 
 
A different situation was found within the sulfonamide class of inhibitors, as 
reported in Table 3.20. In this case, the low activity showed by 5-sulfonamido-
substituted compound 3.244 shifted our main interest in the development of 
sulfonamide derivatives bearing this kind of substituents in position 6. In any case, the 
30% inhibition at 50 μM of this compound, being much better than the data obtained 
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with its amide analogue 3.221b, already confirmed that the sulfonamide class could be 
more promising than the previous amide series. From an analysis of the activity shown 
by the first 6-sulfonamide compounds obtained (3.242 and 3.243), it is evident that the 
presence of a phenyl ring on the sulfonamido-nitrogen atom is highly beneficial, 
contrarily to what had been previously observed for amide derivatives 3.220b and 
3.220c. As a matter of fact, N,N-dimethyl-substituted compound 3.242 had basically no 
activity on LDH-A, whereas its N-methyl-N-phenyl-substituted analog 3.243 proved to 
be a very promising sulfonamide derivative, with a Ki value of 17.1 μM (NADH) and 
9.3 μM (Pyr) on LDH-A, and no activity detected on LDH-B. Substituting the methyl 
with a bulkier alkyl chain (N-butyl analogue 3.255), the activity was substantially 
unmodified versus the cofactor NADH, while it decreased versus the substrate pyruvate, 
but still maintaining the high selectivity against the desired isoform. The para-
substituted derivatives 3.256-3.259 were selective LDH-A inhibitors (Ki values ranging 
from 125 to 6 μM), and in particular the para-chlorophenyl-substituted compound 3.259 
gave excellent results (Ki = 6.6 μM vs. NADH and 5.6 μM vs. Pyr). When the chlorine 
atom was moved from the para position of the phenyl ring of 3.259 to the ortho- 
(3.276), or meta-positions (3.275), the activities of the resulting compounds suffered 
from a slightly decrease, but both compounds maintained acceptable inhibition values 
on LDH-A. When a phenyl ring was inserted as a “linker” between the sulfonamide 
group and the NHI nucleus, we obtained results comparable to those achieved in the 
absence of this spacer moiety. In fact, derivative 3.260 possessing two methyl groups on 
the nitrogen was completely inactive (see compound 3.242 for comparison). On the 
other hand, derivative 3.261, where one of the two N-methyl groups is replaced by a 
phenyl ring, displayed a good potency (Ki = 16 μM vs. NADH and 22.5 μM vs. Pyr) on 
the enzyme (see compound 3.243 for comparison). 
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Table 3.20. Inhibition data on LDH-5 (LDH-A4) and LDH-1 (LDH-B4) for compounds 3.242-3.244, 3.255-
3.261, 3.275-3.276. 
Cpd Structure Inhibition values LDH-5a LDH-1b
3.242  
5% indolee 
5% - 
3.243 N COOH
OH
S
OO
N
CH3
 
Ki = 17.1 μM (NADH) 
 9.3 μM (Pyr) n.a.
c 
3.244 
 
30%d - 
3.255 
 
Ki = 17 μM (NADH) 
   100 μM (Pyr) n.a. 
3.256 
 
Ki = 20 μM (NADH) 
 20 μM (Pyr) n.a. 
3.257 
 
Ki = 26 μM (NADH) 
 6 μM (Pyr) n.a. 
3.258 N
OH
COOH
S
N
OO
CH3
F  
Ki = 125 μM (NADH) 
 28 μM (Pyr) n.a. 
3.259 
 
Ki = 6.6 μM (NADH) 
 5.6 μM (Pyr) n.a. 
3.260 
 
n.a. - 
3.261 Ki = 16 μM (NADH)      22.5 μM (Pyr) n.a. 
3.275 NOH
COOH
S
N
OO
CH3
Cl  
Ki = 48 μM (NADH) 
 43 μM (Pyr) n.a. 
3.276 
 
Ki = 14 μM (NADH) 
 25 μM (Pyr) n.a. 
 
 
a compounds tested at 250 μM. b compounds tested at 100 μM, c compounds tested at 125 μM, d compounds 
tested at 50 μM, e compounds tested as a mixture with the reported percentage of indole. n.a. = not active. 
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3.10.3. Molecular modelling studies 
In order to analyze the interaction of a representative sulfonamide derivative, 
compound 3.243 was docked in the minimized structure of the protein extracted from 
the complex with compound 3.139. 
Molecular modelling studies demonstrated that the substitution of the phenyl ring in 
position 6 (3.139) with the N-methyl-N-phenylsufonamide group in compound 3.243 
determines a different interaction of the aromatic ring. As showed in Fig. 3.56, the 
docking of compound 3.243 highlights the same disposition of the 1-hydroxy-H-indole-
2-carboxylic scaffold already showed by 3.139, 3.112 and 3.114 (see Section 3.8.3), 
with the formation of the H-bonds with R169, T248 and the water molecule that 
mediates the interaction with the catalytic H193. Furthermore, as shown in Fig. 3.56, 
the phenyl ring of 3.243 displays a favourable T-shaped, perpendicular arrangement 
with the aromatic ring of Y247 [141]. 
 
 
Figure 3.56. Docking analysis of compound 3.243. Overall disposition of the ligand into LDH (A, residues 
240-245 are hidden for a better visualization) and LDH-ligand interactions (B). 
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3.11. CELLULAR ASSAYS 
 
During my PhD, I spent a research period (July 2009-December 2009) in the group 
of Prof. Paul J. Hergenrother at the Department of Chemistry at Urbana-Champaign 
(Illinois, USA). In this period, a series of derivatives, previously synthesized in our 
laboratory in Pisa, were tested under my supervision in cellular assays based on 
cytotoxicity on selected cell lines and then they were submitted to cell-based NMR 
studies to confirm their mechanism of action. 
 
3.11.1. Cytotoxicity assays 
The compounds were screened in triplicate on three different cell lines: HeLa 
(cervical cancer), U-937 (lymphoma) and CHO-K1 (chinese hamster ovary). They were 
assayed at two concentrations, 100 μM and 1 mM, and at two different incubation 
times, 24 h and 72 h. Briefly, compounds were dissolved in DMSO stock solutions (10 
mM and 100 mM, with 1% DMSO final concentration in wells), cells were grown in 
96-well plates in RPMI-1640 media supplemented with 10% FBS and 1% 
Penicillin/Streptomycin (for HeLa and U-937 cells) or in Ham’s F-12K media (for 
CHO-K1 cells). Cells treated with compounds or controls were incubated under 
normoxia in a 37 ºC, 5% CO2, 95% humidity incubator and in a hypoxic incubator (1% 
O2). In each cytotoxicity experiment, the percentage of non-viable cells was calculated 
for each compound and the data were compared with those of control compounds that 
modulate glycolytic metabolism, such as 3-bromopyruvate (3-BP) and 2-deoxyglucose 
(2-DG) that inhibit the first glycolytic enzyme hexokinase. For assessing cell death, 
sulforhodamine B assay [142] was used in the HeLa and CHO-K1 cell-based 
experiments, while MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) protocol [143] was preferred for U-937 cells. 
The best cytotoxicity data were obtained with HeLa cell line at 100 μM for 72 h, as 
shown in the two bar graphs below (Fig. 3.57-3.58), since many compounds determined 
a decreased survival or the complete death of tumour cells. In the bar graphs, on the y 
axis it is reported the percentage of non-viable cells and on the x axis each compound is 
represented by two bars, the red one for normoxia and the blue one for hypoxia. The 
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smallest member of the NHI class, the unsubstituted derivative 3.89a (Fig. 3.58) 
showed a slight hypoxia-selective cytotoxic action and the 4-CF3-6-phenyl-substituted 
derivative 3.139 (Fig. 3.57) confirmed its inhibition property, reaching nearly a 50% 
activity if compared to that of control compounds 3-BP and 2-DG. The triazole-
containing derivative 3.168a (Fig. 3.57), the carboxy-substituted compound 3.125c and 
the 5-phenyl-substituted NHI 3.112 (Fig. 3.58) showed more pronounced normoxia-
selective action. Some compounds (3.97 and 3.99 in Fig. 3.57 and 3.100 in Fig. 3.58) 
showed unexpected high cytotoxic properties, which cannot be correlate to any 
inhibition of LDH-A and, therefore, is likely due to different mechanisms that are 
currently under investigation. The result generated by compound 3.120c (Fig. 3.58), 
which is also inactive as LDH-A inhibitor, may be explained by considering the 
increased permeability of this methyl ester derivative, when compared to its free 
carboxylic analogues, that may be followed by the hydrolysis of the ester group within 
the cell, thus generating the active compound 3.113 (Fig. 3.58), which displayed a good 
cytotoxicity on the selected cell line (30-35% of non-viable cells). Hence, 3.120c may 
be considered as a prodrug of 3.113, although further studies are needed to definitely 
clarify this aspect. 
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Figure 3.57. Cytotoxicity bar graph of the analyzed compounds tested on HeLa cell line at 100 μM for 72 h 
and of control compounds 3-bromopyruvate (3-BP) and 2-deoxyglucose (2-DG) tested at different 
concentrations, in hypoxic (blue bars) and normoxic (red bars) conditions. 
 
Figure 3.58. Cytotoxicity bar graph of the analyzed compounds tested on HeLa cell line at 100 μM for 72 h, 
in hypoxic (blue bars) and normoxic (red bars) conditions. 
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3.11.2. Cell-based NMR studies 
On the basis of the enzymatic studies and cytotoxicity assays, we identified three 
compounds, phenyl-substituted NHI 3.112, 3.113 and 3.139 (Fig. 3.59), whose potency 
on the enzyme was accompanied by an adequate cytotoxic action in vitro. In order to 
confirm if their cytotoxic action might be related to LDH-A inhibition, 13C-NMR 
studies were performed to discover if these molecules influence the hypoxic tumour 
metabolism and, in particular, to detect their ability to reduce the cellular production of 
lactate. This approach was recently reported as a noninvasive method to detect 
modifications of the cellular glucose metabolism in real time [144]. 
 
N
COOH
OH
CF3
3.139
N
COOH
OH
3.112
N
COOH
OH
3.113  
Figure 3.59. Structures of compounds 3.112, 3.113 and 3.139, chosen for further cellular assays. 
 
Briefly, compounds were dissolved in DMSO stock solutions (10 mM and 50 mM, 
with 1% DMSO final concentration in wells), cells were grown in RPMI-1640 media 
supplemented with 10% FBS and 1% Penicillin/Streptomycin, glucose-free DMEM 
without phenol red was supplemented with D-[1,6-13C2]glucose to obtain 10 mM D-
[1,6-13C2]-glucose-DMEM media to be used in the experiment. The three promising 
compounds were tested at 100 and 500 μM for 6 h and 12 h on HeLa cell line in the 
medium enriched with D-[1,6-13C2]glucose in normoxic conditions. Vehicle and 
gossypol at 50 μM, which is an unspecific lactate dehydrogenase inhibitor, were used as 
controls. After the incubation times, 13C-spectra of each sample were acquired. For 
NMR experiments, 100 μL of deuterium oxide was added to each sample and 13C-
spectra were acquired with a 500 MHz Varian system.  
D-[1,6-13C2]Glucose undergoes a glycolytic transformation by producing [3-
13C]pyruvate, which is then transformed by LDH into [3-13C]lactate (Fig. 3.60). The 
relative formation of lactate was measured by integrating the area corresponding to 
lactate-C3 peak at 20.28 ppm relative to the integration of the glucose-C6 peak at 60.95 
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ppm, so lactate/glucose ratio was calculated for each compound and compared to 
DMSO control. The vehicle peak at 38.87 ppm relative to the solvent DMSO was used 
as an internal standard. 
 
 
Figure 3.60. Formation of labeled [3-13C]lactate from D-[1,6-13C2]glucose and relevant 13C NMR peak 
frequencies. 
 
If a compound influences the hypoxic tumour metabolism and in particular inhibits 
LDH-A, the ratio of carbon lactate peak over the carbon glucose peak should be reduced 
when compared to control experiments. Consequently, a confirmation of LDH-mediated 
cytotoxic activity may be found for those compounds showing low levels of [3-
13C]lactate compared with D-[1,6-13C2]glucose amount in tumour cells, corresponding 
to a low lactate/glucose ratio. In the bar graphs below, quantitative results relative to the 
experiments performed after 6 h (Fig. 3.61) or 12 h (Fig. 3.62) of incubation are shown. 
On the y axis it is reported the lactate/glucose ratio and on the x axis each compound is 
represented by two bars, the red one relative to 100 μM and the blue one relative to 500 
μM concentration. It is evident that the ratios between lactate and glucose in HeLa cells 
incubated with compounds 3.139 and 3.113 at the concentration of 500 μM are 
markedly lower than the same ratio detected in DMSO control, whereas at 100 μM the 
effects are less important for compound 3.139, showing lactate/glucose ratios slightly 
smaller than that of DMSO, or not detectable for compound 3.113. In particular, 
compound 3.139 proved to be the most efficient inhibitor of cellular production of 
lactate, since no detectable amounts of lactate could be reported at any time interval 
when tested at 500 μM. Modest results were obtained for compound 3.112, for which 
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the decrease in lactate production compared with the control values is less significant, in 
spite of its remarkable activity on the enzyme. 
 
 
Figure 3.61. Effect of LDH inhibitors 3.139, 3.112, and 3.113 on the production of labeled [3-13C]lactate 
from D-[1,6-13C2]glucose in HeLa cells after 6 h, at 500 μM (blue bars) and 100 μM (red bars), bars relative to 
controls (DMSO and gossypol) are in yellow. 
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Figure 3.62. Effect of LDH inhibitors 3.139, 3.112 and 3.113 on the production of labeled [3-13C]lactate from 
D-[1,6-13C2]glucose in HeLa cells after 12 h, at 500 μM (blue bars) and 100 μM (red bars), bars relative to 
controls (DMSO and gossypol) are in yellow. 
 
These results can be further explained by observing NMR spectra of the tested 
compounds (Fig. 3.63). After addition of D-[1,6-13C2]glucose to the cell culture the 
lactate/glucose area ratio in untreated cells increased over time with a value of 0.16 after 
6 h and a higher value of 0.45 after 12 h, thus showing a progressive conversion of 
glucose to lactate over that period of time (Fig. 3.63, panels A and B). Treatment of 
cells with a 500 μM solution of compound 3.113 (panel C) caused a sensible reduction 
of that ratio (Lac/Glu = 0.124) after 12 h, whereas a remarkable drop of lactate 
production was caused by the same concentration of 3.139 (panel D), which showed 
basically no detectable amounts of lactate in the 13C NMR spectrum (Lac/Glu < 0.01). 
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Figure 3.63. 13C NMR spectra of HeLa cells fed with D-[1,6-13C2]glucose: (A) untreated (DMSO control) 
after 6 h; (B) untreated (DMSO control) after 12 h; (C) 12 h after addition of 3.113 (500 μM); (D) 12 h after 
addition of 3.139 (500 μM).  
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3.12. CONCLUSIONS 
 
The classes of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylic 
scaffold reported in this Chapter represent, to the best of our knowledge, the first 
example in Medicinal Chemistry of this type of small organic molecules specifically 
designed and synthesized to inhibit human LDH-A, in order to interfere with the 
peculiar metabolism of hypoxic tumours. 
Enzymatic assays demonstrated the competitive behaviour against both the cofactor 
NADH and the substrate pyruvate for these derivatives, suggesting that they likely 
occupy both binding sites. Furthermore, their selectivity for the desired A isoform 
versus the B isoform of the enzyme appeared evident for almost all the compounds.  
Molecular modeling studies suggested the possible binding mode of some 
representative examples of these derivatives in the LDH-A active site and they specified 
the main residues likely involved in the interactions with the inhibitors. 
Furthermore, enzymatic assays demonstrated the importance of the OH-COOH 
moiety for the inhibitory activity of the N-hydroxy-2-carboxy-substituted indoles. The 
presence of a trifluoromethyl group in position 4 of the heterocycle together with an aryl 
ring in position 6 and even the substitution of the central scaffold with a N-methyl-N-
arylsulfonamido group in position 6 led to the production of some of the most active 
LDH-A inhibitors. The promising enzymatic data for the best compounds were also 
supported by cellular experiments revealing their ability to reduce the production of 
lactate even in in vitro cell-based experiments, thus confirming their mechanism of 
action in living cells. 
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4.1. EXPERIMENTAL SECTION 
 
4.1.1. General details 
Commercially available chemicals were purchased from Sigma-Aldrich or Alfa 
Aesar and used without further purification. NMR spectra were obtained with a Varian 
Gemini 200 MHz spectrometer. Chemical shifts (δ) are reported in parts per million 
downfield from tetramethylsilane and referenced from solvent references. Electron 
impact (EI, 70 eV) mass spectra were obtained on a HP-5988A mass spectrometer. 
Purity was routinely measured by HPLC on a Waters SunFire RP 18 (3.0 x 150 mm, 5 
μm) column (Waters, Milford, MA, www.waters.com) using a Beckmann SystemGold 
instrument consisting of chromatography 125 Solvent Module and a 166 UV Detector. 
Mobile phases: 10 mM ammonium acetate in Millipore purified water (A) and HPLC 
grade acetonitrile (B). A gradient was formed from 5% to 80% of B in 10 minutes and 
held at 80% for 10 min; flow rate was 0.7 mL/min and injection volume was 30 μL; 
retention times (HPLC, tR) are given in minutes. Compound HPLC purity was 
determined by monitoring at 254 and 300 nm and was found in the range 96-99%, 
unless otherwise noted. Chromatographic separations were performed on silica gel 
columns by flash (Kieselgel 40, 0.040–0.063 mm; Merck) or gravity column (Kieselgel 
60, 0.063–0.200 mm; Merck) chromatography. Reactions were followed by thin-layer 
chromatography (TLC) on Merck aluminum silica gel (60 F254) sheets that were 
visualized under a UV lamp. Evaporation was performed in vacuo (rotating evaporator). 
Sodium sulfate was always used as the drying agent. Microwave assisted reaction were 
run in a CEM or Biotage microwave synthesizer. 
The following abbreviations, reagents, expressions or equipments, which are utilized 
in the following description, are explained as follows: RT (room temperature, 20-25 
°C), molar equivalents (eq.), N,N-dimethylformamide (DMF), 1,2-dimetoxyethane 
(DME), dichloromethane (DCM), chloroform (CHCl3), ethylacetate (EtOAc), 
tetrahydrofuran (THF), methanol (MeOH), diethylether (Et2O), dimethylsulfoxide 
(DMSO), sodium hydride (NaH), dimethyl oxalate (“(COOMe)2”), stannous chloride 
dihydrate (SnCl2•2H2O), sodium hypophosphite monohydrate (H2PO2Na•H2O), 
palladium 10% on charcoal (Pd-C), lithium hydroxide (LiOH), hydrochloric acid (HCl), 
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acetic acid (AcOH), diethylamine (Et2NH), triethylamine (Et3N), sodium bicarbonate 
(NaHCO3), normal concentration (N), millimoles (mmol), aqueous solution (aq.), thin 
layer chromatography (TLC), nuclear magnetic resonance (NMR), electronic impact 
mass spectrometry (EI/MS).  
Compounds 3.89a-e, 3.89k-n, 3.111 and 3.138 were previously synthesized by 
undergraduate students during experimental thesis in the same research laboratory, 
therefore their preparation is not reported in this Thesis. 
 
4.1.2. Synthetic procedures and characterization data 
 
3-((4-Nitrobenzylidene)amino)propanenitrile (2.24) 
 
A solution of commercially available 4-nitrobenzaldehyde 2.23 (0.65 g, 4.3 mmol) 
in anhydrous CH2Cl2 (30 mL) was treated with BAPN (0.95 g, 13 mmol) and stirred at 
RT overnight before being concentrated in vacuo. The crude product 2.24 was then used 
in the next step without any further purification. 
 
3-((4-Nitrobenzyl)amino)propanenitrile (2.25) 
 
The crude product 2.24 was dissolved in CH3OH (30 mL) and treated slowly and 
cautiously with NaBH4 (1.2 g, 32 mmol) at 0 °C under nitrogen. After 1 h the reaction 
was diluted with ice water and extracted with CH2Cl2. The combined organic phase was 
washed with brine, dried over anhydrous sodium sulphate and concentrated in vacuo. 
The crude product was purified by flash chromatography (n-hexane/EtOAc, 4:6) 
affording 3-(4-nitrobenzylamino)propanenitrile 2.25 (0.76 g, 3.7 mmol, 86% yield). 1H 
NMR (CDCl3) δ (ppm): 2.55 (t, 2H, J = 6.4 Hz), 2.95 (t, 2H, J = 6.4 Hz), 3.96 (s, 2H), 
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7.53 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.1 Hz), 8.20 (AA’XX’, 2H, JAX = 8.6 Hz, 
JAA’/XX’ = 2.1 Hz). 13C NMR (50 MHz, CDCl3) δ (ppm): 19.1, 44.6, 52.5, 118.6, 123.2, 
123.9, 128.7, 147.2. MS m/z 206 (M +H+). 
 
3-((4-Nitrobenzyl)amino)propanenitrile hydrochloride (2.19) 
O2N
N
H
N
HCl.
 
Compound 2.25 was dissolved in CH3OH and treated with a saturated Et2O·HCl 
solution. Compound 2.19 precipitated from the resulting mixture as a white solid (0.84 
g, 3.5 mmol, 95% yield): 1H NMR (D2O) δ (ppm): 3.06 (t, 2H, J = 6.8 Hz), 3.53 (t, 2H, 
J = 6.8 Hz), 4.47 (s, 2H), 7.75 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz), 8.35 ppm 
(AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.3 Hz). 13C NMR (50 MHz, D2O) δ (ppm): 15.5, 
43.3, 51.0, 118.0, 124.9, 131.5, 138.0, 149.0. Anal. calcd for C10H12ClN3O2·H2O: C 
46.25, H 5.43, N 16.18, found: C 45.93, H 5.53, N 16.39. 
 
3-((2-Nitrobenzylidene)amino)propanenitrile (2.27) 
N
H
N
NO2  
A solution of commercially available 2-nitrobenzaldehyde 2.26 (0.33 g, 2.2 mmol) 
in anhydrous CH2Cl2 (20 mL) was treated with BAPN (0.46 g, 6.6 mmol) and stirred at 
RT overnight before being concentrated in vacuo. The crude product 2.27 was then used 
in the next step without any further purification. 
 
3-((2-Nitrobenzyl)amino)propanenitrile (2.28) 
N
H
N
NO2  
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The crude product 2.27 was dissolved in CH3OH (20 mL) and treated slowly and 
cautiously with NaBH4 (0.62 g, 16 mmol) at 0 °C under nitrogen. After 1 h the reaction 
was diluted with ice water and extracted with CH2Cl2. The combined organic phase was 
washed with brine, dried over anhydrous sodium sulphate and concentrated in vacuo. 
The crude product was purified by flash chromatography (n-hexane/EtOAc, 1:1) 
affording 3-(2-nitrobenzylamino)propanenitrile 2.28 (0.39 g, 1.9 mmol, 86% yield). 1H 
NMR (CDCl3) δ (ppm): 2.54 (t, 2H, J = 6.6 Hz), 2.96 (t, 2H, J = 6.6 Hz), 4.10 (s, 2H), 
7.44 (ddd, 1H, J = 8.0, 6.3, 2.5 Hz), 7.56-7.68 (m, 2H), 7.96 (dd, 1H, J = 7.8, 1.1 Hz). 
13C NMR (50 MHz, CDCl3) δ (ppm): 19.0, 44.8, 50.2, 118.6, 123.1, 124.9, 128.3, 
131.1, 133.4, 149.1. MS m/z 206 (M +H+). 
 
3-((2-Nitrobenzyl)amino)propanenitrile hydrochloride (2.20) 
 
The intermediate 2.28 was dissolved in CH3OH and treated with a saturated 
Et2O·HCl solution. Compound 2.20 precipitated from the resulting mixture as a white 
solid (0.39 g, 1.6 mmol, 85% yield). 1H NMR (D2O) δ (ppm): 3.11 (t, 2H, J = 6.9 Hz), 
3.64 (t, 2H, J = 6.9 Hz), 4.60 (s, 2H), 7.71-7.88 (m, 3H), 8.32 (dd, 1H, J = 8.1, 1.2 Hz). 
13C NMR (50 MHz, D2O) δ (ppm): 15.1, 43.4, 49.3, 117.7 125.7 126.3, 131.9 134.0, 
135.5 148.4. Anal. calcd for C10H12ClN3O2·0.5H2O: C 47.91, H 5.23, N 16.76, found: C 
48.15, H 5.32, O 16.87. 
 
4-Nitrobenzyl (2-cyanoethyl)carbamate (2.21) 
 
A solution of commercially available 4-nitrobenzylchloroformate 2.29 (1.95 g, 9.04 
mmol) in anhydrous CH2Cl2 (50 mL) was treated at RT under nitrogen with BAPN (1.9 
g, 27 mmol). After 1 h at RT the reaction mixture was diluted with water and extracted 
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with CH2Cl2. The combined organic phase was washed with brine, dried over anhydrous 
sodium sulphate and concentrated in vacuo. The crude product was purified by flash 
chromatography (n-hexane/EtOAc, 4:6) to afford 2.21 as a white solid (2.0 g, 8.0 mmol, 
89% yield). 1H NMR (CDCl3) δ (ppm): 2.64 (t, 2H, J = 6.2 Hz), 3.50 (q, 2H, J = 6.2 
Hz), 5.22 (s, 2H), 5.30 (bs, 1H), 7.51 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.1 Hz), 8.2 
(AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz). 13C NMR (50 MHz, CDCl3) δ (ppm): 
19.0, 37.5, 65.7, 117.9, 123.9, 128.3, 143.5, 147.8, 155.8. MS m/z 249 (M+). Anal. calcd 
for C11H11N3O4: C 53.01, H 4.45, N 16.86, found: C 53.17, H 4.32, O 17.11. 
 
3-(((5-Nitrofuran-2-yl)methylene)amino)propanenitrile (2.31) 
 
A solution of commercially available 5-nitrofuran-1-carbaldehyde 2.30 (1.02 g, 7.23 
mmol) in anhydrous CH2Cl2 (50 mL) was treated with BAPN (1.5 g, 22 mmol) and 
stirred at RT overnight before being concentrated in vacuo. The crude product 2.31 was 
then used in the next step without any further purification. 
 
3-(((5-Nitrofuran-2-yl)methyl)amino)propanenitrile (2.32) 
N
H
N
O
O2N
 
The crude product 2.31 was dissolved in CH3OH (50 mL) and treated slowly and 
cautiously with NaBH4 (2.0 g, 54 mmol) at 0 °C under nitrogen (caution: it is extremely 
important to maintain the temperature below 0 °C during the addition of NaBH4, which 
must be very slow!). After 1 h the reaction was diluted with ice water and extracted with 
CH2Cl2. The combined organic phase was washed with brine, dried over anhydrous 
sodium sulphate and concentrated in vacuo. The crude product was purified by flash 
chromatography (n-hexane/EtOAc, 2:8) affording 3-((5-nitrofuran-2-
yl)methylamino)propanenitrile 2.32 (0.83 g, 4.3 mmol, 59% yield). 1H NMR (CDCl3) δ 
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(ppm): 2.55 (t, 2H, J = 6.5 Hz), 2.98 (t, 2H, J = 6.5 Hz), 3.94 (s, 2H), 6.51 (d, 1H, J = 
3.7 Hz), 7.28 (d, 1H, J = 3.7 Hz). MS m/z 196 (M +H+). 
 
3-(((5-Nitrofuran-2-yl)methyl)amino)propanenitrile hydrochloride (2.22) 
 
Compound 2.32 was dissolved in CH3OH and treated with a saturated Et2O·HCl 
solution. Compound 2.22 precipitated from the resulting mixture as a white solid (0.88 
g, 3.8 mmol, 88% yield). 1H NMR (D2O) δ (ppm): 3.09 (t, 2H, J = 6.8 Hz), 3.57 (t, 2H, 
J = 6.8 Hz), 4.57 (s, 2H), 7.02 (d, 1H, J = 3.8 Hz), 7.59 (d, 1H, J = 3.8 Hz). 13C NMR 
(50 MHz, D2O) δ (ppm): 15.2, 42.8, 43.3, 113.7, 116.6, 117.5, 147.7, 154.9. Anal. calcd 
for C8H10ClN3O3·0.5H2O: C 39.93, H 4.61, N 17.46, found: C 39.64, H 4.82, O 17.34. 
 
Methyl 3-(5-fluoro-2-nitrophenyl)-2-oxopropanoate (3.91f) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 722 mg, 18.0 
mmol) in 18 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing commercially available 5-fluoro-2-nitrotoluene 
3.90f (700 mg, 4.51 mmol) and dimethyl oxalate (2.66 g, 22.5 mmol) in 13 mL of 
anhydrous DMF. The mixture was left under stirring at the same temperature for 10 
minutes and then it was slowly warmed to room temperature. The mixture was then left 
under stirring at RT for 1 h. Once the disappearance of the precursor was verified by 
TLC, the reaction mixture was slowly poured in an ice-water mixture; the water phase 
was acidified with 1N aqueous HCl and extracted several times with EtOAc. The 
combined organic phase was washed with saturated NaHCO3 solution and brine, then 
dried over anhydrous sodium sulphate. Evaporation under vacuum of the organic 
solvent afforded a crude product which was purified by column chromatography over 
silica gel using n-hexane/EtOAc 7:3 as the eluent, to yield the nitroaryl-ketoester 
derivative 3.91f (780 mg, 3.23 mmol, 72% yield). 1H NMR (CDCl3) δ (ppm): 3.95 (s, 
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3H), 4.54 (s, 2H), 7.04 (dd, 1H, J = 8.4, 2.7 Hz), 7.19 (ddd, 1H, J = 9.2, 7.2, 2.7 Hz), 
8.26 (dd, 1H, J = 9.2, 5.1 Hz); signals imputable to the enol form (~ 25%) δ (ppm): 3.96 
(s, 3H), 6.99 (d, 1H, J = 1.1 Hz), 7.96-8.03 (m, 2H). 
 
Methyl 5-fluoro-1-hydroxy-1H-indole-2-carboxylate (3.92f) 
 
Ketoester 3.91f (525 mg, 2.18 mmol) was dissolved in anhydrous DME (2.2 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (1.10 g, 4.88 mmol) in DME (2.2 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 3 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
CHCl3 as the eluent, to give the N-hydroxyindol-ester derivative 3.92f (169 mg, 0.808 
mmol, 37% yield). 1H NMR (CDCl3) δ (ppm): 4.00 (s, 3H), 6.98 (d, 1H, J = 0.9 Hz), 
7.13 (td, 1H, J = 9.0, 2.4 Hz), 7.27 (dd, 1H, J = 9.5, 2.0 Hz), 7.49 (dd, 1H, J = 9.2, 4.4 
Hz), 10.27 (bs, 1H). 
 
5-Fluoro-1-hydroxy-1H-indole-2-carboxylic acid (3.89f) 
 
Methyl ester 3.92f (150 mg, 0.717 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (7.2 mL) and treated with 2.3 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 1 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
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with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.89f (140 mg, 0.717 .mmol, >99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 6.98 (s, 1H), 7.18 (td, 1H, J = 9.2, 2.4), 7.39-7.48 (m, 2H). 
MS m/z 195 (M+, 100%), 133 (M+ –CO2 –H2O, 28%). 
 
3-(3-Methoxy-2,3-dioxopropyl)-4-nitrobenzoic acid (3.91g) 
COOMe
O
NO2
HOOC
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 926 mg, 23.2 
mmol) in 16 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing commercially available 3-methyl-4-nitrobenzoic 
acid 3.90g (700 mg, 3.86 mmol) and dimethyl oxalate (2.74 g, 23.2 mmol) in 11 mL of 
anhydrous DMF. The mixture was left under stirring at the same temperature for 10 
minutes and then it was slowly warmed to room temperature. The mixture was then left 
under stirring at RT for 5 h. Once the disappearance of the precursor was verified by 
TLC, the reaction mixture was slowly poured in an ice-water mixture; the water phase 
was acidified with 1N aqueous HCl and extracted several times with EtOAc. The 
combined organic phase was washed with saturated NaHCO3 solution and brine, then 
dried over anhydrous sodium sulphate. Evaporation under vacuum of the organic 
solvent afforded a crude product which was purified by column chromatography over 
silica gel using CHCl3/MeOH 9:1 with 0.05% trifluoroacetic acid as the eluent, to yield 
the nitroaryl-ketoester derivative 3.91g (432 mg, 1.62 mmol, 42% yield). 1H NMR 
(CDCl3) δ (ppm): 3.95 (s, 3H), 4.61 (s, 2H), 7.90-8.21 (m, 3H); signals imputable to the 
enol form (~ 26%) δ (ppm): 3.91 (s, 3H), 6.85 (s, 1H), 8.97 (d, 1H, J = 1.8 Hz). 
 
1-Hydroxy-2-(methoxycarbonyl)-1H-indole-5-carboxylic acid (3.92g) 
 
Chapter 4 
225 
 
Ketoester 3.91g (282 mg, 1.06 mmol) was dissolved in anhydrous DME (1.1 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (572 mg, 2.53 mmol) in DME (1.1 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 2 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 4:6 as the eluent to yield a mixture (38.5 mg) of the N-hydroxyindol-
ester derivative 3.92g (85%, 32.7 mg, 0.139 mmol, 13% yield) with its indole analogue 
(15%) 1H NMR (acetone-d6) δ (ppm): 3.91 (s, 3H), 7.27 (d, 1H, J = 0.9 Hz), 7.61 (dt, 
1H, J = 8.8, 0.9 Hz), 8.04 (dd, 1H, J = 8.8, 1.5 Hz), 8.46 (dd, 1H, J = 1.5, 0.7 Hz), 10.66 
(bs, 1H); signals imputable to the indole (~ 15%) δ (ppm): 3.92 (s, 3H), 7.35-7.37 (m, 
1H), 7.98 (dd, 1H, J = 8.8, 1.5 Hz), 8.48-8.50 (m, 1H). 
 
1-Hydroxy-1H-indole-2,5-dicarboxylic acid (3.89g) 
N
COOH
OH
HOOC
 
Methyl ester 3.92g (35 mg, 0.149 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.6 mL) and treated with 0.5 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.89g (24.0 mg, 0.109 mmol, 73% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 7.29 (d, 1H, J = 0.7 Hz), 7.61 (dt, 1H, J = 8.8, 0.7 Hz), 8.03 
(dd, 1H, J = 8.8, 1.5 Hz), 8.47 (dd, 1H, J = 1.5, 0.7 Hz); signals imputable to the indole 
(~ 10%) δ (ppm): 7.36-7.38 (m, 1H), 7.96 (d, 1H, J = 1.5 Hz). MS m/z 221 (M+, 78%), 
205 (M+ –O, 100%), 133 (M+ -2 CO2, 57%). 
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Methyl 3-(4-fluoro-2-nitrophenyl)-2-oxopropanoate (3.91h) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 721 mg, 18.0 
mmol) in 18 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing commercially available 4-fluoro-2-nitrotoluene 
3.90h (700 mg, 4.51 mmol) and dimethyl oxalate (2.66 mg, 22.5 mmol) in 13 mL of 
anhydrous DMF. The mixture was left under stirring at the same temperature for 10 
minutes and then it was slowly warmed to room temperature. The mixture was then left 
under stirring at RT for 3 h. Once the disappearance of the precursor was verified by 
TLC, the reaction mixture was slowly poured in an ice-water mixture; the water phase 
was acidified with 1N aqueous HCl and extracted several times with EtOAc. The 
combined organic phase was washed with saturated NaHCO3 solution and brine, then 
dried over anhydrous sodium sulphate. Evaporation under vacuum of the organic 
solvent afforded a crude product which was purified by column chromatography over 
silica gel using n-hexane/EtOAc 7:3 as the eluent, to yield the nitroaryl-ketoester 
derivative 3.91h (961 mg, 3.98 mmol, 88% yield). 1H NMR (CDCl3) δ (ppm): 3.90 (s, 
3H), 4.52 (s, 2H), 7.28-7.41 (m, 2H), 7.90 (dd, 1H, J = 8.2, 2.0 Hz); signals imputable 
to the enolic form (~ 13%) δ (ppm): 3.92 (m, 3H), 6.68 (bs, 1H, exchangeable), 6.87 (s, 
1H), 7.64 (dd, 1H, J = 8.2, 2.7 Hz), 8.26 (dd, 1H, J = 9.0, 5.7 Hz). 
 
Methyl 6-fluoro-1-hydroxy-1H-indole-2-carboxylate (3.92h) 
 
Ketoester 3.91h (619 mg, 2.57 mmol) was dissolved in anhydrous DME (4.3 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (1.30 g, 5.76 mmol) in DME (4.3 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
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for 5 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
CHCl3 as the eluent, to give the N-hydroxyindol-ester derivative 3.92h (206 mg, 0.985 
mmol, 38% yield). 1H NMR (CDCl3) δ (ppm): 3.98 (s, 3H), 6.90 (td, 1H, J = 9.0, 2.4 
Hz), 7.02 (d, 1H, J = 0.9 Hz), 7.18 (dd, 1H, J = 9.2, 2.4 Hz), 7.57 (dd, 1H, J = 9.0, 5.1 
Hz), 10.20 (bs, 1H). 
 
6-Fluoro-1-hydroxy-1H-indole-2-carboxylic acid (3.89h) 
 
Methyl ester 3.92h (178 mg, 0.851 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (8.6 mL) and treated with 2.7 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 2 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.89h (144 mg, 0.738 mmol, 87% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): δ 6.97 (ddd, 1H, J = 9.7, 8.8, 2.4 Hz), 7.04 (d, 1H, J = 0.7), 
7.18 (ddd, 1H, J = 9.9, 1.8, 0.9 Hz), 7.67 (ddd, 1H, J = 8.6, 5.3, 0.4 Hz). MS m/z 195 
(M+, 100%), 177 (M+ –H2O, 43%), 133 (M+ –CO2 –H2O, 72%). 
 
Methyl 3-(5-cyano-2-nitrophenyl)-2-oxopropanoate (3.91i) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 395 mg, 9.88 
mmol) in 9.6 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing commercially available 4-methyl-3-
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nitrobenzonitrile 3.90i (400 mg, 2 47 mmol) and dimethyl oxalate (1.46 g, 12.4 mmol) 
in 7.1 mL of anhydrous DMF. The mixture was left under stirring at the same 
temperature for 10 minutes and then it was slowly warmed to room temperature. The 
mixture was then left under stirring at RT for 4 h. Once the disappearance of the 
precursor was verified by TLC, the reaction mixture was slowly poured in an ice-water 
mixture; the water phase was acidified with 1N aqueous HCl and extracted several 
times with EtOAc. The combined organic phase was washed with saturated NaHCO3 
solution and brine, then dried over anhydrous sodium sulphate. Evaporation under 
vacuum of the organic solvent afforded a crude product which was purified by column 
chromatography over silica gel using n-hexane/EtOAc 7:3 as the eluent, to yield the 
nitroaryl-ketoester derivative 3.91i (251 mg, 1.01 mmol, 41% yield). 1H NMR (CDCl3) 
δ (ppm): 3.96 (s, 3H), 4.60 (s, 2H), 7.65 (d, 1H, J = 2.0 Hz), 7.84 (dd, 1H, J = 8.1, 1.7 
Hz), 8.27 (d, 1H, J = 8.6 Hz); signals imputable to the enol form (~ 22%) δ (ppm): 3.97 
(s, 3H). 6.81 (s, 1H), 7.95 (d, 1H, J = 8.4 Hz), 8.64 (d, 1H, J = 1.6 Hz). 
 
Methyl 5-cyano-1-hydroxy-1H-indole-2-carboxylate (3.92i) 
 
Ketoester 3.91i (90 mg, 0.363 mmol) was dissolved in anhydrous DME (0.4 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (183 mg, 0.812 mmol) in DME (0.4 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 10 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 7:3 as the eluent, to give a mixture (30.0 mg) of the N-hydroxyindol-
ester derivative 3.92i (70%, 21.0 mg, 0.0.971 mmol, 27% yield) with its indole 
analogue (30%). 1H NMR (CDCl3) δ (ppm): 4.03 (s, 3H), 7.12 (d, 1H, J = 0.7 Hz), 7.50-
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7.55 (m, 2H), 7.62 (d, 1H, J = 8.8 Hz), 8.03-8.08 (m, 1H), 10.66 (bs, 1H); signals 
imputable to the indole (~ 30%) δ (ppm): 3.98 (s, 3H), 7.27-7.28 (m, 1H), 9.25 (bs, 1H). 
 
5-Cyano-1-hydroxy-1H-indole-2-carboxylic acid (3.89i) 
 
Methyl ester 3.92i (29.5 mg, 0.136 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.4 mL) and treated with 0.44 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
1.5 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.89i (28.0 mg, 0.138 mmol, >99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.15 (s, 1H), 7.57-7.61 (m, 2H), 8.24 (s, 1H) ; signals 
imputable to the indole (~ 30%) δ (ppm): 7.22 (d, 1H, J = 0.8 Hz). 
 
Methyl 3-(4-cyano-2-nitrophenyl)-2-oxopropanoate (3.91j) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 493 mg, 12.3 
mmol) in 12 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing commercially available 4-methyl-3-
nitrobenzonitrile 3.90j (500 mg, 3.08 mmol) and dimethyl oxalate (1.82 g, 15.4 mmol) 
in 8.9 mL of anhydrous DMF. The mixture was left under stirring at the same 
temperature for 10 minutes and then it was slowly warmed to room temperature. The 
mixture was then left under stirring at RT for 1 h. Once the disappearance of the 
precursor was verified by TLC, the reaction mixture was slowly poured in an ice-water 
mixture; the water phase was acidified with 1N aqueous HCl and extracted several 
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times with EtOAc. The combined organic phase was washed with saturated NaHCO3 
solution and brine, then dried over anhydrous sodium sulphate. Evaporation under 
vacuum of the organic solvent afforded a crude residue (382 mg) containing the desired 
nitroaryl-ketoester derivative 3.91j, which was submitted to the following step without 
any further purification. 1H NMR (CDCl3) δ (ppm): 3.89 (s, 3H); 4.63 (s, 2H); 7.50 (d, 
1H, J = 8.1 Hz); 7.90 (dd, 1H, J = 8.0, 1.7 Hz); 8.14 (d, 1H, J = 1.6 Hz); signals 
imputable to the enol form (~ 42%) δ (ppm): 3.93 (s, 3H); 6.86 (s, 1H); 7.80 (dd, 1H, J 
= 8.4, 1.3 Hz); 8.44-8.49 (m, 2H). 
 
Methyl 6-cyano-1-hydroxy-1H-indole-2-carboxylate (3.92j) 
 
The crude residue 3.91j (382 mg) was dissolved in anhydrous DME (1.5 mL) and 
the resulting solution was added dropwise to a cooled (0 °C) solution of SnCl2·2H2O 
(778.3 mg, 3.45 mmol) in DME (1.5 mL) containing 4Å molecular sieves, previously 
activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator over 
anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT. 
Once the disappearance of the precursor is verified by TLC, the reaction mixture was 
diluted with water and repeatedly extracted with EtOAc. The combined organic phase 
was dried over anhydrous sodium sulphate and evaporated to afford a crude residue that 
was purified by column chromatography over silica gel using n-hexane/EtOAc 7:3 as 
the eluent, to give the N-hydroxyindol-ester derivative 3.92j (34 mg, 0.157 mmol, 2 
steps: 5% yield). 
 
6-Cyano-1-hydroxy-1H-indole-2-carboxylic acid (3.89j) 
N
COOH
OH
NC
 
Methyl ester 3.92j (34 mg, 0.157 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.6 mL) and treated with 0.5 mL of 2N aqueous solution of LiOH. The 
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reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 1 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.89j (31.8 mg, 0.157 mmol, >99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.12 (d, 1H, J = 0.9 Hz), 7.41 (dd, 1H, J = 8.2, 1.5 Hz), 7.83 
(dd, 1H, J = 8.2, 0.7 Hz), 7.97 (dt, 1H, J = 1.5, 0.7 Hz). 
 
5-(4-Methyl-3-nitrophenyl)-2H-tetrazole (3.90o) 
CH3
NO2
N
HN
N N  
Commercially available 4-methyl-3-nitrobenzonitrile 3.90j (500 mg, 3.08 mmol) 
was dissolved in water (6.2 mL) and treated with sodium azide (221 mg, 3.39 mmol) 
and zinc bromide hydrate (694 mg, 3.08 mmol). The resulting suspension was refluxed 
for 36 h, then treated with aqueous 3 N HCl (until pH 1) and EtOAc. Stirring was 
continued until all the white solid was dissolved. The organic phase was separated and 
the water phase was extracted again with EtOAc. The combined organic phase was 
concentrated and the residue was recovered with aqueous 0.25 N NaOH and stirred for 
30 min. The suspension was filtered to remove Zn(OH)2 and the resulting solution was 
acidified with 3N HCl to precipitate the tetrazole derivative. The solid was then 
dissolved in EtOAc and MeOH and the solution was dried and concentrated to give pure 
3.90o (571 mg, 90% yield); 1H NMR (DMSO-d6) δ (ppm): 2.61 (s, 3H), 7.76 (d, 1H, J = 
7.9 Hz), 8.32 (dd, 1H, J = 8.1, 1.8 Hz), 8.67 (d, 1H, J = 1.6 Hz). 
 
Methyl 3-(2-nitro-4-(2H-tetrazol-5-yl)phenyl)-2-oxopropanoate (3.91o) 
COOMe
O
NO2
N
HN
N N  
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A stirred suspension of sodium hydride (60% dispersion in mineral oil, 858 mg, 21.5 
mmol) in 15 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.90o (550 mg, 2.68 
mmol) and dimethyl oxalate (3.16 g, 26.8 mmol) in 5.1 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
24 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using CH2Cl2/MeOH 9:1 
as the eluent, to yield the nitroaryl-ketoester derivative 3.91o (375 mg, 1.29 mmol, 48% 
yield). 1H NMR (DMSO-d6) δ (ppm): 3.80 (s, 3H), 4.71 (s, 2H), 8.34 (dd, 1H, J = 8.5, 
1.7 Hz), 8.43 (d, 1H, J = 8.4 Hz), 8.57 (d, 1H, J = 1.6 Hz); signals imputable to the enol 
form (~ 40%) δ (ppm): 3.76 (s, 3H), 6.67 (s, 1H), 8.65 (dd, 1H, J = 8.4, 1.8 Hz), 8.74 (d, 
1H, J = 1.8 Hz). 
 
Methyl 1-hydroxy-6-(2H-tetrazol-5-yl)-1H-indole-2-carboxylate (3.92o) 
 
Ketoester 3.91o (300 mg, 1.03 mmol) was dissolved in THF (1.7 mL) and the 
resulting solution was added to an aqueous solution (1.7 mL) of sodium hypophosphite 
monohydrate (339 mg, 3.19 mmol). Then 10 mg of 10% palladium over charcoal was 
added and the resulting suspension was stirred ar RT. After 24 h the disappearance of 
the precursor is verified by TLC and the mixture was concentrated, diluted with water 
and repeatedly extracted with EtOAc. The combined organic phase was dried over 
anhydrous sodium sulphate and evaporated to afford a crude residue that was purified 
by column chromatography over over silica gel using CH2Cl2/MeOH 9:1 with 0.01% 
Chapter 4 
233 
 
acetic acid as the eluent, to give the N-hydroxyindole 3.92o (41.6 mg, 0.160 mmol, 16% 
yield). 1H NMR (DMSO-d6) δ (ppm): 3.88 (s, 3H); 7.13 (d, 1H, J = 0.9 Hz), 7.79-7-80 
(m, 2H), 8.12-8.15 (m, 1H), 11.64 (bs, 1H). 
 
1-Hydroxy-6-(2H-tetrazol-5-yl)-1H-indole-2-carboxylic acid (3.89o) 
N
COOH
OH
N
HN
N N  
Methyl ester 3.92o (35.0 mg, 0.135 mol) was dissolved in a 1:1 mixture of 
THF/methanol (1.4 mL) and treated with 0.4 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
24 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.89o (32.1 mg, 0.131 mmol, 97% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.11 (d, 1H, J = 0.9 Hz), 7.79 (dd, 1H, J = 7.8, 1.5 Hz), 7.86 
(d, 1H, J = 7.8 Hz), 8.17-8.19 (m, 1H). 13C NMR (DMSO-d6) δ (ppm): 104.63, 108.58, 
118.82, 122.66, 123.28, 128.85, 135.40, 160.84. MS m/z 268 (M+Na+, 10%), 252 
(M+Na+ –O, 9%), 181 (M+Na+ –CO2 –HN3, 54%), 163 (M+Na+ –H2O –CO2 –HN3, 
100%). HPLC, tR 1.4 min. 
 
N'-hydroxy-4-methyl-3-nitrobenzimidamide (3.93) 
CH3
NO2
N
NH2
HO
 
Commercially available 4-methyl-3-nitrobenzonitrile 3.90j (1.00 g, 6.17 mmol), 
DIEA (3.2 mL, 2.39 g, 18.5 mmol), hydroxylamine hydrochloride (644 mg, 9.26 mmol) 
and abs. EtOH (19 mL) were added in a vial. The resulting mixture was stirred at 80 °C. 
The reaction was monitored by TLC and, after 20 h, EtOH was removed under reduced 
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pressure. The residue was solubilized in AcOEt and then extracted with 1N aqueous 
HCl. 1M aqueous Na2CO3 solution was then added to the aqueous solution to pH 9-10. 
A solid precipitated, so it was filtered, washed with water and dried. The aqueous layer 
was further extracted with CH2Cl2, dried over anhydrous sodium sulphate and 
evaporated. Both the precipitate and the crude residue deriving from the extraction 
contained the amidoxime 3.93 (1.16 g, 5.94 mmol, yield 96%), which was used for the 
next step without any further purification. 1H NMR (CD3OD) δ (ppm): 2.57 (s, 3H), 
7.46 (d, 1H, J = 8.1 Hz), 7.83 (dd, 1H, J = 8.2, 1.8 Hz), 8.23 (d, 1H, J = 1.8 Hz). 
 
3-(4-Methyl-3-nitrophenyl)-1,2,4-oxadiazol-5(4H)-one (3.90p) 
CH3
NO2
N
O
NH
O  
Amidoxime 3.93 (500 mg, 2.56), DBU (0.42 mL, 0.43 g, 2.8 mmol), CDI (623 mg, 
3.84 mmol) and 13 mL of 1,4-dioxane were refluxed in a vial at 110 °C for 3 h. Then, 
dioxane was removed under reduced pressure. The residue was dissolved CH2Cl2 and 
washed several times with 1N aqueous HCl. The organic phase was dried over 
anhydrous sodium sulphate and evaporated to afford the desired nitrotoluene derivative 
3.90p (479 mg, 2.17, 85% yield), which was used for the next step without any further 
purification. 1H NMR (CD3OD) δ (ppm): 2.65 (s, 3H), 7.65 (d, 1H, J = 7.9 Hz), 7.98 
(dd, 1H, J = 8.1, 1.8 Hz), 8.39 (d, 1H, J = 1.8 Hz). 
 
Methyl 3-(2-nitro-4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl)-2-
oxopropanoate (3.91p) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 435 mg, 10.9 
mmol) in 7.5 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
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dropwise with a solution containing the nitrotoluene precursor 3.90p (300 mg, 1.36 
mmol) and dimethyl oxalate (1.61 g, 13.6 mmol) in 3.9 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
16 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using CH2Cl2/MeOH 
95:5 as the eluent, to yield the nitroaryl-ketoester derivative 3.91p (402 mg, 1.31 mmol, 
96% yield). 1H NMR (CD3OD) δ (ppm): 3.90 (s, 3H), 4.86 (s, 2H), 8.01 (dd, 1H, J = 
8.4, 1.6 Hz), 8.28 (d, 1H, J = 1.8 Hz), 8.51 (d, 1H, J = 8.4 Hz); signals imputable to the 
enol form (~ 30%) δ (ppm): 3.92 (s, 3H), 7.66 (d, 1H, J = 8.1 Hz), 8.10 (dd, 2H, J = 8.1, 
1.8 Hz), 8.56 (d, 1H, J = 1.8 Hz). 
 
Methyl 1-hydroxy-6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-2-
carboxylate (3.92p) 
N
O
NH
O
N
COOMe
OH
 
Ketoester 3.91p (300 mg, 0.976 mmol) was dissolved in THF (1.6 mL) and the 
resulting solution was added to an aqueous solution (1.6 mL) of sodium hypophosphite 
monohydrate (322 mg, 3.04 mmol). Then 10 mg of 10% palladium over charcoal was 
added and the resulting suspension was stirred at RT for 24 h. Then it was monitored by 
TLC and H2PO2Na.H2O (59.8 mg, 0.564 mmol) and Pd/C (4.5 mg) were added. After 
further 12h the disappearance of the precursor is verified by TLC and the mixture was 
concentrated, diluted with water and repeatedly extracted with EtOAc. The combined 
organic phase was dried over anhydrous sodium sulphate and evaporated to afford a 
crude residue that was purified by column chromatography over over silica gel using 
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CHCl3/MeOH 95:5 as the eluent, to give the N-hydroxyindole 3.92p (35.5 mg, 0.129 
mmol, 13% yield). 1H NMR (CD3OD) δ (ppm): 3.94 (s, 3H); 7.14 (d, 1H, J = 0.7 Hz); 
7.54 (dd, 1H, J = 8.4, 1.5 Hz); 7.77 (d, 1H, J = 8.6 Hz); 7.97 (s, 1H J = 0.7 Hz). 
 
1-Hydroxy-6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-2-carboxylic acid 
(3.89p) 
N
O
NH
O
N
COOH
OH
 
Methyl ester 3.92p (25.0 mg, 0.0908 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.91 mL) and treated with 0.27 mL of 2N aqueous solution of LiOH. 
The reaction was kept under stirring in the dark at RT and it was monitored by TLC. 
After 24 h, the reaction mixture was concentrated, diluted with water and washed with 
Et2O. Then, the aqueous phase was treated with 1N aqueous HCl and extracted several 
times with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.89p (23.5 mg, 0.0899 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.22 (d, 1H, J = 0.9 Hz), 7.66 (dd, 1H, J = 8.4, 1.6 Hz), 7.88 
(d, 1H, J = 8.4 Hz), 8.10 (s, 1H). 13C NMR (DMSO-d6) δ (ppm): 106.15, 109.19, 
118.55, 120.84, 124.29, 124.69, 129.13, 131.70, 158.50, 160.20, 161.59. 
 
Methyl 2-((2-nitrophenyl)amino)acetate (3.95) 
 
A solution containing methyl glycinate hydrochloride (890 mg, 7.09 mmol), 1-
fluoro-2-nitrobenzene 3.94 (0.75 mL, 1.0 g, 7.1 mmol) and sodium bicarbonate (1.19 g, 
14.2 mmol) in methanol (8.1 mL) was heated to reflux for 24 hours. Evaporation under 
vacuum of methanol afforded a crude product which is taken up with H2O and EtOAc. 
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The organic phase was washed with brine and dried over anhydrous sodium sulphate. 
Evaporation under vacuum of the organic solvent afforded a crude product which was 
purified by column chromatography over silica gel using a 9:1 n-hexane/EtOAc mixture 
as the eluent, to yield the N-arylglycinic derivative 3.95 (357 mg, 1.70 mmol, 24% 
yield). 1H NMR (CDCl3) δ (ppm): 3.83 (s, 3H), 4.11 (d, 2H, J = 5.5 Hz), 6.69 (d, 1H, J 
= 8.6 Hz), 6.73 (td, 1H, J = 7.8, 1.3 Hz), 7.46 (td, 1H, J = 7.9, 1.6 Hz), 8.21 (dd, 1H, J = 
8.5, 1.6 Hz), 8.39 (bs, 1H). 
 
Methyl 1-hydroxy-1H-benzo[d]imidazole-2-carboxylate (3.96) 
 
A freshly prepared solution of sodium methoxide (79.8 mg, 3.47 mmol) in MeOH 
(19.3 mL) was treated with the N-arylglycinic derivative 3.95 (270 mg, 1.28 mmol) 
prepared in the previous step. The resulting mixture was left under stirring at RT for 5 
h. Once the disappearance of the glycinic precursor was verified by TLC, the reaction 
mixture was diluted with water and acidified with AcOH. The resulting suspension was 
extracted several times with Et2O. The combined organic phase was washed with brine 
and dried over anhydrous sodium sulphate. Evaporation under vacuum of the organic 
solvent afforded a crude product which was purified by column chromatography over 
silica gel using a 95:5 mixture of EtOAc/MeOH as the eluent, to yield the N-
hydroxybenzimidazol-ester derivative 3.96 (90.3 mg, 0.470 mmol, 37% yield). 1H NMR 
(CD3OD) δ (ppm): 4.04 (s, 3H), 7.29-7.51 (m, 2H), 7.63-7.74 (m, 2H). MS m/z 192 
(M+, 100%), 162 (M+ –O –CH2, 25%), 134 (M+ –CO2 –CH2, 35%). 
 
1-Hydroxy-1H-benzo[d]imidazole-2-carboxylic acid (3.97) 
 
A solution containing the N-hydroxybenzimidazol-ester derivative 3.96 (80.0 mg, 
0.416 mmol) in 4 mL of a 1:1 mixture of MeOH and THF was treated at RT with 1.3 of 
Experimental section 
238 
 
an aqueous 2N solution of LiOH. The reaction mixture was left under stirring in the 
dark at the same temperature for 2 h. Once the disappearance of the precursor was 
verified by TLC, most of the organic solvent was evaporated under vacuum and the 
reaction mixture was diluted with water, acidified with aqueous 1N solution of HCl and 
extracted several times with EtOAc. The combined organic phase was washed with 
brine and dried over anhydrous sodium sulphate. Evaporation under vacuum of the 
organic solvent afforded the final N-hydroxybenzimidazol-carboxylic acid product 3.97 
(30.0 mg, 0.168 mmol, 40% yield). 1H NMR (CD3OD) δ (ppm): 7.36-7.49 (m, 2H), 
7.67-7.70 (m, 2H), 8.65 (bs, 1H). 
 
1-Azido-2-nitrobenzene (3.102) 
 
A solution of NaNO2 (599 mg, 8.69 mmol) in H2O (1.9 mL) was added dropwise to 
a stirred solution of commercially available 2-nitroaniline 3.101 (1.00 g, 7.24 mmol) in 
a mixture of concentrated HCl solution (3.8 mL) and H2O (6.7 mL) at –5 °C. The 
mixture was stirred at 0 °C for 1 h. A solution of NaN3 (471 mg, 7.24 mmol) in H2O 
(1.9 mL) was added dropwise to the cooled mixture so that the temperature did not 
exceed 5 °C (vigorous foaming). The mixture was stirred for 1 h at 0-5 °C and then for 
2 h at RT. The reaction was worked up by dilution with EtOAc. The organic layer was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation of the organic solvent yielded the azide derivative 3.102 (1.16 g, 
7.07 mmol, 98% yield), which was directly used for the next step, without 1H NMR 
analysis.  
 
Benzo[c][1,2,5]oxadiazole 1-oxide (3.103) 
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A solution of the azide 3.102 (1.15 g, 7.01 mmol) in toluene (17.5 mL) was added 
dropwise over boiling toluene (52.6 mL). The mixture was refluxed overnight. Removal 
of the solvent under vacuum afforded benzofuroxane 3.103 (974 mg, 7.16 mmol, >99% 
yield). 1H NMR (CDCl3) δ (ppm): 7.26-7.38 (m, 2H). 7.38-7.47 (m, 2H). 
 
1-Hydroxy-2-(methoxycarbonyl)-1H-benzo[d]imidazole 3-oxide (3.105a) 
 
The benzofurazan-oxide precursor 3.103 (900 mg, 6.61 mmol) was dissolved in 
MeOH (8.3 mL), methyl phenylsulfonylacetate (0.54 mL, 0.71 g, 3.3 mmol) was added 
and the crystals were dissolved by warming the mixture. Subsequently, 8% methanolic 
KOH solution (8.3 mL) was added and the solution was left at RT for 12 h. The solvent 
was evaporated to dryness, then water was added to the resulting residue and the 
aqueous phase was treated with 1N aqueous HCl and extracted several times with 
EtOAc. The combined ethyl acetate organic phase was dried over anhydrous sodium 
sulphate. After filtration, the solvent was removed in vacuo to give a crude which was 
purified by column chromatography over silica gel using n-hexane n-hexane/EtOAc 9:1 
as the eluent, to give d the N-hydroxyindol-N-oxide-ester derivative 3.105a (423 mg, 
2.03 mmol, 31% yield). 1H NMR (CDCl3) δ (ppm): 4.72 (s, 3H), 7.20-7.55 (m, 4H). 
 
2-Carboxy-1-hydroxy-1H-benzo[d]imidazole 3-oxide (3.98) 
N
N
OH
COOH
O
 
Methyl ester 3.105a (415 mg, 1.99 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (20 mL) and treated with 6 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
48 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
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Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford a crude, that was purified by flash 
chromatography (n-hexane/ EtOAc 8:2) to yield the desired N-hydroxybenzimidazol-N-
oxide-carboxylic acid product 3.98 (32.1 mg, 0.165 mmol, 8% yield) without any 
further purification. 1H NMR (acetone-d6) δ (ppm): 6.60-6.90 (m, 3H), 7.26 (bs, 1H), 
11.64 (bs, 1H). 
 
6-Chloro-1-hydroxy-2-(methoxycarbonyl)-1H-benzo[d]imidazole 3-oxide (3.105b) 
 
A solution containing commercially available 5-chlorobenzofurazan-3-oxide 3.104 
(500 mg, 2.93 mmol) and methyl nitroacetate (0.32 mL, 0.42 g, 3.5 mmol) in THF (2.9 
mL) was slowly treated at RT with Et2NH (0.36 mL, 0.26 g, 3.5 mmol). After 
completion of the addition, the resulting mixture was left under stirring overnight. Then, 
the reaction mixture is diluted with water, acidified with a aqueous 1N solution of HCl, 
and extracted several times with EtOAc. The combined organic phase is washed with 
brine and dried over anhydrous sodium sulphate. Evaporation under vacuum of the 
organic solvent affords a crude product which is purified by column chromatography 
over silica gel using n-hexane/EtOAc 6:4 as the eluent, to yield the N-hydroxyindol-N-
oxide-ester derivative 3.105b (117 mg, 0.482 mmol, 16% yield). 1H NMR (CDCl3) δ 
(ppm); tautomer A: 4.08 (s, 3H), 7.42 (dd, 1H, J = 8.8, 1.6 Hz), 7.57 (d, 1H, J = 8.8 Hz), 
7.78 (d, 1H, J = 1.8 Hz); tautomer B: 4.09 (s, 3H), 7.32 (dd, 1H, J = 8.8, 1.8 Hz), 7.64 
(d, 1H, J = 1.8 Hz), 7.71 (d, 1H, J = 8.8 Hz). 
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2-Carboxy-6-chloro-1-hydroxy-1H-benzo[d]imidazole 3-oxide (3.99) 
N
N
OH
COOH
O
Cl
 
Methyl ester 3.105b (100 mg, 0.412 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2.1 mL) and treated with 1.2 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the final N-hydroxybenzimidazol-N-oxide-
carboxylic acid product 3.99 (40.7 mg, 0.178 mmol, 43% yield) without any further 
purification. 1H NMR (CD3OD) δ (ppm); tautomer A: 7.35 (dd, 1H, J = 8.6, 1.9 Hz), 
7.55 (d, 1H, J = 8.8 Hz), 8.33 (d, 1H, J = 2.4 Hz); tautomer B: 7.28 (dd, 1H, J = 8.6, 2.0 
Hz), 7.61 (d, 1H, J = 8.9 Hz), 7.64 (d, 1H, J = 2.0 Hz). 13C NMR (CD3OD) δ (ppm): 
110.33, 111.60, 119.36, 121.00, 124.49, 125.00, 129.61, 130.45. 
 
4-Nitro-[1,1'-biphenyl]-3-amine (3.107) 
 
A solution of commercially available 5-chloro-2-nitroaniline 3.106 (1.00 g, 5.79 
mmol) in dioxane (20.3 mL) was treated with cesium carbonate (3.21 g, 9.84 mmol), 
phenylboronic acid (1.13 g, 9.26 mmol), Pd2(dba)3 (170 mg, 0.185 mmol) and 0.8 mL 
of a 20% solution of tricyclohexylphosphine (0.446 mmol) in toluene, and the resulting 
mixture was heated to 80 °C in a sealed vial for 24 h. The reaction mixture was then 
cooled to RT, diluted with EtOAc and filtered through a Celite pad. The organic filtrate 
was concentrated under vacuum and the crude product was purified by flash 
chromatography (n-hexane/EtOAc 8:2) to yield pure 3.107 (212 mg, 0.990 mmol, 17% 
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yield). 1H NMR (CDCl3) δ (ppm): 6.15 (bs, 2H), 6.94 (dd, 1H, J = 8.8, 1.8 Hz), 6.98 (d, 
1H, J = 1.3 Hz), 7.42-7.51 (m, 3H), 7.56-7.60 (m, 2H), 8.19 (d, 1H, J = 8.8 Hz). 
 
3-Azido-4-nitro-1,1'-biphenyl (3.108) 
 
A solution of NaNO2 (77.3 mg, 1.12 mmol) in H2O (0.2 mL) was added dropwise to 
a stirred solution of the synthesized amine derivative 3.107 (200 mg, 0.934 mmol) in a 
mixture of concentrated HCl solution (0.5 mL) and H2O (0.9 mL) at –5 °C. The mixture 
was stirred at 0 °C for 1 h. A solution of NaN3 (60.7 mg, 0.934 mmol) in H2O (0.2 mL) 
was added dropwise to the cooled mixture so that the temperature did not exceed 5 °C 
(vigorous foaming). The mixture was stirred for 1 h at 0-5 °C and then for 12 h at RT. 
The reaction was worked up by dilution with EtOAc. The organic layer was washed 
with saturated NaHCO3 solution and brine, then dried over anhydrous sodium sulphate. 
After evaporation of the organic solvent, the crude was purified by column 
chromatography over silica gel using n-hexane/EtOAc 9:1 as the eluent, to yield the 
azide derivative 3.108 (199 mg, 0.828 mmol, 89% yield). 1H NMR (CDCl3) δ (ppm): 
7.41-7.63 (m, 7H), 8.05 (d, 1H, J = 8.4 Hz). 
 
5-Phenylbenzo[c][1,2,5]oxadiazole 1-oxide (3.109) 
N
O
N
O
 
A solution of the azide 3.108 (198 mg, 0.824 mmol) in toluene (2.1 mL) was added 
dropwise over boiling toluene (6.2 mL). The mixture was refluxed for 4 h. Removal of 
the solvent under vacuum afforded a crude product that was purified by column 
chromatography over silica gel using n-hexane/EtOAc 9:1 as the eluent, to yield 
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benzofuroxane 3.109 (91.2 mg, 0.430 mmol, 52% yield). 1H NMR (CDCl3) δ (ppm): 
7.265-7.27 (m, 1H), 7.46-7.64 (m, 7H). 
 
1-Hydroxy-2-(methoxycarbonyl)-6-phenyl-1H-benzo[d]imidazole 3-oxide (3.110) 
N
N
OH
COOMe
O
 
A solution containing 3.109 (44.0 mg, 0.207 mmol) and methyl nitroacetate (0.02 
mL, 0.030 g, 0.25 mmol) in THF (0.2 mL) was slowly treated at RT with Et2NH (0.03 
mL, 0.018 g, 0.25 mmol). After completion of the addition, the resulting mixture was 
left under stirring for 3 days. Then, the reaction mixture is diluted with water, acidified 
with a aqueous 1N solution of HCl, and extracted several times with EtOAc. The 
combined organic phase is washed with brine and dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent affords a crude product 
which is purified by column chromatography over silica gel using n-hexane/EtOAc 3:7 
as the eluent, to yield the N-hydroxyindol-N-oxide-ester derivative 3.110 (5.0 mg, 0.018 
mmol, 8% yield). 1H NMR (CDCl3) δ (ppm): 4.07 (s, 3H), 7.34-7.51 (m, 5H), 7.60-7.66 
(m, 3H). 
 
2-Carboxy-1-hydroxy-6-phenyl-1H-benzo[d]imidazole 3-oxide (3.100) 
N
N
OH
COOH
O
 
Methyl ester 3.110 (5.0 mg, 0.018 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.4 mL) and treated with 0.1 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
days, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
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with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.100 (4.4 mg, 0.016 mmol, 90% yield) without any further purification. 1H 
NMR (CD3OD) δ (ppm): 7.40-7.53 (m, 3H), 7.66-7.75 (m, 2H), 7.85-8.02 (m, 3H), 9.20 
(bs, 1H).  
 
3-Methyl-4-nitrobiphenyl (3.118b) 
CH3
NO2  
A solution of Pd(OAc)2 (31 mg, 0.14 mmol) and triphenylphosphine (183 mg, 0.699 
mmol) in absolute ethanol (10 mL) and anhydrous toluene (10 mL) was stirred at RT 
under nitrogen for 10 min. After that period, commercially available 5-chloro-2-
nitrotoluene 3.115 (800 mg, 4.66 mmol), 10 mL of 2M aqueous Na2CO3, and 
phenylboronic acid (910 mg, 7.46 mmol) were sequentially added. The resulting 
mixture was heated at 100 °C in a sealed vial under nitrogen overnight. After being 
cooled to RT, the mixture was diluted with water and extracted with EtOAc. The 
combined organic phase were dried and concentrated. The crude product was purified 
by flash chromatography (n-hexane) to yield 3.118b (930 mg, 4.36 mmol, 94% yield). 
1H NMR (DMSO-d6) δ (ppm): 2.69 (s, 3H); 7.40-7.63 (m, 7H); 8.09 (d, 1H, J = 10 Hz). 
 
Methyl 3-(4-nitrobiphenyl-3-yl)-2-oxopropanoate (3.119b) 
COOMe
O
NO2  
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 563 mg, 14.1 
mmol) in 9.9 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.118b (750 mg, 3.52 
mmol) and dimethyl oxalate (2.08 g, 17.6 mmol) in 6.6 mL of anhydrous DMF. The 
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mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
12 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.119b (814 mg, 2.72 mmol, 
77% yield). 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 4.62 (s, 2H), 7.44-7.67 (m, 6H), 
7.70 (dd, 1H, J = 8.6, 2.0 Hz), 8.28 (d, 1H, J = 8.6 Hz); signals imputable to the enol 
form (~ 30%) δ (ppm): 3.97 (s, 3H), 6.66 (d, 1H, exchangeable, J = 1.5 Hz), 7.06 (d, 
1H, J = 1.3 Hz), 8.04 (d, 1H, J = 8.4 Hz), 8.46 (d, 1H, J = 2.0 Hz). 
 
Methyl 1-hydroxy-5-phenyl-1H-indole-2-carboxylate (3.120b) 
 
Ketoester 3.119b (400 mg, 1.34 mmol) was dissolved in THF (2.2 mL) and the 
resulting solution was added to an aqueous solution (2.2 mL) of sodium hypophosphite 
monohydrate (439 mg, 4.14 mmol). Then 14 mg of 10% palladium over charcoal was 
added and the resulting suspension was stirred ar RT. After 4 h the disappearance of the 
precursor is verified by TLC and the mixture was concentrated, diluted with water and 
repeatedly extracted with EtOAc. The combined organic phase was dried over 
anhydrous sodium sulphate and evaporated to afford a crude residue that was purified 
by column chromatography over over silica gel using n-hexane/CH2Cl2 2:8 as the 
eluent, to give the N-hydroxyindole 3.120b (69.0 mg, 0.258 mmol, 19% yield). 1H 
NMR (CDCl3) δ (ppm): 4.01 (s, 3H), 7.08 (s, 1H), 7.33-7.37 (m, 1H), 7.40-7.49 (m, 
2H), 7.60-7.66 (m, 4H), 7.82-7.84 (m, 1H), 10.27 (bs, 1H). 
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1-Hydroxy-5-phenyl-1H-indole-2-carboxylic acid (3.112) 
 
Methyl ester 3.120b (60.0 mg, 0.224 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2.2 mL) and treated with 0.68 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
24 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.112 (51.1 mg, 0.202 mmol, 90% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.04 (d, 1H, J = 0.9 Hz), 7.32-7.36 (m, 1H), 7.42-7.53 (m, 
2H), 7.60-7.70 (m, 4H), 7.90 (t, 1H, J = 0.9 Hz). 13C NMR (DMSO-d6) δ (ppm): 104.51, 
110.10, 119.85, 119.93, 121.46, 124.10, 126.66 (2C), 127.34, 128.85 (2C), 132.67, 
135.00, 140.94, 161.39. MS m/z 253 (M+, 100%), 237 (M+ –O, 40%), 190 (M+ –H2O –
CO2 –H, 62%), 165 (M+ –H2O –CO2 –C2H2, 12%). HPLC, tR 9.4 min. 
 
4-Methyl-3-nitrobiphenyl (3.118c) 
 
A solution of Pd(OAc)2 (31 mg, 0.14 mmol) and triphenylphosphine (182 mg, 0.694 
mmol) in absolute ethanol (10 mL) and anhydrous toluene (10 mL) was stirred at RT 
under nitrogen for 10 min. After that period, commercially available 4-bromo-2-
nitrotoluene 3.90d (1.00 g, 4.63 mmol), 10 mL of 2M aqueous Na2CO3, and 
phenylboronic acid (904 mg, 7.41 mmol) were sequentially added. The resulting 
mixture was heated at 100 °C in a sealed vial under nitrogen overnight. After being 
cooled to RT, the mixture was diluted with water and extracted with EtOAc. The 
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combined organic phase were dried and concentrated. The crude product was purified 
by flash chromatography (n-hexane/ EtOAc 95:5) to yield 3.118c (966 mg, 4.53 mmol, 
98% yield). 1H NMR (CDCl3) δ (ppm): 2.64 (s, 3H); 7.39-7.52 (m, 4H); 7.58-7.63 (m, 
2H); 7.73 (dd, 1H, J = 7.4, 2.0 Hz); 8.21 (d, 1H, J = 1.8 Hz). 
 
Methyl 3-(3-nitrobiphenyl-4-yl)-2-oxopropanoate (3.119c) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 375 mg, 9.38 
mmol) in 9.2 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.118c (500 mg, 2.34 
mmol) and dimethyl oxalate (1.38 g, 11.7 mmol) in 6.9 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
4 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.119c (567 mg, 1.89 mmol, 
81% yield). 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 4.58 (s, 2H), 7.40 (d, 1H, J = 8.1 
Hz), 7.44-7.54 (m, 3H), 7.58-7.65 (m, 2H), 7.85 (dd, 1H, J = 7.9, 2.0 Hz), 8.40 (d, 1H, J 
= 2.0 Hz); signals imputable to the enol form (~ 20%) δ (ppm): 3.92 (s, 3H), 6.70 (bs, 
1H, exchangeable), 6.97 (s, 1H), 7.83 (dd, 1H, J = 8.2, 1.9 Hz), 8.13 (d, 1H, J = 1.8 Hz), 
8.40 (d, 1H, J = 8.4 Hz). 
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Methyl 1-hydroxy-6-phenyl-1H-indole-2-carboxylate (3.120c) 
 
Triethylamine (0.93 mL, 0.68 g, 6.7 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (453 mg, 2.01 mmol) and PhSH (0.62 mL, 0.66 g, 6.0 mmol) in 
acetonitrile (10.5 mL) at room temperature to generate a yellow precipitate over a 
period of 5 min. Then, 3.119c (400 mg, 1.34 mmol) was transferred to the suspension 
and stirred at room temperature for 5 more min. After complete consumption of the 
starting material, the mixture was diluted with water and repeatedly extracted with 
EtOAc. The combined organic phase was dried over anhydrous sodium sulphate, diluted 
with toluene and a catalytic amount of p-toluensulfonic acid was added. Then, it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 7:3 as the eluent, to give the N-hydroxyindole 3.120c 
(182 mg, 0.681 mmol, 51% yield). 1H NMR (CDCl3) δ (ppm): 4.01 (s, 3H), 7.05 (d, 1H, 
J = 0.9 Hz), 7.36-7.51 (m, 4H), 7.67-7.75 (m, 4H), 10.26 (bs, 1H). 13C NMR (CDCl3) δ 
(ppm): 52.58, 103.89, 107.75, 120.48, 121.26, 121.72, 123.03, 127.47, 127.56 (2C), 
128.91 (2C), 134.01, 139.23, 141.45, 164.54. 
 
1-Hydroxy-6-phenyl-1H-indole-2-carboxylic acid (3.113) 
 
Methyl ester 3.120c (129 mg, 0.483 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (4.8 mL) and treated with 1.4 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
12 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
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product 3.113 (121 mg, 0.478 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.03 (s, 1H), 7.36-7.52 (m, 4H), 7.62-7.64 (m, 1H), 7.70-
7.75 (m, 3H). 13C NMR (acetone-d6) δ (ppm): 106.08, 108.19, 121.37, 121.83, 123.63, 
127.05, 127.96 (2C), 128.06, 129.68 (2C), 137.49, 139.25, 142.18, 162.05. MS m/z 253 
(M+, 100%), 191 (M+ –H2O –CO2, 65%), 190 (M+ –H2O –CO2 –H, 86%), 165 (M+ –
H2O –CO2 –C2H2, 32%). HPLC, tR 9.2 min. 
 
Methyl 6-phenyl-1H-indole-2-carboxylate (3.121) 
 
Ketoester 3.119c (300 mg, 1.00 mmol) was dissolved in anhydrous DME (1.0 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (505 mg, 2.24 mmol) in DME (1.0 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 24 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a 66:34 mixture of the indol-ester derivative 3.121 with its N-hydroxyindole 
analogue 3.120c that was purified by column chromatography over silica gel using n-
hexane/EtOAc 8:2 as the eluent, to give the indol-ester derivative 3.121 (40.0 mg, 0.159 
mmol, 16% yield). 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 7.27 (dd, 1H, J = 2.0, 0.9 
Hz), 7.36-7.51 (m, 4H), 7.61-7.68 (m, 3H), 7.75 (d, 1H, J = 8.4 Hz), 8.93 (bs, 1H). 
 
6-Phenyl-1H-indole-2-carboxylic acid (3.122) 
 
Methyl ester 3.121 (40.0 mg, 0.159 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.6 mL) and treated with 0.5 mL of 2N aqueous solution of LiOH. The 
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reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
72 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.122 (37.5 mg, 0.158 mmol, 99% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 7.23 (dd, 1H, J = 2.2, 0.9 Hz), 7.34-7.52 (m, 4H), 7.67-7.80 
(m, 4H), 10.94 (bs, 1H). 13C NMR (acetone-d6) δ (ppm): 108.70, 111.19, 121.00, 
123.38, 126.10, 127.80, 127.89 (2C), 129.62 (2C), 129.65, 138.76, 142.60, 162.60. MS 
m/z 237 (M+, 38%), 191 (M+ –HCOOH, 40%), 190 (M+ –HCOOH –H, 100%). HPLC, 
tR = 9.2 min. 
 
1,2-Dichloro-4-methyl-5-nitrobenzene (3.117) 
 
To a mixture of 3,4-dichlorotoluene 3.116 (0.8 mL, 1.00 g, 6.21 mmol) and 
concentrated H2SO4 (10 mL) was added portionwise KNO3 (791 mg, 7.82 mmol) at 5 
°C, and the resulting mixture was stirred at room temperature for 2 h. After cooling to 0 
°C, the mixture was poured into ice-water. The resulting precipitate was collected with 
filtration and dried. Subsequently, the solid was dissolved in Et2O, washed with brine, 
and dried over anhydrous sodium sulphate. After removal of the solvent, the residue 
was purified by column chromatography on silica gel using n-hexane/EtOAc 100:1 as 
the eluent to obtain 3, 4-dichloro-6-nitrotoluene 3.117 (465 mg, 2.26 mmol, 36% yield). 
1H NMR (CDCl3) δ (ppm): 2.59 (s, 3H); 7.47 (s, 1H); 8.13 (s, 1H). 
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1,2-Diphenyl-4-methyl-5-nitrobenzene (3.118d) 
 
Dichloro-aryl derivative 3.117 (460 mg, 2.23 mmol) was placed in a vial together 
with phenylboronic acid (1.09 g, 8.93 mmol), potassium phosphate (2.08 g, 9.81 mmol), 
Pd(OAc)2 (13 mg, 0.059 mmol), tetrabutylammonium bromide (1.12 g, 34.6 mmol) and 
water (5 mL). The vial was sealed and heated under stirring at 125 °C for 48 h. The 
reaction mixture was cooled to RT and then diluted with water. The water phase was 
acidified with 1N aqueous HCl and repeatedly extracted with EtOAc. The combined 
organic phase was dried over anhydrous sodium sulphate and evaporated to afford a 
crude residue that was purified by column chromatography over silica gel using n-
hexane as the eluent, to give pure 3.118d (587 mg, 2.03 mmol, 91% yield). 1H NMR 
(CDCl3) δ (ppm): 2.70 (s, 3H), 7.10-7.18 (m, 4H), 7.22-7.30 (m, 6H), 7.41 (s, 1H), 8.11 
(s, 1H). 
 
Methyl 3-(4,5-diphenyl-2-nitrophenyl)-2-oxopropanoate (3.119d) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 315 mg, 7.88 
mmol) in 6 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.118d (570 mg, 1.97 
mmol) and dimethyl oxalate (1.16 g, 9.85 mmol) in 6 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
60 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
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was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
8:2 as the eluent, to yield the nitroaryl-ketoester derivative 3.119d (288 mg, 0.767 
mmol, 38% yield). 1H NMR (CDCl3) δ (ppm): 3.97 (s, 3H), 4.62 (s, 2H), 7.11-7.20 (m, 
3H), 7.23-7.30 (m, 7H), 7.36 (s, 1H), 8.28 (s, 1H), signals imputable to the enol form (~ 
18%) δ (ppm): 6.53 (s, 1H); 7.06 (d, 1H, J = 1.3 Hz), 8.03 (s, 1H), 8.31 (s, 1H). 
 
Methyl 1-hydroxy-5,6-diphenyl-1H-indole-2-carboxylate (3.120d) 
 
To a solution containing the ketoester 3.119d (145 mg, 0.386 mmol) in 4 mL of 
MeOH, was added lead powder (400 mg, 1.93 mol) and 0.4 mL of HCO2HNEt3. The 
mixture was stirred at 55 °C for 12 h, cooled to RT, and filtered over a pad of Celite. 
The solvent was removed under reduced pressure and the residue purified by column 
chromatography over silica gel using n-hexane/EtOAc 1:1 as the eluent, to give the N-
hydroxyindole 3.120d (50.0 mg, 0.146 mmol, 38% yield). 1H NMR (CDCl3) δ (ppm): 
4.01 (s, 3H), 7.09 (d, 1H, J = 0.5 Hz), 7.16-7.21 (m, 10H), 7.61 (s, 1H), 7.68 (s, 1H), 
10.25 (bs, 1H). 
 
1-Hydroxy-5,6-diphenyl-1H-indole-2-carboxylic acid (3.114) 
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Methyl ester 3.120d (48.0 mg, 0.140 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2 mL) and treated with 0.4 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.114 (37.0 mg, 0.112 mol, 80% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 7.06-7.28 (m, 11H), 7.54 (s, 1H), 7.70 (s, 1H). 13C NMR 
(acetone-d6) δ (ppm): 106.28, 111.80, 121.88, 124.85, 126.80, 127.18, 127.51, 128.49 
(2C), 128.56 (2C), 130.73 (2C), 130.84 (2C), 135.32, 136.47, 139.65, 142.93, 143.02, 
162.01. 
 
Methyl 1-methoxy-6-phenyl-1H-indole-2-carboxylate (3.123) 
 
A solution of 3.120c (250 mg, 0.935 mnol) in anhydrous THF was treated with DBU 
(0.5 mL) and iodomethane (0.2 mL), and the resulting mixture was stirred at RT for 1 h. 
The solvent was evaporated, then an aqueous 1N HCl solution was added and the 
mixture was extracted with AcOEt. The organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford a crude residue that was purified by column 
chromatography (n-hexane/ethyl acetate 95:5, to give pure 3.123 (55.5 mg, 0.197 mmol, 
21% yield); 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 4.24 (s, 3H), 7.13 (d, 1H, J = 0.7 
Hz), 7.37-7.52 (m, 4H), 7.67-7.72 (m, 4H). 
 
1-Methoxy-6-phenyl-1H-indole-2-carboxylic acid (3.124) 
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Methyl ester 3.123 (44.0 mg, 0.156 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.6 mL) and treated with 0.46 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
72 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.124 (41.2 mg, 0.154 mmol, 99% yield) without any further purification. 1H 
NMR (CDCl3) δ (ppm): 4.26 (s, 3H), 7.31 (s, 1H), 7.39-7.53 (m, 4H), 7.67-7.76 (m, 
4H). 13C NMR (CDCl3) δ (ppm): 66.40 (OMe), 107.66, 109.35, 121.19, 121.86, 123.37, 
124.59, 127.62 (2C), 128.11, 128.98 (2C), 136.43, 140.16, 141.38, 164.60. MS m/z 267 
(M+, 50%), 253 (M+ –CH2, 30%), 237 (M+ –O –CH2, 9%), 191 (M+ –CH2 –H2O –CO2, 
40%), 190 (M+ –CH2 –H2O –CO2 –H, 100%), 165 (M+ –CH2 –H2O –CO2 –C2H2, 21%). 
HPLC, tR = 8.6 min (purity = 93%, major impurity accounting for >6% of residual peak 
area identified as CG-277). 
 
4'-Methyl-3'-nitrobiphenyl-4-carboxylic acid (3.130a) 
 
A solution of Pd(OAc)2 (20.8 mg, 0.0927 mmol) and triphenylphosphine (122 mg, 
0.464 mmol) in absolute ethanol (6.9 mL) and anhydrous toluene (6.9 mL) was stirred 
at RT under nitrogen for 10 min in a vial. After that period, commercially available 4-
bromo-2-nitrotoluene 3.90d (667 mg, 3.09 mmol), 6.9 mL of 2M aqueous Na2CO3, and 
4-carboxyphenylboronic acid 3.129a (820 mg, 4.94 mmol) were sequentially added. 
The vial was sealed and heated under stirring at 105 °C in a microwave reactor for 20 
min. The reaction mixture was then diluted with water and extracted with EtOAc. The 
combined organic phase were dried and concentrated. The crude product was purified 
by flash chromatography (n-hexane/EtOAc 1:1) to yield 3.130a (388 mg, 1.51 mmol, 
49% yield). 1H NMR (DMSO-d6) δ (ppm): 2.56 (s, 3H), 7.63 (d, 1H, J = 8.1 Hz), 7.89 
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(AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 2.0 Hz), 8.03 (dd, 1H, J = 9.9, 2.0 Hz), 8.05 
(AA’XX’, 2H, J AX = 8.6 Hz, JAA’/XX’ = 2.0 Hz), 8.31 (d, 1H, J = 2.0 Hz). 
 
4'-(3-Methoxy-2,3-dioxopropyl)-3'-nitrobiphenyl-4-carboxylic acid (3.131a) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 350 mg, 8.76 
mmol) in 5.7 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.130a (376 mg, 1.46 
mmol) and dimethyl oxalate (1.04 g, 8.76 mmol) in 2.6 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
18 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
2:8 with 0.01% trifluoroacetic acid as the eluent, to yield the nitroaryl-ketoester 
derivative 3.131a (159 mg, 0.463 mmol, 32% yield). 1H NMR (DMSO-d6) δ (ppm): 
3.86 (s, 3H), 4.66 (s, 2H), 7.50-7.66 (m, 2H), 7.93 (d, 1H, J = 8.1 Hz), 8.03-8.14 (m, 
3H), 8.41 (d, 1H, J = 1.8 Hz); signals imputable to the enol form (~ 70%) δ (ppm): 3.84 
(s, 3H), 6.62 (s, 1H), 8.30 (d, 1H, J =1.8 Hz), 8.36 (d, 1H, J = 8.4 Hz). 
 
4-(1-Hydroxy-2-(methoxycarbonyl)-1H-indol-6-yl)benzoic acid (3.132a) 
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Ketoester 3.131a (150 mg, 0.437 mmol) was dissolved in anhydrous DME (0.4 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (221 mg, 0.979 mmol) in DME (0.4mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 8 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 4:6 with 0.01% trifluoroacetic acid as the eluent, to give a mixture 
(10.6 mg) of the N-hydroxyindol-ester derivative 3.132a (80%, 8.5 mg, 0.027 mmol, 
6% yield) with its indole analogue (20%)  1H NMR (acetone-d6) δ (ppm): 3.91 (s, 3H), 
7.14 (d, 1H, J = 0.9 Hz), 7.53 (dd, 1H, J = 8.4, 1.6 Hz), 7.79 (dd, 1H, J = 8.4, 0.6 Hz), 
7.86 (t, 1H, J = 0.9 Hz), 7.88-7.94 (m, 2H), 8.13-8.20 (m, 2H), 10.48 (bs, 1H); signals 
imputable to the indole (~ 20%) δ (ppm): 3.92 (s, 3H), 7.22-7.24 (m, 1H). 
 
6-(4-Carboxyphenyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.125a) 
 
Methyl ester 3.132a (10.6 mg, 0.0341 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.3 mL) and treated with 0.1 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT. After 12 h, it was monitored by TLC 
and another portion of LiOH (0.2 mL) was added. After further 72 h, it was 
concentrated, diluted with water and washed with Et2O. Then, the aqueous phase was 
treated with 1N aqueous HCl and extracted several times with EtOAc. The combined 
ethyl acetate organic phase was dried over anhydrous sodium sulphate and evaporated 
to afford the desired N-hydroxyindol-carboxylic acid product 3.125a (10.0 mg, 0.0336 
mmol, 99% yield) without any further purification. 1H NMR (acetone-d6) δ (ppm): 7.04 
(s, 1H), 7.49 (dd, 1H, J = 8.4, 1.4 Hz), 7.76 (d, 1H, J = 8.6 Hz), 7.83 (d, 1H, J = 1.2 
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Hz), 7.88-7.92 (m, 2H), 8.13-8.17 (m, 2H); signals imputable to the indole (~ 30%) δ 
(ppm): 7.24-7.27 (m, 1H) 
 
4'-Methyl-3'-nitrobiphenyl-3-carboxylic acid (3.130b) 
 
A solution of Pd(OAc)2 (16.2 mg, 0.0723 mmol) and triphenylphosphine (94.8 mg, 
0.362 mmol) in absolute ethanol (5.4 mL) and anhydrous toluene (5.4 mL) was stirred 
at RT under nitrogen for 10 min in a vial. After that period, commercially available 4-
bromo-2-nitrotoluene 3.90d (520 mg, 2.41 mmol), 5.4 mL of 2M aqueous Na2CO3, and 
3-carboxyphenylboronic acid 3.129b (639 mg, 3.85 mmol) were sequentially added. 
The vial was sealed and heated under stirring at 105 °C in a microwave reactor for 20 
min. The reaction mixture was then diluted with water and extracted with EtOAc. The 
combined organic phase were dried and concentrated. The crude product was purified 
by flash chromatography (n-hexane/EtOAc 1:1) to yield 3.130b (469 mg, 1.82 mmol, 
76% yield). 1H NMR (acetone-d6) δ (ppm): 2.62 (s, 3H), 7.47-7.76 (m, 3H), 7.96-8.13 
(m, 2H), 8.29 (d, 1H, J = 1.8 Hz), 8.35 (t, 1H, J = 1.6 Hz). 
 
4'-(3-Methoxy-2,3-dioxopropyl)-3'-nitrobiphenyl-3-carboxylic acid (3.131b) 
COOMe
O
NO2
COOH  
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 131 mg, 3.27 
mmol) in 2.1 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.130b (140 mg, 0.544 
mmol) and dimethyl oxalate (386 mg, 3.27 mmol) in 1.0 mL of anhydrous DMF. The 
Experimental section 
258 
 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
4 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using EtOAc as the 
eluent, to yield the nitroaryl-ketoester derivative 3.131b (110 mg, 0.320 mmol, 59% 
yield). 1H NMR (acetone-d6) δ (ppm): 3.91 (s, 3H), 4.74 (s, 2H), 7.51-7.76 (m, 3H), 
7.70-8.19 (m, 2H), 8.39-8.49 (m, 2H), 10.40 (bs, 1H); signals imputable to the enol 
form (~ 20%) δ (ppm): 6.81 (s, 1H). 
 
3-(1-Hydroxy-2-(methoxycarbonyl)-1H-indol-6-yl)benzoic acid (3.132b) 
 
Ketoester 3.131b (100 mg, 0.291 .mmol) was dissolved in anhydrous DME (0.2 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (147 mg, 0.653 mmol) in DME (0.2 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 6 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
CHCl3/MeOH 95:5 as the eluent, to give the N-hydroxyindol-ester derivative 3.132b 
(30 mg, 0.0964 , 33% yield). 1H NMR (acetone-d6) δ (ppm): 3.91 (s, 3H), 7.14 (d, 1H, J 
= 0.8 Hz), 7.52 (dd, 1H, J = 8.3, 1.6 Hz), 7.65 (t, 1H, J = 7.7 Hz), 7.78-7.82 (m, 2H), 
8.01-8.08 (m, 2H), 8.39 (t, 1H, J = 1.7 Hz). 
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6-(3-Carboxyphenyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.125b) 
 
Methyl ester 3.132b (30.0 mg, 0.0964 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1 mL) and treated with 0.3 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
48 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.125b (26.8 mg, 0.0902 mmol, 94% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.06 (d, 1H, J = 0.7 Hz), 7.46 (dd, 1H, J = 8.4, 1.0 Hz), 7.62 
(t, 1H, J = 7.7 Hz), 7.76 (d, 1H, J = 8.1 Hz), 7.92-8.02 (m, 3H), 8.24 (t, 1H, J = 3.0 Hz). 
 
3-(4'-Methyl-3'-nitrobiphenyl-4-yl)propanoic acid (3.130c) 
 
A solution of Pd(OAc)2 (22 mg, 0.096 mmol) and triphenylphosphine (126 mg, 
0.480 mmol) in absolute ethanol (7.2 mL) and anhydrous toluene (7.2 mL) was stirred 
at RT under nitrogen for 10 min. After that period, commercially available 4-bromo-2-
nitrotoluene 3.90d (696 mg, 3.22 mmol), 7.2 mL of 2M aqueous Na2CO3, and 4-(2-
carboxyethyl)benzeneboronic acid 3.129c (1.00 g, 5.15 mmol) were sequentially added. 
The resulting mixture was heated at 100 °C in a sealed vial under nitrogen overnight. 
After being cooled to RT, the mixture was diluted with water and extracted with EtOAc. 
The combined organic phase were dried and concentrated. The crude product was 
purified by flash chromatography (CHCl3/MeOH 95:5) to yield 3.130c (871 mg, 3.05 
mmol, 95% yield). 1H NMR (acetone-d6) δ (ppm): 2.59 (s, 3H), 2.67 (t, 2H, J = 8.0 Hz), 
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2.99 (t, 2H, J = 7.5 Hz), 7.40 (AA’XX’, 2H, JAX = 8.3 Hz, JAA’/XX’ = 2.0 Hz), 7.56 (d, 1H, 
J = 7.9 HZ), 7.67 (AA’XX’, 2H, JAX = 8.4 Hz, JAA’/XX’ = 2.0 Hz), 7.90 (dd, 1H, J = 7.9, 
2.0 Hz), 8.20 (d, 1H, J = 2.0 Hz). 
 
3-(4'-(3-Methoxy-2,3-dioxopropyl)-3'-nitrobiphenyl-4-yl)propanoic acid (3.131c) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 506 mg, 12.6 
mmol) in 8.7 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.130c (450 mg, 1.58 
mmol) and dimethyl oxalate (1.87 g, 15.8 mmol) in 4.5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
18 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
4:6 as the eluent, to yield the nitroaryl-ketoester derivative 3.131c (227 mg, 0.611 
mmol, 39% yield). 1H NMR (acetone-d6) δ (ppm): 2.69 (t, 2H, J = 7.9 Hz), 2.96 (t, 2H, 
J = 7.7 Hz), 3.90 (s, 3H), 4.70 (s, 2H), 7.44 (AA’XX’, 2H, JAX = 8.1 Hz, JAA’/XX’ = 2.2 
Hz), 7.62 (d, 1H, J = 8.1 Hz), 7.73 (AA’XX’, 2H, JAX = 8.2 Hz, JAA’/XX’ = 2.2 Hz), 8.02 
(dd, 1H, J = 8.2, 1.8 Hz), 8.38 (d, 1H, J = 2.0 Hz); signals imputable to the enol form (~ 
28%) δ (ppm): 6.80 (s, 1H), 8.01 (dd, 1H, J = 8.2, 2.0 Hz), 8.18 (d, 1H, J = 2.0 Hz), 
8.45 (d, 1H, J = 8.2 Hz). 
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3-(4-(1-Hydroxy-2-(methoxycarbonyl)-1H-indol-6-yl)phenyl)propanoic acid 
(3.132c) 
N
COOMe
OH
HOOC  
Ketoester 3.131c (150 mg, 0.404 mmol) was dissolved in THF (0.7 mL) and the 
resulting solution was added to an aqueous solution (0.7 mL) of sodium hypophosphite 
monohydrate (133 mg, 1.25 mmol). Then 4.1 mg of 10% palladium over charcoal was 
added and the resulting suspension was stirred at RT for 21h. Then it was monitored by 
TLC and H2PO2Na.H2O (133 mg, 1.25 mmol) and Pd/C (4.1 mg) were added. After 
further 26 h the disappearance of the precursor is verified by TLC and the mixture was 
concentrated, diluted with water and repeatedly extracted with EtOAc. The combined 
organic phase was dried over anhydrous sodium sulphate and evaporated to afford a 
crude residue that was purified by column chromatography over over silica gel using n-
CHCl3/MeOH 95:5 as the eluent, to give the N-hydroxyindole 3.132c (21.2 mg, 0.0625 
mmol, 15% yield). 1H NMR (acetone-d6) δ (ppm): 2.68 (t, 2H, J = 8.1 Hz), 2.98 (t, 2H, 
J = 7.5 Hz), 3.90 (s, 3H), 7.11 (d, 1H, J = 0.7 Hz), 7.39 (AA’XX’, 2H, JAX = 8.2 Hz, 
JAA’/XX’ = 2.0 Hz), 7.67 (AA’XX’, 2H, JAX = 8.2 Hz, JAA’/XX’ = 2.1 Hz), 7.71-7.75 (m, 
2H), 10.50 (bs, 1H). 
 
6-(4-(2-Carboxyethyl)phenyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.125c) 
 
Methyl ester 3.132c (20.0 mg, 0.0589 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.6 mL) and treated with 0.2 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
48 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
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sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.125c (19.0 mg, 0.0584 mmol, 99% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 2.68 (t, 2H, J = 7.2 Hz), 2.99 (t, 2H, J = 7.5 Hz), 7.13 (d, 
1H, J = 0.9 Hz), 7.39 (AA’/XX’, 2H, JAX = 8.1 Hz, JAA’/XX’ = 2.0 Hz), 7.45 (dd, 1H, J = 
8.8, 1.5 Hz), 7.68 (AA’/XX’, 2H, JAX = 8.2 Hz, JAA’/XX’ = 1.9 Hz), 7.71-7.77 (m, 2H). 
13C NMR (acetone-d6) δ (ppm): 32.44, 35.81, 106.13, 107.99, 121.34, 123.59, 127.64, 
127.96 (2C), 129.75 (2C), 131.61, 131.90, 139.16, 140.04, 141.17, 160.83, 173.76. MS 
m/z 325 (M+, 14%); 255 (M+ –C3H2O2, 32%); 175 (M+ –C9H10O2, 16%); 149 (M+ –
C9H6O3N, 100%).  
 
Methyl(4'-methyl-3'-nitrobiphenyl-4-yl)sulfane (3.133) 
 
A solution of Pd(OAc)2 (21.8 mg, 0.0972 mmol) and triphenylphosphine (128 mg, 
0.486 mmol) in absolute ethanol (7.3 mL) and anhydrous toluene (7.3 mL) was stirred 
at RT under nitrogen for 10 min. After that period, commercially available 4-bromo-2-
nitrotoluene 3.90d (700 mg, 3.24 mmol), 7.3 mL of 2M aqueous Na2CO3, and 4-
(methylthio)benzenboronic acid (871 mg, 5.18 mmol) were sequentially added. The 
resulting mixture was heated at 100 °C in a sealed vial under nitrogen overnight. After 
being cooled to RT, the mixture was diluted with water and extracted with EtOAc. The 
combined organic phase were dried and concentrated. The crude product was purified 
by flash chromatography (n-hexane/EtOAc 6:4) to yield 3.133 (770 mg, 2.97 mmol, 
92% yield). 1H NMR (CDCl3) δ (ppm): 2.53 (s, 3H), 2.63 (s, 3H), 7.35 (AA’XX’, 2H, 
JAX = 8.4 Hz; JAA’XX’ = 2.0 Hz), 7.39 (d, 1H, J = 8.1 Hz), 7.52 (AA’XX’, 2H, JAX = 6.8 
Hz; JAA’XX’ = 2.0 Hz), 7.70 (dd, 1H, J = 8.0, 1.9 Hz), 8.18 (d, 1H, J = 2.0 Hz). 
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Methyl 3-(4'-(methylthio)-3-nitrobiphenyl-4-yl)-2-oxopropanoate (3.134) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 432 mg, 10.8 
mmol) in 7 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.133 (700 mg, 2.70 
mmol) and dimethyl oxalate (1.59 g, 13.5 mmol) in 5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
12 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
6:4 as the eluent, to yield the nitroaryl-ketoester derivative 3.134 (806 mg, 2.33 mmol, 
86% yield). 1H NMR (CDCl3) δ (ppm): 2.53 (s, 3H), 3.95 (s, 3H), 4.56 (s, 2H), 7.31-
7.40 (m, 3H), 7.51-7.59 (m, 2H), 7.82 (d, 1H, J = 7.9 Hz), 8.37 (d, 1H, J = 2.0 Hz); 
signals imputable to the enol form (~ 76%) δ (ppm): 3.96 (s, 3H), 6.68 (d, 1H, 
exchangeable, J = 1.5 Hz), 6.96 (d, 1H, J = 1.5 Hz), 7.35 (AA’XX’, JAX = 8.6 Hz, JAA’XX’ 
= 1.7 Hz), 7.55 (AA’XX’, JAX = 8.8 Hz, JAA’XX’ = 2.0 Hz), 7.80 (dd, 1H, J = 7.9, 1.9 Hz); 
8.11 (d, 1H, J = 2.0 Hz), 8.33 (d, 1H, J = 8.2 Hz). 
 
Methyl 3-(4'-(methylsulfonyl)-3-nitrobiphenyl-4-yl)-2-oxopropanoate (3.131d) 
NO2
COOMe
O
SH3C
O O  
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An aqueous solution (5.3 mL) of Oxone® (50% w/v, 2.67 g, 4.34 mmol) was added 
dropwise to a stirred solution of the methylthio-derivative 3.134 (500 mg, 1.45 mmol) 
in 1,4-dioxane (14.5 mL) at 0 °C, and the reaction was allowed to proceed with stirring 
at RT for 12 h. The reaction mixture was diluted with water, extracted with EtOAc, the 
organic phase was washed successively with water and brine, and dried over anhydrous 
sodium sulphate. After filtration, the solvent from the organic fraction was evaporated 
to give the desired crude product 3.131d (556 mg, 1.47 mmol, >99% yield) which was 
used in the next reaction without any further purification. 1H NMR (CDCl3) δ (ppm): 
3.12 (s, 3H), 3.96 (s, 3H), 4.62 (s, 2H), 7.47 (d, 1H, J = 7.9 Hz), 7.78-7.90 (m, 3H), 8.07 
(AA’XX’, 2H, JAX = 8.6 Hz, JAA’XX’ = 2.0 Hz), 8.42 (d, 1H J = 1.8 Hz); signals 
imputable to the enol form (~ 44%) δ (ppm): 3.97 (s, 3H), 6.80 (bs, 1H), 6.98 (s, 1H, 
exchangeable), 8.40 (d, 1H, J = 7.4 Hz). 
 
Methyl 1-hydroxy-6-(4-(methylsulfonyl)phenyl)-1H-indole-2-carboxylate (3.132d) 
 
Ketoester 3.131d (500 mg, 1.32 mmol) was dissolved in anhydrous DME (1.2 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (670 mg, 2.97 mmol) in DME (1.2 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 5 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 1:1 as the eluent, to give the N-hydroxyindol-ester derivative 3.132d 
(25.8 mg, 0.0747 mmol, 6% yield). 1H NMR (DMSO-d6) δ (ppm): 3.27 (s, 3H), 3.88 (s, 
3H), 7.14 (s, 1H), 7.53 (dd, 1H, J = 8.6, 1.5 Hz), 7.78-7.82 (m, 2H), 8.02 (s, 4H), 11.59 
(bs, 1H). 
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1-Hydroxy-6-(4-(methylsulfonyl)phenyl)-1H-indole-2-carboxylic acid (3.125d) 
N
OH
COOH
S
H3C
O O  
Methyl ester 3.132d (23.0 mg, 0.0666 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.7 mL) and treated with 0.2 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
12 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.125d (21.6 mg, 0.0652 mmol, 98% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 3.26 (s, 3H), 7.06 (s, 1H), 7.50 (dd, 1H, J = 8.2, 1.4 Hz), 
7.76-7.80 (m, 2H), 8.01 (s, 4H). 13C NMR (DMSO-d6) δ (ppm): 43.65, 104.40, 107.95, 
119.89, 121.15, 122.95, 127.65 (2C), 127.78 (2C), 131.42, 134.89, 136.17, 139.21, 
145.49, 161.06.  
 
4'-Methoxy-4-methyl-3-nitrobiphenyl (3.130e) 
 
A solution of Pd(OAc)2 (15.6 mg, 0.0693 mmol) and triphenylphosphine (90.9 mg, 
0.347 mmol) in absolute ethanol (5.2 mL) and anhydrous toluene (5.2 mL) was stirred 
at RT under nitrogen for 10 min in a vial. After that period, commercially available 4-
bromo-2-nitrotoluene 3.90d (500 mg, 2.31 mmol), 5.2 mL of 2M aqueous Na2CO3, and 
4-methoxyphenylboronic acid 3.129e (563 mg, 3.70 mmol) were sequentially added. 
The vial was sealed and heated under stirring at 105 °C in a microwave reactor for 20 
min. The reaction mixture was then diluted with water and extracted with EtOAc. The 
combined organic phase were dried and concentrated. The crude product was purified 
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by flash chromatography (n-hexane/ EtOAc 9:1) to yield 3.130e (513 mg, 2.11 mmol, 
91% yield). 1H NMR (CDCl3) δ (ppm): 2.62 (s, 3H), 3.86 (s, 3H), 7.00 (AA’XX’, 2H, 
JAX = 8.8 Hz, JAA’/XX’ = 2.7 Hz), 7.37 (d, 1H, J = 7.9 Hz), 7.54 (AA’XX’, 2H, JAX = 8.8 
Hz, JAA’/XX’ = 2.7 Hz), 7.68 (dd, 1H, J = 7.9, 2.0 Hz), 8.16 (d, 1H, J = 2.0 Hz). 
 
Methyl 3-(4'-methoxy-3-nitrobiphenyl-4-yl)-2-oxopropanoate (3.131e) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 263 mg, 6.58 
mmol) in 3.9 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.130e (400 mg, 1.64 
mmol) and dimethyl oxalate (968 mg, 8.20 mmol) in 2.9 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
6 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.131e (432 mg, 1.31 mmol, 
80% yield). 1H NMR (CDCl3) δ (ppm): 3.87 (s, 3H), 3.95 (s, 3H), 4.55 (s, 2H), 7.00 
(AA’XX’, 2H, JAX = 9.0 Hz, JAA’/XX’ = 2.6 Hz), 7.36 (d, 1H, J = 7.9 Hz), 7.56 (AA’XX’, 
2H, JAX = 8.8 Hz, JAA’/XX’ = 2.6 Hz), 7.79 (dd, 1H, J = 7.9, 2.0 Hz), 8.35 (d, 1H, J = 2.0 
Hz); signals imputable to the enol form (~ 19%) δ (ppm): 6.67 (bs, 1H), 8.08 (d, 1H, J = 
1.8 Hz), 8.31 (d, 1H, J = 8.4 Hz). 
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Methyl 1-hydroxy-6-(4-methoxyphenyl)-1H-indole-2-carboxylate (3.132e) 
N
OH
COOMe
H3CO  
Ketoester 3.131e (280 mg, 0.850 mmol) was dissolved in anhydrous DME (0.9 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (430 mg, 1.90 mmol) in DME (0.9 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 5 h, then it was monitored by TLC and another portion of SnCl2·2H2O (430 mg, 1.90 
mmol) was added. After further 2.5 h, another portion of SnCl2·2H2O (430 mg, 1.90 
mmol mmol) was added. 4.5 h Later, the mixture was diluted with water and repeatedly 
extracted with EtOAc. The combined organic phase was dried over anhydrous sodium 
sulphate and evaporated to afford a crude residue that was purified by column 
chromatography over silica gel using n-hexane/EtOAc 7:3 as the eluent, to give the N-
hydroxyindol-ester derivative 3.132e (48.6 mg, 0.163 mmol, 19% yield). 1H NMR 
(CDCl3) δ (ppm): 3.87 (s, 3H), 4.00 (s, 3H), 7.00 (AA’XX’, 2H, J AX  = 8.4 Hz, J AA’/XX’ 
= 2.6 Hz), 7.04 (d, 1H, J = 0.7 Hz), 7.37 (dd, 1H, J = 8.4, 1.6 Hz), 7.59-7.69 (m, 4H), 
10. 26 (bs, 1H). 
 
1-Hydroxy-6-(4-methoxyphenyl)-1H-indole-2-carboxylic acid (3.125e) 
 
Methyl ester 3.132e (45.0 mg, 0.151 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.5 mL) and treated with 0.5 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
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with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.125e (42.3 mg, 0.149 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 3.81 (s, 3H), 7.02-7.06 (m, 3H), 7.38 (dd, 1H, J = 8.3, 1.6 
Hz), 7.57 (d, 1H, J = 1.4 Hz), 7.64-7.70 (m, 3H). 13C NMR (DMSO-d6) δ (ppm): 55.18, 
104.61, 106.34, 114.36, 119.71, 119.91, 122.53, 127.03, 127.88, 132.93, 136.73, 
141.67, 158.71, 161.03. MS m/z 283 (M+, 21%), 267 (M+ –O, 100%). 
 
4-Methyl-3-nitro-3'-(trifluoromethoxy)biphenyl (3.130f) 
 
Commercially available 1-bromo-3-trifluoromethoxybenzene 3.128f (0.260 mL, 424 
mg, 1.76 mmol) was placed in a vial together with 4-methyl-3-nitrobenzeneboronic acid 
3.127 (350 mg, 1.94 mmol), sodium carbonate (560 mg, 5.28 mmol), Pd(OAc)2 (1.6 mg, 
0.0070 mmol), tetrabutylammonium bromide (567 mg, 1.76 mmol) and water (5.5 mL). 
The vial was sealed and heated under stirring at 150 °C in a microwave reactor for 5 
min. The reaction mixture was then diluted with water and repeatedly extracted with 
EtOAc. The combined organic phase was dried over anhydrous sodium sulphate and 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 95:5 as the eluent, to give pure 3.130f (482 mg, 1.62 
mmol, 92% yield). 1H NMR (CDCl3) δ (ppm): 2.65 (s, 3H), 7.27-7.28 (m, 1H), 7.42-
7.54 (m, 4H), 7.71 (dd, 1H, J = 8.2, 2.1 Hz), 8.19 (d, 1H, J = 2.0 Hz) 
 
Methyl 3-(3-nitro-3'-(trifluoromethoxy)biphenyl-4-yl)-2-oxopropanoate (3.131f) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 259 mg, 6.32 
mmol) in 4.4 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
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dropwise with a solution containing the nitrotoluene precursor 3.130f (470 mg, 1.58 
mmol) and dimethyl oxalate (933 mg, 7.90 mmol) in 3.0 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
72 h, then it was heated at 40 °C for 12 h. Once the disappearance of the precursor was 
verified by TLC, the reaction mixture was slowly poured in an ice-water mixture; the 
water phase was acidified with 1N aqueous HCl and extracted several times with 
EtOAc. The combined organic phase was washed with saturated NaHCO3 solution and 
brine, then dried over anhydrous sodium sulphate. Evaporation under vacuum of the 
organic solvent afforded a crude product which was purified by column 
chromatography over silica gel using n-hexane/EtOAc 7:3 as the eluent, to yield the 
nitroaryl-ketoester derivative 3.131f (548 mg, 1.43 mmol, 90% yield). 1H NMR (CDCl3) 
δ (ppm): 3.96 (s, 3H), 4.59 (s, 2H), 7.28-7.33 (m, 1H), 7.40-7.59 (m, 4H), 7.83 (dd, 1H, 
J = 7.9, 2.0 Hz), 8.38 (d, 1H, J = 1.8 Hz); signals imputable to the enol form (~ 20%) δ 
(ppm): 3.97 (s, 3H), 6.73 (d, 1H, J = 1.5 Hz), 6.97 (d, 1H, J = 1.5 Hz), 8.11 (d, 1H, J = 
1.8 Hz), 8.36 (d, 1H, J = 7.1 Hz). 
 
Methyl 1-hydroxy-6-(3-(trifluoromethoxy)phenyl)-1H-indole-2-carboxylate 
(3.132f) 
 
Triethylamine (0.18 mL, 0.13 g, 1.3 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (88.3 mg, 0.391 mmol) and PhSH (0.12 mL, 0.13 g, 1.2 mmol) in 
acetonitrile (2.1 mL) at room temperature to generate a yellow precipitate over a period 
of 5 min. Then, 3.131f (100 mg, 0.261 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
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evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 7:3 as the eluent, to give the N-hydroxyindole 3.132f 
(55.9 mg, 0.159 mmol, 61% yield). 1H NMR (CDCl3) δ (ppm): 4.01 (s, 3H), 7.06 (d, 
1H, J = 0.9 Hz), 7.18-7.25 (m, 1H), 7.36 (dd, 1H, J = 8.3, 1.7 Hz), 7.48 (t, 1H, J = 8.1 
Hz), 7.52-7.54 (m, 1H), 7.62 (dt, 1H, J = 7.7, 2.8 Hz), 7.69-7.73 (m, 2H), 10.33 (bs, 
1H). 
 
1-Hydroxy-6-(3-(trifluoromethoxy)phenyl)-1H-indole-2-carboxylic acid (3.125f) 
 
Methyl ester 3.132f (50.0 mg, 0.142 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.4 mL) and treated with 0.43 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.125f (39.6 mg, 0.117 mmol, 83% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 7.16 (d, 1H, J = 0.7 Hz), 7.31-7.38 (m, 1H), 7.49 (dd, 1H, J 
= 8.4, 1.6 Hz), 7.63 (t, 1H, J = 7.9 Hz), 7.68-7.70 (m, 1H), 7.77-7.83 (m, 3H). 13C NMR 
(acetone-d6): δ 105.95, 108.72, 120.34, 120.55, 121.23, 121.62 (q, J = 253.4 Hz), 
122.41, 123.94, 126.94, 127.53, 131.48, 137.31, 137.49, 144.81, 150.62, 162.27. MS 
m/z 337 (M+, 56%), 321 (M+ –O, 63%), 293 (M+ –CO2, 5%), 275 (M+ –CO2 –H2O, 8%), 
249 (M+ –CO2 –H2O –C2H2, 13%), 190 (M+ –C6H4F3O +H, 100%), 177 (M+ –C7H4F3O 
+H, 20%). HPLC, tR = 10.4 min. 
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4-Methyl-3-nitro-4'-(trifluoromethoxy)biphenyl (3.130g) 
 
Commercially available 1-bromo-4-trifluoromethoxybenzene 3.128g (0.150 mL, 
250 mg, 1.04 mmol) was placed in a vial together with 4-methyl-3-nitrobenzeneboronic 
acid 3.127 (207 mg, 1.14 mmol), sodium carbonate (331 mg, 3.12 mmol), Pd(OAc)2 
(0.9 mg, 0.004 mmol), tetrabutylammonium bromide (335 mg, 1.04 mmol) and water 
(1.8 mL). The vial was sealed and heated under stirring at 150 °C in a microwave 
reactor for 5 min. The reaction mixture was then diluted with water and repeatedly 
extracted with EtOAc. The combined organic phase was dried over anhydrous sodium 
sulphate and evaporated to afford a crude residue that was purified by column 
chromatography over silica gel using n-hexane/EtOAc 95:5 as the eluent, to give pure 
3.130g (134 mg, 0.451 mmol, 43% yield). 1H NMR (CDCl3) δ (ppm): 2.65 (s, 3H), 
7.28-7.36 (m, 2H), 7.43 (d, 1H, J = 7.9 Hz), 7.62 (AA’XX’, 2H, JAX = 8.4 Hz, JAA’/XX’ = 
2.2 Hz), 7.69 (dd, 1H, J = 8.0, 1.7 Hz), 8.18 (d, 1H, J = 1.8 Hz). 
 
Methyl 3-(3-nitro-4'-(trifluoromethoxy)biphenyl-4-yl)-2-oxopropanoate (3.131g) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 70.1 mg, 
1.75 mmol) in 1.2 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.130g (130 mg, 0.437 
mmol) and dimethyl oxalate (259 mg, 2.19 mmol) in 0.8 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
24 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
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aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.131g (94.6 mg, 0.247 
mmol, 56% yield). 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 4.59 (s, 2H), 7.30-7.38 (m, 
2H), 7.42 (d, 1H, J = 8.1 Hz), 7.60-7.68 (m, 2H), 7.81 (dd, 1H, J = 7.8, 2.0 Hz), 8.37 (d, 
1H, J = 2.2 Hz); signals imputable to the enol form (~ 22%) δ (ppm): 6.72 (bs, 1H), 
6.97 (bs, 1H), 8.10 (d, 1H, J = 2.0 Hz). 
 
Methyl 1-hydroxy-6-(4-(trifluoromethoxy)phenyl)-1H-indole-2-carboxylate 
(3.132g) 
 
Triethylamine (0.16 mL, 0.12 g, 1.2 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (79.4 mg, 0.352 mmol) and PhSH (0.11 mL, 0.12 g, 1.1 mmol) in 
acetonitrile (1.8 mL) at room temperature to generate a yellow precipitate over a period 
of 5 min. Then, 3.131g (90.0 mg, 0.235 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 8:2 as the eluent, to give a mixture (48.3 mg) of the N-
hydroxyindol-ester derivative 3.132g (92%, 44.4 mg, 0.126 mmol, 54% yield) with its 
indole analogue (8%) 1H NMR (CDCl3) δ (ppm): 4.01 (s, 3H), 7.06 (s, 1H), 7.24-7.38 
(m, 3H), 7.65-7.73 (m, 4H), 10.32 (bs, 1H); signals imputable to the indole (~ 8%) δ 
(ppm): 3.97 (s, 3H), 7.18 (s, 1H), 110.06 (bs, 1H). 
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1-Hydroxy-6-(4-(trifluoromethoxy)phenyl)-1H-indole-2-carboxylic acid (3.125g) 
N
OH
COOH
F3CO  
Methyl ester 3.132g (43.0 mg, 0.122 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.2 mL) and treated with 0.37 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 4 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.125g (22.6 mg, 0.0670 mmol, 55% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 7.16 (d, 1H, J = 0.9 Hz), 7.42-7.50 (m, 3H), 7.75-7.80 (m, 
2H), 7.88 (AA´XX´, 2H, JAX = 8.9 Hz, JAA´/XX´ = 2.6 Hz); signals imputable to the indole 
(~ 10%) δ (ppm): 7.19-7.21 (m, 1H). 13C NMR (acetone-d6) δ (ppm): 106.02, 108.48, 
121.23, 121.43 (q, J = 256.5 Hz), 122.06, 122.23 (2C), 123.81, 127.34, 129.66 (2C), 
137.36, 137.60, 141.42, 149.21, 161.98. MS m/z 337 (M+, 82%), 321 (M+ –O, 61%), 
293 (M+ –CO2, 6%), 275 (M+ –CO2 –H2O, 18%), 249 (M+ –CO2 –H2O –C2H2, 21%), 
190 (M+ –C6H4F3O +H, 100%). 
 
4-Methyl-3-nitro-4'-(trifluoromethyl)biphenyl (3.130h) 
 
Commercially available 4-bromo-2-nitrotoluene 3.90d (540 mg, 2.50 mmol) was 
placed in a vial together with 4-trifluoromethylphenylboronic acid 3.129h (617 mg, 
3.25 mmol), potassium phosphate (902 mg, 4.25 mmol), Pd(OAc)2 (7.4 mg, 0.033 
mmol), tetrabutylammonium bromide (5.0 g, 15 mmol) and water (0.5 mL). The vial 
was sealed and heated under stirring at 125 °C for 24 h. The reaction mixture was 
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cooled to RT and then diluted with water. The water phase was acidified with 1N 
aqueous HCl and repeatedly extracted with EtOAc. The combined organic phase was 
dried over anhydrous sodium sulphate and evaporated to afford a crude residue that was 
purified by column chromatography over silica gel using n-hexane/EtOAc 88:2 as the 
eluent, to give pure 3.130h (510 mg, 1.81 mmol, 73% yield). 1H NMR (CDCl3) δ (ppm): 
2.66 (s, 3H), 7.46 (d, 1H, J = 8.2 Hz), 7.73 (s, 4H), 7-73-7.77 (m, 1H), 8.22 (d, 1H, J = 
2.0 Hz). 
 
Methyl 3-(3-nitro-4'-(trifluoromethyl)biphenyl-4-yl)-2-oxopropanoate (3.131h) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 280 mg, 7.00 
mmol) in 5 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.130h (492 mg, 1.75 
mmol) and dimethyl oxalate (1.03 g, 8.8 mmol) in 5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT. 
Once the disappearance of the precursor was verified by TLC, the reaction mixture was 
slowly poured in an ice-water mixture; the water phase was acidified with 1N aqueous 
HCl and extracted several times with EtOAc. The combined organic phase was washed 
with saturated NaHCO3 solution and brine, then dried over anhydrous sodium sulphate. 
Evaporation under vacuum of the organic solvent afforded a crude product which was 
purified by column chromatography over silica gel using n-hexane/EtOAc 7:3 as the 
eluent, to yield the nitroaryl-ketoester derivative 3.131h (400 mg, 1.09 mmol, 62% 
yield). 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 4.60 (s, 2H), 7.45 (d, 1H, J = 8.1 Hz), 
7.75 (s, 4H), 7.86 (dd, 1H, J = 7.9, 1.8 Hz), 8.41 (d, 1H, J = 1.8 Hz). 
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Methyl 1-hydroxy-6-(4-(trifluoromethyl)phenyl)-1H-indole-2-carboxylate (3.132h) 
 
Triethylamine (0.42 mL, 0.30 g, 3.0 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (203 mg, 0.898 mmol) and PhSH (0.28 mL, 0.30 g, 2.7 mmol) in 
acetonitrile (5 mL) at room temperature to generate a yellow precipitate over a period of 
5 min. Then, 3.131h (220 mg, 0.599 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using CH2Cl2/MeOH 98:2 as the eluent, to give the N-hydroxyindole 3.132h 
(101 mg, 0.301 mmol, 50% yield). 1H NMR (CDCl3) δ (ppm): 4.02 (s, 3H), 7.07 (d, 1H, 
J = 0.7 Hz), 7.39 (dd, 1H, J = 8.6, 1.6 Hz), 7.69-7.82 (m, 6H), 10.36 (bs, 1H). 
 
1-Hydroxy-6-(4-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid (3.125h) 
 
Methyl ester 3.132h (80.0 mg, 0.241 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2.4 mL) and treated with 0.72 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 2 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.125h (69.0 mg, 0.215 mmol, 89% yield) without any further purification. 1H 
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NMR (acetone-d6) δ (ppm): 7.17 (d, 1H, J = 0.7 Hz), 7.52 (dd, 1H, J = 8.4, 1.6 Hz), 
7.81 (dd, 1H, J = 8.4, 0.7 Hz), 7.82-7.90 (m, 3H), 7.96-8.03 (m, 2H). 13C NMR 
(acetone-d6) δ (ppm): 106.00, 108.83, 121.23, 122.45, 123.94, 125.48 (q, J = 269.7 Hz), 
126.54 (q, 2C, J = 3.7 Hz), 127.60, 128.62 (2C), 129.35 (q, J = 34.8 Hz), 137.36, 
137.38, 146.10, 161.99. MS m/z 321 (M+, 100%), 305 (M+ –O, 18%). 
 
4'-Fluoro-4-methyl-3-nitrobiphenyl (3.130i) 
 
Commercially available 4-bromo-2-nitrotoluene 3.90d (540 mg, 2.50 mmol) was 
placed in a vial together with 4-fluorophenylboronic acid 3.129i (455 mg, 3.25 mmol), 
potassium phosphate (902 mg, 4.25 mmol), Pd(OAc)2 (7.4 mg, 0.033 mmol), 
tetrabutylammonium bromide (5.0 g, 15 mmol) and water (0.5 mL). The vial was sealed 
and heated under stirring at 125 °C for 24 h. The reaction mixture was cooled to RT and 
then diluted with water. The water phase was acidified with 1N aqueous HCl and 
repeatedly extracted with EtOAc. The combined organic phase was dried over 
anhydrous sodium sulphate and evaporated to afford a crude residue that was purified 
by column chromatography over silica gel using n-hexane/EtOAc 88:2 as the eluent, to 
give pure 3.130i (400 mg, 1.73 mmol, 69% yield). 1H NMR (CDCl3) δ (ppm): 2.64 (s, 
3H), 7.10-7.23 (m, 2H), 7.41 (d, 1H, J = 7.9 Hz), 7.50-7.62 (m, 2H), 7.68 (dd, 1H, J = 
8.0, 1.9 Hz), 8.16 (d, 1H, J = 1.8 Hz). 
 
Methyl 3-(4'-fluoro-3-nitrobiphenyl-4-yl)-2-oxopropanoate (3.131i) 
NO2
COOMe
O
F  
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 272 mg, 6.76 
mmol) in 5 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
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dropwise with a solution containing the nitrotoluene precursor 3.130i (390 mg, 1.69 
mmol) and dimethyl oxalate (998 mg, 8.45 mmol) in 5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT. 
Once the disappearance of the precursor was verified by TLC, the reaction mixture was 
slowly poured in an ice-water mixture; the water phase was acidified with 1N aqueous 
HCl and extracted several times with EtOAc. The combined organic phase was washed 
with saturated NaHCO3 solution and brine, then dried over anhydrous sodium sulphate. 
Evaporation under vacuum of the organic solvent afforded a crude product which was 
purified by column chromatography over silica gel using n-hexane/EtOAc 8:2 as the 
eluent, to yield the nitroaryl-ketoester derivative 3.131i (300 mg, 0.946 mmol, 56% 
yield). 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 4.58 (s, 2H), 7.13-7.24 (m, 2H), 7.39 (d, 
1H, J = 7.9 Hz), 7.54-7.64 (m, 2H), 7.80 (dd, 1H, J = 7.9, 2.0 Hz), 8.35 (d, 1H, J = 2.0 
Hz); signals imputable to the enol form (~ 24%) δ (ppm): 3.94 (s, 3H), 6.96 (s, 1H), 
8.08 (d, 1H, J = 2.0 Hz). 
 
Methyl 6-(4-fluorophenyl)-1-hydroxy-1H-indole-2-carboxylate (3.132i) 
N
OH
COOMe
F  
Triethylamine (0.28 mL, 0.20 g, 2.0 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (135 mg, 0.600 mmol) and PhSH (0.19 mL, 0.20 g, 1.8 mmol) in 
acetonitrile (5 mL) at room temperature to generate a yellow precipitate over a period of 
5 min. Then, 3.131i (127 mg, 0.400 mmol) was transferred to the suspension and stirred 
at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using CH2Cl2/MeOH 95:2 as the eluent, to give the N-hydroxyindole 3.132i 
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(50.0 mg, 0.175 mmol, 44% yield). 1H NMR (CDCl3) δ (ppm): 4.01 (s, 3H), 7.05 (d, 
1H, J = 0.9 Hz), 7.10-7.20 (m, 2H), 7.34 (dd, 1H, J = 8.5, 1.6 Hz), 7.60-7.71 (m, 4H), 
10.31 (bs, 1H). 
 
6-(4-fluorophenyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.125i) 
 
Methyl ester 3.132i (35.0 mg, 0.123 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2.0 mL) and treated with 0.37 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.125i (31.0 mg, 0.114 mmol, 93% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 7.15 (d, 1H, J = 0.6 Hz), 7.18-7.32 (m, 2H), 7.42 (dd, 1H, J 
= 8.6, 1.6 Hz), 7.67-7.86 (m, 4H). 13C NMR (acetone-d6) δ (ppm): 106.19, 108.17, 
116.32 (d, 2C, J = 21.0 Hz), 121.26, 121.77, 123.68, 127.13, 129.79 (d, 2C, J = 8.2 Hz), 
137.50, 138.14, 138.52 (d, J = 3.7 Hz), 161.90, 163.15 (d, J = 244.5 Hz). MS m/z 271 
(M+, 100%), 255 (M+ –O, 33%), 208 (M+ –CO2 –F, 55%). 
 
4'-Chloro-4-methyl-3-nitrobiphenyl (3.130j) 
 
Commercially available 4-bromo-2-nitrotoluene 3.90d (432 mg, 2.00 mmol) was 
placed in a vial together with 4-chlorobenzeneboronic acid 3.129j (313 mg, 2.00 mmol), 
sodium carbonate (636 mg, 6.00 mmol), Pd(OAc)2 (1.8 mg, 0.0080 mmol), 
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tetrabutylammonium bromide (644 mg, 2.00 mmol) and water (4 mL). The vial was 
sealed and heated under stirring at 150 °C in a microwave reactor for 5 min. The 
reaction mixture was then diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 88:2 as the eluent, to give pure 3.130j (440 mg, 1.78 mmol, 89% 
yield). 1H NMR (CDCl3) δ (ppm): 2.64 (s, 3H), 7.40-7.56 (m, 5H), 7.69 (dd, 1H, J = 7.7, 
1.8 Hz), 8.17 (d, 1H, J = 2.0 Hz). 
 
Methyl 3-(4'-chloro-3-nitrobiphenyl-4-yl)-2-oxopropanoate (3.131j) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 240 mg, 6.00 
mmol) in 10 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.130j (372 mg, 1.50 
mmol) and dimethyl oxalate (886 mg, 7.51 mmol) in 5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT. 
Once the disappearance of the precursor was verified by TLC, the reaction mixture was 
slowly poured in an ice-water mixture; the water phase was acidified with 1N aqueous 
HCl and extracted several times with EtOAc. The combined organic phase was washed 
with saturated NaHCO3 solution and brine, then dried over anhydrous sodium sulphate. 
Evaporation under vacuum of the organic solvent afforded a crude product which was 
purified by column chromatography over silica gel using n-hexane/EtOAc 8:2 as the 
eluent, to yield the nitroaryl-ketoester derivative 3.131j (260 mg, 0.779 mmol, 52% 
yield). 1H NMR (CDCl3) δ (ppm): 3.95 (s, 3H), 4.58 (s, 2H), 7.40-7.60 (m, 5H), 7.81 
(dd, 1H, J = 8.0, 1.9 Hz), 8.36 (d, 1H, J = 1.8 Hz); signals imputable to the enol form (~ 
23%) δ (ppm): 3.96 (s, 3H), 6.72 (d, 1H, exchangeable, J = 1.5 Hz), 6.96 (d, 1H, J = 1.5 
Hz), 8.09 (d, 1H, J = 2.0 Hz). 
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Methyl 6-(4-chlorophenyl)-1-hydroxy-1H-indole-2-carboxylate (3.132j) 
 
Triethylamine (0.45 mL, 0.32 g, 3.2 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (216 mg, 0.962 mmol) and PhSH (0.31 mL, 0.32 g, 2.9 mmol) in 
acetonitrile (5 mL) at room temperature to generate a yellow precipitate over a period of 
5 min. Then, 3.131j (214 mg, 0.641 mmol) was transferred to the suspension and stirred 
at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 8:2 as the eluent, to give the N-hydroxyindole 3.132j 
(66.0 mg, 0.219 mmol, 34% yield). 1H NMR (CDCl3) δ (ppm): 4.01 (s, 3H), 7.05 (d, 
1H, J = 0.9 Hz), 7.35 (dd, 1H, J = 8.6, 1.5 Hz), 7.43 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’XX’ 
= 2.3 Hz), 7.62 (AA’XX’, 2H, J = JAX = 8.8 Hz, JAA’XX’ = 2.2 Hz), 7.66-7.72 (m, 2H), 
10.33 (bs, 1H). 
 
6-(4-Chlorophenyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.125j) 
 
Methyl ester 3.132j (62.0 mg, 0.205 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (3 mL) and treated with 0.62 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
complete consumption of the starting material, the reaction mixture was concentrated, 
diluted with water and washed with Et2O. Then, the aqueous phase was treated with 1N 
aqueous HCl and extracted several times with EtOAc. The combined ethyl acetate 
organic phase was dried over anhydrous sodium sulphate and evaporated to afford the 
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desired N-hydroxyindol-carboxylic acid product 3.125j (55.0 mg, 0.191 mmol, 93% 
yield) without any further purification. 1H NMR (DMSO-d6) δ (ppm): 7.04 (d, 1H, J = 
0.8 Hz), 7.41 (dd, 1H, J = 8.4, 1.4 Hz), 7.52 (AA´XX´, 2H, JAX = 8.4 Hz, JAA´/XX´ = 2.0 
Hz), 7.65 (s, 1H), 7.68-7.82 (m, 3H). 13C NMR (DMSO-d6) δ (ppm): 104.49, 107.16, 
119.71, 120.58, 122.77, 127.52, 128.58 (2C), 128.85 (2C), 132.04, 135.53, 136.31, 
139.39, 161.08. MS m/z 289 (37Cl: M+, 15%), 287 (35Cl: M+, 30%), 271 (35Cl: M+ –O, 
55%), 190 (35Cl: M+ –Cl –H2O –CO2, 100%). HPLC, tR = 10.2 min. 
 
3'-Methyl-4'-nitrobiphenyl-3-carboxylic acid (3.135a) 
 
A solution of Pd(OAc)2 (25.2 mg, 0.112 mmol) and triphenylphosphine (147 mg, 
0.560 mmol) in absolute ethanol (3.8 mL) and anhydrous toluene (3.8 mL) was stirred 
at RT under nitrogen for 10 min. After that period, commercially available 5-chloro-2-
nitrotoluene 3.115 (646 mg, 3.76 mmol), 3.8 mL of 2M aqueous Na2CO3, and 3-
carboxybenzeneboronic acid 3.129b (1.00 g, 6.03 mmol) were sequentially added. The 
resulting mixture was heated at 100 °C in a sealed vial under nitrogen overnight. After 
being cooled to RT, the mixture was diluted with water and extracted with EtOAc. The 
combined organic phase were dried and concentrated. The crude product was purified 
by flash chromatography (CHCl3/MeOH 95:5) to yield 3.135a (1.18 g, 4.59 mmol, 
>99% yield). 1H NMR (acetone-d6) δ (ppm): 2.69 (s, 3H), 7.67 (t, 1H, J = 7.8 Hz), 7.80 
(dd, 1H, J = 8.4, 2.0 Hz), 7.84 (dt, 1H, J = 8.8, 2.0 Hz), 8.02 (dt, 1H, J = 7.8, 1.4 Hz), 
8.10 (d, 1H, J = 8.4 Hz), 8.14 (d, 1H, J = 2.0 Hz), 8.36 (t, 1H, J = 2.0 Hz). 
 
3'-(3-Methoxy-2,3-dioxopropyl)-4'-nitrobiphenyl-3-carboxylic acid (3.136a) 
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A stirred suspension of sodium hydride (60% dispersion in mineral oil, 870 mg, 21.8 
mmol) in 15.0 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.135a (700 mg, 2.72 
mmol) and dimethyl oxalate (3.21 g, 27 mmol) in 7.75 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
21 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using CHCl3/MeOH 95:5 
as the eluent, to yield the nitroaryl-ketoester derivative 3.136a (739 mg, 2.15 mmol, 
79% yield). 1H NMR (acetone-d6) δ (ppm): 3.90 (s, 3H), 4.82 (s, 2H), 7.69 (t, 1H, J = 
7.6 Hz), 8.03-8.08 (m, 2H), 8.13 (dt, 1H, J = 7.7, 1.4 Hz), 8.27-8.33 (m, 2H), 8.38 (t, 
1H, J = 1.4 Hz); signals imputable to the enol form (~ 12%) δ (ppm): 3.91 (s, 3H), 6.92 
(bs, 1H), 8.00 (t, 1H, J = 2.2 Hz).  
 
3-(1-Hydroxy-2-(methoxycarbonyl)-1H-indol-5-yl)benzoic acid (3.137a) 
 
Ketoester 3.136a (300 mg, 0.874 mmol) was dissolved in THF (1.5 mL) and the 
resulting solution was added to an aqueous solution (1.5 mL) of sodium hypophosphite 
monohydrate (286 mg, 2.70 mmol). Then 8.8 mg of 10% palladium over charcoal was 
added and the resulting suspension was stirred ar RT. After 26 h the disappearance of 
the precursor is verified by TLC and the mixture was concentrated, diluted with water 
and repeatedly extracted with EtOAc. The combined organic phase was dried over 
anhydrous sodium sulphate and evaporated to afford a crude residue that was purified 
by column chromatography over silica gel using CHCl3/MeOH 95:5 as the eluent, to 
Chapter 4 
283 
 
give the N-hydroxyindole 3.137a (57.7 mg, 0.185 mmol, 21% yield). 1H NMR 
(acetone-d6) δ (ppm): 3.90 (s, 3H); 7.19 (s, 1H), 7.60 (t, 1H, J = 7.3 Hz), 7.72 (dd, 1H, J 
= 8.4, 1.4 Hz), 7.74 (dt, 1H, J = 7.3, 1.4 Hz), 7.93-8.02 (m, 3H), 8.33 (t, 1H, J = 1.4 
Hz).  
 
5-(3-Carboxyphenyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.126a) 
 
Methyl ester 3.137a (32.0 mg, 0.103 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.03 mL) and treated with 0.31 mL of 2N aqueous solution of LiOH. 
The reaction was kept under stirring in the dark at RT. After 23h. it was monitored by 
TLC and another portion of LiOH (0.31 mL) was added. After further 24 h, the reaction 
mixture was concentrated, diluted with water and washed with Et2O. Then, the aqueous 
phase was treated with 1N aqueous HCl and extracted several times with EtOAc. The 
combined ethyl acetate organic phase was dried over anhydrous sodium sulphate and 
evaporated to afford the desired N-hydroxyindol-carboxylic acid product 3.126a (25.8 
mg, 0.0868 mmol, 84% yield) without any further purification. 1H NMR (acetone-d6) δ 
(ppm): 7.18 (d, 1H, J = 0.9 Hz), 7.58 (td, 1H, J = 7.5, 0.4 Hz), 7.62 (dt, 1H, J = 8.8, 0.7 
Hz), 7.71 (dd, 1H, J = 8.6, 1.6 Hz), 7.91 (dd, 1H, J = 2.0, 1.3 Hz), 7.94-8.00 (m, 2H), 
8.31 (t, 1H, J = 1.6 Hz). 
 
3-(3'-Methyl-4'-nitrobiphenyl-4-yl)propanoic acid (3.135b) 
 
A solution of Pd(OAc)2 (11 mg, 0.048 mmol) and triphenylphosphine (63 mg, 0.24 
mmol) in absolute ethanol (3.6 mL) and anhydrous toluene (3.6 mL) was stirred at RT 
under nitrogen for 10 min. After that period, commercially available 5-chloro-2-
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nitrotoluene 3.115 (276 mg, 1.61 mmol), 3.6 mL of 2M aqueous Na2CO3, and 4-(2-
carboxyethyl)benzeneboronic acid 3.129c (500 mg, 2.58 mmol) were sequentially 
added. The resulting mixture was heated at 100 °C in a sealed vial under nitrogen 
overnight. After being cooled to RT, the mixture was diluted with water and extracted 
with EtOAc. The combined organic phase were dried and concentrated. The crude 
product was purified by flash chromatography (CHCl3/MeOH 95:5) to yield 3.135b 
(427 mg, 1.50 mmol, 93% yield). 1H NMR (acetone-d6) δ (ppm): 2.66 (s, 3H), 2.68 (t, 
2H, J = 7.6 Hz), 2.99 (t, 2H, J = 7.6 Hz), 7.28 (d, 1H, J = 1.5 Hz), 7.43 (AA’XX’, 2H, 
JAX = 8.6 Hz, JAA’XX’ = 2.0 Hz), 7.66-7.71 (m, 3H), 8.08 (d, 1H, J = 8.4 Hz). 
 
3-(3'-(3-Methoxy-2,3-dioxopropyl)-4'-nitrobiphenyl-4-yl)propanoic acid (3.136b) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 467 mg, 11.7 
mmol) in 8.1 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.135b (416 mg, 1.46 
mmol) and dimethyl oxalate (1.72 g, 14.6 mmol) in 4.2 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
16 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
4:6 as the eluent, to yield the nitroaryl-ketoester derivative 3.136b (247 mg, 0.665 
mmol, 46% yield). 1H NMR (acetone-d6) δ (ppm): 2.68 (t, 2H, J = 7.7 Hz), 2.99 (t, 2H, 
J = 7.8 Hz), 3.90 (s, 3H), 4.77 (s, 2H), 7.44 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 1.8 
Hz), 7.72 (AA’XX’, 2H, JAX = 8.4 Hz, JAA’/XX’ = 1.8 Hz), 7.86-7.92 (m, 2H), 8.26 (d, 1H, 
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J = 8.2 Hz); signals imputable to the enol form (~ 26%) δ (ppm): 3.83 (s, 3H), 6.07 (bs, 
1H, exchangeable), 6.92 (s, 1H), 8.57 (d, 1H, J = 1.8 Hz). 
 
3-(4-(1-Hydroxy-2-(methoxycarbonyl)-1H-indol-5-yl)phenyl)propanoic acid 
(3.137b) 
 
Ketoester 3.136b (100 mg, 0.269 mmol) was dissolved in THF (0.5 mL) and the 
resulting solution was added to an aqueous solution (0.5 mL) of sodium hypophosphite 
monohydrate (88.4 g, 0.834 mmol). Then 2.7 mg of 10% palladium over charcoal was 
added and the resulting suspension was stirred at RT for 22h. Then it was monitored by 
TLC and H2PO2Na.H2O (88.4 g, 0.834 mmol) and Pd/C (2.7 mg) were added. After 
further 72 h, another portion of H2PO2Na.H2O (44.2 mg, 0.417 mmol) and Pd/C (1.4 
mg) was added. The disappearance of the precursor is verified by TLC after 8 h and the 
mixture was concentrated, diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 6:4 with 0.01% trifluoroacetic acid as the eluent, to give a mixture 
(19.8 mg) of the N-hydroxyindol-ester derivative 3.137b (85%, 16.8 mg, 0.0496 mmol, 
18% yield) with its indole analogue (15%). 1H NMR (acetone-d6) δ (ppm): 2.66 (t, 2H, J 
= 7.3 Hz), 2.97 (t, 2H, J = 7.7 Hz), 3.90 (s,3H), 7.14 (s, 1H), 7.32-7.40 (m, 2H), 7.59-
7.71 (m, 4H), 7.89-7.92 (m, 1H); 10.50 (bs, 1H), signals imputable to the indole (~ 
15%) δ (ppm): 7.24-7.25 (m, 1H), 7.93-7.95 (m, 1H), 11.00 (bs, 1H). 
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5-(4-(2-Carboxyethyl)phenyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.126b) 
 
Methyl ester 3.137b (19.8 mg, 0.0583 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.6 mL) and treated with 0.2 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
24 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.126b (17.5 mg, 0.538 mmol, 92% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 2.67 (t, 2H, J = 7.8 Hz), 2.97 (t, 2H, J = 7.6 Hz), 7.17 (s, 
1H), 7.36 (d, 2H, J = 8.0 Hz), 7.58-7.69 (m, 4H), 7.91-7.92 (m, 1H), 10.85 (bs, 1H); 
signals imputable to the indole (~ 15%) δ (ppm): 7.24-7.27 (m, 1H), 7.69-7.71 (m, 1H), 
7.93-7.95 (m, 1H). 13C NMR (acetone-d6) δ (ppm): 31.15, 35.85, 106.57, 110.81, 
120.97, 122.83, 125.80, 127.78 (2C), 129.64 (2C), 134.77, 140.27, 140.46, 161.85, 
173.78. MS m/z 325 (M+, 12%), 255 (M+ –C3H2O2, 100%), 175 (M+ –C9H10O2, 18%), 
149 (M+ –C9H6O3N, 31%). 
 
4'-Methoxy-3-methyl-4-nitrobiphenyl (3.135c) 
 
Commercially available 5-chloro-2-nitrotoluene 3.115 (500 mg, 2.91 mmol) was 
placed in a vial together with 4-methoxyphenylboronic acid  3.129e (532 mg, 3.50 
mmol), sodium carbonate (928 mg, 8.76 mmol), Pd(OAc)2 (2.6 mg, 0.011 mmol), 
tetrabutylammonium bromide (940 mg, 2.91 mmol) and water (5 mL). The vial was 
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sealed and heated under stirring at 175 °C in a microwave reactor for 5 min. The 
reaction mixture was then diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 9:1 as the eluent, to give pure 3.135c (705 mg, 2.90 mmol, 99% yield). 
1H NMR (CDCl3) δ (ppm): 2.69 (s, 3H), 3.87 (s, 3H), 7.01 (AA’XX’, 2H, JAX = 8.8 Hz, 
JAA’/XX’ = 2.5 Hz), 7.46-7.60 (m, 4H), 8.08 (d, 1H, J = 9.2 Hz). 
 
Methyl 3-(4'-methoxy-4-nitrobiphenyl-3-yl)-2-oxopropanoate (3.136c) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 400 mg, 10.0 
mmol) in 10 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.135c (608 mg, 2.50 
mmol) and dimethyl oxalate (1.48 g, 12.5 mmol) in 10 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT. 
Once the disappearance of the precursor was verified by TLC, the reaction mixture was 
slowly poured in an ice-water mixture; the water phase was acidified with 1N aqueous 
HCl and extracted several times with EtOAc. The combined organic phase was washed 
with saturated NaHCO3 solution and brine, then dried over anhydrous sodium sulphate. 
Evaporation under vacuum of the organic solvent afforded a crude product which was 
purified by column chromatography over silica gel using n-hexane/EtOAc 7:3 as the 
eluent, to yield the nitroaryl-ketoester derivative 3.136c (548 mg, 1.66 mmol, 67% 
yield). 1H NMR (CDCl3) δ (ppm): 3.87 (s, 3H), 3.95 (s, 3H), 4.60 (s, 2H), 6.96-7.05 (m, 
2H), 7.46 (d, 1H, J = 2.0 Hz), 7.56 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.5 Hz), 7.64 
(dd, 1H, J = 8.6, 2.0 Hz), 8.24 (d, 1H, J = 8.6 Hz); signals imputable to the enol form (~ 
13%) δ (ppm): 6.70 (bs, 1H), 8.02 (d, 1H, J = 8.4 Hz),  8.57 (d, 1H, J = 2.0 Hz). 
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Methyl 1-hydroxy-5-(4-methoxyphenyl)-1H-indole-2-carboxylate (3.137c) 
 
Ketoester 3.136c (329 mg, 1.00 mmol) was dissolved in anhydrous DME (1.5 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (562 mg, 2.49 mmol) in DME (1.5 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 24 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
CH2Cl2 as the eluent, to give the N-hydroxyindol-ester derivative 3.137c (30 mg, 0.101 
mmol, 10% yield). 1H NMR (CDCl3) δ (ppm): 3.86 (s, 3H), 4.01 (s, 3H), 6.99 
(AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz), 7.06 (s, 1H), 7.52-7.56 (m, 4H), 7.77 (t, 
1H, J = 1.3 Hz), 10.25 (bs, 1H). 
 
1-Hydroxy-5-(4-methoxyphenyl)-1H-indole-2-carboxylic acid (3.126c) 
 
Methyl ester 3.137c (28.0 mg, 0.0942 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2 mL) and treated with 0.3 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
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product 3.126c (26.0 mg, 0.0918 mmol, 97% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 3.79 (s, 3H), 6.96-7.08 (m, 3H), 7.47 (d, 1H, J = 8.6 Hz), 
7.52-7.66 (m, 3H), 7.83 (s, 1H). 13C NMR (DMSO-d6) δ (ppm): 55.16, 104.90, 110,06, 
114.28, 119.20, 121.53, 124.10, 127.19, 127.70, 132.58, 133.31, 135.11, 158.27, 
161.20. MS m/z 284 (M+H+, 20%), 283 (M+, 100%), 267 (M+ –O, 99%), 252 (M+ –
CH3O, 19%). 
 
3-Methyl-4-nitro-4'-(trifluoromethyl)biphenyl (3.135d) 
 
Commercially available 5-chloro-2-nitrotoluene 3.115 (429 mg, 2.50 mmol) was 
placed in a vial together with 4-trifluoromethylphenylboronic acid 3.129h (475 mg, 
2.50 mmol), sodium carbonate (794 mg, 7.50 mmol), Pd(OAc)2 (2.2 mg, 0.010 mmol), 
tetrabutylammonium bromide (805 mg, 2.50 mmol) and water (5 mL). The vial was 
sealed and heated under stirring at 175 °C in a microwave reactor for 5 min. The 
reaction mixture was then diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 99:1 as the eluent, to give pure 3.135d (478 mg, 1.70 mmol, 68% 
yield). 1H NMR (CDCl3) δ (ppm): 2.70 (s, 3H), 7.52-7.59 (m, 2H), 7.67-7.78 (m, 4H), 
8.11 (d, 1H, J = 9.0 Hz). 
 
Methyl 3-(4-nitro-4'-(trifluoromethyl)biphenyl-3-yl)-2-oxopropanoate (3.136d) 
COOMe
O
NO2
F3C
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 256 mg, 6.40 
mmol) in 6 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
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dropwise with a solution containing the nitrotoluene precursor 3.135d (450 mg, 1.60 
mmol) and dimethyl oxalate (944 mg, 8.00 mmol) in 4 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT. 
Once the disappearance of the precursor was verified by TLC, the reaction mixture was 
slowly poured in an ice-water mixture; the water phase was acidified with 1N aqueous 
HCl and extracted several times with EtOAc. The combined organic phase was washed 
with saturated NaHCO3 solution and brine, then dried over anhydrous sodium sulphate. 
Evaporation under vacuum of the organic solvent afforded a crude product which was 
purified by column chromatography over silica gel using n-hexane/EtOAc 8:2 as the 
eluent, to yield the nitroaryl-ketoester derivative 3.136d (339 mg, 0.923 mmol, 58% 
yield). 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 4.63 (s, 2H), 7.52 (d, 1H, J = 2.0 Hz), 
7.68-7.80 (m, 5H), 8.31 (d, 1H, J = 8.6 Hz); signals imputable to the enol form (~ 8%) δ 
(ppm): 3.97 (s, 3H), 6.71 (bs, 1H, exchangeable), 7.04 (bs, 1H), 7.60 (dd, 1H, J = 8.6, 
2.2 Hz), 8.05 (d, 1H, J = 8.4 Hz), 8.48 (d, 1H, J = 2.0 Hz). 
 
Methyl 1-hydroxy-5-(4-(trifluoromethyl)phenyl)-1H-indole-2-carboxylate (3.137d) 
 
Triethylamine (0.46 mL, 0.33 g, 3.30 mmol) was added dropwise to a stirred 
solution of SnCl2·2H2O (224 mg, 0.988 mmol) and PhSH (0.30 mL, 0.33 g, 3.0 mmol) 
in acetonitrile (5 mL) at room temperature to generate a yellow precipitate over a period 
of 5 min. Then, 3.136d (242 mg, 0.659 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
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silica gel using n-hexane/EtOAc 8:2 as the eluent, to give the N-hydroxyindole 3.137d 
(69.0 mg, 0.206 mmol, 31% yield). 1H NMR (CDCl3) δ (ppm): 4.02 (s, 3H), 7.10 (s, 
1H), 7.61-7.77 (m, 6H), 7.85 (t, 1H, J = 1.3 Hz), 10.35 (bs, 1H). 
 
1-Hydroxy-5-(4-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid (3.126d) 
 
Methyl ester 3.137d (60.0 mg, 0.179 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2 mL) and treated with 0.54 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. Once 
the disappearance of the precursor was verified, the reaction mixture was concentrated, 
diluted with water and washed with Et2O. Then, the aqueous phase was treated with 1N 
aqueous HCl and extracted several times with EtOAc. The combined ethyl acetate 
organic phase was dried over anhydrous sodium sulphate and evaporated to afford the 
desired N-hydroxyindol-carboxylic acid product 3.126d (52.0 mg, 0.162 mmol, 90% 
yield) without any further purification. 1H NMR (DMSO-d6) δ (ppm): 7.10 (s, 1H), 7.56 
(d, 1H, J = 8.6 Hz), 7.70 (dd, 1H, J = 8.6, 1.6 Hz), 7.80 (d, 2H, J = 8.4 Hz), 7.92 (d, 2H, 
J = 8.2 Hz), 8.02 (s, 1H). 13C NMR (DMSO-d6) δ (ppm): 105.11, 110.31, 120.67, 
121.42, 124.10, 124.41 (q, J = 271.0 Hz), 125.61 (q, 2C, J = 3.6 Hz), 126.93 (q, J = 
30.7 Hz), 127.25 (2C), 127.59, 131.02, 135.62, 144.84, 161.00. 
 
4'-Fluoro-3-methyl-4-nitrobiphenyl (3.135e) 
CH3
NO2
F
 
Commercially available 5-chloro-2-nitrotoluene 3.115 (429 mg, 2.50 mmol) was 
placed in a vial together with 4-fluorobenzeneboronic acid 3.129i (350 mg, 2.50 mmol), 
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sodium carbonate (795 mg, 7.50 mmol), Pd(OAc)2 (2.2 mg, 0.010 mmol), 
tetrabutylammonium bromide (806 mg, 2.50 mmol) and water (5 mL). The vial was 
sealed and heated under stirring at 175 °C in a microwave reactor for 5 min. The 
reaction mixture was then diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 99:1 as the eluent, to give pure 3.135e (500 mg, 2.16 mmol, 86% 
yield). 1H NMR (CDCl3) δ (ppm): 2.69 (s, 3H), 7.10-7.23 (m, 2H), 7.46-7.53 (m, 2H), 
7.53-7.63 (m, 2H), 8.08 (d, 1H, J = 9.0 Hz). 
 
Methyl 3-(4'-fluoro-4-nitrobiphenyl-3-yl)-2-oxopropanoate (3.136e) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 280 mg, 7.00 
mmol) in 6 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.135e (404 mg, 1.75 
mmol) and dimethyl oxalate (1.03 g, 8.75 mmol) in 4 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT 
overnight. Once the disappearance of the precursor was verified by TLC, the reaction 
mixture was slowly poured in an ice-water mixture; the water phase was acidified with 
1N aqueous HCl and extracted several times with EtOAc. The combined organic phase 
was washed with saturated NaHCO3 solution and brine, then dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using n-
hexane/EtOAc 8:2 as the eluent, to yield the nitroaryl-ketoester derivative 3.136e (369 
mg, 1.16 mmol, 66% yield). 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 4.61 (s, 2H), 7.12-
7.24 (m, 2H), 7.47 (d, 1H; J = 2.0 Hz), 7.55-7.69 (m, 3H), 8.28 (d, 1H, J = 8.6 Hz); 
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signals imputable to the enol form (~ 19%) δ (ppm): 3.97 (s, 3H), 6.67 (bs, 1H, 
exchangeable), 7.05 (s, 1H), 8.04 (d, 1H, J = 8.4 Hz), 8.41 (d, 1H, J = 2.0 Hz). 
 
Methyl 5-(4-fluorophenyl)-1-hydroxy-1H-indole-2-carboxylate (3.137e) 
N
OH
COOMe
F
 
Triethylamine (0.66 mL, 0.48 g, 4.7 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (318 mg, 1.41 mmol) and PhSH (0.44 mL, 0.47 g, 4.3 mmol) in 
acetonitrile (5 mL) at room temperature to generate a yellow precipitate over a period of 
5 min. Then, 3.136e (300 mg, 0.946 mmol) was transferred to the suspension and stirred 
at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using CH2Cl2/MeOH 9:1 as the eluent, to give the N-hydroxyindole 3.137e 
(86.0 mg, 0.301 mmol, 32% yield). 1H NMR (CDCl3) δ (ppm): 4.01 (s, 3H), 7.07 (s, 
1H), 7.08-7.19 (m, 2H), 7.52-7.64 (m, 4H), 7.77 (t, 1H, J = 1.3 Hz), 10.30 (bs, 1H). 
 
5-(4-Fluorophenyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.126e) 
 
Methyl ester 3.137e (75.0 mg, 0.263 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2.6 mL) and treated with 0.8 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. Then, 
the reaction mixture was concentrated, diluted with water and washed with Et2O. The 
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aqueous phase was treated with 1N aqueous HCl and extracted several times with 
EtOAc. The combined ethyl acetate organic phase was dried over anhydrous sodium 
sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid product 
3.126e (65.0 mg, 0.240 mmol, 91% yield) without any further purification. 1H NMR 
(acetone-d6) δ (ppm): 7.17 (d, 1H, J = 0.7 Hz), 7.18-7.28 (m, 2H), 7.56-7.63 (m, 4H), 
7.91 (dd, 1H, J = 1.5, 0.9 Hz). 13C NMR (DMSO-d6) δ (ppm): 101.65, 109.80, 115.48 
(d, 2C, J = 21.1 Hz), 119.71, 121.26, 122.95, 127.41, 128.39 (d, 2C, J = 7.3 Hz), 
130.96, 133.06, 137.65 (d, J = 2.7 Hz), 161.21 (d, J = 242.6 Hz), 162.50. MS m/z 271 
(M+, 60%), 255 (M+ –O, 100%), 208 (M+ –CO2 –F, 88%). 
 
4'-Chloro-3-methyl-4-nitrobiphenyl (3.135f) 
 
Commercially available 5-chloro-2-nitrotoluene 3.115 (429 mg, 2.50 mmol) was 
placed in a vial together with 4-chlorobenzeneboronic acid  3.129j (391 mg, 2.50 
mmol), sodium carbonate (795 mg, 7.50 mmol), Pd(OAc)2 (2.2 mg, 0.010 mmol), 
tetrabutylammonium bromide (806 mg, 2.50 mmol) and water (5 mL). The vial was 
sealed and heated under stirring at 175 °C in a microwave reactor for 5 min. The 
reaction mixture was then diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 99:1 as the eluent, to give pure 3.135f (522 mg, 2.11 mmol, 84% 
yield). 1H NMR (CDCl3) δ (ppm): 2.69 (s, 3H), 7.41-7.58 (m, 6H), 8.09 (d, 1H, J = 9.2 
Hz). 
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Methyl 3-(4'-chloro-4-nitrobiphenyl-3-yl)-2-oxopropanoate (3.136f) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 240 mg, 6.00 
mmol) in 5 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.135f (372 mg, 1.50 
mmol) and dimethyl oxalate (885 mg, 7.50 mmol) in 5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT 
overnight. Once the disappearance of the precursor was verified by TLC, the reaction 
mixture was slowly poured in an ice-water mixture; the water phase was acidified with 
1N aqueous HCl and extracted several times with EtOAc. The combined organic phase 
was washed with saturated NaHCO3 solution and brine, then dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using n-
hexane/EtOAc 8:2 as the eluent, to yield the nitroaryl-ketoester derivative 3.136f (428 
mg, 1.28 mmol, 86% yield). 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 4.61 (s, 2H), 7.42-
7.51 (m, 3H), 7.51-7.60 (m, 3H), 8.28 (d, 1H, J = 8.4 Hz); signals imputable to the enol 
form (~ 68%) δ (ppm): 3.97 (s, 3H), 6.69 (d, 1H, exchangeable, J = 1.5 Hz), 7.04 (d, 
1H, J = 1.5 Hz), 7.65 (dd, 1H, J = 8.5, 2.1 Hz), 8.04 (d, 1H, J = 8.6 Hz), 8.43 (d, 1H, J = 
2.0 Hz). 
 
Methyl 5-(4-chlorophenyl)-1-hydroxy-1H-indole-2-carboxylate (3.137f) 
N
OH
COOMe
Cl
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Triethylamine (0.45 mL, 0.32 g, 3.2 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (216 mg, 0.962 mmol) and PhSH (0.30 mL, 0.32 g, 2.9 mmol) in 
acetonitrile (5 mL) at room temperature to generate a yellow precipitate over a period of 
5 min. Then, 3.136f (214 mg, 0.641 mmol) was transferred to the suspension and stirred 
at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 8:2 as the eluent, to give the N-hydroxyindole 3.137f 
(55.0 mg, 0.182 mmol, 28% yield). 1H NMR (CDCl3) δ (ppm): 4.01 (s, 3H), 7.08 (s, 
1H), 7.41 (AA’XX’, 2H, JAX = 8.4 Hz, JAA’/XX’ = 2.0 Hz), 7.53-7.59 (m, 4H), 7.79 (t, 1H, 
J = 1.1 Hz), 10.32 (bs, 1H). 
 
5-(4-Chlorophenyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.126f) 
 
Methyl ester 3.137f (50.0 mg, 0.165 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (3 mL) and treated with 0.5 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. The 
aqueous phase was treated with 1N aqueous HCl and extracted several times with 
EtOAc. The combined ethyl acetate organic phase was dried over anhydrous sodium 
sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid product 
3.126f (48.0 mg, 0.167 mmol, >99% yield) without any further purification. 1H NMR 
(DMSO-d6) δ (ppm): 7.07 (s, 1H), 7.44-7.56 (m, 3H), 7.63 (dd, 1H, J = 8.7, 1.6 Hz), 
7.71 (AA’/XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 1.5 Hz), 7.93 (d, 1H, J = 0.8 Hz). 13C NMR 
(DMSO-d6) δ (ppm): 105.11, 110.24, 120.07, 121.44, 124.08, 127.43, 128.38 (2C), 
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128.78 (2C), 131.42, 135.46, 139.70, 161.10. MS m/z 289 (37Cl: M+, 40%), 287 (35Cl: 
M+, 100%), 271 (35Cl: M+ –O, 85%). HPLC, tR = 9.9 min 
 
5-Iodo-2-methyl-1-nitro-3-(trifluoromethyl)benzene (3.147) 
CH3
NO2
CF3
I  
To H2SO4 (4.4 mL, 96%) stirring under a nitrogen atmosphere at 0-5 °C was added 
N-iodosuccinimide (1.27 g, 5.66 mmol) portionwise. The resulting dark red coloured 
mixture was stirred at 0-5 °C for 40 min., after which time 2-methyl-3-
nitrobenzotrifluoride 3.90l (1.00 g, 3.77 mmol), in H2SO4 (3.0 mL, 96%), was added 
dropwise over 1h. The solution was stirred at 5-10 °C for 5 h and warmed slowly to RT 
over 16 h. The resulting solution was poured carefully into ice and extracted with 
EtOAc. The extracts were combined, washed with saturated aqueous sodium 
hydrogensulphite and water. The organic phase was then dried over anhydrous sodium 
sulphate. After filtration, the solvent was removed in vacuo to give a crude which was 
purified by column chromatography over silica gel using n-hexane as the eluent, to give 
the iodo-derivative 3.147 (798 mg, 2.41 mmol, 64% yield). 1H NMR (CDCl3) δ (ppm): 
2.50 (q, 3H, J = 1.5 Hz), 8.17 (d, 2H, J = 1.5 Hz). 
 
4-Methyl-3-nitro-5-(trifluoromethyl)biphenyl (3.148a) 
 
Iodo-aryl derivative 3.147 (500 mg, 1.51 mmol) was placed in a vial together with 
phenylboronic acid (203 mg, 1.66 mmol), sodium carbonate (480 mg, 4.53 mmol), 
Pd(OAc)2 (1.4 mg, 0.006 mmol), tetrabutylammonium bromide (486 mg, 1.51 mmol) 
and water (3 mL). The vial was sealed and heated under stirring at 150 °C in a 
microwave reactor for 5 min. The reaction mixture was then diluted with water and 
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repeatedy extracted with EtOAc. The organic phase was dried and evaporated to afford 
a crude residue that was purified by column chromatography (n-hexane/EtOAc 9:1) to 
give pure 3.148a (407 mg, 1.45 mmol, 96% yield). 1H NMR (CDCl3) δ (ppm): 2.60 (q, 
3H, J = 1.5 Hz), 7.44-7.62 (m, 5H), 8.07 (d, 1H, J = 1.5 Hz), 8.11 (d, 1H, J = 1.5 Hz). 
MS m/z 281 (M+, 58%), 264 (M+ –OH, 100%). 
 
Methyl 3-(3-nitro-5-(trifluoromethyl)biphenyl-4-yl)-2-oxopropanoate (3.149a) 
COOMe
O
NO2
CF3
 
Potassium tert-butoxide (142 mg, 1.20 mmol) was dispersed in anhydrous diethyl 
ether (2.0 mL) at 0 °C under nitrogen, and dry methanol was added (0.2 mL) until 
complete dissolution was obtained. Next, dimethyl oxalate (142 mg, 1.20 mmol) was 
added and stirring was continued at 0 °C for 15 min. Finally, a solution of the 
nitrotoluene derivative 3.148a (281 mg, 1.00 mmol) in dry Et2O (1.5 mL) was slowly 
added at the same temperature and the resulting reddish suspension was then left under 
stirring at RT for 48 h. The mixture was diluted with EtOAc and 1N aqueous HCl. The 
combined organic phase was washed with saturated NaHCO3 solution and brine, then 
dried over anhydrous sodium sulphate. Evaporation under vacuum of the organic 
solvent afforded a crude product which was purified by column chromatography over 
silica gel using n-hexane/EtOAc 9:1 as the eluent, to yield the nitroaryl-ketoester 
derivative 3.149a (311 mg, 0.847 mmol, 85% yield). 1H NMR (CDCl3) δ (ppm): 3.98 (s, 
3H), 4.71 (s, 2H), 7.48-7.65 (m, 5H), 8.19 (d, 1H, J = 1.8 Hz), 8.44 (d, 1H, J = 1.8 Hz); 
signals imputable to the enol form (~ 10%) δ (ppm): 3.95 (s, 3H), 6.19 (d, 1H, 
exchangeable, J = 1.6 Hz), 6.80-6.82 (m, 1H). MS m/z 367 (M+, 5%), 308 (M+ –
COOCH3, 17%), 280 (M+ –COOCH3 –CO, 100%). 
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Methyl 1-hydroxy-6-phenyl-4-(trifluoromethyl)-1H-indole-2-carboxylate (3.150a) 
 
Ketoester 3.149a (311 mg, 0.847 mmol) was dissolved in anhydrous DME (1.5 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (428 mg, 1.90 mmol) in DME (1.5 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 72 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 8:2 as the eluent, to give the N-hydroxyindol-ester derivative 3.150a 
(114 mg, 0.340 mmol, 40% yield). 1H NMR (CDCl3) δ (ppm): 4.04 (s, 3H), 7.21 (qd, 
1H, J = 1.6, 1.0 Hz), 7.40-7.54 (m, 3H), 7.66-7.71 (m, 3H), 7.91-7.94 (m, 1H), 10.52 
(bs, 1H). 13C NMR (acetone-d6) δ (ppm): 52.85, 102.34, 111.30, 119.10 (q, J = 4.6 Hz, 
III), 122.55, 125.08 (q, J = 32.8 Hz), 124.44 (q, J = 270.4 Hz), 125.14, 127.51 (2C), 
128.05, 129.13 (2C), 134.02, 135.30, 138.43, 140.16, 164.27. MS m/z 335 (M+, 100%), 
321 (M+ –CH2, 90%), 319 (M+ –O, 7%), 305 (M+ –CH2 –O, 9%), 259 (M+ –CH2 –H2O 
–CO2, 81%), 190 (M+ –CH2 –H2O –CO2 –CF3, 81%). HPLC, tR 12.1 min. 
 
1-Hydroxy-6-phenyl-4-(trifluoromethyl)-1H-indole-2-carboxylic acid (3.139) 
 
Methyl ester 3.150a (14.0 mg, 0.0418 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.42 mL) and treated with 0.13 mL of 2N aqueous solution of LiOH. 
The reaction was kept under stirring in the dark at RT and it was monitored by TLC. 
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After 12 h, the reaction mixture was concentrated, diluted with water and washed with 
Et2O. Then, the aqueous phase was treated with 1N aqueous HCl and extracted several 
times with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.139 (12.6 mg, 0.0392 mmol, 94% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 7.20 (qd, 1H, J = 1.8, 0.7 Hz), 7.43-7.58 (m, 3H), 7.80-7.85 
(m, 3H), 8.04-8.06 (m, 1H). 13C NMR (acetone-d6) δ (ppm): 103.43, 112.32, 117.22, 
119.01 (q, J = 4.8 Hz), 123.81 (q, J = 33.0 Hz), 125.47 (q, J = 262.8 Hz), 128.07, 
128.71 (2C), 129.53, 129.89 (2C), 133.64, 137.54, 138.52, 140.71, 161.45. MS m/z 321 
(M+, 100%), 305 (M+ –O, 10%), 259 (M+ –H2O –CO2, 41%), 190 (M+ –H2O –CO2 –
CF3, 38%). HPLC, tR = 10.5 min. 
 
4'-Chloro-4-methyl-3-nitro-5-(trifluoromethyl)biphenyl (3.148b) 
 
Iodo-aryl derivative 3.147 (500 mg, 1.51 mmol) was placed in a vial together with 
4-chlorobenzeneboronic acid 3.129j (260 mg, 1.66 mmol), sodium carbonate (480 mg, 
4.53 mmol), Pd(OAc)2 (1.4 mg, 0.0060 mmol), tetrabutylammonium bromide (486 mg, 
1.51 mmol) and water (3 mL). The vial was sealed and heated under stirring at 150 °C 
in a microwave reactor for 5 min. The reaction mixture was then diluted with water and 
repeatedly extracted with EtOAc. The combined organic phase was dried over 
anhydrous sodium sulphate and evaporated to afford a crude residue that was purified 
by column chromatography over silica gel using n-hexane as the eluent, to give pure 
3.148b (260 mg, 0.824 mmol, 55% yield). 1H NMR (CDCl3) δ (ppm): 2.60 (q, 3H, J = 
1.6 Hz), 7.45-7.56 (m, 4H), 8.03 (d, 1H, J = 2.0 Hz), 8.07 (d, 1H, J = 1.5 Hz). 
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Methyl 3-(4'-chloro-3-nitro-5-(trifluoromethyl)biphenyl-4-yl)-2-oxopropanoate 
(3.149b) 
 
Potassium tert-butoxide (170 mg, 1.52 mmol) was dispersed in anhydrous diethyl 
ether (1.50 mL) at 0 °C under nitrogen, and dry methanol was added (0.05 mL) until 
complete dissolution was obtained. Next, dimethyl oxalate (180 mg, 1.52 mmol) was 
added and stirring was continued at 0 °C for 15 min. Finally, a solution of the 
nitrotoluene derivative 3.148b (240 mg, 0.760 mmol) in dry Et2O (0.50 mL) was slowly 
added at the same temperature and the resulting reddish suspension was then left under 
stirring at RT for 48 h. The mixture was diluted with EtOAc and 1N aqueous HCl. The 
combined organic phase was washed with saturated NaHCO3 solution and brine, then 
dried over anhydrous sodium sulphate. Evaporation under vacuum of the organic 
solvent afforded a crude product which was purified by column chromatography over 
silica gel using n-hexane/EtOAc 9:1 as the eluent, to yield the nitroaryl-ketoester 
derivative 3.149b (215 mg, 0.535 mmol, 70% yield). 1H NMR (CDCl3) δ (ppm): 3.97 (s, 
3H), 4.71 (s, 2H), 7.46-7.60 (m, 4H), 8.15 (d, 1H, J = 1.8 Hz), 8.41 (d, 1H, J = 1.8 Hz); 
signals imputable to the enol form (~ 15%) δ (ppm): 3.96 (s, 3H), 6.23 (d, 1H, 
exchangeable, J = 1.6 Hz), 6.80 (dq, 1H, J = 1.8, 1.1 Hz), 8.08 (d, 1H, J = 1.8 Hz), 8.19 
(d, 1H, J = 1.6 Hz). 
 
Methyl 6-(4-chlorophenyl)-1-hydroxy-4-(trifluoromethyl)-1H-indole-2-carboxylate 
(3.150b) 
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Ketoester 3.149b (100 mg, 0.249 mmol) was dissolved in anhydrous DME (0.6 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (119 mg, 0.625 mmol) in DME (0.6 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
overnight, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 8:2 as the eluent, to give the N-hydroxyindol-ester derivative 3.150b 
(52.7 mg, 0.143 mmol, 57% yield). 1H NMR (CDCl3) δ (ppm): 4.04 (s, 3H), 7.21 (qd, 
1H, J = 1.6, 1.1 Hz), 7.46 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz), 7.62 (AA’XX’, 
2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz), 7.65-7.67 (m, 1H), 7.87-7.90 (m, 1H), 10.55 (bs, 
1H). 
 
6-(4-Chlorophenyl)-1-hydroxy-4-(trifluoromethyl)-1H-indole-2-carboxylic acid 
(3.141) 
 
Methyl ester 3.150b (32.0 mg, 0.0866 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.0 mL) and treated with 0.26 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.141 (30.5 mg, 0.0857 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.00 (qd, 1H, J = 1.8, 0.7 Hz), 7.55 (d, 2H, J = 8.4 Hz), 7.76 
(s, 1H), 7.84 (d, 2H, J = 8.6 Hz), 7.98 (s, 1H). 13C NMR (DMSO-d6) δ (ppm): 101.19, 
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111.55, 115.81, 115.83, 117.43 (q, J = 5.5 Hz), 121.93 (q, J = 33.0 Hz), 124.38 (q, J = 
271.9 Hz), 128.87 (2C), 128.98 (2C), 132.73, 134.82, 136.11, 137.92, 160.68. MS m/z 
357 (37Cl: M+, 32%), 355 (35Cl: M+, 100%), 341 (37Cl: M+ –O, 10%), 339 (35Cl: M+ –O, 
93% ), 295 (37Cl: M+ –H2O –CO2, 36%), 293 (35Cl: M+ –H2O –CO2, 72% ), 258 (M+ –
H2O –CO2 –Cl, 77%). HPLC, tR = 11.0 min. 
 
2,4-Dichloro-4'-methyl-3'-nitro-5'-(trifluoromethyl)biphenyl (3.148c) 
 
A solution of Pd(OAc)2 (10 mg, 0.045 mmol) and triphenylphosphine (59.0 mg, 
0.225 mmol) in absolute ethanol (3.4 mL) and anhydrous toluene (3.4 mL) was stirred 
at RT under nitrogen for 10 min. After that period, compound 3.147 (497 mg, 1.50 
mmol), 3.4 mL of 2M aqueous Na2CO3, and 2,4-dichlorobenzeneboronic acid (458 mg, 
2.40 mmol) were sequentially added. The resulting mixture was heated at 100 °C in a 
sealed vial under nitrogen overnight. After being cooled to RT, the mixture was diluted 
with water and extracted with EtOAc. The combined organic phase were dried and 
concentrated. The crude product was purified by flash chromatography (n-hexane) to 
yield 3.148c (280 mg, 0.800 mmol, 53% yield). 1H NMR (CDCl3) δ (ppm): 2.62 (q, 3H, 
J = 1.5 Hz), 7.33 (d, 1H, J = 8.2 Hz), 7.38 (dd, 1H, J = 8.4, 2.0 Hz), 7.55 (d, 1H, J = 2.0 
Hz), 7.92 (d, 1H, J = 1.8 Hz), 7.98 (d, 1H, J = 1.8 Hz). 
 
Methyl 3-(2',4'-dichloro-3-nitro-5-(trifluoromethyl)biphenyl-4-yl)-2-
oxopropanoate (3.149c) 
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Potassium tert-butoxide (96.0 mg, 0.857 mmol) was dispersed in anhydrous diethyl 
ether (1.0 mL) at 0 °C under nitrogen, and dry methanol was added (0.04 mL) until 
complete dissolution was obtained. Next, dimethyl oxalate (101 mg, 0.857 mmol) was 
added and stirring was continued at 0 °C for 15 min. Finally, a solution of the 
nitrotoluene derivative 3.148c (250 mg, 0.714 mmol) in dry Et2O (1.0 mL) was slowly 
added at the same temperature and the resulting reddish suspension was then left under 
stirring at RT for 48 h. The mixture was diluted with EtOAc and 1N aqueous HCl. The 
combined organic phase was washed with saturated NaHCO3 solution and brine, then 
dried over anhydrous sodium sulphate. Evaporation under vacuum of the organic 
solvent afforded a crude product which was purified by column chromatography over 
silica gel using n-hexane/EtOAc 9:1 as the eluent, to yield the nitroaryl-ketoester 
derivative 3.149c (88.0 mg, 0.202 mmol, 28% yield). 1H NMR (CDCl3) δ (ppm): 3.98 
(s, 3H), 4.74 (s, 2H), 7.33 (d, 1H, J = 8.4 Hz), 7.41 (dd, 1H, J = 8.2, 2.0 Hz), 7.57 (d, 
1H, J = 1.8 Hz), 8.06 (d, 1H, J = 1.6 Hz), 8.33 (d, 1H, J = 1.8 Hz); signals imputable to 
the enol form (~ 30%) δ (ppm): 3.96 (s, 3H), 7.10 (s, 1H). 
 
Methyl 6-(2,4-dichlorophenyl)-1-hydroxy-4-(trifluoromethyl)-1H-indole-2-
carboxylate (3.150c) 
 
Ketoester 3.149c (85.0 mg, 0.194 mmol) was dissolved in anhydrous DME (0.75 
mL) and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (92.0 mg, 0.487 mmol) in DME (0.75 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
overnight, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
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n-hexane/EtOAc 9:1 as the eluent, to give the N-hydroxyindol-ester derivative 3.150c 
(18.0 mg, 0.0445 mmol, 23% yield). 1H NMR (CDCl3) δ (ppm): 4.05 (s, 3H), 7.23 (qd, 
1H, J = 1.6, 0.9 Hz), 7.35 (d, 1H, J = 1.1 Hz), 7.49-7.55 (m, 2H), 7.78 (t, 1H, J = 1.1 
Hz), 10.53 (bs, 1H). 
 
6-(2,4-Dichlorophenyl)-1-hydroxy-4-(trifluoromethyl)-1H-indole-2-carboxylic acid 
(3.142) 
 
Methyl ester 3.150c (18.0 mg, 0.0445 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.50 mL) and treated with 0.14 mL of 2N aqueous solution of LiOH. 
The reaction was kept under stirring in the dark at RT and it was monitored by TLC. 
After 3 h, the reaction mixture was concentrated, diluted with water and washed with 
Et2O. Then, the aqueous phase was treated with 1N aqueous HCl and extracted several 
times with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.142 (15.3 mg, 0.0392 mmol, 88% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 7.20 (qd, 1H, J = 1.6, 0.8 Hz), 7.53 (dd, 1H, J = 8.6, 2.0 
Hz), 7.58-7.63 (m, 2H), 7.68 (d, 1H, J = 1.8 Hz), 7.89 (s, 1H). 13C NMR (acetone-d6) δ 
(ppm): 103.06, 115.42, 117.49, 120.90 (q, J = 4.8 Hz), 123.10 (q, J = 32.5 Hz), 125.41 
(q, J = 272.9 Hz), 128.47, 129.17, 130.31, 133.79, 133.92, 134.79, 135.05, 136.45, 
139.07, 161.70. MS m/z 393 (37/37Cl: M+, 11%), 391 (37/35Cl: M+ , 64%), 389 (35/35Cl: 
M+, 100%), 377 (37/37Cl: M+ –O, 4%), 375 (37/35Cl: M+ –O, 24% ), 373 (35/35Cl: M+ –O, 
37% ), 331 (37/37Cl: M+ –H2O –CO2, 13%), 329 (37/35Cl: M+ –H2O –CO2, 55% ), 327 
(35/35Cl: M+ –H2O –CO2, 82% ), 294 (37Cl: M+ –H2O –CO2 –Cl, 38%), 292 (35Cl: M+ –
H2O –CO2 –Cl, 92% ). HPLC, tR = 11.9 min. 
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6-Phenyl-3-methyl-2-nitro-4-(trifluoromethyl)biphenyl (3.152) 
CH3
NO2
CF3
 
Commercially available 3,4-dichloro-2-nitro-6-trifluoromethyltoluene 3.151 (274 
mg, 1.00 mmol) was placed in a vial together with phenylboronic acid (366 mg, 3.00 
mmol), sodium carbonate (636 mg, 6.00 mmol), Pd(OAc)2 (2.5 mg, 0.01 mmol), 
tetrabutylammonium bromide (660 mg, 2.00 mmol) and water (3 mL). The vial was 
sealed and heated under stirring at 175 °C in a microwave reactor for 10 min. The 
reaction mixture was then diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 95:5 as the eluent, to give pure 3.152 (296 mg, 0.828 mmol, 83% 
yield). 1H NMR (CDCl3) δ (ppm): 2.47 (q, 3H, J = 1.5 Hz), 7.01-7.11 (m, 5H), 7.16-
7.28 (m, 5H), 7.82 (s, 1H). 
 
Methyl 3-(6-phenyl-2-nitro-4-(trifluoromethyl)biphenyl-3-yl)-2-oxopropanoate 
(3.153) 
COOMe
O
NO2
CF3
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 130 mg, 3.25 
mmol) in 5 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.152 (290 mg, 0.812 
mmol) and dimethyl oxalate (479 mg, 4.06 mmol) in 5 mL of anhydrous DMF. The 
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mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
12 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
8:2 as the eluent, to yield the nitroaryl-ketoester derivative 3.153 (342 mg, 0.771 mmol, 
95% yield). 1H NMR (CDCl3) δ (ppm): 3.95 (s, 3H), 4.42 (s, 2H), 7.05-7.09 (m, 5H), 
7.21-7.25 (m, 5H), 7.91 (s, 1H); signals imputable to the enol form (~ 11%) δ (ppm): 
3.92 (s, 3H), 6.15 (d, 1H, exchangeable, J = 1.2 Hz), 6.54-6.56 (m, 1H). 
 
Methyl 1-hydroxy-6,7-diphenyl-4-(trifluoromethyl)-1H-indole-2-carboxylate 
(3.154) 
N
COOMe
OH
CF3
 
A stirred suspension of Zn dust (82.0 mg, 1.25 mmol) and iodine (16.0 mg, 0.0625 
mmol) in anhydrous THF (1 mL) was heated to reflux  for approximately 3 h and then 
allowed to cool to RT. A solution of 1N aqueous NH4Cl (2.0 mL) and ketoester 3.153 
(111 mg, 0.270 mmol) in anhydrous THF (1 mL) was added to the activated Zn 
suspension and stirring was continued until the complete consumption of starting 
material in the absence of light at RT. The crude reaction mixture was purified directly 
by column chromatography over silica gel using n-hexane/EtOAc 8:2 as the eluent, to 
give the N-hydroxyindole 3.154 (16.0 mg, 0.0389 mmol, 14% yield). 1H NMR (CDCl3) 
δ (ppm): 4.00 (s, 3H), 7.09-7.31 (m, 11H), 7.54 (s, 1H), 10.26 (bs, 1H). 
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1-Hydroxy-6,7-diphenyl-4-(trifluoromethyl)-1H-indole-2-carboxylic acid (3.140) 
N
COOH
OH
CF3
 
Methyl ester 3.154 (12.0 mg, 0.0292 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.0 mL) and treated with 0.1 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 2 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.140 (10.0 mg, 0.0252 mmol, 86% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.02-7.22 (m, 11H), 7.41 (d, 1H, J = 0.8 Hz). 13C NMR 
(DMSO-d6) δ (ppm): 101.08, 116.65, 119.73, 120.40 (q, J = 4.0 Hz), 123.92 (q, J = 32.3 
Hz), 124.09 (q, J = 269.3 Hz), 126.48, 126.70 (2C), 127.59 (2C), 128.67, 129.36, 
129.87 (2C), 130.85 (2C), 133.20, 135.62, 137.12, 140.06, 160.60. MS m/z 397 (M+, 
14%), 381 (M+ –O, 38%), 335 (M+ –H2O –CO2, 100%). HPLC, tR = 11.2 min. 
 
Methyl 3-(3-nitro-5-(trifluoromethyl)biphenyl-4-yl)-2-oxobut-3-enoate (3.157a) 
 
Potassium tert-butoxide (320 mg, 2.85 mmol) was dispersed in anhydrous diethyl 
ether (4.6 mL) at 0 °C under nitrogen, and dry methanol was added (0.5 mL) until 
complete dissolution was obtained. Next, dimethyl oxalate (336 mg, 2.85 mmol) was 
added and stirring was continued at 0 °C for 15 min. Finally, a solution of the 
nitrotoluene derivative 3.148a (400 mg, 1.42 mmol) in dry Et2O (1.8 mL) was slowly 
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added at the same temperature and the resulting reddish suspension was then left under 
stirring at RT for 48 h. The reaction mixture was then filtered to obtain a reddish solid, 
corresponding to the potassium salt of the nitroaryl-ketoester derivative 3.149a (304 
mg). To a solution of derivative 3.149a (304 mg) in THF (25 mL) at 0 °C was added 
dimethylmethylene ammonium chloride (211 mg, 2.25 mmol) and the reaction mixture 
stirred for 12 h at RT. After cooling to 0 °C, the reaction mixture was quenched with 
saturated aqueous NH4Cl solution, diluted with EtOAc, washed with H2O and dried 
over anhydrous sodium sulphate. After concentration, the residue was subjected to flash 
column chromatography using n-hexane/EtOAc 9:1 as the eluent to give the α,β-
unsaturated ketoester 3.157a (159 mg, 0.419 mmol, 2 steps: 30% yield). 1H NMR 
(CDCl3) δ (ppm): 3.93 (s, 3H), 6.18 (s, 1H), 6.83 (s, 1H), 7.50-7.60 (m, 3H), 7.63-7.68 
(m, 2H), 8.22 (d, 1H, J = 1.8 Hz), 8.46 (d, 1H, J = 1.8 Hz). 
 
Methyl 1-hydroxy-3-methyl-6-phenyl-4-(trifluoromethyl)-1H-indole-2-carboxylate 
(3.158a) 
 
Triethylsilane (0.13 mL, 92.0 mg, 0.792 mmol) and α,β-unsaturated ketoester 
3.157a (60.0 mg, 0.158 mmol) were added at room temperature to a solution of 
SnCl2·2H2O (89.3 mg, 0.396 mmol) in DME (1.0 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at 40 
°C for 3 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 85:15 as the eluent, to give the N-hydroxyindol-ester derivative 3.158a 
(8.3 mg, 0.024 mmol, 15% yield). 1H NMR (CDCl3) δ (ppm): 2.68 (s, 3H), 4.07 (s, 3H), 
7.36-7.54 (m, 3H), 7.66-7.78 (m, 3H), 7.90-7.94 (m, 1H), 10.72 (bs, 1H). 
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1-Hydroxy-3-methyl-6-phenyl-4-(trifluoromethyl)-1H-indole-2-carboxylic acid 
(3.155) 
 
Methyl ester 3.158a (8.3 mg, 0.0238 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.4 mL) and treated with 0.10 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 4 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.155 (4.5 mg, 0.0134 mmol, 56% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 2.67 (q, 3H, J = 1.8 Hz), 7.38-7.58 (m, 3H), 7.78-7.84 (m, 
3H), 8.03 (dq, 1H, J = 1.5, 0.7 Hz). 13C NMR (DMSO-d6) δ (ppm): 10.63 (q, J = 5.2 
Hz), 111.43, 111.63, 116.18, 117.76 (q, J = 4.6 Hz), 121.60 (q, J = 32.0 Hz), 124.37 (q, 
J = 269.9 Hz), 126.96 (2C), 127.67, 127.88, 129.16 (2C), 135.50, 136.50, 139.08, 
162.02. MS m/z 335 (M+, 18%), 320 (M+ –CH3, 18%), 319 (M+ –O, 100%), 318 (M+ –
OH, 6%), 291 (M+ –CO2, 5%), 275 (M+ –CO2 –H2O, 46%). 
 
Methyl 3-(4'-chloro-3-nitro-5-(trifluoromethyl)biphenyl-4-yl)-2-oxobut-3-enoate 
(3.157b) 
 
Potassium tert-butoxide (224 mg, 2.00 mmol) was dispersed in anhydrous diethyl 
ether (2.0 mL) at 0 °C under nitrogen, and dry methanol was added (0.05 mL) until 
complete dissolution was obtained. Next, dimethyl oxalate (236 mg, 2.00 mmol) was 
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added and stirring was continued at 0 °C for 15 min. Finally, a solution of the 
nitrotoluene derivative 3.148b (316 mg, 1.00 mmol) in dry Et2O (2.0 mL) was slowly 
added at the same temperature and the resulting reddish suspension was then left under 
stirring at RT for 48 h. The reaction mixture was then filtered to obtain a reddish solid, 
corresponding to the potassium salt of the nitroaryl-ketoester derivative 3.149b (331 
mg). To a solution of derivative 3.149b (331 mg) in THF (25 mL) at 0 °C was added 
dimethylmethylene ammonium chloride (211 mg, 2.25 mmol) and the reaction mixture 
stirred for 12 h at RT. After cooling to 0 °C, the reaction mixture was quenched with 
saturated aqueous NH4Cl solution, diluted with EtOAc, washed with H2O and dried 
over anhydrous sodium sulphate. After concentration, the residue was subjected to flash 
column chromatography using n-hexane/EtOAc 9:1 as the eluent to give the α,β-
unsaturated ketoester 3.157b (84.0 mg, 0.203 mmol, 2 steps: 20% yield). 1H NMR 
(CDCl3) δ (ppm): 3.93 (s, 3H), 6.17 (s, 1H), 6.83 (s, 1H), 7.49-7.62 (m, 4H), 8.18 (d, 
1H, J = 1.8 Hz), 8.42 (d, 1H, J = 1.8 Hz). 
 
Methyl 6-(4-chlorophenyl)-1-hydroxy-3-methyl-4-(trifluoromethyl)-1H-indole-2-
carboxylate (3.158b) 
 
Triethylsilane (0.14 mL, 105 mg, 0.900 mmol) and α,β-unsaturated ketoester 3.157b 
(75.0 mg, 0.181 mmol) were added at room temperature to a solution of SnCl2·2H2O 
(102 mg, 0.452 mmol) in DME (1.13 mL) containing 4Å molecular sieves, previously 
activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator over 
anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at 40 °C 
for 3 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 9:1 as the eluent, to give the N-hydroxyindol-ester derivative 3.158b 
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(15.0 mg, 0.0391 mmol, 22% yield). 1H NMR (CDCl3) δ (ppm): 2.67 (q, 3H, J = 1.6 
Hz), 4.08 (s, 3H), 7.45 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 2.3 Hz), 7.62 (AA’XX’, 
2H, JAX = 8.6 Hz, JAA’/XX’ = 2.2 Hz), 7.70 (s, 1H), 7.89 (s, 1H), 10.74 (bs, 1H). 
 
6-(4-Chlorophenyl)-1-hydroxy-3-methyl-4-(trifluoromethyl)-1H-indole-2-
carboxylic acid (3.156) 
 
Methyl ester 3.158b (15.0 mg, 0.0391 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.0 mL) and treated with 0.12 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.156 (14.0 mg, 0.0379 mmol, 97% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 2.67 (q, 3H, J = 1.6 Hz), 7.55 (AA′XX′, 2H, JAX = 8.6 Hz, 
JAA′/XX′ = 2.4 Hz), 7.81 (s, 1H), 7.85 (AA′XX′, 2H, JAX = 8.8 Hz, JAA′/XX′ = 2.2 Hz), 8.04 
(s, 1H). 13C NMR (acetone-d6) δ (ppm): 11.24 (q, J = 5.5 Hz), 112.62, 114.86, 117.81, 
119.04 (q, J = 6.4 Hz), 123.63 (q, J = 33.6 Hz), 125.35 (q, J = 271.0 Hz), 127.12, 
129.63 (2C), 129.89 (2C), 134.27, 136.37, 137.61, 139.39, 163.04. MS m/z 371 (37Cl: 
M+, 20%), 369 (35Cl: M+, 58%), 355 (37Cl: M+ –O, 37%), 353 (35Cl: M+ –O, 100% ), 
309 (37Cl: M+ –H2O –CO2, 46%), 307 (35Cl: M+ –H2O –CO2, 74% ). HPLC, tR 11.6 min. 
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4'-Phenyl-4-methyl-3-nitrobiphenyl (3.162a) 
 
Commercially available 4-bromo-2-nitrotoluene 3.90d (500 mg, 2.31 mmol) was 
placed in a vial together with biphenyl-4-boronic acid 3.161a (503 mg, 2.54 mmol), 
sodium carbonate (735 mg, 6.93 mmol), Pd(OAc)2 (3.8 mg, 0.017 mmol), 
tetrabutylammonium bromide (746 mg, 2.31 mmol) and water (3 mL). The vial was 
sealed and heated under stirring at 150 °C in a microwave reactor for 5 min. The 
reaction mixture was then diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 95:5 as the eluent, to give pure 3.162a (558 mg, 1.93 .mmol, 84% 
yield). 1H NMR (CDCl3) δ (ppm): 2.66 (s, 3H), 7.38-7.52 (m, 4H), 7.65 (AA’XX’, 2H, 
JAX = 7.0 Hz, JAA’/XX’ = 1.5 Hz), 7.70 (s, 4H), 7.78 (dd, 1H, J = 8.0, 1.9 Hz), 8.26 (d, 1H, 
J = 2.0 Hz). 
 
Methyl 3-(4'-phenyl-3-nitrobiphenyl-4-yl)-2-oxopropanoate (3.163a) 
NO2
COOMe
O
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 304 mg, 7.60 
mmol) in 5.3 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.162a (550 mg, 1.90 
mmol) and dimethyl oxalate (1.12 g, 9.50 mmol) in 3.6 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
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5.5h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
6:4 as the eluent, to yield the nitroaryl-ketoester derivative 3.163a (555 mg, 1.48 mmol, 
78% yield). 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 4.59 (s, 2H), 7.38-7.53 (m, 4H), 
7.65 (AA’XX’, 2H, JAX = 6.8 Hz, JAA’/XX’ = 1.8 Hz), 7.72 (s, 4H), 7.90 (dd, 1H, J = 8.0, 
1.9 Hz), 8.45 (d, 1H, J = 1.8 Hz); signals imputable to the enol form (~ 40%) δ (ppm): 
3.97 (s, 3H), 6.70 (d, 1H, exchangeable, J = 1.5 Hz), 6.99 (d, 1H, J = 1.3 Hz), 7.72 (s, 
4H), 8.19 (d, 1H, J = 2.0 Hz), 8.36 (d, 1H, J = 8.4 Hz). 
 
Methyl 6-(biphenyl-4-yl)-1-hydroxy-1H-indole-2-carboxylate (3.164a) 
 
Triethylamine (0.28 mL, 0.20 g, 2.0 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (135 mg, 0.60 mmol) and PhSH (0.18 mL, 0.20 g, 1.8 mmol) in 
acetonitrile (3.1 mL) at room temperature to generate a yellow precipitate over a period 
of 5 min. Then, 3.163a (150 mg, 0.400 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 7:3 as the eluent, to give a mixture (93.1 mg) of the N-
hydroxyindol-ester derivative 3.164a (80%, 74.5 mg, 0.217 mmol, 54% yield) with its 
indole analogue (20%) . 1H NMR (CDCl3) δ (ppm): 4.01 (s, 3H), 7.06 (s, 1H), 7.33-7.51 
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(m, 4H), 7.65-7.80 (m, 8H), 10.31 (bs, 1H); signals imputable to the indole (~ 20%) δ 
(ppm): 3.97 (s, 3H); 7.18 (s, 1H). 
 
6-(Biphenyl-4-yl)-1-hydroxy-1H-indole-2-carboxylic acid (3.159a) 
 
Methyl ester 3.164a (50.0 mg, 0.146 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.5 mL) and treated with 0.44 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
5h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.159a (44.5 mg, 0.135 mmol, 93% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 7.16 (d, 1H, J = 0.7 Hz), 7.34-7.56 (m, 3H), 7.72-7.90 (m, 
9H); signals imputable to the indole (~ 10%) δ (ppm): 7.21 (s, 1H). 13C NMR (acetone-
d6) δ (ppm): 106.10, 108.23, 121.37, 122.12, 123.78, 126.29, 127.65 (2C), 128.18, 
128.26 (2C), 128.51 (2C), 129.77 (2C), 137.54, 138.85, 140.84, 141.33, 141.44, 162.40. 
MS m/z 329 (M+, 7%), 313 (M+ –O, 100%), 267 (M+ –OH –COOH, 41%), 190 (M+ –
OH –COOH –C6H5, 27%). HPLC, tR = 10.4 min. 
 
1-(4-Methyl-3-nitrophenyl)naphthalene (3.162b) 
CH3
NO2
 
Commercially available 4-bromo-2-nitrotoluene 3.90d (570 mg, 2.64 mmol) was 
placed in a vial together with 1-naphtaleneboronic acid 3.161b (500 mg, 2.91 mmol), 
sodium carbonate (839 mg, 7.92 mmol), Pd(OAc)2 (2.4 mg, 0.011 mmol), 
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tetrabutylammonium bromide (852 mg, 2.64 mmol) and water (3 mL). The vial was 
sealed and heated under stirring at 150 °C in a microwave reactor for 5 min. The 
reaction mixture was then diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 95:5 as the eluent, to give pure 3.162b (642 mg, 2.44 mmol, 92% 
yield). 1H NMR (CDCl3) δ (ppm): 2.71 (s, 3H), 7.40-7.58 (m, 5H), 7.65 (dd, 1H, J = 7.9, 
1.8 Hz), 7.81 (ddd, 1H, J = 8.2, 1.5, 0.7 Hz), 7.89-7.96 (m, 2H), 8.12 (d, 1H, J = 1.6 
Hz). 
 
Methyl 3-(4-(naphthalen-1-yl)-2-nitrophenyl)-2-oxopropanoate (3.163b) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 377 mg, 9.43 
mmol) in 6.6 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.162b (620 mg, 2.36 
mmol) and dimethyl oxalate (1.39 g, 11.8 mmol) in 4.4 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
12 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
8:2 as the eluent, to yield the nitroaryl-ketoester derivative 3.163b (526 mg, 1.51 mmol, 
64% yield). 1H NMR (CDCl3) δ (ppm): 3.98 (s, 3H), 4.64 (s, 2H), 7.42-7.60 (m, 5H), 
7.74-7.88 (m, 2H), 7.90-7.98 (m, 2H), 8.33 (d, 1H, J = 1.8 Hz); signals imputable to the 
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enol form (~ 25%) δ (ppm): 6.73 (d, 1H, exchangeable, J = 1.3 Hz), 7.03 (bs, 1H), 8.06 
(d, 1H, J = 1.8 Hz), 8.39 (d, 1H, J = 8.2 Hz). 
 
Methyl 1-hydroxy-6-(naphthalen-1-yl)-1H-indole-2-carboxylate (3.164b) 
 
Triethylamine (0.30 mL, 0.22 g, 2.1 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (136 mg, 0.601 mmol) and PhSH (0.20 mL, 0.21 g, 1.9 mmol) in 
acetonitrile (3.4 mL) at room temperature to generate a yellow precipitate over a period 
of 5 min. Then, 3.163b (150 mg, 0.429 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 8:2 as the eluent, to give a mixture (104 mg) of the N-
hydroxyindol-ester derivative 3.164b (91%, 94.6 mg, 0.298 mmol, 70% yield) with its 
indole analogue (9%) 1H NMR (CDCl3) δ (ppm):4.02 (s, 3H), 7.12 (d, 1H, J = 0.9 Hz), 
7.29 (dd, 1H, J = 8.3, 1.6 Hz), 7.39-7.59 (m, 4H), 7.67 (t, 1H, J = 0.6 Hz), 7.73 (dd, 1H, 
J = 8.4, 0.7 Hz), 7.86-7.98 (m, 3H), 10.26 (bs, 1H); signals imputable to the indole (~ 
9%) δ (ppm): 3.98 (s, 3H), 7.22 (s, 1H), 11.05 (bs, 1H). 
 
1-Hydroxy-6-(naphthalen-1-yl)-1H-indole-2-carboxylic acid (3.159b) 
N
OH
COOH
 
Methyl ester 3.164b (93.0 mg, 0.293 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2.9 mL) and treated with 0.9 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
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1.5 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.159b (72.9 mg, 0.240 mmol, 82% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.11 (d, 1H, J = 0.9 Hz), 7.21 (dd, 1H, J = 8.2, 1.6 Hz), 
7.45-7.64 (m, 5H), 7.77 (dd, 1H, J = 8.2, 0.6 Hz), 7.86 (dd, 1H, J = 7.9, 1.3 Hz), 7.97 
(d, 1H, J = 8.6 Hz), 8.02 (dd, 1H, J = 7.9, 1.6 Hz); signals imputable to the indole (~ 
9%) δ (ppm): 7.16 (s, 1H). 13C NMR (DMSO-d6) δ (ppm): 104.65, 110.28, 120.26, 
121.97, 122.84, 125.30, 125.50, 125.83, 126.24, 126.99, 127.34, 127.48, 128.28, 
130.94, 133.38, 135.99, 136.66, 139.86, 161.06. MS m/z 303 (M+, 53%), 287 (M+ –O, 
87%), 241 (M+ –OH –COOH, 100%). HPLC, tR 10.3 min. 
 
2-(4-Methyl-3-nitrophenyl)naphthalene (3.162c) 
 
Commercially available 4-bromo-2-nitrotoluene 3.90d (570 mg, 2.64 mmol) was 
placed in a vial together with 2-naphtaleneboronic acid 3.161c (500 mg, 2.91 mmol), 
sodium carbonate (839 mg, 7.92 mmol), Pd(OAc)2 (2.4 mg, 0.011 mmol), 
tetrabutylammonium bromide (852 mg, 2.64 mmol) and water (3 mL). The vial was 
sealed and heated under stirring at 150 °C in a microwave reactor for 5 min. The 
reaction mixture was then diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 98:2 as the eluent, to give pure 3.162c (677 mg, 2.57 mmol, 97% 
yield). 1H NMR (CDCl3) δ (ppm): 2.67 (s, 3H), 7.45 (d, 1H, J = 7.7 Hz), 7.50-7.58 (m, 
2H), 7.73 (dd, 1H, J = 8.4, 1.8 Hz), 7.83-7.98 (m, 4H), 8.07 (t, 1H, J = 1.0 Hz), 8.35 (d, 
1H, J = 2.0 Hz). 
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Methyl 3-(4-(naphthalen-2-yl)-2-nitrophenyl)-2-oxopropanoate (3.163c) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 377 mg, 9.43 
mmol) in 6.6 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.162c (620 mg, 2.36 
mmol) and dimethyl oxalate (1.39 g, 11.8 mmol) in 4.4 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
12 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.163c (644 mg, 1.84 mmol, 
78% yield). 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 4.60 (s, 2H), 7.44 (d, 1H, J = 8.1 
Hz), 7.51-7.57 (m, 2H), 7.77 (t, 1H, J = 1.8 Hz), 7.87-8.11 (m, 5H), 8.53 (d, 1H, J = 1.8 
Hz); signals imputable to the enol form (~ 42%) δ (ppm): 3.97 (s, 3H), 6.72 (d, 1H, 
exchangeable, J = 1.5 Hz), 7.00 (d, 1H, J = 1.5 Hz), 7.72 (t, 1H, J = 1.9 Hz), 8.27 (d, 
1H, J = 1.8 Hz), 8.39 (d, 1H, J = 8.4 Hz). 
 
Methyl 1-hydroxy-6-(naphthalen-2-yl)-1H-indole-2-carboxylate (3.164c) 
N
OH
COOMe
 
Triethylamine (0.40 mL, 0.29 g, 2.9 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (181 mg, 0.802 mmol) and PhSH (0.30 mL, 0.29 g, 2.6 mmol) in 
acetonitrile (4.5 mL) at room temperature to generate a yellow precipitate over a period 
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of 5 min. Then, 3.163c (200 mg, 0.573 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 8:2 as the eluent, to give a mixture (110 mg) of the N-
hydroxyindol-ester derivative 3.164c (91%, 100 mg, 0.315 mmol, 55% yield) with its 
indole analogue (9%). 1H NMR (CDCl3) δ (ppm): 4.02 (s, 3H), 7.08 (d, 1H, J = 0.9 Hz), 
7.47-7.58 (m, 3H), 7.74 (dd, 1H, J = 8.4, 0.7 Hz), 7.82-7.97 (m, 5H), 8.15 (d, 1H, J = 
1.6 Hz), 10.33 (bs, 1H); signals imputable to the indole (~ 9%) δ (ppm): 3.98 (s, 3H), 
7.19 (s, 1H). 
 
1-Hydroxy-6-(naphthalen-2-yl)-1H-indole-2-carboxylic acid (3.159c) 
 
Methyl ester 3.164c (70.0 mg, 0.221 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2.2 mL) and treated with 0.7 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
3.5 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.159c (66.5 mg, 0.219 mmol, 99% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 7.17 (d, 1H, J = 0.9 Hz), 7.51-7.57 (m, 2H), 7.63 (dd, 1H, J 
= 8.5, 1.6 Hz), 7.81 (dd, 1H, J = 8.4, 0.6 Hz), 7.92-7.97 (m, 3H), 7.99-8.06 (m, 2H), 
8.29 (d, 1H, J = 1.5 Hz); signals imputable to the indole (~ 13%) δ (ppm): 3.98 (s, 3H), 
7.21 (s, 1H). 13C NMR (DMSO-d6) δ (ppm): 104.52, 107.40, 120.09, 120.40, 120.49, 
122.68, 125.23 (2C), 125.95, 126.30, 127.37, 128.14, 128.39, 132.09, 133.35, 136.50, 
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136.68, 137.86, 161.08. MS m/z 303 (M+, 44%), 287 (M+ –O, 100%), 241 (M+ –OH –
COOH, 57%). HPLC, tR = 10.1 min. 
 
3-(4-Methyl-3-nitrophenyl)furan (3.162d) 
 
A solution of Pd(OAc)2 (20.6 mg, 0.0918 mmol) and triphenylphosphine (120 mg, 
0.459 mmol) in absolute ethanol (6.9 mL) and anhydrous toluene (6.9 mL) was stirred 
at RT under nitrogen for 10 min. After that period, commercially available 3-
bromofuran 3.161d (0.28 mL, 450 mg, 3.06 mmol), 6.9 mL of 2M aqueous Na2CO3, 
and 4-methyl-3-nitrobenzeneboronic acid 3.127 (886 mg, 4.90 mmol) were sequentially 
added. The resulting mixture was heated at 100 °C in a sealed vial under nitrogen 
overnight. After being cooled to RT, the mixture was diluted with water and extracted 
with EtOAc. The combined organic phase were dried and concentrated. The crude 
product was purified by flash chromatography (n-hexane/ EtOAc 95:5) to yield 3.162d 
(437 mg, 2.15 mmol, 70% yield). 1H NMR (CDCl3) δ (ppm): 2.60 (s, 3H), 6.72 (dd, 1H, 
J = 1.9, 1.0 Hz), 7.34 (d, 1H, J = 7.7 Hz), 7.51 (pseudo-t, 1H, J = 1.7 Hz), 7.60 (dd, 1H, 
J = 7.9, 1.8 Hz), 7.79 (t, 1H, J = 0.7 Hz), 8.07 (d, 1H, J = 1.8 Hz). 
 
Methyl 3-(4-(furan-3-yl)-2-nitrophenyl)-2-oxopropanoate (3.163d) 
NO2
COOMe
O
O  
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 296 mg, 7.40 
mmol) in 5.2 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.162d (376 mg, 1.85 
mmol) and dimethyl oxalate (1.09 g, 9.25 mmol) in 3.5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
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4h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.163d (431 mg, 1.49 mmol, 
81% yield). 1H NMR (CDCl3) δ (ppm): 3.94 (s, 3H), 4.54 (s, 2H), 6.74 (dd, 1H, J = 1.7, 
0.8 Hz), 7.32 (d, 1H, J = 8.1 Hz), 7.53 (dd, 1H, J = 2.9, 1.6 Hz), 7.72 (dd, 1H, J = 7.8, 
1.9 Hz), 7.82-7.85 (m, 1H), 8.26 (d, 1H, J = 1.6 Hz); signals imputable to the enol form 
(~ 28%) δ (ppm): 3.95 (s, 3H), 6.66 (d, 1H, exchangeable, J = 1.6 Hz), 6.94 (d, 1H, J = 
1.1 Hz), 7.70 (dd, 1H, J = 8.2, 2.0 Hz), 7.99 (d, 1H, J = 1.8 Hz), 8.28 (d, 1H, J = 8.6 
Hz). 
 
Methyl 6-(furan-3-yl)-1-hydroxy-1H-indole-2-carboxylate (3.164d) 
 
Triethylamine (0.24 mL, 0.17 g, 1.7 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (117 mg, 0.519 mmol) and PhSH (0.16 mL, 0.17 g, 1.6 mmol) in 
acetonitrile (2.7 mL) at room temperature to generate a yellow precipitate over a period 
of 5 min. Then, 3.163d (100 mg, 0.346 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 7:3 as the eluent, to give a mixture (70.4 mg) of the N-
hydroxyindol-ester derivative 3.164d (90%, 63.4 mg, 0.246 mmol, 71% yield) with its 
indole analogue (10%). 1H NMR (CDCl3) δ (ppm): 4.00 (s, 3H), 6.80 (dd, 1H, J = 1.8, 
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0.9 Hz), 7.02 (d, 1H, J = 0.9 Hz), 7.29 (dd, 1H, J = 8.5, 1.4 Hz), 7.51 (pseudo-t, 1H, J = 
1.6 Hz), 7.60-7.66 (m, 2H), 7.82 (dd, 1H, J = 1.5, 0.9 Hz), 10.32 (bs, 1H); signals 
imputable to the indole (~ 10%) δ (ppm): 3.96 (s, 3H), 7.16 (d, 1H, J = 1.5 Hz), 11.07 
(bs, 1H). 
 
6-(Furan-3-yl)-1-hydroxy-1H-indole-2-carboxylic acid (3.159d) 
 
Methyl ester 3.164d (30.0 mg, 0.117 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.2 mL) and treated with 0.35 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
12h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.159d (27.7 mg, 0.114 mmol, 97% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 7.01 (dd, 1H, J = 1.8, 0.9 Hz), 7.10 (d, 1H, J = 0.9 Hz), 
7.42 (dd, 1H, J = 8.4, 1.5 Hz), 7.65-7.72 (m, 3H), 8.13 (dd, 1H, J = 1.5, 0.9 Hz); signals 
imputable to the indole (~ 15%) δ (ppm): 7.18 (d, 1H, J = 2.2 Hz), 7.48 (dd, 1H, J = 8.0, 
1.2 Hz). 13C NMR (acetone-d6) δ (ppm): 106.24, 106.75, 109.61, 120.33, 121.52, 
123.59, 127.75, 129.64, 130.64, 137.34, 140.02, 144.86, 162.14. MS m/z 243 (M+, 
56%), 227 (M+ –O, 100%), 180 (M+ –CO2 –H2O, 26%). HPLC, tR = 8.6 min. 
 
5-(4-Methyl-3-nitrophenyl)benzo[d][1,3]dioxole (3.162e) 
CH3
NO2O
O  
Commercially available 4-bromo-1,2-(methylenedioxy)benzene 3.161e (0.30 mL, 
505 mg, 2.51 mmol) was placed in a vial together with 4-methyl-3-nitrobenzeneboronic 
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acid 3.127 (500 mg, 2.76 mmol), sodium carbonate (798 mg, 7.53 mmol), Pd(OAc)2 
(2.3 mg, 0.010 mmol), tetrabutylammonium bromide (809 mg, 2.51 mmol) and water (5 
mL). The vial was sealed and heated under stirring at 150 °C in a microwave reactor for 
5 min. The reaction mixture was then diluted with water and repeatedly extracted with 
EtOAc. The combined organic phase was dried over anhydrous sodium sulphate and 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 95:5 as the eluent, to give pure 3.162e (574 mg, 2.23 
mmol, 89% yield). 1H NMR (CDCl3) δ (ppm): 2.62 (s, 3H), 6.02 (s, 2H), 6.90 (d, 1H, J 
= 8.6 Hz), 7.04-7-10 (m, 2H), 7.37 (d, 1H, J = 7.7 Hz), 7.64 (dd, 1H, J = 8.0, 2.1 Hz), 
8.12 (d, 1H, J = 1.8 Hz). 
 
Methyl 3-(4-(benzo[d][1,3]dioxol-5-yl)-2-nitrophenyl)-2-oxopropanoate (3.163e) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 354 mg, 8.85 
mmol) in 8.3 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.162e (569 mg, 2.21 
mmol) and dimethyl oxalate (1.30 g, 11.1 mmol) in 4.1 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
12h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.163e (566 mg, 1.65 mmol, 
75% yield). 1H NMR (CDCl3) δ (ppm): 3.95 (s, 3H), 4.56 (s, 2H), 6.04 (s, 2H), 6.92 (d, 
1H, J = 8.6 Hz), 7.08-7.13 (m, 2H), 7.35 (d, 1H, J = 7.9 Hz), 7.76 (dd, 1H, J = 7.9, 2.0 
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Hz), 8.31 (d, 1H, J = 2.0 Hz); signals imputable to the enol form (~ 36%) δ (ppm): 6.69 
(d, 1H, J = 1.5 Hz), 7.74 (dd, 1H, J = 8.6, 2.6 Hz), 8.05 (d, 1H, J = 2.0 Hz), 8.30 (d, 1H, 
J = 7.5 Hz). 
 
Methyl 6-(benzo[d][1,3]dioxol-5-yl)-1-hydroxy-1H-indole-2-carboxylate (3.164e) 
 
Triethylamine (0.20 mL, 0.15 g, 1.5 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (98.6 mg, 0.437 mmol) and PhSH (0.13 mL, 0.14 g, 1.3 mmol) in 
acetonitrile (2.3 mL) at room temperature to generate a yellow precipitate over a period 
of 5 min. Then, 3.163e (100 mg, 0.291 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 6:4 as the eluent, to give the N-hydroxyindole 3.164e 
(57.8 mg, 0.186 mmol, 64% yield). 1H NMR (CDCl3) δ (ppm): 4.00 (s, 3H), 6.02 (s, 
2H), 6.91 (d, 1H, J = 8.6 Hz), 7.04 (s, 1H), 7.15-7.18 (m, 2H), 7.32 (dd, 1H, J = 8.8, 1.5 
Hz), 7.63-7.67 (m, 2H), 10.29 (bs, 1H). 
 
6-(Benzo[d][1,3]dioxol-5-yl)-1-hydroxy-1H-indole-2-carboxylic acid (3.159e) 
 
Methyl ester 3.164e (50.0 mg, 0.161 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.6 mL) and treated with 0.48 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
24h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
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Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.159e (47.4 mg, 0.159 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 6.07 (s, 2H), 7.01 (d, 1H J = 8.1 Hz), 7.02 (s, 1H), 7.19 (dd, 
1H, J = 8.5, 1.3 Hz), 7.29 (d, 1H, J = 1.5 Hz), 7.36 (dd, 1H, J = 8.6, 1.5 Hz), 7.54-7.58 
(m, 1H), 7.67 (d, 1H, J = 8.8 Hz). 13C NMR (DMSO-d6) δ (ppm): 101.14, 104.65, 
106.78, 107.29, 108.69, 119.98, 120.11, 120.46, 122.53, 127.16, 134.97, 136.50, 
136.86, 146.69, 147.95, 161.13. MS m/z 297 (M+, 19%), 281 (M+ –O, 100%), 235 (M+ –
O –CH2O2, 36%). 
 
2,2-Difluoro-5-(4-methyl-3-nitrophenyl)benzo[d][1,3]dioxole (3.162f) 
CH3
NO2O
OF
F
 
Commercially available 5-bromo-2,2-difluoro-1,3-benzodioxole 3.161f (0.34 mL, 
595 mg, 2.51 mmol) was placed in a vial together with 4-methyl-3-nitrobenzeneboronic 
acid 3.127 (500 mg, 2.76 mmol), sodium carbonate (798 mg, 7.53 mmol), Pd(OAc)2 
(2.3 mg, 0.010 mmol), tetrabutylammonium bromide (810 mg, 2.51 mmol) and water (5 
mL). The vial was sealed and heated under stirring at 150 °C in a microwave reactor for 
5 min. The reaction mixture was then diluted with water and repeatedly extracted with 
EtOAc. The combined organic phase was dried over anhydrous sodium sulphate and 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 9:1 as the eluent, to give pure 3.162f (798 mg, 2.72 
mmol, >99% yield). 1H NMR (CDCl3) δ (ppm): 2.64 (s, 3H), 7.16 (d, 1H, J = 8.8 Hz), 
7.29 (d, 1H, J = 1.6 Hz), 7.31 (dd, 1H, J = 6.8, 1.6 Hz), 7.42 (d, 1H, J = 7.9 Hz), 7.65 
(dd, 1H, J = 8.0, 1.9 Hz), 8.13 (d, 1H, J = 1.8 Hz). 
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Methyl 3-(4-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-2-nitrophenyl)-2-oxopropanoate 
(3.163f) 
NO2
COOMe
OO
OF
F
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 431 mg, 10.8 
mmol) in 7.6 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.162f (790 mg, 2.69 
mmol) and dimethyl oxalate (1.59 g, 13.5 mmol) in 5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
12h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
6:4 as the eluent, to yield the nitroaryl-ketoester derivative 3.163f (749 mg, 1.96 mmol, 
73% yield). 1H NMR (CDCl3) δ (ppm): 3.95 (s, 3H), 4.58 (s, 2H), 7.14-7.20 (m, 1H), 
7.31-7.36 (m, 2H), 7.41 (d, 1H, J = 7.9 Hz), 7.77 (dd, 1H, J = 7.9, 2.0 Hz), 8.32 (d, 1H, 
J = 1.6 Hz); signals imputable to the enol form (~ 44%) δ (ppm): 3.96 (s, 3H), 6.74 (d, 
1H, exchangeable, J = 1.5 Hz), 6.95 (d, 1H, J = 1.1 Hz), 7.74 (dd, 1H, J = 8.5, 2.0 Hz), 
8.05 (d, 1H, J = 2.0 Hz), 8.34 (d, 1H, J = 8.1 Hz). 
 
Methyl 6-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1-hydroxy-1H-indole-2-carboxylate 
(3.164f) 
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Triethylamine (0.37 mL, 0.27 g, 2.6 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (178 mg, 0.791 mmol) and PhSH (0.24 mL, 0.26 g, 2.4 mmol) in 
acetonitrile (4.1 mL) at room temperature to generate a yellow precipitate over a period 
of 5 min. Then, 3.163f (200 mg, 0.527 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 6:4 as the eluent, to give the N-hydroxyindole 3.164f 
(94.9 mg, 0.273 mmol, 52% yield). 1H NMR (CDCl3) δ (ppm): 4.01 (s, 3H), 7.05 (d, 
1H, J = 0.9 Hz), 7.14 (d, 1H, J = 8.8 Hz), 7.30 (dd, 1H, J = 8.4, 1.6 Hz), 7.37 (d, 1H, J = 
1.8 Hz), 7.38 (dd, 1H, J = 6.2, 1.8 Hz), 7.66 (t, 1H, J = 0.8 Hz), 7.69 (dd, 1H, J = 8.4, 
0.7 Hz), 10.34 (bs, 1H). 
 
6-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-1-hydroxy-1H-indole-2-carboxylic acid 
(3.159f) 
 
Methyl ester 3.164f (60.0 mg, 0.173 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.7 mL) and treated with 0.5 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT. After 36 h it was monitored by TLC 
and another portion of LiOH (0.25 mL) was added. After further 6 h, the reaction 
mixture was concentrated, diluted with water and washed with Et2O. Then, the aqueous 
phase was treated with 1N aqueous HCl and extracted several times with EtOAc. The 
combined ethyl acetate organic phase was dried over anhydrous sodium sulphate and 
evaporated to afford the desired N-hydroxyindol-carboxylic acid product 3.159f (55.6 
mg, 0.167 mmol, 96% yield) without any further purification. 1H NMR (DMSO-d6) δ 
(ppm): 7.04 (d, 1H, J = 0.7 Hz), 7.41 (dd, 1H, J = 8.3, 1.0 Hz), 7.49 (d, 1H, J = 8.4 Hz), 
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7.57 (dd, 1H, J = 8.4, 1.1 Hz), 7.66 (d, 1H, J = 0.9 Hz), 7.72 (d, 1H, J = 8.4 Hz), 7.82 
(d, 1H, J = 1.6 Hz). 13C NMR (DMSO-d6) δ (ppm): 104.58, 107.53, 108.89, 110.35, 
120.04, 120.56, 122.73, 123.11, 127.54, 131.23 (t, J = 262 Hz), 135.66, 136.33, 137.81, 
142.05, 143.43, 161.06. MS m/z 333 (M+, 26%), 317 (M+ -O, 12%), 289 (M+ -CO2, 
5%), 271 (M+ -CO2 -H2O, 7%), 245 (M+ -CO2 -H2O -C2H2, 14%), 177 (M+ –C7H3F2O2 
+H, 100%). HPLC, tR = 10.5 min. 
 
4-(4-Chlorophenoxy)-2-methyl-1-nitrobenzene (3.165) 
 
p-Chlorophenol (995 mg, 7.74 mmol), potassium carbonate (1.07 g, 7.74 mmol) and 
dimethylsulfoxide (12.5 mL) were stirred at RT for 15 min in a vial. After that period, 
commercially available 5-fluoro-2-nitrotoluene 3.90f (800 mg, 5.16 mmol) was added. 
The resulting mixture was heated at 80 °C in a sealed vial for 24 h. After being cooled 
to RT, the mixture was diluted with water and extracted with EtOAc. The combined 
organic phase was washed with brine and then dried over anhydrous sodium sulphate 
and concentrated. The crude product was purified by flash chromatography (n-hexane/ 
EtOAc 8:2) to yield 3.165 (1.05 g, 3.98 mmol, 77% yield). 1H NMR (CDCl3) δ (ppm): 
2.55 (s, 3H), 6.97 (dd, 1H, J = 9.1, 2.8 Hz), 7.06 (d, 1H, J = 2.7 Hz),7.20 (AA’XX’, 2H, 
JAX = 8.8 Hz, JAA’/XX’ = 2.7 Hz), 7.53 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.7 Hz), 8.08 
(d, 1H, J = 9.0 Hz). 
 
Methyl 3-(5-(4-chlorophenoxy)-2-nitrophenyl)-2-oxopropanoate (3.166) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 425 mg, 10.6 
mmol) in 9 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.165 (700 mg, 2.66 
mmol) and dimethyl oxalate (1.57 g, 13.3 mmol) in 6 mL of anhydrous DMF. The 
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mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
5 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
8:2 as the eluent, to yield the nitroaryl-ketoester derivative 3.166 (747 mg, 2.14 mmol, 
80% yield). 1H NMR (CDCl3) δ (ppm): 3.94 (s, 3H), 4.49 (s, 2H), 6.82 (d, 1H, J = 2.7 
Hz), 6.89 (dd, 1H, J = 9.1, 2.7 Hz), 7.05 (AA’XX’, 2H, JAX = 9.0 Hz, JAA’/XX’ = 2.7 Hz), 
7.40 (AA’XX’, 2H, JAX = 9.0 Hz, JAA’/XX’ = 2.7 Hz), 8.21 (d, 1H, J = 9.2 Hz); signals 
imputable to the enol form (~ 12%) δ (ppm): 6.91 (dd, 1H, J = 9.2, 2.7 Hz), 7.78 (d, 1H, 
J = 2.7 Hz), 8.00 (d, 1H, J = 9.2 Hz). 
 
Methyl 5-(4-chlorophenoxy)-1-hydroxy-1H-indole-2-carboxylate (3.167) 
 
Ketoester 3.166 (700 mg, 2.00 mmol) was dissolved in anhydrous DME (3.5 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (1.01 g, 4.48 mmol) in DME (3.5 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 3 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 8:2 as the eluent, to give the N-hydroxyindol-ester derivative 3.167 
(25.0 mg, 0.0787 mmol, 4% yield). 1H NMR (CDCl3) δ (ppm): 4.00 (s, 3H), 6.90 
(AA’XX’, 2H, JAX = 9.0 Hz, JAA’/XX’ = 2.8 Hz), 6.96 (d, 1H, J = 0.9 Hz), 7.11 (dd, 1H, J 
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= 9.0, 2.2 Hz), 7.22 (d, 1H, J = 2.4 Hz), 7.26 (AA’XX’, 2H, JAX = 9.0 Hz, JAA’/XX’ = 2.8 
Hz), 7.54 (d, 1H, J = 9.0 Hz). 
 
5-(4-Chlorophenoxy)-1-hydroxy-1H-indole-2-carboxylic acid (3.160) 
 
Methyl ester 3.167 (25.0 mg, 0.0787 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.6 mL) and treated with 0.24 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 2 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.160 (19.0 mg, 0.0626 mmol, 79% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 6.98 (AA’XX’, 2H, JAX = 9.1 Hz, JAA’/XX’ = 2.8 Hz), 7.10 (d, 
1H, J = 0.9 Hz), 7.14 (dd, 1H, J = 9.0, 2.2 Hz), 7.33 (d, 1H, J = 2.2 Hz), 7.36 (AA’XX’, 
2H, JAX = 9.0 Hz, JAA’/XX’ = 2.8 Hz), 7.59 (dt, 1H, J = 9.0, 0.8 Hz). 
 
1-Azido-2-methyl-3-nitrobenzene (3.174) 
N3
CH3
NO2  
A solution of NaNO2 (1.36 g, 19.7 mmol) in H2O (4.3 mL) was added dropwise to a 
stirred solution of commercially available 2-methyl-3-nitroaniline 3.171 (2.50 g, 16.4 
mmol) in a mixture of concentrated HCl solution (8.6 mL) and H2O (15 mL) at –5 °C. 
The mixture was stirred at 0 °C for 1 h. A solution of NaN3 (1.07 g, 16.4 mmol) in H2O 
(4.3 mL) was added dropwise to the cooled mixture so that the temperature did not 
exceed 5 °C (vigorous foaming). The mixture was stirred for 1 h at 0-5 °C and then for 
12 h at RT. The reaction was worked up by dilution with EtOAc. The organic layer was 
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washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. After evaporation of the organic solvent, the crude was purified by column 
chromatography over silica gel using n-hexane/EtOAc 8:2 as the eluent, to yield the 
azide derivative 3.174 (2.39 g, 13.4 mmol, 82% yield). 1H NMR (CDCl3) δ (ppm): 2.36 
(s, 3H), 7.32-7.41 (m, 2H), 7.54-7.64 (m, 1H). MS m/z 178 (M+, 33%), 162 (M+ –O, 
76%), 104 (M+ –O2 –N3, 100%). 
 
4-Azido-2-methyl-1-nitrobenzene (3.175) 
 
A solution of NaNO2 (1.73 g, 25.2 mmol) in H2O (6.6 mL) was added dropwise to a 
stirred solution of commercially available 3-methyl-4-nitroaniline 3.172 (3.19 g, 21.0 
mmol) in a mixture of concentrated HCl solution (10 mL) and H2O (20 mL) at –5 °C. 
The mixture was stirred at 0 °C for 1 h. A solution of NaN3 (1.37 g, 21.0 mmol) in H2O 
(6.6 mL) was added dropwise to the cooled mixture so that the temperature did not 
exceed 5 °C (vigorous foaming). The mixture was stirred for 1 h at 0-5 °C and then for 
3 h at RT. The reaction was worked up by dilution with EtOAc. The organic layer was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. After evaporation of the organic solvent, the crude was purified by column 
chromatography over silica gel using n-hexane/EtOAc 7:3 as the eluent, to yield the 
azide derivative 3.175 (3.17 g, 17.8 mmol, 85% yield). 1H NMR (CDCl3) δ (ppm): 2.63 
(s, 3H), 6.92-6.70 (m, 2H), 8.07 (d, 1H, J = 8.2 Hz). 
 
4-Azido-1-methyl-2-nitrobenzene (3.176) 
 
A solution of NaNO2 (1.63 g, 23.6 mmol) in H2O (5.1 mL) was added dropwise to a 
stirred solution of commercially available 4-methyl-3-nitroaniline 3.173 (3.00 g, 19.7 
mmol) in a mixture of concentrated HCl solution (10.4 mL) and H2O (18.1 mL) at –5 
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°C. The mixture was stirred at 0 °C for 1 h. A solution of NaN3 (1.28 g, 19.7 mmol) in 
H2O (5.2 mL) was added dropwise to the cooled mixture so that the temperature did not 
exceed 5 °C (vigorous foaming). The mixture was stirred for 1 h at 0-5 °C and then for 
15 h at RT. The reaction was worked up by dilution with EtOAc. The organic layer was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. After evaporation of the organic solvent, the crude was purified by column 
chromatography over silica gel using n-hexane/EtOAc 8:2 as the eluent, to yield the 
azide derivative 3.176 (3.15 g, 17.7 mmol, 90% yield). 1H NMR (CDCl3) δ (ppm): 2.57 
(s, 3H), 7.16 (dd, 1H, J = 8.2, 2.4 Hz), 7.33 (d, 1H, J = 8.2 Hz), 7.64 (d, 1H, J = 2.4 
Hz). 
 
1-(2-Methyl-3-nitrophenyl)-4-phenyl-1H-1,2,3-triazole (3.180a) 
 
Phenylacetylene 3.177 (1.3 mL, 1.2 g, 12 mmol) and azide 3.174 (1.07 g, 6.00 
mmol) were suspended in a 1:1 mixture of water and tert-butyl alcohol (24 mL). A 
freshly prepared sodium ascorbate aqueous solution (119 mg, 0.600 mmol, in 0.6 mL of 
water) was added, followed by copper (II) sulfate pentahydrate aqueous solution (15 
mg, 0.060 mmol, in 0.2 mL of water). The heterogeneous mixture was stirred 
vigorously in the dark overnight. The reaction mixture was diluted with water, cooled in 
ice and the precipitate was collected by filtration. After washing the precipitate with 
cold water, it was dried and then subjected to flash chromatography using n-
hexane/EtOAc 7:3 as the eluent, to yield the triazole derivative 3.180a (831 mg, 2.96 
mmol, 49% yield). 1H NMR (CDCl3) δ (ppm): 2.36 (s, 3H), 7.36-7.59 (m, 4H), 7.68 
(dd, 1H, J = 7.9, 1.5 Hz), 7.88-7.94 (m, 2H), 8.01 (s, 1H), 8.06 (dd, 1H, J = 8.1, 1.5 Hz). 
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Methyl 3-(2-nitro-6-(4-phenyl-1H-1,2,3-triazol-1-yl)phenyl)-2-oxopropanoate 
(3.181a) 
N
N
N
NO2
COOMe
O
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 457 mg, 11.4 
mmol) in 10 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.180a (800 mg, 2.85 
mmol) and dimethyl oxalate (1.68 g, 14.3 mmol) in 6.8 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
4 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
6:4 as the eluent, to yield the nitroaryl-ketoester derivative 3.181a (848 mg, 2.31 mmol, 
81% yield). 1H NMR (CDCl3) δ (ppm): 3.91 (s, 3H), 4.35 (s, 2H), 7.35-7.52 (m, 3H), 
7.68-7.90 (m, 3H), 7.87 (dd, 1H, J = 8.1, 1.6 Hz), 8.04 (s, 1H), 8.32 (dd, 1H, J = 7.7, 2.0 
Hz). 
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Methyl 1-hydroxy-4-(4-phenyl-1H-1,2,3-triazol-1-yl)-1H-indole-2-carboxylate 
(3.182a) 
 
Ketoester 3.181a (500 mg, 1.37 mmol) was dissolved in anhydrous DME (1.4 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (692 mg, 3.07 mmol) in DME (1.4 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 6.5 h, then it was monitored by TLC and another portion of SnCl2·2H2O (116 mg, 
0.514 mmol) was added. After further 12 h, it was diluted with water and repeatedly 
extracted with EtOAc. The combined organic phase was dried over anhydrous sodium 
sulphate and evaporated to afford a crude residue that was purified by column 
chromatography over silica gel using n-hexane/EtOAc 6:4 as the eluent, to give the N-
hydroxyindol-ester derivative 3.182a (268 mg, 0.802 mmol, 59% yield). 1H NMR 
(CDCl3) δ (ppm): 4.01 (s, 3H), 7.34-7.53 (m, 6H), 7.66 (dt, 1H, J = 7.9, 1.1 Hz), 7.92-
7.99 (m, 2H), 8.29 (s, 1H), 10.50 (bs, 1H). 
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1-Hydroxy-4-(4-phenyl-1H-1,2,3-triazol-1-yl)-1H-indole-2-carboxylic acid (3.168a) 
N
N
N
N
COOH
OH  
Methyl ester 3.182a (260 mg, 0.778 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (7.8 mL) and treated with 2.3 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 1 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.168a (247 mg, 0.771 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.35-7.44 (m, 2H), 7.48-7.56 (m, 3H), 7.59-7.65 (m, 2H), 
8.00-8.05 (m, 2H), 9.35 (s, 1H). 13C NMR (DMSO-d6) δ (ppm): 103.25, 110.51, 112.86, 
113.41, 120.82, 124.84, 125.44 (2C), 127.88, 128.21, 128.92 (2C), 129.78, 130.20, 
136.99, 146.77, 160.77. MS m/z 321 (M+H+). 
 
4-Butyl-1-(2-methyl-3-nitrophenyl)-1H-1,2,3-triazole (3.180b) 
N
N
N
CH3
NO2
H3C
3
 
1-Hexyne 3.178 (0.77 mL, 0.55 g, 6.7 mmol) and azide 3.174 (1.20 g, 6.74 mmol) 
were suspended in a 1:1 mixture of water and tert-butyl alcohol (27 mL). A freshly 
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prepared sodium ascorbate aqueous solution (134 mg, 0.674 mmol, in 0.8 mL of water) 
was added, followed by copper (II) sulfate pentahydrate aqueous solution (16.8 mg, 
0.0674 mmol, in 0.2 mL of water). The heterogeneous mixture was stirred vigorously in 
the dark at RT for 4 h, then it was checked by TLC and heated to 80 °C for 72 h. The 
reaction mixture was diluted with water, cooled in ice and the precipitate was collected 
by filtration. After washing the precipitate with cold water, it was dried and then 
subjected to flash chromatography using n-hexane/EtOAc 7:3 as the eluent, to yield the 
triazole derivative 3.180b (263 mg, 1.01 mmol, 15% yield). 1H NMR (CDCl3) δ (ppm): 
0.96 (t, 3H, J = 7.3 Hz), 1.35-1.53 (sext, 2H, J = 7.3 Hz), 1.63-1.82 (m, 2H), 2.29 (s, 
3H), 2.83 (t, 2H, J = 7.7 Hz), 7.50 (s, 1H), 7.51 (t, 1H, J = 8.0 Hz), 7.61 (dd, 1H, J = 
7.9, 1.5 Hz), 8.02 (dd, 1H, J = 8.1, 1.6 Hz). 
 
Methyl 3-(2-(4-butyl-1H-1,2,3-triazol-1-yl)-6-nitrophenyl)-2-oxopropanoate 
(3.181b) 
N
N
N
NO2
COOMe
O
H3C
3
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 154 mg, 3.84 
mmol) in 2.5 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.180b (250 mg, 0.961 
mmol) and dimethyl oxalate (567 mg, 4.81 mmol) in 1.7 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
24 h, then it was heated to 60 °C overnight. Once the disappearance of the precursor 
was verified by TLC, the reaction mixture was slowly poured in an ice-water mixture; 
the water phase was acidified with 1N aqueous HCl and extracted several times with 
EtOAc. The combined organic phase was washed with saturated NaHCO3 solution and 
brine, then dried over anhydrous sodium sulphate. Evaporation under vacuum of the 
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organic solvent afforded a crude product which was purified by column 
chromatography over silica gel using n-hexane/EtOAc 1:1 as the eluent, to yield the 
nitroaryl-ketoester derivative 3.181b (181 mg, 0.523 mmol, 54% yield). 1H NMR 
(CDCl3) δ (ppm): 0.95 (t, 3H, J = 7.2 Hz), 1.22-1.49 (m, 2H), 1.60-1.77 (m, 2H), 2.78 
(t, 2H, J = 7.7 Hz), 3.92 (s, 3H), 4.29 (s, 2H), 7.53 (s, 1H), 7.63-7.73 (m, 2H), 8.27 (dd, 
1H, J = 6.7, 3.0 Hz); signals imputable to the enol form (~ 4%) δ (ppm): 6.49 (s, 1H). 
 
Methyl 4-(4-butyl-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylate 
(3.182b) 
N
N
N
N
COOMe
OH
H3C
3
 
Ketoester 3.181b (175 mg, 0.505 mmol) was dissolved in anhydrous DME (0.5 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (255 mg, 1.13 mmol) in DME (0.5 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 3 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 6:4 as the eluent, to give the N-hydroxyindol-ester derivative 3.182b 
(99.5 mg, 0.317 mmol, 63% yield). 1H NMR (CDCl3) δ (ppm): 0.97 (t, 3H, J = 7.2 Hz), 
1.22-1.54 (m, 2H), 1.62.1.82 (m, 2H), 2.83 (t, 2H, J = 7.7 Hz), 3.99 (s, 3H), 7.29 (dd, 
1H, J = 7.4, 0.9 Hz), 7.37-7.45 (m, 2H), 7.62 (dt, 1H, J = 8.4, 0.9 Hz), 7.81 (s, 1H), 
10.64 (bs, 1H). 
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4-(4-Butyl-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylic acid (3.168b) 
 
Methyl ester 3.182b (90.0 mg, 0.286 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2.9 mL) and treated with 0.9 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 2 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.168b (81.0 mg, 0.270 mmol, 94% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 0.93 (t, 3H, J = 7.2 Hz), 1.39 (sext., 2H, J = 7.3 Hz), 1.69 
(quint., 2H, J = 7.5 Hz), 2.75 (t, 2H, J = 7.6 Hz), 7.32 (d, 1H, J = 0.7 Hz), 7.42-7.53 (m, 
2H), 7.57 (ddd, 1H, J = 7.1, 2.2, 0.6 Hz), 8.62 (s, 1H). 13C NMR (DMSO-d6) δ (ppm): 
13.76, 21.77, 24.68, 31.00, 103.41, 110.08, 112.48, 113.30, 121.29, 124.86, 127.68, 
129.96, 137.01, 147.53, 160.73. MS m/z 301 (M +H+), 285 (M+H+ –O). 
 
2-(1-(2-Methyl-3-nitrophenyl)-1H-1,2,3-triazol-4-yl)ethanol (3.180c) 
 
3-Butyn-1-ol 3.179 (0.47 mL, 0.43 g, 6.2 mmol) and azide 3.174 (1.10 g, 6.18 
mmol) were suspended in a 1:1 mixture of water and tert-butyl alcohol (24.7 mL). A 
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freshly prepared sodium ascorbate aqueous solution (122 mg, 0.618 mmol, in 0.6 mL of 
water) was added, followed by copper (II) sulfate pentahydrate aqueous solution (15.4 
mg, 0.0618 mmol, in 0.2 mL of water). The heterogeneous mixture was stirred 
vigorously in the dark at 80 °C overnight. The reaction mixture was diluted with water 
and repeatedly extracted with EtOAc. The combined organic phase was dried over 
anhydrous sodium sulphate and evaporated to afford a crude residue, that was purified 
by flash chromatography using EtOAc as the eluent, to yield the triazole derivative 
3.180c (1.52 g, 6.12 mmol, 99% yield). 1H NMR (CDCl3) δ (ppm): 2.29 (s, 3H), 3.08 (t, 
2H, J = 5.8 Hz), 4.04 (t, 2H, J = 5.8 Hz), 7.47-7.64 (m, 2H), 7.67 (s, 1H), 8.03 (dd, 1H, 
J = 8.0, 1.0 Hz). 
 
Methyl 3-(2-(4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-6-nitrophenyl)-2-
oxopropanoate (3.181c) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 774 mg, 19.3 
mmol) in 12.8 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.180c (1.20 g, 4.84 
mmol) and dimethyl oxalate (2.86 g, 24.2 mmol) in 8.4 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
1 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using EtOAc as the 
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eluent, to yield the nitroaryl-ketoester derivative 3.181c (1.11 g, 3.32 mmol, 69% yield). 
1H NMR (CDCl3) δ (ppm): 3.03 (t, 2H, J = 5.9 Hz), 3.92 (s, 3H), 4.00 (t, 2H, J = 5.9 
Hz), 4.30 (s, 2H), 7.68-7.74 (m, 2H), 7.71 (s, 1H), 8.27 (dd, 1H, J = 6.9, 2.8 Hz); signals 
imputable to the enol form (~ 17%) δ (ppm): 3.85 (s, 3H), 6.51 (s, 1H) 
 
Methyl 1-hydroxy-4-(4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-1H-indole-2-
carboxylate (3.182c) 
 
Ketoester 3.181c (500 mg, 1.50 mmol) was dissolved in anhydrous DME (1.6 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (759 mg, 3.37 mmol) in DME (1.6 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 45 min., then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
EtOA/acetone 9:1 as the eluent, to give the N-hydroxyindol-ester derivative 3.182c (229 
mg, 0.758 mmol, 51% yield). 1H NMR (acetone-d6) δ (ppm): 3.01 (t, 2H, J = 6.0 Hz), 
3.90 (t, 2H, J = 5.9 Hz), 3.92 (s, 3H), 7.49 (d, 1H, J = 0.6 Hz), 7.51-7.58 (m, 2H), 7.67 
(ddd, 1H, J = 5.2, 4.0, 0.9 Hz), 8.41 (s, 1H), 10.71 (bs, 1H). 
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1-Hydroxy-4-(4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-1H-indole-2-carboxylic 
acid (3.168c) 
N
N
N
N
COOH
OH
HO
2
 
Methyl ester 3.182c (85.0 mg, 0.281 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2.8 mL) and treated with 0.8 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 2 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.168c (80.2 mg, 0.278 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 2.90 (t, 2H, J = 7.0 Hz), 3.74 (t, 2H, J = 6.9 Hz), 7.32 (d, 
1H, J = 0.7 Hz), 7.46-7.52 (m, 2H), 7.56-7.60 (m, 1H), 8.60 (s, 1H). 13C NMR (DMSO-
d6) δ (ppm): 29.18, 60.22, 103.39, 110.13, 112.54, 113.34, 121.95, 124.88, 127.70, 
129.94, 137.04, 145.05, 160.70. MS m/z 287 (M+ –H). 
 
1-(3-Methyl-4-nitrophenyl)-4-phenyl-1H-1,2,3-triazole (3.184a) 
 
Phenylacetylene 3.177 (1.3 mL, 1.2 g, 12 mmol) and azide 3.175 (1.06 g, 5.93 
mmol) were suspended in a 1:1 mixture of water and tert-butyl alcohol (23.6 mL). A 
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freshly prepared sodium ascorbate aqueous solution (117 mg, 0.593 mmol, in 0.6 mL of 
water) was added, followed by copper (II) sulfate pentahydrate aqueous solution (14.9 
mg, 0.0593 mmol, in 0.2 mL of water). The heterogeneous mixture was stirred 
vigorously in the dark for 24 h. The reaction mixture was diluted with water, cooled in 
ice and the precipitate was collected by filtration. After washing the precipitate with 
cold water, it was dried and then subjected to flash chromatography using n-
hexane/EtOAc 7:3 as the eluent, to yield the triazole derivative 3.184a (617 mg, 2.20 
mmol, 37% yield). 1H NMR (CDCl3) δ (ppm): 2.75 (s, 3H), 7.40-7.54 (m, 3H), 7.81 (dd, 
1H, J = 9.0, 2.6 Hz), 7.87-7.95 (m, 3H), 8.22 (d, 1H, J = 8.8 Hz), 8.27 (s, 1H). 
 
Methyl 3-(2-nitro-5-(4-phenyl-1H-1,2,3-triazol-1-yl)phenyl)-2-oxopropanoate 
(3.185a) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 352 mg, 8.81 
mmol) in 5.8 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.184a (617 mg, 2.20 
mmol) and dimethyl oxalate (1.30 g, 11.0 mmol) in 3.9 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT 
overnight. Once the disappearance of the precursor was verified by TLC, the reaction 
mixture was slowly poured in an ice-water mixture; the water phase was acidified with 
1N aqueous HCl and extracted several times with EtOAc. The combined organic phase 
was washed with saturated NaHCO3 solution and brine, then dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using n-
hexane/EtOAc 7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.185a (335 
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mg, 0.914 mmol, 42% yield). 1H NMR (CDCl3) δ (ppm): 3.97 (s, 3H), 4.68 (s, 2H), 
7.40-7.54 (m, 3H), 7.88-7.98 (m, 4H), 8.29 (s, 1H), 8.41 (d, 1H, J = 8.2 Hz). 
 
Methyl 1-hydroxy-5-(4-phenyl-1H-1,2,3-triazol-1-yl)-1H-indole-2-carboxylate 
(3.186a) 
N
COOMe
OH
NN N
 
Ketoester 3.185a (325 mg, 0.887 mmol) was dissolved in anhydrous DME (1.3 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (448 mg, 1.99 mmol) in DME (1.3 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
overnight, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 4:6 as the eluent, to give the N-hydroxyindol-ester derivative 3.186a 
(31.0 mg, 0.0927 mmol, 10% yield). 1H NMR (DMSO-d6) δ (ppm): 3.90 (s, 3H); 7.25 
(d, 1H, J = 0.7 Hz), 7.38 (tt, 1H, J = 7.4, 1.3 Hz), 7.46-7.55 (m, 2H), 7.71 (d, 1H, J = 
9.0 Hz), 7.89-7.99 (m, 3H), 8.23 (dd, 1H, J = 2.0, 1.5 Hz), 9.30 (s, 1H), 11.74 (bs, 1H). 
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1-Hydroxy-5-(4-phenyl-1H-1,2,3-triazol-1-yl)-1H-indole-2-carboxylic acid (3.169a) 
N
COOH
OH
NN N
 
Methyl ester 3.186a (28.0 mg, 0.0837 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.8 mL) and treated with 0.3 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
1.5 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.169a (25.7 mg, 0.0802 mmol, 96% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.16 (s, 1H), 7.34-7.54 (m, 3H), 7.67 (d, 1H, J = 8.8 Hz), 
7.88 (dd, 1H, J = 8.8, 2.0 Hz), 7.95-7.99 (m, 2H), 8.20 (d, 1H, J = 1.8 Hz), 9.29 (s, 1H). 
13C NMR (DMSO-d6) δ (ppm): 104.52, 110.70, 113.57, 117.76, 119.73, 120.56, 125.12 
(2C), 127.85, 128.45, 128.70 (2C), 129.00, 130.31, 134.68, 146.89, 160.77. MS m/z 321 
(M+H+, 10%), 287 (M+ –O –OH, 100%). 
 
4-Butyl-1-(3-methyl-4-nitrophenyl)-1H-1,2,3-triazole (3.184b) 
CH3
NO2
NN N
3H3C
 
1-Hexyne 3.178 (0.68 mL, 0.49 g, 5.9 mmol) and azide 3.175 (1.06 g, 5.93 mmol) 
were suspended in a 1:1 mixture of water and tert-butyl alcohol (23.6 mL). A freshly 
prepared sodium ascorbate aqueous solution (117 mg, 0.593 mmol, in 0.6 mL of water) 
was added, followed by copper (II) sulfate pentahydrate aqueous solution (14.9 mg, 
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0.0593 mmol, in 0.2 mL of water). The heterogeneous mixture was stirred vigorously in 
the dark overnight. The reaction mixture was diluted with water, cooled in ice and the 
precipitate was collected by filtration. After washing the precipitate with cold water, it 
was dried and then subjected to flash chromatography using n-hexane/EtOAc 7:3 as the 
eluent, to yield the triazole derivative 3.184b (813 mg, 3.12 mmol, 53% yield). 1H NMR 
(CDCl3) δ (ppm): 0.96 (t, 3H, J = 7.1 Hz), 1.43 (sext., 2H, J = 7.1 Hz), 1.64-1.80 (m, 
2H), 2.71 (s, 3H), 2.81 (t, 2H, J = 7.3 Hz), 7.71 (dd, 1H, J = 9.0, 2.6 Hz), 7.79 (s, 1H), 
7.80 (d, 1H, J = 2.6 Hz), 8.17 (d, 1H, J = 8.8 Hz). 
 
Methyl 3-(5-(4-butyl-1H-1,2,3-triazol-1-yl)-2-nitrophenyl)-2-oxopropanoate 
(3.185b) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 493 mg, 12.3 
mmol) in 8 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.184b (802 mg, 3.08 
mmol) and dimethyl oxalate (1.82 g, 15.4 mmol) in 5.5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
2.5 h. Once the disappearance of the precursor was verified by TLC, the reaction 
mixture was slowly poured in an ice-water mixture; the water phase was acidified with 
1N aqueous HCl and extracted several times with EtOAc. The combined organic phase 
was washed with saturated NaHCO3 solution and brine, then dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using n-
hexane/EtOAc 7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.185b (840 
mg, 2.43 mmol, 79% yield). 1H NMR (CDCl3) δ (ppm): 0.96 (t, 3H, J = 7.2 Hz), 1.42 
(sext., 2H, J = 7.1 Hz), 1.64-1.81 (m, 2H), 2.82 (t, 2H, J = 7.6 Hz), 3.96 (s, 3H), 4.65 (s, 
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2H), 7.80-7.91 (m, 3H), 8.36 (d, 1H, J = 9.7 Hz); signals imputable to the enol form (~ 
20%) δ (ppm): 6.91 (s, 1H, exchangeable), 7.03 (s, 1H), 8.09 (d, 1H, J = 9.0 Hz), 8.62 
(d, 1H, J = 2.4 Hz). 
 
Methyl 5-(4-butyl-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylate 
(3.186b) 
N
COOMe
OH
NN N
H3C 3
 
Ketoester 3.185b (500 mg, 1.44 mmol) was dissolved in anhydrous DME (2 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (733 mg, 3.25 mmol) in DME (2 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 5 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 6:4 as the eluent, to give the N-hydroxyindol-ester derivative 3.186b 
(33.2 mg, 0.106 mmol, 7% yield). 1H NMR (CDCl3) δ (ppm): 0.95 (t, 3H, J = 7.3 Hz), 
1.40 (sext., 2H, J = 7.1 Hz), 1.71 (quint., 2H, J = 7.5 Hz), 2.80 (t, 2H, J = 7.9 Hz), 4.01 
(s, 3H), 7.10 (s, 1H), 7.64-7.72 (m, 3H), 7.91 (t, 1H, J = 1.2 Hz). 
 
5-(4-Butyl-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylic acid (3.169b) 
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Methyl ester 3.186b (31.2 mg, 0.0993 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1 mL) and treated with 0.3 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.169b (29.4 mg, 0.0979 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 0.93 (t, 3H, J = 7.3 Hz), 1.38 (sext., 2H, J = 7.5 Hz), 1.66 
(quint., 2H, J = 7.5 Hz), 2.70 (t, 2H, J = 7.6 Hz), 7.12 (s, 1H), 7.61 (d, 1H, J = 9.0 Hz), 
7.81 (dd, 1H, J = 9.1, 1.9 Hz), 8.11 (d, 1H, J = 1.6 Hz), 8.53 (s, 1H). 
 
2-(1-(3-Methyl-4-nitrophenyl)-1H-1,2,3-triazol-4-yl)ethanol (3.184c) 
CH3
NO2
NN N
2HO
 
3-Butyn-1-ol 3.179 (0.47 mL, 0.44 g, 6.3 mmol) and azide 3.175 (1.11 g, 6.26 
mmol) were suspended in a 1:1 mixture of water and tert-butyl alcohol (25.3 mL). A 
freshly prepared sodium ascorbate aqueous solution (124 mg, 0.626 mmol, in 0.7 mL of 
water) was added, followed by copper (II) sulfate pentahydrate aqueous solution (15.6 
mg, 0.0626 mmol, in 0.2 mL of water). The heterogeneous mixture was stirred 
vigorously in the dark at 80 °C for 3.5 h. The reaction mixture was diluted with water 
and repeatedly extracted with EtOAc. The combined organic phase was dried over 
anhydrous sodium sulphate and evaporated to afford a crude residue, that was purified 
by flash chromatography using EtOAc as the eluent, to yield the triazole derivative 
3.184c (1.04 g, 4.19 mmol, 67% yield). 1H NMR (CDCl3) δ (ppm): 2.72 (s, 3H), 3.06 (t, 
2H, J = 5.9 Hz), 4.00 (t, 2H, J = 5.7 Hz), 7.73 (dd, 1H, J = 8.8, 2.2 Hz), 7.80 (d, 1H, J 
= 2.0 Hz), 7.96 (s, 1H), 8.18 (d, 1H, J = 8.8 Hz). 
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Methyl 3-(5-(4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-2-nitrophenyl)-2-
oxopropanoate (3.185c) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 322 mg, 8.04 
mmol) in 5.2 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.184c (500 mg, 2.01 
mmol) and dimethyl oxalate (1.19 g, 10.1 mmol) in 3.5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
1 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using EtOAc as the 
eluent, to yield the nitroaryl-ketoester derivative 3.185c (392 mg, 1.17 mmol, 58% 
yield). 1H NMR (CDCl3) δ (ppm): 1.25 (t, 2H, J = 7.1 Hz), 3.06 (t, 2H, J = 5.7 Hz), 
3.96 (s, 3H), 4.65 (s, 2H), 7.81-7.94 (m, 2H), 8.35 (d, 1H, J = 8.1 Hz); signals 
imputable to the enol form (~ 22%) δ (ppm): 3.97 (s, 3H), 7.01 (s, 1H), 8.10 (d, 1H, J = 
8.8 Hz), 8.64 (d, 1H, J = 2.4 Hz). 
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Methyl 1-hydroxy-5-(4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-1H-indole-2-
carboxylate (3.186c) 
N
COOMe
OH
NN N
HO 2
 
Ketoester 3.185c (375 mg, 1.12 mmol) was dissolved in anhydrous DME (1.2 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (567 mg, 2.51 mmol) in DME (1.6 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 2 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
CHCl3/MeOH 95:5 as the eluent, to give the N-hydroxyindol-ester derivative 3.186c 
(101 mg, 0.334 mmol, 30% yield). 1H NMR (DMSO-d6) δ (ppm): 2.86 (t, 2H, J = 7.1 
Hz), 3.71 (td, 2H, J = 6.9, 5.3 Hz), 3.88 (s, 3H), 4.77 (t, 1H, J = 5.3 Hz), 7.20 (d, 1H, J 
= 0.7 Hz), 7.64 (d, 1H, J = 9.0 Hz), 7.83 (dd, 1H, J = 8.8, 2.0 Hz), 8.13 (d, 1H, J = 1.5 
Hz), 8.53 (s, 1H), 11.70 (bs, 1H). 
 
1-Hydroxy-5-(4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-1H-indole-2-carboxylic 
acid (3.169c) 
 
Methyl ester 3.186c (36.3 mg, 0.120 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.3 mL) and treated with 0.36 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
Chapter 4 
351 
 
2.5 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.169c (33.3 mg, 0.116 mmol, 96% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 2.86 (t, 2H, J = 6.9 Hz), 3.71 (t, 2H, J = 6.9 Hz), 7.12 (s, 
1H), 7.61 (d, 1H, J = 9.0 Hz), 7.80 (dd, 1H, J = 9.0, 1.9 Hz), 8.10 (d, 1H, J = 1.7 Hz), 
8.52 (s, 1H). MS m/z 288 (M+ 47%), 272 (M+ –O, 50%), 226 (M+ –C2H5O, –OH 52%), 
181 (M+ –OH, –COOH, –C2H5O, 100%). 
 
1-(3-Methyl-4-nitrophenyl)-1H-1,2,3-triazole-4-carboxylic acid (3.184d) 
 
Propiolic acid 3.183 (0.35 mL, 0.39 g, 5.6 mmol) and azide 3.175 (1.00 g, 5.62 
mmol) were suspended in a 1:1 mixture of water and tert-butyl alcohol (22.5 mL). A 
freshly prepared sodium ascorbate aqueous solution (111 mg, 0.562 mmol, in 0.6 mL of 
water) was added, followed by copper (II) sulfate pentahydrate aqueous solution (15 
mg, 0.056 mmol, in 0.2 mL of water). The heterogeneous mixture was stirred 
vigorously in the dark at RT overnight, then it was heated to 80 °C for 12 h. The 
reaction mixture was diluted with water, cooled in ice and the precipitate was collected 
by filtration. After washing the precipitate with cold water, it was dried and then 
subjected to flash chromatography using CH2Cl2/MeOH/CH3COOH 90:8:2 as the 
eluent, to yield the triazole derivative 3.184d (992 mg, 4.00 mmol, 71% yield), which 
was directly used for the next step, without 1H NMR analysis.  
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1-(3-(3-Methoxy-2,3-dioxopropyl)-4-nitrophenyl)-1H-1,2,3-triazole-4-carboxylic 
acid (3.185d) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 773 mg, 19.3 
mmol) in 12.6 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.184d (799 mg, 3.22 
mmol) and dimethyl oxalate (2.28 g, 19.3 mmol) in 15.7 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
7 days. Once the disappearance of the precursor was verified by TLC, the reaction 
mixture was slowly poured in an ice-water mixture; the water phase was acidified with 
1N aqueous HCl and extracted several times with EtOAc. The combined organic phase 
was washed with saturated NaHCO3 solution and brine, then dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using 
CH2Cl2/MeOH/CH3COOH 90:8:2 as the eluent, to yield the nitroaryl-ketoester 
derivative 3.185d (452 mg, 1.35 mmol, 42% yield). 1H NMR (DMSO-d6) δ (ppm): 3.87 
(s, 3H), 4.72 (s, 2H), 8.01 (m, 1H), 8.16-8.29 (m, 2H), 8.37 (d, 1H, J = 8.8 Hz), 9.53 (s, 
1H); signals imputable to the enol form (~ 64%) δ (ppm): 3.83 (s, 3H), 6.68 (s, 1H), 
8.00 (dd, 1H, J = 9.1, 2.2 Hz), 8.97 (s, 1H), 9.48 (s, 1H). 
 
 
 
 
 
 
Chapter 4 
353 
 
1-(1-Hydroxy-2-(methoxycarbonyl)-1H-indol-5-yl)-1H-1,2,3-triazole-4-carboxylic 
acid (3.186d) 
 
Ketoester 3.185d (401 mg, 1.20 mmol) was dissolved in anhydrous DME (1.5 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (606 mg, 2.69 mmol) in DME (1.7 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 5 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
CH2Cl2/MeOH/CH3COOH 90:8:2 as the eluent, to give a mixture (85.9 mg) of the N-
hydroxyindol-ester derivative 3.186d (78%, 67.0 mg, 0.222 mmol, 18% yield) with its 
indole analogue (22%). 1H NMR (DMSO-d6) δ (ppm): 3.88 (s, 3H), 7.20 (s, 1H), 7.66 
(d, 1H, J = 8.8 Hz), 7.88 (dd, 1H, J = 8.3, 2.0 Hz), 8.22 (d, 1H, J = 2.0 Hz), 9.07 (s, 
1H); signals imputable to the indole (~ 22%) δ (ppm): 3.90 (s, 3H), 7.28 (s, 1H). 
 
5-(4-Carboxy-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylic acid 
(3.169d) 
 
Methyl ester 3.186d (78.8 mg, 0.261 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (3 mL) and treated with 0.8 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
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h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.169d (74.4 mg, 0.258 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.14 (d, 1H, J = 0.7 Hz), 7.65 (d, 1H, J = 9.0 Hz), 7.87 (dd, 
1H, J = 9.0, 2.2 Hz), 8.23 (d, 1H, J = 2.0 Hz), 9.32 (s, 1H), 12.13 (bs, 1H); signals 
imputable to the indole (~ 37%) δ (ppm): 7.22 (d, 1H, J = 1.3 Hz), 7.61 (d, 1H, J = 8.8 
Hz), 7.81 (dd, 1H, J = 9.0, 2.2 Hz), 9.31 (s, 1H). 
 
2-(1-(4-Methyl-3-nitrophenyl)-1H-1,2,3-triazol-4-yl)ethanol (3.190a) 
CH3
NO2N
N N
HO
2
 
3-Butyn-1-ol 3.179 (0.42 mL, 0.39 g, 5.6 mmol) and azide 3.176 (1.00 g, 5.62 
mmol) were suspended in a 1:1 mixture of water and tert-butyl alcohol (22.5 mL). A 
freshly prepared sodium ascorbate aqueous solution (111 mg, 0.562 mmol, in 0.6 mL of 
water) was added, followed by copper (II) sulfate pentahydrate aqueous solution (14.0 
mg, 0.0562 mmol, in 0.2 mL of water). The heterogeneous mixture was stirred 
vigorously in the dark at 80 °C for 4 h. The reaction mixture was diluted with water and 
repeatedly extracted with EtOAc. The combined organic phase was dried over 
anhydrous sodium sulphate and evaporated to afford a crude residue, that was purified 
by flash chromatography using EtOAc as the eluent, to yield the triazole derivative 
3.190a (1.21 g, 4.87 mmol, 87% yield). 1H NMR (DMSO-d6) δ (ppm): 2.57 (s, 3H), 
2.86 (t, 2H, J = 6.8 Hz), 3.71 (q, 2H, J = 6.3 Hz), 4.78 (t, 1H, J = 5.5 Hz), 7.74 (d, 1H, J 
= 8.4 Hz), 8.18 (dd, 1H, J = 8.2, 2.4 Hz), 8.50 (d, 1H, J = 2.4 Hz), 8.74 (s, 1H). 
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Methyl 3-(4-(4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-2-nitrophenyl)-2-
oxopropanoate (3.191a) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 387 mg, 9.67 
mmol) in 6.3 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.190a (600 mg, 2.42 
mmol) and dimethyl oxalate (1.43 g, 12.1 mmol) in 4.3 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
1.5 h. Once the disappearance of the precursor was verified by TLC, the reaction 
mixture was slowly poured in an ice-water mixture; the water phase was acidified with 
1N aqueous HCl and extracted several times with EtOAc. The combined organic phase 
was washed with saturated NaHCO3 solution and brine, then dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using EtOAc as 
the eluent, to yield the nitroaryl-ketoester derivative 3.191a (432 mg, 1.29 mmol, 53% 
yield). 1H NMR (CDCl3) δ (ppm): 3.07 (t, 2H, J = 5.9 Hz), 3.97 (s, 3H), 4.03 (t, 2H, J = 
5.9 Hz), 4.63 (s, 2H), 7.99 (s, 1H), 8.12 (dd, 1H, J = 8.4, 2.2 Hz), 8.31 (d, 1H, J = 2.4 
Hz), 8.47 (d, 1H, J = 8.8 Hz); signals imputable to the enol form (~ 59%) δ (ppm): 3.96 
(s, 3H), 6.95 (s, 1H), 7.52 (d, 1H, J = 8.2 Hz), 8.54 (d, 1H, J = 2.4 Hz). 
 
Methyl 1-hydroxy-6-(4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-1H-indole-2-
carboxylate (3.192a) 
 
Ketoester 3.191a (250 mg, 0.748 mmol) was dissolved in anhydrous DME (0.7 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
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SnCl2·2H2O (378 mg, 1.68 mmol) in DME (0.7 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 24 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
CH2Cl2/MeOH 95:5 as the eluent, to give a mixture (23 mg) of the N-hydroxyindol-
ester derivative 3.192a (81%, 18.6 mg, 0.0616 mmol, 8% yield) with its indole analogue 
(19%). 1H NMR (CDCl3) δ (ppm): 3.01 (t, 2H, J = 6.6 Hz), 3.90 (t, 2H, J = 6.6 Hz), 
3.94 (s, 3H), 7.16 (d, 1H, J = 0.9 Hz), 7.59 (dd, 1H, J = 8.7, 1.9 Hz), 7.81 (dd, 1H, J = 
8.2, 0.6 Hz), 7.93-7.95 (m, 1H), 8.41 (s, 1H); signals imputable to the indole (~ 19%) δ 
(ppm): 3.95 (s, 3H), 7.25 (d, 1H; J = 0.9 Hz), 7.84 (dd, 1H, J = 8.6, 0.6 Hz), 7.89-7.91 
(m, 1H), 8.34 (s, 1H). 
 
1-Hydroxy-6-(4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-1H-indole-2-carboxylic 
acid (3.170a) 
 
Methyl ester 3.192a (23.0 mg, 0.0761 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.8 mL) and treated with 0.2 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 2 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.170a (21.7 mg, 0.0753 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 2.87 (t, 2H, J = 6.4 Hz), 3.72 (t, 2H, J = 6.9 Hz), 7.11 (d, 
1H, J = 0.8 Hz), 7.65 (dd, 1H, J = 8.6, 2.0 Hz), 7.83 (d, 1H, J = 8.8 Hz), 7.88-7.91 (m, 
1H), 8.69 (s, 1H); signals imputable to the indole (~ 19%) δ (ppm): 7.18 (s, 1H), 7.86 
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(d, 1H, J = 8.6 Hz), 8.57 (s, 1H). 13C NMR (DMSO-d6) δ (ppm): 29.27, 60.20, 100.48, 
104.87, 110.77, 113.15, 120.49, 120.89, 123.70, 128.85, 135.53, 145.53, 160.80. MS 
m/z 288 (M+). 
 
1-(4-Methyl-3-nitrophenyl)-1H-1,2,3-triazole-4-carboxylic acid (3.190b) 
CH3
NO2N
N N
HOOC
 
Propiolic acid 3.183 (0.37 mL, 0.41 g, 5.9 mmol) and azide 3.176 (1.05 g, 5.89 
mmol) were suspended in a 1:1 mixture of water and tert-butyl alcohol (23.6 mL). A 
freshly prepared sodium ascorbate aqueous solution (117 mg, 0.589 mmol, in 0.6 mL of 
water) was added, followed by copper (II) sulfate pentahydrate aqueous solution (14.7 
mg, 0.0589 mmol, in 0.2 mL of water). The heterogeneous mixture was stirred 
vigorously in the dark for 24 h. The reaction mixture was diluted with water, cooled in 
ice and the precipitate was collected by filtration. After washing the precipitate with 
cold water, it was dried and then subjected to flash chromatography using 
CH2Cl2/MeOH 85:15 as the eluent, to yield the triazole derivative 3.190b (777 mg, 3.13 
mmol, 53% yield). 1H NMR (DMSO-d6) δ (ppm): 2.58 (s, 3H), 7.76 (d, 1H, J = 8.4 Hz), 
8.26 (dd, 1H, J = 8.4, 2.2 Hz), 8.60 (d, 1H, J = 2.2 Hz), 9.44 (s, 1H). 
 
1-(4-(3-Methoxy-2,3-dioxopropyl)-3-nitrophenyl)-1H-1,2,3-triazole-4-carboxylic 
acid (3.191b) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 677 mg, 16.9 
mmol) in 11 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.190b (700 mg, 2.82 
mmol) and dimethyl oxalate (2.00 g, 16.9 mmol) in 5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
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slowly warmed to room temperature. The mixture was then left under stirring at RT 
overnight. Once the disappearance of the precursor was verified by TLC, the reaction 
mixture was slowly poured in an ice-water mixture; the water phase was acidified with 
1N aqueous HCl and extracted several times with EtOAc. The combined organic phase 
was washed with saturated NaHCO3 solution and brine, then dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using 
CHCl3/MeOH 9:1 with 0.05% trifluoroacetic acid as the eluent, to yield the nitroaryl-
ketoester derivative 3.191b (1.10 g, 3.46 mmol, > 99% yield). 1H NMR (DMSO-d6) δ 
(ppm): 3.86 (s, 3H), 4.70 (s, 2H), 7.77 (d, 1H, J = 8.4 Hz), 8.35-8.40 (m, 1H), 8.72 (d, 
1H, J = 2.4 Hz), 9.59 (s, 1H), 10.56 (bs, 1H); signals imputable to the enol form (~ 
63%) δ (ppm): 3.85 (s, 3H), 6.63 (s, 1H), 8.43 (d, 1H, J = 9.0 Hz), 8.60 (d, 1H, J = 2.2 
Hz), 9.55 (s, 1H). 
 
1-(1-Hydroxy-2-(methoxycarbonyl)-1H-indol-6-yl)-1H-1,2,3-triazole-4-carboxylic 
acid (3.192b) 
N
COOMe
OH
N
N N
HOOC
 
Ketoester 3.191b (500 mg, 1.50 mmol) was dissolved in anhydrous DME (1.5 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (756 mg, 3.35 mmol) in DME (1.5 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 5 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by crystallization using EtOAc and distilled n-
hexane, to give a mixture (28.5 mg) of the N-hydroxyindol-ester derivative 3.192b 
(84%, 23.9 mg, 0.0792 mmol, 5% yield) with its indole analogue (16%).1H NMR 
(DMSO-d6) δ (ppm): 3.89 (s, 3H), 7.20 (d, 1H, J = 0.9 Hz), 7.74 (dd, 1H, J = 8.7, 1.9 
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Hz), 7.89 (d, 1H, J = 8.8 Hz), 8.07 (d, 1H, J = 1.8 Hz), 9.50 (s, 1H), 11.72 (bs, 1H); 
signals imputable to the indole (~ 16%) δ (ppm): 9.40 (s, 1H). 
 
6-(4-Carboxy-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylic acid 
(3.170b) 
 
Methyl ester 3.192b (24.5 mg, 0.0811 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.8 mL) and treated with 0.2 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
48 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.170b (19.7 mg, 0.0684 mmol, 84% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.13 (s, 1H), 7.71 (dd, 1H, J = 8.6, 1.8 Hz), 7.87 (d, 1H, J = 
8.6 Hz), 8.04 (d, 1H, J = 1.4 Hz), 9.48 (s, 1H); signals imputable to the indole (~ 26%) δ 
(ppm): 7.18-7.21 (m, 1H), 9.38 (s, 1H). 
 
3-(1-(4-Methyl-3-nitrophenyl)-1H-1,2,3-triazol-4-yl)propanoic acid (3.190c) 
CH3
NO2N
N N
HOOC
2
 
4-Pentynoic acid 3.187 (551 mg, 5.62 mmol) and azide 3.176 (1.00 g, 5.62 mmol) 
were suspended in a 1:1 mixture of water and tert-butyl alcohol (22.5 mL). A freshly 
prepared sodium ascorbate aqueous solution (111 mg, 0.562 mmol, in 0.6 mL of water) 
was added, followed by copper (II) sulfate pentahydrate aqueous solution (14 mg, 0.056 
mmol, in 0.2 mL of water). The heterogeneous mixture was stirred vigorously in the 
dark at RT overnight, then it was heated at 100 °C for 3 days. The reaction mixture was 
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diluted with water, cooled in ice and the precipitate was collected by filtration. After 
washing the precipitate with cold water, it was dried and then subjected to flash 
chromatography using n-hexane/EtOAc 2:8 as the eluent, to yield the triazole derivative 
3.190c (607 mg, 2.20 mmol, 39% yield). 1H NMR (CD3OD) δ (ppm): 2.63 (s, 3H), 2.77 
(t, 2H, J = 7.3 Hz), 3.08 (t, 2H, J = 7.4 Hz), 7.66 (d, 1H, J = 8.8 Hz), 8.07 (dd, 1H, J = 
8.2, 2.4 Hz), 8.43 (s, 1H), 8.47 (d, 1H, J = 2.4 Hz). 
 
3-(1-(4-(3-Methoxy-2,3-dioxopropyl)-3-nitrophenyl)-1H-1,2,3-triazol-4-
yl)propanoic acid (3.191c) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 504 mg, 12.6 
mmol) in 8.2 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.190c (580 mg, 2.10 
mmol) and dimethyl oxalate (1.49 g, 12.6 mmol) in 3.7 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
5 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using CHCl3/MeOH 9:1 
as the eluent, to yield the nitroaryl-ketoester derivative 3.191c (403 mg, 1.11 mmol, 
53% yield). 1H NMR (DMSO-d6) δ (ppm): 2.68 (t, 2H, J = 7.1 Hz), 2.96 (t, 2H, J = 7.1 
Hz), 3.86 (s, 3H), 4.68 (s, 2H), 7.74 (d, 1H, J = 8.4 Hz), 8.26-8-31 (m, 1H), 8.60 (d, 1H, 
J = 2.0 Hz), 8.80 (s, 1H), 12.20 (bs, 1H); signals imputable to the enol form (~ 72%) δ 
(ppm): 3.84 (s, 3H), 6.63 (s, 1H), 8.25 (dd, 1H, J = 8.8, 2.2 Hz), 8.41 (d, 1H, J = 8.6 
Hz), 8.48 (d, 1H, J = 2.4 Hz), 8.76 (s, 1H). 
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3-(1-(1-Hydroxy-2-(methoxycarbonyl)-1H-indol-6-yl)-1H-1,2,3-triazol-4-
yl)propanoic acid (3.192c) 
 
Ketoester 3.191c (380 mg, 1.05 mmol) was dissolved in anhydrous DME (1.2 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (530 mg, 2.35 mmol) in DME (1.2 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 5 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
CHCl3/MeOH 9:1 as the eluent, to give a mixture (84.1 mg) of the N-hydroxyindol-ester 
derivative 3.192c (68%, 57.2 mg, 0.173 mmol, 16% yield) with its indole analogue 
(32%). 1H NMR (DMSO-d6) δ (ppm): 2.69 (t, 2H, J = 7.5 Hz), 2.95 (t, 2H, J = 7.4 Hz), 
3.88 (s, 3H), 7.18 (d, 1H, J = 0.9 Hz), 7.66 (dd, 1H, J = 8.7, 1.9 Hz), 7.86 (d, 1H, J = 
8.8 Hz), 7.92 (d, 1H, J = 1.6 Hz), 8.71 (s, 1H), 11.69 (bs, 1H), 12.28 (bs, 1H); signals 
imputable to the indole (~ 32%) δ (ppm): 3.90 (s, 3H), 7.24-7.27 (m, 1H), 7.57 (dd, 1H, 
J = 8.7, 1.9 Hz), 8.59 (s, 1H). 
 
6-(4-(2-Carboxyethyl)-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylic 
acid (3.170c) 
N
COOH
OH
N
N N
HOOC
2
 
Methyl ester 3.192c (35.0 mg, 0.106 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.1 mL) and treated with 0.3 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 5 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
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Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.170c (33.2 mg, 0.105 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 2.69 (t, 2H, J = 7.4 Hz), 2.95 (t, 2H, J = 7.3 Hz), 7.10 (s, 
1H), 7.64 (dd, 1H, J = 8.5, 1.9 Hz), 7.52 (d, 1H, J = 9.0 Hz), 7.90 (d, 1H, J = 2.3 Hz), 
8.70 (s, 1H), 12.10 (bs, 1H); signals imputable to the indole (~ 31%) δ (ppm): 7.17-7.19 
(m, 1H), 7.54 (dd, 1H, J = 8.4, 2.0 Hz), 8.58 (s, 1H). 13C NMR (DMSO-d6) δ (ppm): 
20.98, 33.17, 98.22, 101.03, 115.86, 115.96 (2C), 120.95, 124.24, 134.26, 135.84, 
149.81, 161.08, 173.93. 
 
4-(1-(4-Methyl-3-nitrophenyl)-1H-1,2,3-triazol-4-yl)butanoic acid (3.190d) 
CH3
NO2N
N N
HOOC
3
 
5-Hexynoic acid 3.188 (0.69 mL, 0.66 g, 5.9 mmol) and azide 3.176 (1.05 g, 5.89 
mmol) were suspended in a 1:1 mixture of water and tert-butyl alcohol (23.6 mL). A 
freshly prepared sodium ascorbate aqueous solution (117 mg, 0.589 mmol, in 0.6 mL of 
water) was added, followed by copper (II) sulfate pentahydrate aqueous solution (14.7 
mg, 0.0589 mmol, in 0.2 mL of water). The heterogeneous mixture was stirred 
vigorously in the dark for 24 h. The reaction mixture was diluted with water, cooled in 
ice and the precipitate was collected by filtration. After washing the precipitate with 
cold water, it was dried and then subjected to flash chromatography using n-
hexane/EtOAc 3:7 as the eluent, to yield the triazole derivative 3.190d (1.24 g, 4.27 
mmol, 72% yield). 1H NMR (DMSO-d6) δ (ppm): 1.90 (quint., 2H, J = 7.6 Hz), 2.33 (t, 
2H, J = 7.4 Hz), 2.57 (s, 3H), 2.74 (t, 2H, J = 7.6 Hz), 7.73 (d, 1H, J = 8.4 Hz), 8.18 
(dd, 1H, J = 8.4, 2.4 Hz), 8.51 (d, 1H, J = 2.4 Hz), 8.77 (s, 1H), 12.11 (bs, 1H). 
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4-(1-(4-(3-Methoxy-2,3-dioxopropyl)-3-nitrophenyl)-1H-1,2,3-triazol-4-yl)butanoic 
acid (3.191d) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 385 mg, 9.64 
mmol) in 10 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.190d (700 mg, 2.41 
mmol) and dimethyl oxalate (1.42 g, 12.1 mmol) in 7 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
4 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using CH2Cl2/MeOH 9:1 
as the eluent, to yield the nitroaryl-ketoester derivative 3.191d (960 mg, 2.55 mmol, > 
99% yield). 1H NMR (CDCl3) δ (ppm): 2.08 (quint., 2H, J = 7.1 Hz), 2.46 (t, 2H, J = 
7.2 Hz), 2.88 (t, 2H, J = 7.4 Hz), 3.93 (s, 3H), 4.61 (s, 2H), 7.50 (d, 1H, J = 8.4 Hz), 
7.94 (s, 1H), 8.09 (dd, 1H, J = 8.2, 2.4 Hz), 8.51 (d, 1H, J = 2.4 Hz); signals imputable 
to the enol form (~ 36%) δ (ppm): 3.94 (s, 3H), 6.92 (s, 1H), 7.91 (s, 1H), 8.29 (d, 1H, J 
= 2.2 Hz), 8.46 (d, 1H, J = 8.8 Hz). 
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4-(1-(1-Hydroxy-2-(methoxycarbonyl)-1H-indol-6-yl)-1H-1,2,3-triazol-4-
yl)butanoic acid (3.192d) 
4-(1-(1-Hydroxy-2-(methoxycarbonyl)-1H-indol-6-yl)-1H-1,2,3-triazol-5-
yl)butanoic acid (3.195) 
 
Ketoester 3.191d (509 mg, 1.35 mmol) was dissolved in anhydrous DME (1.4 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (684 mg, 3.03 mmol) in DME (1.4 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 3 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
CH2Cl2/MeOH 9:1 as the eluent, to give two different mixtures: a) 73.7 mg of the 1,4-
regioisomer 3.192d (83%, 61.2 mg, 0.178 mmol, 13% yield) with its indole analogue 
(17%); b) 17.6 mg of the 1,5-regioisomer 3.195 (79%, 13.9 mg, 0.0404 mmol) with its 
indole analogue (21%). 3.192d, 1H NMR (CDCl3) δ (ppm): 2.10 (quint., 2H, J = 7.3 
Hz), 2.48 (t, 2H, J = 7.1 Hz), 2.87 (t, 2H, J = 7.4 Hz), 4.01 (s, 3H), 7.09 (s, 1H), 7.50 
(dd, 1H, J = 8.6, 1.4 Hz), 7.74 (d, 1H, J = 8.6 Hz), 7.86 (s, 1H), 7.94-7.96 (m, 1H); 
signals imputable to the indole (~ 17%) δ (ppm): 3.98 (s, 3H). 3.195, 1H NMR (CDCl3) 
δ (ppm): 2.08 (quint., 2H, J = 7.5 Hz), 2.43 (t, 2H, J = 7.3 Hz), 2.87 (t, 2H, J = 7.6 Hz), 
4.01 (s, 3H), 7.09 (s, 1H), 7.38-7.45 (m, 1H), 7.72 (d, 1H, J = 8.8 Hz), 7.84 (s, 1H), 
8.06-8.13 (m, 1H); signals imputable to the indole (~ 21%) δ (ppm): 3.98 (s, 3H). 
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6-(4-(3-Carboxypropyl)-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylic 
acid (3.170d) 
N
COOH
OH
N
N N
HOOC
3
 
Methyl ester 3.192d (70.0 mg, 0.203 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2 mL) and treated with 0.6 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 1 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.170d (59.8 mg, 0.181 mmol, 89% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 1.91 (quint., 2H, J = 7.1 Hz), 2.34 (t, 2H, J = 7.3 Hz), 2.74 
(t, 2H, J = 7.5 Hz), 7.10 (d, 1H, J = 0.9 Hz), 7.67 (dd, 1H, J = 8.6, 1.8 Hz), 7.83 (d, 1H, 
J = 8.6 Hz), 7.92 (t, 1H, J = 1.1 Hz), 8.74 (s, 1H), 12.12 (bs, 1H); signals imputable to 
the indole (~ 30%) δ (ppm): 7.17-7.18 (m, 1H), 7.56 (dd, 1H, J = 8.6, 1.9 Hz), 7.87-7.89 
(m, 1H), 8.61 (s, 1H). 
 
6-(5-(3-Carboxypropyl)-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylic 
acid (3.196) 
 
Methyl ester 3.195 (14.0 mg, 0.0407 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.4 mL) and treated with 0.12 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 1 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
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sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.196 (13.3 mg, 0.0403 mmol, 99% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 2.00-2.09 (m, 2H), 2.45 (t, 2H, J = 7.1 Hz), 2.86 (t, 2H, J = 
7.4 Hz), 7.20 (d, 1H, J = 0.9 Hz), 7.70 (dd, 1H, J = 8.6, 2.0 Hz), 7.87 (d, 1H, J = 8.6 
Hz), 8.03 (t, 1H, J = 1.0 Hz), 8.48 (s, 1H), 11.24 (bs, 1H); signals imputable to the 
indole (~ 10%) δ (ppm): 7.29 (dd, 1H, J = 2.2, 0.9 Hz), 7.62 (dd, 1H, J = 8.8, 2.0 Hz), 
7.89 (d, 1H, J = 8.6 Hz), 8.06-8.10 (m, 1H), 8.37 (s, 1H). 
 
2-(1-(4-Methyl-3-nitrophenyl)-1H-1,2,3-triazol-4-yl)pyridine (3.190e) 
 
2-Ethynylpyridine 3.189 (0.57 mL, 0.58 g, 5.6 mmol) and azide 3.176 (1.00 g, 5.61 
mmol) were suspended in a 1:1 mixture of water and tert-butyl alcohol (22.5 mL). A 
freshly prepared sodium ascorbate aqueous solution (111 mg, 0.561 mmol, in 0.6 mL of 
water) was added, followed by copper (II) sulfate pentahydrate aqueous solution (15 
mg, 0.056 mmol, in 0.2 mL of water). The heterogeneous mixture was stirred 
vigorously in the dark at RT for 4 h, then it was heated to 45 °C overnight. The reaction 
mixture was diluted with water, cooled in ice and the precipitate was collected by 
filtration. After washing the precipitate with cold water, it was dried and then subjected 
to flash chromatography using n-hexane/EtOAc 6:4 as the eluent, to yield the triazole 
derivative 3.190e (1.44 g, 5.12 mmol, 91% yield). 1H NMR (CDCl3) δ (ppm): 2.70 (s, 
3H), 7.32 (ddd, 1H, J = 7.7, 4.9, 1.1 Hz), 7.55 (d, 1H, J = 8.4 Hz), 7.85 (td, 1H, J = 7.9, 
1.7 Hz), 8.03 (dd, 1H, J = 8.4, 2.4 Hz), 8.23 (d, 1H, J = 7.9 Hz), 8.47 (d, 1H, J = 2.4 
Hz), 8.63 (d, 1H, J = 4.6 Hz), 8.66 (s, 1H). 
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Methyl 3-(2-nitro-4-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)phenyl)-2-
oxopropanoate (3.191e) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 400 mg, 10.0 
mmol) in 6.5 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.190e (700 mg, 2.49 
mmol) and dimethyl oxalate (1.48 g, 12.5 mmol) in 4.5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT 
overnight, then it was heated to 60 °C for 24 h. Once the disappearance of the precursor 
was verified by TLC, the reaction mixture was slowly poured in an ice-water mixture; 
the water phase was acidified with 1N aqueous HCl and extracted several times with 
EtOAc. The combined organic phase was washed with saturated NaHCO3 solution and 
brine, then dried over anhydrous sodium sulphate. Evaporation under vacuum of the 
organic solvent afforded a crude product which was purified by column 
chromatography over silica gel using n-hexane/EtOAc 4:6 as the eluent, to yield the 
nitroaryl-ketoester derivative 3.191e (469 mg, 1.28 mmol, 51% yield). 1H NMR 
(DMSO-d6) signals imputable to the ketonic form δ (ppm): 3.87 (s, 3H), 4.70 (s, 2H), 
8.77 (d, 1H, J = 2.2 Hz); signals imputable to the enol form (~ 71%) δ (ppm): 3.85 (s, 
3H), 6.64 (s, 1H), 7.42 (ddd, 1H, J = 6.8, 4.8, 1.1 Hz), 7.77 (d, 1H, J = 8.1 Hz), 7.96 (td, 
1H, J = 7.7, 1.3 Hz), 8.14 (d, 1H, J = 8.1 Hz), 8.40-8.46 (m, 2H), 8.64-8.70 (m, 2H). 
 
Methyl 1-hydroxy-6-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)-1H-indole-2-
carboxylate (3.192e) 
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Ketoester 3.191e (466 mg, 1.27 mmol) was dissolved in anhydrous DME (1.5 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (641 mg, 2.84 mmol) in DME (2 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 5 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 3:7 as the eluent, to give the N-hydroxyindol-ester derivative 3.192e 
(23.3 mg, 0.0695 mmol, 5% yield). 1H NMR (acetone-d6) δ (ppm): 3.93 (s, 3H), 7.31 (d, 
1H, J = 0.6 Hz), 7.35 (ddd, 1H, J = 7.5, 4.9, 1.2 Hz). 7.78 (dd, 1H, J = 8.6, 2.0 Hz), 
7.88-7.97 (m, 2H), 8.17-8.23 (m, 2H), 8.64 (dq, 1H, J = 4.9, 1.8 Hz ), 8.96 (s, 1H), 
11.35 (bs, 1H). 
 
1-Hydroxy-6-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)-1H-indole-2-carboxylic acid 
(3.170e) 
 
Methyl ester 3.192e (20.0 mg, 0.0596 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.6 mL) and treated with 0.2 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 5 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.170e (19.0 mg, 0.0591 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.20 (d, 1H, J = 1.8 Hz), 7.38-7.43 (m, 1H), 7.71 (dd, 1H, J 
= 8.6, 2.0 Hz), 7.88 (d, 1H, J = 8.8 Hz), 7.96 (t, 1H, J = 8.1 Hz), 8.02 (s, 1H), 8.11-8.16 
(m, 1H), 8.63-8.69 (m, 1H), 9.31 (s, 1H), 12.17 (bs, 1H). MS m/z 322 (M+H+ 100%), 
295 (M+ –HCN, 60%). 
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1,3-Bis(1-(4-methyl-3-nitrophenyl)-1H-1,2,3-triazol-4-yl)propane (3.198) 
N
N N
N
N NO2N
H3C
NO2
CH3
 
1,6-Heptadiyne 3.197 (1.3 mL, 1.0 g, 11 mmol) and azide 3.176 (4.00 g, 22.5 mmol) 
were suspended in a 1:1 mixture of water and tert-butyl alcohol (89.8 mL). A freshly 
prepared sodium ascorbate aqueous solution (445 mg, 2.25 mmol, in 2.2 mL of water) 
was added, followed by copper (II) sulfate pentahydrate aqueous solution (56.0 mg, 
0.225 mmol, in 0.7 mL of water). The heterogeneous mixture was stirred vigorously in 
the dark for 48 h. The reaction mixture was diluted with water, cooled in ice and the 
precipitate was collected by filtration. After washing the precipitate with cold water, it 
was dried and then subjected to flash chromatography using n-hexane/EtOAc 4:6 as the 
eluent, to yield the dimer 3.198 (3.68 g, 8.21 mmol, 73% yield). 1H NMR (DMSO-d6) δ 
(ppm): 2.10 (t, 2H, J = 7.3 Hz), 2.57 (s, 6H), 2.84 (t, 4H, J = 7.4 Hz), 7.73 (d, 2H, J = 
8.8 Hz), 8.17 (dd, 2H, J = 8.2, 2.4 Hz), 8.49 (d, 2H, J = 2.4 Hz), 8.77 (s, 2H). 
 
Dimethyl 3,3'-((4,4'-(propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(2-nitro-
4,1-phenylene))bis(2-oxopropanoate) (3.199) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 2.36 g, 58.9 
mmol) in 77 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.198 (3.30 g, 7.36 
mmol) and dimethyl oxalate (8.69 g, 73.6 mmol) in 26 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT 
overnight. Once the disappearance of the precursor was verified by TLC, the reaction 
mixture was slowly poured in an ice-water mixture; the water phase was acidified with 
1N aqueous HCl and extracted several times with EtOAc. The combined organic phase 
was washed with saturated NaHCO3 solution and brine, then dried over anhydrous 
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sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using 
EtOAc/MeOH 9:1 as the eluent, to yield the nitroaryl-ketoester derivative 3.199 (3.08 g, 
4.96 mmol, 67% yield). 1H NMR (DMSO-d6) δ (ppm): 2.05-2.16 (m, 2H), 2.79-2.92 (m, 
4H), 3.86 (s, 6H), 4.67 (s, 4H), 7.73 (d, 2H, J = 7.9 Hz), 8.22-8.32 (m, 2H), 8.62 (d, 2H, 
J = 1.6 Hz), 8.84 (s, 2H); signals imputable to the enol form (~ 66%) δ (ppm): 3.84 (s, 
6H), 6.62 (s, 2H), 8.41 (d, 2H, J = 9.0 Hz), 8.49 (d, 2H, J = 2.0 Hz), 8.80 (s, 2H). 
 
Dimethyl 6,6'-(4,4'-(propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(1-hydroxy-
1H-indole-2-carboxylate) (3.200) 
 
Ketoester 3.199 (800 mg, 1.29 mmol) was dissolved in THF (2.2 mL) and the 
resulting solution was added to an aqueous solution (2.2 mL) of sodium hypophosphite 
monohydrate (424 mg, 4.00 mmol). Then 13 mg of 10% palladium over charcoal was 
added and the resulting suspension was stirred ar RT overnight. Then it was monitored 
by TLC and H2PO2Na.H2O (424 mg, 4.00 mmol) and Pd/C (13 mg) were added and the 
reaction was heated to 40 °C. After an additional hour, the disappearance of the 
precursor is verified by TLC and the mixture was concentrated, diluted with water and 
repeatedly extracted with EtOAc. The combined organic phase was dried over 
anhydrous sodium sulphate and evaporated to afford a crude residue that was purified 
by column chromatography over silica gel using CH2Cl2/MeOH 95:5 as the eluent, to 
give the N-hydroxyindole 3.200 (158 mg, 0.284 mmol, 22% yield). 1H NMR (DMSO-
d6) δ (ppm): 2.13 (t, 2H, J = 6.9 Hz), 2.84 (t, 4H, J = 7.3 Hz), 3.88 (s, 6H), 7.17 (d, 2H, 
J = 0.7 Hz), 7.68 (dd, 2H, J = 8.8, 1.8 Hz), 7.85 (d, 2H, J = 8.6 Hz), 7.93 (t, 2H, J = 0.9 
Hz), 8.76 (s, 2H), 11.73 (bs, 2H). 
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6,6'-(4,4'-(Propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(1-hydroxy-1H-
indole-2-carboxylic acid) (3.170f) 
 
Methyl ester 3.200 (100 mg, 0.180 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.8 mL) and treated with 0.54 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
12 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.170f (85.1 mg, 0.161 mmol, 89% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 2.13 (t, 2H, J = 7.4 Hz), 2.85 (t, 4H, J = 7.1 Hz), 7.11 (s, 
2H), 7.67 (dd, 2H, J = 8.8, 1.6 Hz), 7.84 (d, 2H, J = 8.6 Hz), 7.93 (s, 2H), 8.77 (s, 2H). 
13C NMR (DMSO-d6) δ (ppm): 24.64 (2C), 28.45 (1C), 100.52 (2C), 104.87 (2C), 
113.17 (2C), 120.49 (4C), 123.68 (2C), 128.39 (2C), 134.00 (2C), 135.53 (2C), 147.64 
(2C), 160.80 (2C). MS m/z 546 (M +NH4+, 5%), 256 ((M +NH4+)/2 –OH, 40%), 239 
((M +NH4+)/2 –2OH, 100%). 
 
Methyl 3-bromobenzoate (3.207a) 
 
Commercially available 3-bromobenzoic acid 3.206a (1.00 g, 4.97 mmol) was 
dissolved in MeOH in a sealed vial, catalytic conc. H2SO4 (2 drops) was added and the 
resulting solution was refluxed for 16 h. After being cooled to RT, the mixture was 
concentrated, diluted with EtOAc, washed with saturated NaHCO3 aqueous solution and 
then dried over anhydrous sodium sulphate. The evaporation of the solvent afforded the 
methyl ester 3.207a (1.04 g, 4.84 mmol, 97% yield). 1H NMR (CDCl3) δ (ppm): 3.92 (s, 
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3H), 7.32 (t, 1H, J = 7.9 Hz), 7.69 (dt, 1H, J = 8.0, 1.6 Hz), 7.97 (dt, 1H, J = 7.8, 1.2 
Hz), 8.18 (t, 1H, J = 1.8 Hz). 
 
Methyl 3-(3-hydroxy-3-methylbut-1-yn-1-yl)benzoate (3.208a) 
 
A solution of Pd(OAc)2 (43 mg, 0.19 mmol) and triphenylphosphine (244 mg, 0.930 
mmol) in dry DMF (2.1 mL) was stirred at RT under nitrogen for 10 min. After that 
period, aryl-bromide 3.207a (800 mg, 3.72 mmol), copper iodide (36 mg, 0.19 mmol), 
2-methyl-3-butyn-2-ol (0.44 mL, 0.38 g, 4.5 mmol) and Et3N (11.2 mL) were 
sequentially added under N2. The mixture was stirred under reflux for 60 h. After being 
cooled to RT, the mixture was diluted with water and extracted several times with 
EtOAc. The combined organic phase was washed with saturated NaHCO3 aqueous 
solution and water, dried over anhydrous sodium sulphate and concentrated. The crude 
product was purified by flash chromatography (n-hexane/ EtOAc 8:2) to yield 3.208a 
(717 mg, 3.29 mmol, 88% yield). 1H NMR (CDCl3) δ (ppm): 1.62 (s, 6H), 3.91 (s, 3H), 
7.38 (t, 1H, J = 7.8 Hz), 7.59 (dt, 1H, J = 7.8, 1.5 Hz), 7.97 (dt, 1H, J = 7.8, 1.5 Hz), 
8.09 (t, 1H, J = 1.6 Hz). 
 
3-Ethynylbenzoic acid (3.209a) 
 
Sodium hydroxide (525 mg, 13.1 mmol) was dissolved in refluxing l-butanol (20.7 
mL), 3.208a (717 mg, 3.28 mmol) was added and the mixture was refluxed for 10 min. 
The reaction mixture was cooled in an ice bath, diluted with water, acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
dried over anhydrous sodium sulphate. Evaporation under vacuum of the organic 
solvent afforded compound 3.209a (504 mg, 3.45 mmol, >99% yield). 1H NMR 
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(CDCl3) δ (ppm): 3.14 (s, 1H), 7.45 (t, 1H, J = 7.7 Hz), 7.72 (d, 1H, J = 7.7 Hz), 8.09 
(d, 1H, J = 7.5 Hz), 8.24 (s, 1H). 
 
Methyl 3-ethynylbenzoate (3.210a) 
 
Carboxylic acid 3.209a (495 mg, 3.39 mmol) was dissolved in MeOH in a sealed 
vial, catalytic conc. H2SO4 (2 drops) was added and the resulting solution was refluxed 
for 3 h. After being cooled to RT, the mixture was concentrated, diluted with EtOAc, 
washed with saturated NaHCO3 aqueous solution and then dried over anhydrous sodium 
sulphate. The evaporation of the solvent afforded a crude residue, which was subjected 
to flash chromatography using n-hexane/EtOAc 95:5 as the eluent, to yield the methyl 
ester 3.210a (315 mg, 1.97 mmol, 58% yield). 1H NMR (CDCl3) δ (ppm): 3.12 (s, 1H), 
3.92 (s, 1H), 7.41 (t, 1H, J = 7.8 Hz), 7.67 (dt, 1H, J = 7.7, 1.4 Hz), 8.02 (dt, 1H, J = 
7.8, 1.4 Hz), 8.17 (t, 1H, J = 1.3 Hz). 
 
Methyl 4-bromobenzoate (3.207b) 
Br
COOMe  
Commercially available 4-bromobenzoic acid 3.206b (1.00 g, 4.97 mmol) was 
dissolved in MeOH in a sealed vial, catalytic conc. H2SO4 (2 drops) was added and the 
resulting solution was refluxed for 20 h. After being cooled to RT, the mixture was 
concentrated, diluted with EtOAc, washed with saturated NaHCO3 aqueous solution and 
then dried over anhydrous sodium sulphate. The evaporation of the solvent afforded the 
methyl ester 3.207b (1.00 g, 4.65 mmol, 94% yield). 1H NMR (CDCl3) δ (ppm): 3.92 (s, 
3H), 7.58 (AA’XX’, 2H, JAX = 8.5 Hz, JAA’/XX’ = 2.1 Hz), 7.90 (AA’XX’, 2H, JAX = 8.8 
Hz,  JAA’/XX’ = 2.1 Hz). 
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Methyl 4-(3-hydroxy-3-methylbut-1-yn-1-yl)benzoate (3.208b) 
 
A solution of Pd(OAc)2 (11 mg, 0.050 mmol) and triphenylphosphine (61 mg, 0.23 
mmol) in dry DMF (0.5 mL) was stirred at RT under nitrogen for 10 min. After that 
period, aryl-bromide 3.207b (200 mg, 0.930 mmol), copper iodide (9.5 mg, 0.050 
mmol), 2-methyl-3-butyn-2-ol (0.11 mL, 94 mg, 1.1 mmol) and Et3N (2.8 mL) were 
sequentially added under N2. The mixture was stirred under reflux for 72 h. After being 
cooled to RT, the mixture was diluted with water and extracted several times with 
EtOAc. The combined organic phase was washed with saturated NaHCO3 aqueous 
solution and water, dried over anhydrous sodium sulphate and concentrated. The crude 
product was purified by flash chromatography (n-hexane/ EtOAc 8:2) to yield 3.208b 
(169 mg, 0.774 mmol, 83% yield). 1H NMR (CDCl3) δ (ppm): 1.63 (s, 6H), 3.91 (s, 
3H), 7.47 (AA’XX’, 2H, JAX = 8.4 Hz, JAA’/XX’ = 1.7 Hz), 7.97 (AA’XX’, 2H, JAX = 8.3 
Hz, JAA’/XX’ = 1.7 Hz). 
 
4-Ethynylbenzoic acid (3.209b) 
 
Sodium hydroxide (106 mg, 2.64 mmol) was dissolved in refluxing l-butanol (4.2 
mL), 3.208b (145 mg, 0.664 mmol) was added and the mixture was refluxed for 15 min. 
The reaction mixture was cooled in an ice bath, diluted with water, acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
dried over anhydrous sodium sulphate. Evaporation under vacuum of the organic 
solvent afforded compound 3.209b (62.6 mg, 0.428 mmol, 65% yield). 1H NMR 
(CD3OD) δ (ppm): 3.72 (s, 1H), 7.56 (d, 2H, J = 7.9 Hz), 7.99 (d, 2H, J = 7.9 Hz). 
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Methyl 4-ethynylbenzoate (3.210b) 
 
Carboxylic acid 3.209b (60.0 mg, 0.411 mmol) was dissolved in MeOH in a sealed 
vial, catalytic conc. H2SO4 (2 drops) was added and the resulting solution was refluxed 
for 4 h. After being cooled to RT, the mixture was concentrated, diluted with EtOAc, 
washed with saturated NaHCO3 aqueous solution and then dried over anhydrous sodium 
sulphate. The evaporation of the solvent afforded the methyl ester the methyl ester 
3.210b (59.0 mg, 0.368 mmol, 90% yield). 1H NMR (CD3OD) δ (ppm): 3.75 (s, 1H), 
3.91 (s, 3H), 7.57 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 1.8 Hz), 7.99 (AA’XX’, 2H, JAX 
= 8.6 Hz, JAA’/XX’ = 1.7 Hz). 
 
Methyl 3-(1-(2-methyl-3-nitrophenyl)-1H-1,2,3-triazol-4-yl)benzoate (3.211) 
N
N
N
COOMe
NO2
CH3
 
Alkyne 3.210a (298 mg, 1.86 mmol) and azide 3.174 (331 mg, 1.86 mmol) were 
suspended in a 1:1 mixture of water and tert-butyl alcohol (7.4 mL). A freshly prepared 
sodium ascorbate aqueous solution (36.8 mg, 0.186 mmol, in 0.2 mL of water) was 
added, followed by copper (II) sulfate pentahydrate aqueous solution (4.6 mg, 0.019 
mmol, in 0.06 mL of water). The heterogeneous mixture was stirred vigorously at 200 
°C in a microwave reactor for 15 min. The reaction mixture was diluted with water, 
cooled in ice and the precipitate was collected by filtration. After washing the 
precipitate with cold water, it was dried and then subjected to flash chromatography 
using n-hexane/EtOAc 7:3 as the eluent, to yield the triazole derivative 3.211 (325 mg, 
0.961 mmol, 52% yield). 1H NMR (CDCl3) δ (ppm): 2.37 (s, 3H), 3.96 (s, 3H), 7.56 (t, 
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1H, J = 8.0 Hz), 7.58 (t, 1H, J = 7.8 Hz), 7.69 (dd, 1H, J = 8.0, 1.6 Hz), 8.05-8.09 (m, 
2H), 8.10 (s, 1H), 8.21 (dt, 1H, J = 7.7, 1.5 Hz), 8.51 (t, 1H, J = 1.7 Hz). 
 
Methyl 3-(1-(2-(3-methoxy-2,3-dioxopropyl)-3-nitrophenyl)-1H-1,2,3-triazol-4-
yl)benzoate (3.212) 
N
N
N
COOMe
NO2
COOMe
O
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 152 mg, 3.80 
mmol) in 2.6 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.211 (320 mg, 0.946 
mmol) and dimethyl oxalate (561 mg, 4.75 mmol) in 2.7 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
24 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
6:4 as the eluent, to yield the nitroaryl-ketoester derivative 3.212 (202 mg, 0.476 mmol, 
50% yield). 1H NMR (CDCl3) δ (ppm): 3.90 (s, 3H), 3.95 (s, 3H), 4.37 (s, 2H), 7.56 (t, 
1H, J = 7.8 Hz), 7.69-7.81 (m, 2H), 8.04-8.16 (m, 2H), 8.12 (s, 1H), 8.32 (dd, 1H, J = 
7.4, 2.1 Hz), 8.47 (t, 1H, J = 1.6 Hz). 13C NMR (CDCl3) δ (ppm): 38.70, 52.43, 53.67, 
122.33, 126.45, 127.03 (2C), 129.29, 129.47, 129.89, 129.95, 130.27, 131.06, 131.77, 
138.90, 147.66, 149.85, 160.08, 166.65, 188.34. 
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Methyl 1-hydroxy-4-(4-(3-(methoxycarbonyl)phenyl)-1H-1,2,3-triazol-1-yl)-1H-
indole-2-carboxylate (3.213) 
N
N
N
N
COOMe
OH
COOMe
 
Ketoester 3.212 (150 mg, 0.353 mmol) was dissolved in THF (0.6 mL) and the 
resulting solution was added to an aqueous solution (0.6 mL) of sodium hypophosphite 
monohydrate (114 mg, 1.08 mmol). Then 3.5 mg of 10% palladium over charcoal was 
added and the resulting suspension was stirred ar RT. After 18 h the disappearance of 
the precursor is verified by TLC and the mixture was concentrated, diluted with water 
and repeatedly extracted with EtOAc. The combined organic phase was dried over 
anhydrous sodium sulphate and evaporated to afford a crude residue that was purified 
by column chromatography over silica gel using n-hexane/EtOAc 6:4 as the eluent, to 
give the N-hydroxyindole 3.213 (62.8 mg, 0.160 mmol, 45% yield). 1H NMR (CDCl3) δ 
(ppm): 3.97 (s, 3H), 4.01 (s, 3H), 7.38-7.51 (m, 2H), 7.47 (s, 1H), 7.58 (t, 1H, J = 7.8 
Hz), 7.65-7.69 (m, 1H), 8.06 (dt, 1H, J = 7.7, 1.4 Hz), 8.25 (dt, 1H, J = 1.5 Hz), 8.38 (s, 
1H), 8.53 (t, 1H, J = 1.7 Hz), 10.53 (bs, 1H). 
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4-(4-(3-Carboxyphenyl)-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylic 
acid (3.201) 
N
N
N
N
COOH
OH
COOH
 
Methyl ester 3.213 (52.0 mg, 0.133 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.3 mL) and treated with 0.4 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
27 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.201 (39.5 mg, 0.108 mmol, 82% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.41 (s, 1H), 7.48-7.69 (m, 4H), 7.96 (dt, 1H, J = 8.0, 1.4 
Hz), 8.27 (dt, 1H, J = 7.6, 1.5 Hz), 8.61 (t, 1H, J = 1.6 Hz), 9.50 (s, 1H). 13C NMR 
(DMSO-d6) δ (ppm): 103.27, 110.53, 112.86, 113.35, 121.33, 124.81, 126.14, 127.88, 
128.89, 129.27, 129.60, 129.69, 130.60, 131.51, 136.97, 145.95, 160.73, 167.00. MS 
m/z 365 (M+H+). 
 
Methyl 3-(1-(3-methyl-4-nitrophenyl)-1H-1,2,3-triazol-4-yl)benzoate (3.214a) 
NN N
COOMe
NO2
CH3
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Alkyne 3.210a (350 mg, 2.18 mmol) and azide 3.175 (388 mg, 2.18 mmol) were 
suspended in a 1:1 mixture of water and tert-butyl alcohol (8.7 mL). A freshly prepared 
sodium ascorbate aqueous solution (43.2 mg, 0.218 mmol, in 0.2 mL of water) was 
added, followed by copper (II) sulfate pentahydrate aqueous solution (5.4 mg, 0.022 
mmol, in 0.07 mL of water). The heterogeneous mixture was stirred 200 °C in a 
microwave reactor for 15 min. The reaction mixture was diluted with water, cooled in 
ice and the precipitate was collected by filtration. After washing the precipitate with 
cold water, it was dried and then subjected to flash chromatography using n-
hexane/EtOAc 7:3 as the eluent, to yield the triazole derivative 3.214a (306 mg, 0.904 
mmol, 41% yield). 1H NMR (CDCl3) δ (ppm): 2.76 (s, 3H), 3.97 (s, 3H), 7.57 (t, 1H, J 
= 7.7 Hz), 7.81 (dd, 1H, J = 8.9, 2.4 Hz), 7.89 (d, 1H, J = 2.4 Hz), 8.06 (dt, 1H, J = 8.0, 
1.4 Hz), 8.18-8.26 (m, 2H), 8.37 (s, 1H), 8.50 (t, 1H, J = 1.4 Hz). 
 
Methyl 3-(1-(3-(3-methoxy-2,3-dioxopropyl)-4-nitrophenyl)-1H-1,2,3-triazol-4-
yl)benzoate (3.215a) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 142 mg, 3.56 
mmol) in 2.5 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.214a (300 mg, 0.887 
mmol) and dimethyl oxalate (526 mg, 4.45 mmol) in 2.5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for4 
h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
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washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
6:4 as the eluent, to yield the nitroaryl-ketoester derivative 3.215a (109 mg, 0.257 
mmol, 29% yield). 1H NMR (CDCl3) δ (ppm): 3.97 (s, 3H), 3.98 (s, 3H), 4.69 (s, 2H), 
7.58 (t, 1H, J = 7.7 Hz), 7.93 (dd, 1H, J = 8.9, 2.4 Hz), 7.97 (d, 1H, J = 2.4 Hz), 8.07 
(dt, 1H, J = 7.8, 1.3 Hz), 8.18-8.24 (m, 2H), 8.40 (s, 1H), 8.50 (t, 1H, J = 1.4 Hz); 
signals imputable to the enol form (~ 20%) δ (ppm): 4.00 (s, 3H), 7.05 (s, 1H), 8.38 (s, 
1H). 
 
Methyl 1-hydroxy-5-(4-(3-(methoxycarbonyl)phenyl)-1H-1,2,3-triazol-1-yl)-1H-
indole-2-carboxylate (3.216a) 
NN N
N
COOMe
OH
COOMe
 
Triethylamine (0.17 mL, 0.12 g, 1.2 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (81.3 mg, 0.360 mmol) and PhSH (0.12 mL, 0.12 g, 1.1 mmol) in 
acetonitrile (5 mL) at room temperature to generate a yellow precipitate over a period of 
5 min. Then, 3.215a (100 mg, 0.236 mmol) was transferred to the suspension and stirred 
at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using CHCl3/MeOH 98:2 as the eluent, to give the N-hydroxyindole 3.216a 
(43.0 mg, 0.110 mmol, 46% yield). 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 4.03 (s, 
3H), 7.14 (s, 1H), 7.56 (t, 1H, J = 7.8 Hz), 7.68 (d, 1H, J = 8.7 Hz), 7.77 (dd, 1H, J = 
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8.6, 1.8 Hz), 8.01-8.08 (m, 2H), 8.20 (dt, 1H, J = 7.8, 1.6 Hz), 8.29 (s, 1H), 8.50 (t, 1H, 
J = 1.6 Hz), 10.76 (bs, 1H). 
 
5-(4-(3-Carboxyphenyl)-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylic 
acid (3.202) 
 
Methyl ester 3.216a (40.0 mg, 0.102 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.0 mL) and treated with 0.62 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
12 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.202 (37.0 mg, 0.102 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.13 (s, 1H), 7.64 (t, 1H, J = 7.7 Hz), 7.67 (dd, 1H, J = 8.6, 
1.8 Hz), 7.87 (d, 1H, J = 2.0 Hz), 7.94 (dt, 1H, J = 8.2, 1.4 Hz), 8.18-8.24 (m, 2H), 8.55 
(t, 1H, J = 1.6 Hz), 9.45 (s, 1H). 13C NMR (DMSO-d6) δ (ppm): 104.83, 110.73, 113.59, 
117.82, 120.22, 120.60, 125.84, 128.58, 129.07, 129.21 (2C), 130.31, 130.69, 131.45, 
134.91, 146.11, 160.62, 166.80. 
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Methyl 4-(1-(3-methyl-4-nitrophenyl)-1H-1,2,3-triazol-4-yl)benzoate (3.214b) 
NN N
MeOOC
NO2
CH3
 
Alkyne 3.210b (500 mg, 3.12 mmol) and azide 3.175 (556 mg, 3.12 mmol) were 
suspended in a 1:1 mixture of water and tert-butyl alcohol (12.5 mL). A freshly 
prepared sodium ascorbate aqueous solution (61.8 mg, 0.312 mmol, in 0.3 mL of water) 
was added, followed by copper (II) sulfate pentahydrate aqueous solution (7.8 mg, 
0.031 mmol, in 0.1 mL of water). The heterogeneous mixture was stirred vigorously at 
200 °C in a microwave reactor for 15 min. The reaction mixture was diluted with water, 
cooled in ice and the precipitate was collected by filtration. After washing the 
precipitate with cold water, it was dried and then subjected to flash chromatography 
using n-hexane/EtOAc 7:3 as the eluent, to yield the triazole derivative 3.214b (784 mg, 
2.32 mmol, 74% yield). 1H NMR (DMSO-d6) δ (ppm): 2.66 (s, 3H), 3.89 (s, 3H), 8.00-
8.15 (m, 5H), 8.18 (d, 1H, J = 2.0 Hz), 8.29 (d, 1H, J = 8.2 Hz), 9.63 (s, 1H). 
 
Methyl 4-(1-(3-(3-methoxy-2,3-dioxopropyl)-4-nitrophenyl)-1H-1,2,3-triazol-4-
yl)benzoate (3.215b) 
NN N
MeOOC
NO2
COOMe
O
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 237 mg, 5.92 
mmol) in 4.1 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
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dropwise with a solution containing the nitrotoluene precursor 3.214b (500 mg, 1.48 
mmol) and dimethyl oxalate (874 mg, 7.40 mmol) in 4.2 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
4 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
6:4 as the eluent, to yield the nitroaryl-ketoester derivative 3.215b (234 mg, 0.551 
mmol, 37% yield). 1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 3.98 (s, 3H), 4.69 (s, 2H), 
7.92-8.02 (m, 5H), 8.13-8.18 (m, 2H), 8.38 (s, 1H). 
 
Methyl 1-hydroxy-5-(4-(4-(methoxycarbonyl)phenyl)-1H-1,2,3-triazol-1-yl)-1H-
indole-2-carboxylate (3.216b) 
 
Triethylamine (0.17 mL, 0.12 g, 1.2 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (81.3 mg, 0.360 mmol) and PhSH (0.12 mL, 0.12 g, 1.1 mmol) in 
acetonitrile (5 mL) at room temperature to generate a yellow precipitate over a period of 
5 min. Then, 3.215b (100 mg, 0.236 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
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evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using CHCl3/MeOH 98:2 as the eluent, to give the N-hydroxyindole 3.216b 
(31.1 mg, 0.0793 mmol, 34% yield). 1H NMR (DMSO-d6) δ (ppm): 3.89 (s, 3H), 3.90 
(s, 3H), 7.26 (s, 1H), 7.71 (d, 1H, J = 8.7 Hz), 7.92 (dd, 1H, J = 8.9, 2.0 Hz), 8.10 (s, 
4H), 8.25 (d, 1H, J = 2.0 Hz), 9.48 (s, 1H), 11.77 (bs, 1H). 
 
5-(4-(4-Carboxyphenyl)-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylic 
acid (3.204) 
NN N
N
COOH
OH
HOOC
 
Methyl ester 3.216b (12.0 mg, 0.0306 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.3 mL) and treated with 0.2 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT. After 24 h it was monitored by TLC 
and another portion of LiOH (0.2 mL) was added. After further 72 h, the reaction 
mixture was concentrated, diluted with water and washed with Et2O. Then, the aqueous 
phase was treated with 1N aqueous HCl and extracted several times with EtOAc. The 
combined ethyl acetate organic phase was dried over anhydrous sodium sulphate and 
evaporated to afford the desired N-hydroxyindol-carboxylic acid product 3.204 (11.0 
mg, 0.0302 mmol, 99% yield) without any further purification. 1H NMR (DMSO-d6) δ 
(ppm): 6.74 (s, 1H), 7.52-7.72 (m, 3H), 8.07 (s, 4H), 9.39 (s, 1H). 
 
Methyl 3-(1-(4-methyl-3-nitrophenyl)-1H-1,2,3-triazol-4-yl)benzoate (3.217a) 
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Alkyne 3.210a (418 mg, 2.61 mmol) and azide 3.176 (465 mg, 2.61 mmol) were 
suspended in a 1:1 mixture of water and tert-butyl alcohol (3.5 mL). A freshly prepared 
sodium ascorbate aqueous solution (51.7 mg, 0.261 mmol, in 0.2 mL of water) was 
added, followed by copper (II) sulfate pentahydrate aqueous solution (6.5 mg, 0.026 
mmol, in 0.09 mL of water). The heterogeneous mixture was stirred at 200 °C in a 
microwave reactor for 15 min. The reaction mixture was diluted with water, cooled in 
ice and the precipitate was collected by filtration. After washing the precipitate with 
cold water, it was dried and then subjected to flash chromatography using n-
hexane/EtOAc 7:3 as the eluent, to yield the triazole derivative 3.217a (729 mg, 2.15 
mmol, 83% yield). 1H NMR (CDCl3) δ (ppm): 2.71 (s, 3H), 3.97 (s, 3H), 7.57 (t, 1H, J 
= 7.7 Hz), 7.58 (d, 1H, J = 8.2 Hz), 8.02-8.10 (m, 2H), 8.20 (dt, 1H, J = 7.8, 1.3 Hz), 
8.36 (s, 1H), 8.43 (d, 1H, J = 2.4 Hz), 8.50 (t, 1H, J = 1.7 Hz). 
 
Methyl 3-(1-(4-(3-methoxy-2,3-dioxopropyl)-3-nitrophenyl)-1H-1,2,3-triazol-4-
yl)benzoate (3.218a) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 237 mg, 5.92 
mmol) in 4.1 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.217a (500 mg, 1.48 
mmol) and dimethyl oxalate (874 mg, 7.40 mmol) in 4.2 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
20 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
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4:6 as the eluent, to yield the nitroaryl-ketoester derivative 3.218a (385 mg, 0.907 
mmol, 61% yield). 1H NMR (CDCl3) δ (ppm): 3.93 (s, 3H), 3.97 (s, 3H), 4.65 (s, 2H), 
7.57 (t, 1H, J = 7.7 Hz), 7.58 (d, 1H, J = 8.2 Hz), 8.02-8.10 (m, 2H), 8.20 (dt, 1H, J = 
7.8, 1.3 Hz), 8.41 (s, 1H), 8.43 (d, 1H, J = 2.4 Hz), 8.63 (t, 1H, J = 1.7 Hz); signals 
imputable to the enol form (~ 20%) δ (ppm): 3.98 (s, 3H), 6.98 (s, 1H), 8.45 (d, 1H, J = 
8.2 Hz). 
 
Methyl 1-hydroxy-6-(4-(3-(methoxycarbonyl)phenyl)-1H-1,2,3-triazol-1-yl)-1H-
indole-2-carboxylate (3.219a) 
 
To a solution containing the ketoester 3.218a (100 mg, 0.236 mmol) in 0.8 mL of 
MeOH, was added lead powder (213 mg, 1.03 mmol) and 0.5 mL of HCO2HNEt3. The 
mixture was stirred at 55 °C for 18 h, cooled to RT, and filtered over a pad of Celite. 
The solvent was removed under reduced pressure and the residue purified by column 
chromatography over silica gel using CHCl3/MeOH 98:2 as the eluent, to give the N-
hydroxyindole 3.219a (27.1 mg, 0.0691 mmol, 29% yield). 1H NMR (acetone-d6) δ 
(ppm): 3.85 (s, 3H), 3.92 (s, 3H), 7.20 (d, 1H, J = 0.9 Hz), 7.64 (t, 1H, J = 7.8 Hz), 7.81 
(dd, 1H, J = 8.6, 1.8 Hz), 7.91 (d, 1H, J = 8.7 Hz), 7.98-8.04 (m, 2H), 8.13 (t, 1H, J = 
1.4 Hz), 8.28 (dt, 1H, J = 7.7, 1.2 Hz), 8.63 (dt, 1H, J = 7.2, 1.3 Hz), 10.76 (bs, 1H). 
 
6-(4-(3-Carboxyphenyl)-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylic 
acid (3.203) 
 
Methyl ester 3.219a (25.0 mg, 0.0637 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.6 mL) and treated with 0.2 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
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24 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.203 (22.0 mg, 0.0604 mmol, 95% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 7.24 (d, 1H, J = 0.9 Hz), 7.64 (t, 1H, J = 7.7 Hz), 7.82 (dd, 
1H, J = 8.6, 1.8 Hz), 7.93 (d, 1H, J = 8.8 Hz), 8.05 (dt, 1H, J = 7.8, 1.4 Hz), 8.15 (t, 1H, 
J = 1.0 Hz), 8.30 (dt, 1H, J = 7.8, 1.6 Hz), 8.69 (t, 1H, J = 1.6 Hz), 9.30 (s, 1H). 
 
Methyl 4-(1-(4-methyl-3-nitrophenyl)-1H-1,2,3-triazol-4-yl)benzoate (3.217b) 
 
Alkyne 3.210b (230 mg, 1.44 mmol) and azide 3.176 (256 mg, 1.44 mmol) were 
suspended in a 1:1 mixture of water and tert-butyl alcohol (5.8 mL). A freshly prepared 
sodium ascorbate aqueous solution (28.5 mg, 0.144 mmol, in 0.12 mL of water) was 
added, followed by copper (II) sulfate pentahydrate aqueous solution (3.6 mg, 0.014 
mmol, in 0.5 mL of water). The heterogeneous mixture was stirred vigorously at 200 °C 
in a microwave reactor for 15 min. The reaction mixture was diluted with water, cooled 
in ice and the precipitate was collected by filtration. After washing the precipitate with 
cold water, it was dried and then subjected to flash chromatography using n-
hexane/EtOAc 7:3 as the eluent, to yield the triazole derivative 3.217b (346 mg, 1.02 
mmol, 71% yield). 1H NMR (CDCl3) δ (ppm): 2.70 (s, 3H), 3.95 (s, 3H), 7.58 (d, 1H, J 
= 8.4 Hz), 8.00 (AA’XX’, 2H, JAX = 8.4 Hz, JAA’/XX’= 1.8 Hz), 8.05 (dd, 1H, J = 8.4, 2.4 
Hz), 8.15 (AA’XX’, 2H, JAX = 8.2 Hz, JAA’/XX’= 1.8 Hz), 8.34 (s, 1H), 8.41 (d, 1H, J = 
2.4 Hz). 
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Methyl 4-(1-(4-(3-methoxy-2,3-dioxopropyl)-3-nitrophenyl)-1H-1,2,3-triazol-4-
yl)benzoate (3.218b) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 133 mg, 3.32 
mmol) in 2.3 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.217b (281 mg, 0.831 
mmol) and dimethyl oxalate (490 mg, 4.15 mmol) in 2.4 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
19 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
1:1 as the eluent, to yield the nitroaryl-ketoester derivative 3.218b (114 mg, 0.269 
mmol, 32% yield). 1H NMR (DMSO-d6) δ (ppm): 3.85 (s, 3H), 3.87 (s, 3H), 4.71 (s, 
2H), 7.80 (d, 1H, J = 8.6 Hz), 8.11 (s, 4H), 8.37 (dd, 1H, J = 8.8, 1.8 Hz), 8.70 (d, 1H, J 
= 2.4 Hz), 9.67 (s, 1H); signals imputable to the enol form (~ 70%) δ (ppm): 3.89 (s, 
3H), 6.67 (s, 1H), 8.10 (m, 4H), 8.33 (dd, 1H, J = 8.8, 1.8 Hz), 8.47 (d, 1H, J = 8.8 Hz), 
8.57 (d, 1H, J = 2.2 Hz), 9.63 (s, 1H). 
 
Methyl 1-hydroxy-6-(4-(4-(methoxycarbonyl)phenyl)-1H-1,2,3-triazol-1-yl)-1H-
indole-2-carboxylate (3.219b) 
N
COOMe
OH
N
N N
MeOOC
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Ketoester 3.218b (45.0 mg, 0.106 mmol) was dissolved in anhydrous DME (0.11 
mL) and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (53.6 mg, 0.238 mmol) in DME (0.11 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at RT 
for 48 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
CHCl3/MeOH 98:2 as the eluent, to give a mixture (12.9 mg) of the N-hydroxyindol-
ester derivative 3.219b (85%, 11.0 mg, 0.0280 mmol, 26% yield) with its indole 
analogue (15%). 1H NMR (DMSO-d6) δ (ppm): 3.89 (s, 6H), 7.21 (s, 1H), 7.69 (d, 1H, J 
= 2.4 Hz), 7.77 (dd, 1H, J = 8.6, 1.8 Hz), 7.92 (d, 1H, J = 8.7 Hz), 8.12 (AB, 4H, JAB = 
8.6 Hz), 9.63 (s, 1H), 11.77 (bs, 1H); signals imputable to the indole (~ 15%) δ (ppm): 
7.28-7.30 (m, 1H). 
 
6-(4-(4-Carboxyphenyl)-1H-1,2,3-triazol-1-yl)-1-hydroxy-1H-indole-2-carboxylic 
acid (3.205) 
 
Methyl ester 3.219b (9.0 mg, 0.023 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.23 mL) and treated with 0.1 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
24 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.205 (8.3 mg, 0.023 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.11 (s, 1H), 7.74 (dd, 1H, J = 8.6, 1.5 Hz), 7.89 (d, 1H, J = 
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8.8 Hz), 8.02-8.10 (m, 5H), 9.60 (s, 1H); signals imputable to the indole (~ 26%) δ 
(ppm): 7.18-7.22 (m, 1H). 
 
Methyl 3-(4-(2-methoxy-2-oxoacetylcarbamoyl)-2-nitrophenyl)-2-oxopropanoate 
(3.224) 
NO2
COOMe
O
H
N
O
MeOOC
O  
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 932 mg, 23.3 
mmol) in 16 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing commercially available 4-methyl-3-nitrobenzamide 
3.222 (700 mg, 3.89 mmol) and dimethyl oxalate (2.75 g, 23.3 mmol) in 11 mL of 
anhydrous DMF. The mixture was left under stirring at the same temperature for 10 
minutes and then it was slowly warmed to room temperature. The mixture was then left 
under stirring at RT for 2 h. Once the disappearance of the precursor was verified by 
TLC, the reaction mixture was slowly poured in an ice-water mixture; the water phase 
was acidified with 1N aqueous HCl and extracted several times with EtOAc. The 
combined organic phase was washed with saturated NaHCO3 solution and brine, then 
dried over anhydrous sodium sulphate. Evaporation under vacuum of the organic 
solvent afforded a crude product which was purified by column chromatography over 
silica gel using n-hexane/EtOAc 3:7 as the eluent, to yield the dialkylated nitroaryl-
ketoester derivative 3.224 (860 mg, 2.44 mmol). 1H NMR (CDCl3), signals imputable to 
the formation of the dialkylated product 3.224 δ (ppm): 3.95 (s, 3H), 4.00 (s, 3H); 
signals imputable to the enol form (~ 26%) δ (ppm): 3.96 (s, 3H).  
 
 
Methyl 3-(4-carbamoyl-2-nitrophenyl)-2-oxopropanoate (3.226a) 
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The dialkylated product 3.224 was dissolved in MeOH (8 mL) and silica gel was 
added (1.6 g). The mixture was stirred at RT for 1.5 h. Then, evaporation under vacuum 
of the organic solvent afforded a crude product which was purified by column 
chromatography over silica gel using n-hexane/EtOAc 3:7 as the eluent, to yield the 
amidic nitroaryl-ketoester derivative 3.226a (484 mg, 1.82 mmol, 2 steps: 47% yield). 
1H NMR (DMSO-d6) δ (ppm): 3.85 (s, 3H), 4.66 (s, 2H), 7.70 (d, 1H, J = 7.7 Hz), 8.19 
(dd, 1H, J = 7.7, 1.8 Hz), 8.56 (d, 1H, J = 1.8 Hz), 10.51 (bs, 1H); signals imputable to 
the enol form (~ 67%) δ (ppm): 3.83 (s, 3H), 6.64 (s, 1H),7.61 (d, 1H, J = 8.1 Hz), 8.15 
(dd, 1H, J = 8.1, 1.7 Hz), 8.39 (d, 1H, J = 1.7 Hz). 
 
Methyl 6-carbamoyl-1-hydroxy-1H-indole-2-carboxylate (3.227a) 
N
OH
COOMe
O
H2N
 
Ketoester 3.226a (480 mg, 1.80 mmol) was dissolved in anhydrous DME (1.8 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (911 mg, 4.04 mmol) in DME (1.8 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at 0 
°C for 6.5 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
EtOAc as the eluent, to give a mixture (50.0 mg) of the N-hydroxyindol-ester derivative 
3.227a (50%, 25.0 mg, 0.107 mmol, 6% yield) with its indole analogue (50%) 1H NMR 
(DMSO-d6) δ (ppm): 3.87 (s, 3H), 7.11 (d, 1H, J = 0.9 Hz), 7.58 (dd, 1H, J = 8.8, 1.6 
Hz), 7.69 (d, 1H, J = 8.4 Hz), 8.00 (t, 1H, J = 0.8 Hz), 11.60 (bs, 1H); signals imputable 
to the indole (~ 50%) δ (ppm): 3.89 (s, 3H), 7.19 (dd, 1H, J = 1.9, 0.5 Hz),7.63 (dd, 1H, 
J = 8.8, 1.6 Hz), 12.25 (bs, 1H). 
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6-Carbamoyl-1-hydroxy-1H-indole-2-carboxylic acid (3.220a) 
 
Methyl ester 3.227a (43.0 mg, 0.184 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.8 mL) and treated with 0.6 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 2 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.220a (27.5 mg, 0.125 mmol, 68% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.02 (d, 1H, J = 0.7 Hz), 7.56 (dd, 1H, J = 8.6, 1.5 Hz), 7.67 
(d, 1H, J = 8.4 Hz), 7.99 (s, 1H); signals imputable to the indole (~ 50%) δ (ppm): 7.11 
(dd, 1H, J = 2.0, 0.9 Hz), 7.56 (dd, 1H, J = 7.1, 1.5 Hz). 
 
Methyl 3-(5-carbamoyl-2-nitrophenyl)-2-oxopropanoate (3.226b) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 932 mg, 23.3 
mmol) in 16 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing commercially available 3-methyl-4-nitrobenzamide 
3.223 (700 mg, 3.89 mmol) and dimethyl oxalate (2.75 g, 23.3 mmol) in 11 mL of 
anhydrous DMF. The mixture was left under stirring at the same temperature for 10 
minutes and then it was slowly warmed to room temperature. The mixture was then left 
under stirring at RT for 5 h. Once the disappearance of the precursor was verified by 
TLC, the reaction mixture was slowly poured in an ice-water mixture; the water phase 
was acidified with 1N aqueous HCl and extracted several times with EtOAc. The 
combined organic phase was washed with saturated NaHCO3 solution and brine, then 
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dried over anhydrous sodium sulphate. Evaporation under vacuum of the organic 
solvent afforded a crude, likely corresponding to the imidic derivative 3.225 (3.5 g). 
Hence, the crude residue was dissolved in MeOH (7 mL) and silica gel was added (2.8 
g). The mixture was stirred at RT overnight. Then, evaporation under vacuum of the 
organic solvent afforded a crude product which was purified by column 
chromatography over silica gel using n-hexane/EtOAc 3:7 as the eluent, to yield the 
amidic nitroaryl-ketoester derivative 3.226b (364 mg, 1.37 mmol, 2 steps: 35% yield). 
1H NMR (DMSO-d6) δ (ppm): 3.85 (s, 3H), 4.64 (s, 2H), 7.68-7.74 (m, 2H), 7.88 (dd, 
1H, J = 8.4, 1.8 Hz), 7.96 (d, 1H, J = 1.8 Hz), 8.25 (bs, 1H); signals imputable to the 
enol form (~ 62%) δ (ppm): 3.83 (s, 3H), 6.59 (s, 1H), 8.00 (dd, 1H, J = 8.3, 2.5 Hz), 
8.19 (d, 1H, J = 8.4 Hz), 8.64 (d, 1H J = 1.8 Hz). 
 
Methyl 5-carbamoyl-1-hydroxy-1H-indole-2-carboxylate (3.227b) 
N
OH
COOMe
H2N
O
 
Ketoester 3.226b (350 mg, 1.31 mmol) was dissolved in anhydrous DME (1.5 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (782 mg, 3.47 mmol) in DME (1.5 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at 0 
°C for 2 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
EtOAc as the eluent, to give the N-hydroxyindol-ester derivative 3.227b (87.0 mg, 
0.371 mmol, 28% yield). 1H NMR (DMSO-d6) δ (ppm): 3.87 (s, 3H), 7.18 (d, 1H, J = 
0.9 Hz), 7.25 (bs, 1H), 7.48 (d, 1H, J = 8.8 Hz), 7.86 (dd, 1H, J = 8.8, 1.6 Hz), 7.95 (bs, 
1H), 8.26 (d, 1H, J = 0.9 Hz), 11.59 (bs, 1H). 
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5-Carbamoyl-1-hydroxy-1H-indole-2-carboxylic acid (3.221a) 
 
Methyl ester 3.227b (75.0 mg, 0.320 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (3.2 mL) and treated with 1.0 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.221a (45.6 mg, 0.207 mmol, 65% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 7.11 (d, 1H, J = 0.5 Hz), 7.23 (bs, 1H), 7.45 (d, 1H, J = 8.6 
Hz), 7.84 (dd, 1H, J = 8.8, 1.5 Hz), 7.93 (bs, 1H), 8.24 (s, 1H). 
 
N,4-Dimethyl-3-nitro-N-phenylbenzamide (3.230) 
 
A solution of commercially available 4-methyl-3-nitrobenzoylchloride 3.228 (0.55 
mL, 0.75 mg, 3.8 mmol) in CH2Cl2 (6.0 mL) was added dropwise to N-methylaniline 
(1.25 mL, 1.20 g, 11.3 mmol) and the reaction was kept under stirring at RT for 2 h. 
The reaction mixture was acidified with 1N aqueous HCl, extracted several times with 
CH2Cl2 and the combined organic phase was dried over anhydrous sodium sulphate. 
Evaporation under vacuum of the organic solvent afforded a crude product which was 
purified by column chromatography over silica gel using n-hexane/EtOAc 7:3 as the 
eluent, to yield the amidic derivative 3.230 (904 mg, 3.34 mmol, 89% yield). 1H NMR 
(CDCl3) δ (ppm): 2.51 (s, 3H), 3.51 (s, 3H), 7.03-7.33 (m, 6H), 7.41 (dd, 1H, J = 8.1, 
1.8 Hz), 7.92 (d, 1H, J = 1.8 Hz). 
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Methyl 3-(4-(methyl(phenyl)carbamoyl)-2-nitrophenyl)-2-oxopropanoate (3.232a) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 512 mg, 12.8 
mmol) in 13 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.230 (865 mg, 3.20 
mmol) and dimethyl oxalate (1.89 g, 16.0 mmol) in 10 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
3.5 h. Once the disappearance of the precursor was verified by TLC, the reaction 
mixture was slowly poured in an ice-water mixture; the water phase was acidified with 
1N aqueous HCl and extracted several times with EtOAc. The combined organic phase 
was washed with saturated NaHCO3 solution and brine, then dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using n-
hexane/EtOAc 1:1 as the eluent, to yield the nitroaryl-ketoester derivative 3.232a (976 
mg, 2.74 mmol, 86% yield). 1H NMR (CDCl3) δ (ppm): 3.52 (s, 3H), 3.91 (s, 3H), 4.44 
(s, 2H), 7.04-7.34 (m, 6H), 7.53 (dd, 1H, J = 8.1, 1.6 Hz), 7.84 (d, 1H, J = 1.8 Hz); 
signals imputable to the enol form (~ 69%) δ (ppm): 3.51 (s, 3H), 3.92 (s, 3H), 6.73 (d, 
1H, exchangeable, J = 1.5 Hz), 6.83 (d, 1H, J = 1.1 Hz), 7.48 (dd, 1H, J = 8.4, 1.6 Hz), 
8.08 (d, 1H, J = 8.2 Hz). 
 
Methyl 1-hydroxy-6-(methyl(phenyl)carbamoyl)-1H-indole-2-carboxylate (3.233a) 
 
Ketoester 3.232a (950 mg, 2.67 mmol) was dissolved in anhydrous DME (2.7 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (1.13 g, 5.97 mmol) in DME (2.7 mL) containing 4Å molecular sieves, 
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previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at at 0 
°C for 6 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
CH2Cl2/MeOH 98:2 as the eluent, to give a mixture (134 mg) of the N-hydroxyindol-
ester derivative 3.233a (90%, 121 mg, 0.372 mmol, 14% yield) with its indole analogue 
(10%) 1H NMR (CDCl3) δ (ppm): 3.54 (s, 3H), 3.96 (s, 3H), 6.86 (d, 1H, J = 0.9 Hz), 
6.91 (dd, 1H, J = 8.4, 1.3 Hz), 7.02-7.31 (m, 6H), 7.52 (s, 1H), 10.27 (bs, 1H); signals 
imputable to the indole (~ 10%) δ (ppm): 3.49 (s, 3H), 3.92 (s, 3H), 8.87 (bs, 1H). 
 
1-Hydroxy-6-(methyl(phenyl)carbamoyl)-1H-indole-2-carboxylic acid (3.220b) 
 
Methyl ester 3.233a (100 mg, 0.308 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (3.0 mL) and treated with 0.92 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 2 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.220b (87.0 mg, 0.280 mmol, 91% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 3.40 (s, 3H), 6.91 (d, 1H, J = 0.7 Hz), 6.94 (dd, 1H, J = 8.2, 
1.5 Hz), 7.12-7.28 (m, 5H), 7.36-7.38 (m, 1H), 7.42 (d, 1H, J = 8.4 Hz); signals 
imputable to the indole (~ 10%) δ (ppm): 3.43 (s, 3H), 6.80-7.00 (m, 1H). 
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3-Methyl-4-nitrobenzoyl chloride (3.229) 
 
Oxalyl chloride (0.59 mL, 0.84 g, 6.6 mmol) and catalytic DMF (0.2 mL) were 
added to a suspension of commercially available 3-methyl-4-nitrobenzoic acid 3.90g 
(1.00 g, 5.52 mmol) in CH2Cl2 (20.0 mL) and the reaction was kept under stirring at RT 
for 4 h. Evaporation under vacuum of the organic solvent afforded a crude product 
3.229 (1.10 g) which was immediately used for the next reaction without any 
purification. 
 
N,3-dimethyl-4-nitro-N-phenylbenzamide (3.231) 
 
A solution of 3.229 (1.10 g, 5.52 mmol) in CH2Cl2 (12.0 mL) was added dropwise to 
N-methylaniline (1.80 mL, 1.77 g, 16.6 mmol) and the reaction was kept under stirring 
at RT for 2 h. The reaction mixture was acidified with 1N aqueous HCl, extracted 
several times with CH2Cl2 and the combined organic phase was dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using n-
hexane/EtOAc 7:3 as the eluent, to yield the amidic derivative 3.231 (1.35 g, 4.99 
mmol, 90% yield). 1H NMR (CDCl3) δ (ppm): 2.46 (s, 3H), 3.50 (s, 3H), 7.01-7.31 (m, 
6H), 7.34-7.36 (m, 1H), 7.70 (d, 1H, J = 8.4 Hz). 
 
Methyl 3-(5-(methyl(phenyl)carbamoyl)-2-nitrophenyl)-2-oxopropanoate (3.232b) 
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A stirred suspension of sodium hydride (60% dispersion in mineral oil, 414 mg, 10.4 
mmol) in 10 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.231 (700 mg, 2.59 
mmol) and dimethyl oxalate (1.53 g, 13.0 mmol) in 7 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
21.5 h. Once the disappearance of the precursor was verified by TLC, the reaction 
mixture was slowly poured in an ice-water mixture; the water phase was acidified with 
1N aqueous HCl and extracted several times with EtOAc. The combined organic phase 
was washed with saturated NaHCO3 solution and brine, then dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using n-
hexane/EtOAc 7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.232b (240 
mg, 0.674 mmol, 26% yield). 1H NMR (CDCl3) δ (ppm): 3.48 (s, 3H), 3.88 (s, 3H), 
4.36 (s, 2H), 6.96-7.06 (m, 2H), 7.12-7.32 (m, 5H), 7.89 (d, 1H, J = 8.1 Hz); signals 
imputable to the enol form (~ 26%) δ (ppm): 3.87 (s,3H), 6.67 (bs, 1H, exchangeable), 
6.74 (s, 1H), 7.65 (d, 1H, J = 8.4 Hz), 8.19 (d, 1H, J = 1.6 Hz). 
 
Methyl 1-hydroxy-5-(methyl(phenyl)carbamoyl)-1H-indole-2-carboxylate (3.233b) 
 
Ketoester 3.232b (230 mg, 0.645 mmol) was dissolved in anhydrous DME (0.65 
mL) and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (274 mg, 1.45 mmol) in DME (0.65 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at at 0 
°C for 6.5 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
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CH2Cl2/MeOH 98:2 as the eluent, to give a mixture (55.4 mg) of the N-hydroxyindol-
ester derivative 3.233b (50%, 27.7 mg, 0.854 mmol, 13% yield) with its indole 
analogue (50%) 1H NMR (CDCl3) δ (ppm): 3.52 (s, 3H), 3.91 (s, 3H), 6.85 (s, 1H), 
6.98-7.28 (m, 8H), 10.51 (bs, 1H); signals imputable to the indole (~ 50%) δ (ppm): 
3.53 (s, 3H), 3.96 (s, 3H), 7.50 (t, 1H, J = 1.2 Hz), 7.71-7.73 (m, 1H), 8.92 (bs, 1H). 
 
1-Hydroxy-5-(methyl(phenyl)carbamoyl)-1H-indole-2-carboxylic acid (3.221b) 
 
Methyl ester 3.233b (53.0 mg, 0.163 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.6 mL) and treated with 0.49 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 7 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.221b (50.0 mg, 0.161 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 1.91 (s, 3H), 6.93 (s, 1H), 7.07-7.27 (m, 8H); signals 
imputable to the indole (~ 50%) δ (ppm): 7.50 (d, 1H, J = 1.6 Hz), 7.60-7.63 (m, 1H). 
 
N,N,4-Trimethyl-3-nitrobenzamide (3.234) 
 
A solution of commercially available 4-methyl-3-nitrobenzoylchloride 3.228 (0.50 
mL, 0.68 g, 3.4 mmol) in CH2Cl2 (6.0 mL) was added dropwise to N,N-dimethylaniline 
(2.0 mL, 0.71 g, 16 mmol) and the reaction was kept under stirring at RT for 30 min. 
The reaction mixture was acidified with 1N aqueous HCl, extracted several times with 
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CH2Cl2 and the combined organic phase was dried over anhydrous sodium sulphate. 
Evaporation under vacuum of the organic solvent afforded a crude product which was 
purified by column chromatography over silica gel using CH2Cl2/MeOH 9:1 as the 
eluent, to yield the amidic derivative 3.234 (642 mg, 3.08 mmol, 90% yield). 1H NMR 
(CDCl3) δ (ppm): 2.63 (s, 3H), 3.02 (s, 3H), 3.12 (s, 3H), 7.40 (d, 1H, J = 7.9 Hz), 7.59 
(dd, 1H, J = 7.7, 1.6 Hz), 8.05 (d, 1H, J = 1.6 Hz). 
 
Methyl 3-(4-(dimethylcarbamoyl)-2-nitrophenyl)-2-oxopropanoate (3.236a) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 469 mg, 
11.76 mmol) in 11 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.234 (610 mg, 2.93 
mmol) and dimethyl oxalate (1.73 g, 14.7 mmol) in 9 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
1.5 h. Once the disappearance of the precursor was verified by TLC, the reaction 
mixture was slowly poured in an ice-water mixture; the water phase was acidified with 
1N aqueous HCl and extracted several times with EtOAc. The combined organic phase 
was washed with saturated NaHCO3 solution and brine, then dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using n-
hexane/EtOAc 3:7 as the eluent, to yield the nitroaryl-ketoester derivative 3.236a (821 
mg, 2.79 mmol, 95% yield). 1H NMR (DMSO) δ (ppm): 3.03 (s, 3H), 3.13 (s, 3H), 3.94 
(s, 3H), 4.58 (s, 2H), 7.21 (d, 1H, J = 7.9 Hz), 7.70 (dd, 1H, J = 7.9, 1.6 Hz), 8.24 (d, 
1H, J = 1.6); signals imputable to the enol form (~ 83%) δ (ppm): 3.95 (s, 3H), 6.93 (s, 
1H), 7.65 (dd, 1H, J = 8.2, 1.8 Hz), 7.98 (d, 1H, J = 1.6 Hz), 8.31 (d, 1H, J = 8.2 Hz). 
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Methyl 6-(dimethylcarbamoyl)-1-hydroxy-1H-indole-2-carboxylate (3.237a) 
 
Ketoester 3.236a (507 mg, 1.72 mmol) was dissolved in anhydrous DME (1.7 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (732 mg, 3.86 mmol) in DME (1.7 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at at 0 
°C for 5 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
CH2Cl2/MeOH 95:5 as the eluent, to give a mixture (150 mg) of the N-hydroxyindol-
ester derivative 3.237a (60%, 90.0 mg, 0.343 mmol, 20% yield) with its indole analogue 
(40%) 1H NMR (CDCl3) δ (ppm): 2.94-3.16 (m, 6H), 3.97 (s, 3H), 6.85 (d, 1H, J = 0.9 
Hz), 7.17 (dd, 1H, J = 8.2, 1.3 Hz), 7.21 (dd, 1H, J = 2.0, 0.8 Hz), 7.34 (d, 1H, J = 8.4 
Hz); signals imputable to the indole (~ 40%) δ (ppm): 3.96 (s, 3H), 6.84 (dd, 1H, J = 
8.2, 1.5 Hz), 7.68 (d, 1H, J = 8.4 Hz). 
 
6-(Dimethylcarbamoyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.220c) 
 
Methyl ester 3.237a (130 mg, 0.496 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (5 mL) and treated with 1.5 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
2.5 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
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product 3.220c (122 mg, 0.491 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 2.97 (s, 6H), 7.04 (d, 1H, J = 0.7 Hz); 7.10-7.13 (m, 1H), 
7.42-7.44 (m, 2H); signals imputable to the indole (~ 40%) δ (ppm): 7.08 (dd, 1H, J = 
4.6, 1.5 Hz), 7.68 (d, 1H, J = 8.4 Hz). 
 
(3-Methyl-4-nitrophenyl)(morpholino)methanone (3.235) 
CH3
NO2
O
N
O
 
A solution of 3.229 (918 mg, 4.60 mmol) in CH2Cl2 (10.0 mL) was added dropwise 
to morpholine (1.21 mL, 1.20 g, 13.8 mmol) and the reaction was kept under stirring at 
RT overnight. The reaction mixture was acidified with 1N aqueous HCl, extracted 
several times with CH2Cl2 and the combined organic phase was dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using EtOAc as 
the eluent, to yield the amidic derivative 3.235 (1.01 g, 4.04 mmol, 88% yield). 1H 
NMR (CDCl3) δ (ppm): 2.62 (s, 3H), 3.40-3.78 (m, 8H), 7.32-7.39 (m, 2H), 8.00 (d, 1H, 
J = 8.2 Hz). 
 
Methyl 3-(5-(morpholine-4-carbonyl)-2-nitrophenyl)-2-oxopropanoate (3.236b) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 579 mg, 14.5 
mmol) in 14 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.235 (906 mg, 3.62 
mmol) and dimethyl oxalate (2.14 g, 18.1 mmol) in 11 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
4 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
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was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
1:9 as the eluent, to yield the nitroaryl-ketoester derivative 3.236b (1.17 g, 3.48 mmol, 
96% yield). 50% di forma enolic. 1H NMR (CDCl3) δ (ppm): 3.46-3.80 (m, 8H), 3.94 
(s, 3H), 4.57 (s, 2H), 7.38 (d, 1H, J = 1.8 Hz), 7.46 (dd, 1H, J = 8.4, 1.8 Hz),), 8.21 (d, 
1H, J = 8.4 Hz); signals imputable to the enol form (~ 48%) δ (ppm): 3.95 (s, 3H), 6.91 
(s, 1H), 7.52 (dd, 1H, J = 8.4, 1.8 Hz), 7.96 (d, 1H, J = 8.4 Hz), 8.28 (d, 1H, J = 1.8 
Hz). 
 
Methyl 1-hydroxy-5-(morpholine-4-carbonyl)-1H-indole-2-carboxylate (3.237b) 
 
Ketoester 3.236b (200 mg, 0.595 mmol) was dissolved in anhydrous DME (0.6 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (253 mg, 1.33 mmol) in DME (0.6 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at 0 
°C for 5 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
CH2Cl2/MeOH 95:5 as the eluent, to give a mixture (33.0 mg) of the N-hydroxyindol-
ester derivative 3.237b (85%, 28.1 mg, 0.0922 mmol, 15% yield) with its indole 
analogue (15%) 1H NMR (CDCl3) δ (ppm): 3.40-3.90 (m, 8H), 3.99 (s, 3H), 6.93 (d, 
1H, J = 0.7 Hz), 6.96 (dd, 1H, J = 9.0, 1.3), 7.06 (d, 1H, J = 8.6 Hz), 7.46 (s, 1H); 
signals imputable to the indole (~ 15%) δ (ppm): 3.96 (s, 3H), 7.78 (s, 1H). 
 
Experimental section 
404 
 
1-Hydroxy-5-(morpholine-4-carbonyl)-1H-indole-2-carboxylic acid (3.221c) 
 
Methyl ester 3.237b (32.0 mg, 0.105 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.6 mL) and treated with 0.3 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 2 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.221c (30.2 mg, 0.104 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 3.53-3.59 (m, 8H), 7.08 (d, 1H, J = 0.7 Hz), 7.35 (dd, 1H, J 
= 8.6, 1.5 Hz), 7.47 (d, 1H, J = 8.6 Hz), 7.74 (d, 1H, J = 1.6 Hz); signals imputable to 
the indole (~ 15%) δ (ppm): 7.14-7.16 (m, 1H), 7.28 (dd, 1H, J = 8.4, 1.5 Hz). 
 
N-(Cyclopropylsulfonyl)-4-methyl-3-nitrobenzamide (3.238) 
CH3
NO2
O
H
N
S
O O  
Cyclopropanesulfonamide (300 mg, 2.48 mmol) was dissolved in 45 mL of CH2Cl2 
and the resulting solution was cooled to 0 °C, then commercially available 4-methyl-3-
nitrobenzoylchloride 3.228 (0.76 mL, 1.04 g, 5.20 mmol) and triethylamine (0.41 mL, 
0.30 g, 3.0 mmol) were added dropwise and the reaction was kept under stirring at RT 
for 72 h. The reaction mixture was diluted with CH2Cl2 and washed with saturated 
aqueous sodium NaHCO3 and water. The organic phase was dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using n-
hexane/EtOAc 7:3 as the eluent, to yield the derivative 3.238 (442 mg, 1.55 mmol, 63% 
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yield). 1H NMR (CDCl3) δ (ppm): 1.22-1.34 (m, 4H), 2.68 (s, 3H), 3.51-3.64 (m, 1H), 
7.48 (d, 1H, J = 8.2 Hz), 8.00 (dd, 1H, J = 8.1, 2.0 Hz), 8.45 (d, 1H, J = 1.6 Hz). 
 
Methyl 3-(4-(cyclopropylsulfonylcarbamoyl)-2-nitrophenyl)-2-oxopropanoate 
(3.239) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 432 mg, 10.8 
mmol) in 7.5 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.238 (384 mg, 1.35 
mmol) and dimethyl oxalate (1.59 g, 13.5 mmol) in 3.8 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
18 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using CHCl3/MeOH 95:5 
as the eluent, to yield the nitroaryl-ketoester derivative 3.239 (287 mg, 0.775 mmol, 
57% yield). 1H NMR (CDCl3) δ (ppm): 1.14-1.25 (m, 2H), 1.45-1.54 (m, 2H), 3.07-3.20 
(m, 1H), 3.96 (s, 3H), 4.64 (s, 2H), 7.50 (d, 1H, J = 8.1 Hz), 8.16 (dd, 1H, J = 8.2, 1.8 
Hz), 8.68 (d, 1H, J = 1.7 Hz); signals imputable to the enol form (~ 3%) δ (ppm): 3.97 
(s, 3H), 6.94 (s, 1H), 8.85 (s, 1H). 
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Methyl 6-(cyclopropylsulfonylcarbamoyl)-1-hydroxy-1H-indole-2-carboxylate 
(3.241a) 
 
Ketoester 3.239 (270 mg, 0.729 mmol) was dissolved in THF (1.2 mL) and the 
resulting solution was added to an aqueous solution (1.2 mL) of sodium hypophosphite 
monohydrate (240 mg, 2.26 mmol). Then 7.3 mg of 10% palladium over charcoal was 
added and the resulting suspension was stirred at RT for 24 h. Then it was monitored by 
TLC and H2PO2Na.H2O (240 mg, 2.26 mmol) and Pd/C (7.3 mg) were added. After 
further 5 h the disappearance of the precursor is verified by TLC and the mixture was 
concentrated, diluted with water and repeatedly extracted with EtOAc. The combined 
organic phase was dried over anhydrous sodium sulphate and evaporated to afford a 
crude residue that was purified by column chromatography over silica gel using n-
hexane/EtOAc 5:95 as the eluent, to give the N-hydroxyindole 3.241a (108 mg, 0.319 
mmol, 44% yield). 1H NMR (CD3OD) δ (ppm): 1.08-1.22 (m, 2H), 1.24-1.35 (m, 2H), 
3.10-3.23 (m, 1H), 3.94 (s, 3H), 7.13 (d, 1H, J = 0.9 Hz), 7.64 (dd, 1H, J = 8.4, 1.6 Hz), 
7.74 (dd, 1H, J = 8.4, 1.0 Hz), 8.14 (t, 1H, J = 1.1 Hz). 
 
6-(Cyclopropylsulfonylcarbamoyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.220d) 
 
Methyl ester 3.241a (100 mg, 0.296 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (3 mL) and treated with 0.9 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 5 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
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product 3.220d (92.0 mg, 0.284 mmol, 96% yield) without any further purification. 1H 
NMR (CD3OD) δ (ppm): 1.12-1.19 (m, 2H), 1.29-1.34 (m, 2H), 3.14-3.25 (m, 1H), 7.12 
(t, 1H, J = 0.7 Hz), 7.62 (ddd, 1H, J = 8.4, 1.6, 0.7 Hz), 7.74 (d, 1H, J = 8.4 Hz), 8.13 
(dd, 1H, J = 1.6, 0.8 Hz). 13C NMR (CD3OD) δ (ppm): 6.36 (2C), 32.03, 105.94, 111.93 
(2C), 120.80, 123.51 (2C), 129.33, 136.58, 163.20, 168.83. 
 
Methyl 3-(5-(cyclopropylsulfonylcarbamoyl)-2-nitrophenyl)-2-oxopropanoate 
(3.240) 
NO2
O
N
H
S
O O
O
COOMe
 
The ketoester precursor 3.91g (200 mg, 0.748 mmol) and CDI (281 mg, 1.73 mmol) 
were dissolved in anhydrous THF (5 mL) and the resulting solution was stirred for 1 h 
at RT. Cyclopropanesulfonamide (182 mg, 1.50 mmol) in 1.9 mL of anhydrous THF 
and DBU (0.56 mL, 0.57 g, 3.8 mmol) were sequentially added to the reaction mixture, 
then the reaction was kept under stirring at RT overnight. Then, the mixture was 
concentrated, acidified with 1N aqueous HCl (pH=1) and repeatedly extracted with 
EtOAc. The organic phase was dried over anhydrous sodium sulphate. Evaporation 
under vacuum of the organic solvent afforded a crude product which was purified by 
column chromatography over silica gel using n-hexane/EtOAc 1:0 with 0.01% acetic 
acid as the eluent, to yield the derivative 3.240 (226 mg, 0.610 mmol, 82% yield). 1H 
NMR (CDCl3) δ (ppm): 0.87-1.08 (m, 4H), 3.04-3.16 (m, 1H), 3.85 (s, 3H), 4.65 (s, 
2H), 7.94 (dd, 1H, J = 8.4, 2.0 Hz), 8.19 (d, 1H, J = 8.1 Hz), 8.84 (bs, 1H); signals 
imputable to the enol form (~ 73%) δ (ppm): 3.83 (s, 3H), 6.57 (s, 1H), 8.72 (d, 1H, J = 
1.3 Hz). 
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Methyl 5-(cyclopropylsulfonylcarbamoyl)-1-hydroxy-1H-indole-2-carboxylate 
(3.241b) 
 
Ketoester 3.240 (100 mg, 0.270 mmol) was dissolved in THF (0.4 mL) and the 
resulting solution was added to an aqueous solution (0.4 mL) of sodium hypophosphite 
monohydrate (89.0 mg, 0.840 mmol). Then 2.7 mg of 10% palladium over charcoal was 
added and the resulting suspension was stirred ar RT. After 72 h the disappearance of 
the precursor is verified by TLC and the mixture was concentrated, diluted with water 
and repeatedly extracted with EtOAc. The combined organic phase was dried over 
anhydrous sodium sulphate and evaporated to afford a crude residue that was purified 
by column chromatography over silica gel using CH2Cl2/MeOH 9:1 as the eluent, to 
give the N-hydroxyindole 3.241b (24.2 mg, 0.0715 mmol, 26% yield). 1H NMR 
(CD3OD) δ (ppm): 1.11-1.35 (m, 4H), 3.11-3.23 (m, 1H), 3.93 (s, 3H), 7.24 (d, 1H, J = 
0.9 Hz), 7.58 (dd, 1H, J = 8.8, 0.7 Hz), 7.89 (dd, 1H, J = 8.8, 1.6 Hz), 8.29 (dd, 1H, J = 
1.6, 0.7 Hz). 
 
5-(Cyclopropylsulfonylcarbamoyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.221d) 
 
Methyl ester 3.241b (18.0 mg, 0.0532 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.5 mL) and treated with 0.15 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
72 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
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product 3.221d (15.1 mg, 0.0466 mmol, 88% yield) without any further purification. 1H 
NMR (CD3OD) δ (ppm). 1.12-1.33 (m, 4H), 3.11-3.24 (m, 1H), 7.23 (s, 1H), 7.58 (dd, 
1H, J = 8.8, 0.7 Hz), 7.87 (dd, 1H, J = 8.8, 1.2 Hz), 8.28 (dd, 1H, J = 1.4, 0.7 Hz). 13C 
NMR (CD3OD) δ (ppm): 6.38 (2C), 32.09, 107.83, 110.80 (2C), 122.12, 125.38, 125.60 
(2C), 139.31, 163.15, 168.90. MS m/z 324 (M+ 5%), 322 (M+ –H2, 100%), 279 (M+ –
COOH, 18%). 
 
N,N,4-Trimethyl-3-nitrobenzenesulfonamide (3.246a) 
 
A solution of commercially available 4-methyl-3-nitrobenzenesulfonylchloride 
3.245 (750 mg, 3.18 mmol) in CH2Cl2 (6.0 mL) was added dropwise to N,N-
dimethylaniline (2.00 mL, 712 mg, 15.8 mmol) and the reaction was kept under stirring 
at RT for 30 min. The reaction mixture was acidified with 1N aqueous HCl, extracted 
several times with CH2Cl2 and the combined organic phase was dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using CH2Cl2 as 
the eluent, to yield the sulfonamidic derivative 3.246a (681 mg, 2.79 mmol, 88% yield). 
1H NMR (CDCl3) δ (ppm): 2.63 (s, 3H), 2.76 (s, 6H), 7.55 (d, 1H, J = 8.1 Hz), 7.89 (dd, 
1H, J = 7.9, 1.8 Hz), 8.35 (d, 1H, J = 1.8 Hz). 
 
Methyl 3-(4-(N,N-dimethylsulfamoyl)-2-nitrophenyl)-2-oxopropanoate (3.247a) 
S NO2
COOMe
ON
O O
H3C
CH3
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 274 mg, 11.4 
mmol) in 11 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.246a (650 mg, 2.66 
mmol) and dimethyl oxalate (1.68 g, 14.3 mmol) in 9 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
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slowly warmed to room temperature. The mixture was then left under stirring at RT for 
21 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
1:1 as the eluent, to yield the nitroaryl-ketoester derivative 3.247a (489 mg, 1.48 mmol, 
56% yield). 1H NMR (CDCl3) δ (ppm): 2.81 (s, 6H), 3.96 (s, 3H), 4.64 (s, 2H), 7.53 (d, 
1H, J = 7.9 Hz), 8.02 (dd, 1H, J = 8.1, 2.0 Hz), 8.54 (d, 1H, J = 1.8 Hz); signals 
imputable to the enol form (~ 25%) δ (ppm): 2.79 (s, 6H), 3.98 (s, 3H), 6.93 (s, 1H), 
7.95 (dd, 1H, J = 7.7, 1.3 Hz), 8.26 (d, 1H, J = 1.8 Hz), 8.47 (d, 1H, J = 8.6 Hz). 
 
Methyl 6-(N,N-dimethylsulfamoyl)-1-hydroxy-1H-indole-2-carboxylate (3.248a) 
 
Ketoester 3.247a (250 mg, 0.757 mmol) was dissolved in anhydrous DME (0.7 mL) 
and the resulting solution was added dropwise to a cooled (0 °C) solution of 
SnCl2·2H2O (382 mg, 1.70 mmol) in DME (0.7 mL) containing 4Å molecular sieves, 
previously activated for 18 hours at 130 °C in oven and cooled to RT in a desiccator 
over anhydrous calcium chloride. The reaction mixture was stirred under nitrogen at 0 
°C for 3 h, then it was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 3:7 as the eluent, to give a mixture (149 mg) of the N-hydroxyindol-
ester derivative 3.248a (95%, 142 mg, 0.475 mmol, 63% yield) with its indole analogue 
(5%). 1H NMR (CDCl3) δ (ppm): 2.74 (s, 6H), 4.04 (s, 3H), 7.09 (d, 1H, J = 0.9 Hz), 
7.47 (dd, 1H, J = 8.6, 1.6 Hz), 7.76 (dd, 1H, J = 8.4, 0.7 Hz), 8.05 (dt, 1H, J = 1.6, 0.8 
Hz); signals imputable to the indole (~ 5%) δ (ppm): 2.80 (s, 6H), 4.03 (s, 3H), 7.61 
(dd, 1H, J = 8.0, 1.6 Hz), 8.25 (d, 1H, J = 8.0 Hz).  
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6-(N,N-Dimethylsulfamoyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.242) 
 
Methyl ester 3.248a (140 mg, 0.469 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (4.8 mL) and treated with 1.4 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 1 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.242 (132 mg, 0.464 mmol, 99% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 2.62 (s, 6H), 7.15 (d, 1H, J = 0.7 Hz), 7.41 (dd, 1H, J = 8.4, 
1.6 Hz), 7.77 (d, 1H, J = 1.1 Hz), 7.89 (d, 1H, J = 8.6 Hz); signals imputable to the 
indole (~ 5%) δ (ppm): 2.67 (s, 6H), 7.58 (dd, 1H, J = 8.2, 1.6 Hz), 8.26 (d, 1H, J = 8.4 
Hz), 8.99 (d, 1H, J = 1.8 Hz). MS m/z 284 (M+, 34%), 282 (M+ –H2, 100%). 
 
N,4-dimethyl-3-nitro-N-phenylbenzenesulfonamide (3.246b) 
 
A solution of commercially available 4-methyl-3-nitrobenzenesulfonylchloride 
3.245 (1.10 g, 4.67 mmol) in CH2Cl2 (8 mL) was added dropwise to N-methylaniline 
(1.55 mL, 1.50 g, 14.0 mmol) and the reaction was kept under stirring at RT for 2 h. 
The reaction mixture was acidified with 1N aqueous HCl, extracted several times with 
CH2Cl2 and the combined organic phase was dried over anhydrous sodium sulphate. 
Evaporation under vacuum of the organic solvent afforded the desired sulfonamidic 
derivative 3.246b (1.43 g, 4.67 mmol, >99% yield). 1H NMR (CDCl3) δ (ppm): 2.67 (s, 
3H), 3.22 (s, 3H), 7.07-7.12 (m, 2H), 7.31-7.35 (m, 3H), 7.44 (d, 1H, J = 8.1 Hz), 7.59 
(dd, 1H, J = 8.1, 1.8 Hz), 8.15 (d, 1H, J = 1.6 Hz). 
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Methyl 3-(4-(N-methyl-N-phenylsulfamoyl)-2-nitrophenyl)-2-oxopropanoate 
(3.247b) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 522 mg, 13.0 
mmol) in 9.0 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.246b (1.00 g, 3.26 
mmol) and dimethyl oxalate (1.93 g, 16.3 mmol) in 9.3 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
21 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
1:1 as the eluent, to yield the nitroaryl-ketoester derivative 3.247b (910 mg, 2.32 mmol, 
71% yield). 1H NMR (CDCl3) δ (ppm): 3.25 (s, 3H), 3.95 (s, 3H), 4.61 (s, 2H), 7.08-
7.13 (m, 2H), 7.32-7.35 (m, 3H), 7.42 (d, 1H, J = 8.1 Hz), 7.72 (dd, 1H, J = 8.1, 1.8 
Hz), 8.32 (d, 1H, J = 1.8 Hz). 
 
Methyl 1-hydroxy-6-(N-methyl-N-phenylsulfamoyl)-1H-indole-2-carboxylate 
(3.248b) 
 
Ketoester 3.247b (450 mg, 1.15 mmol) was dissolved in THF (1.9 mL) and the 
resulting solution was added to an aqueous solution (1.9 mL) of sodium hypophosphite 
monohydrate (378 mg, 3.57 mmol). Then 11.6 mg of 10% palladium over charcoal was 
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added and the resulting suspension was stirred ar RT. After 2 h the disappearance of the 
precursor is verified by TLC and the mixture was concentrated, diluted with water and 
repeatedly extracted with EtOAc. The combined organic phase was dried over 
anhydrous sodium sulphate and evaporated to afford a crude residue that was purified 
by column chromatography over silica gel using CHCl3/MeOH 98:2 as the eluent, to 
give the N-hydroxyindole 3.248b (96.1 mg, 0.267 mmol, 23% yield). 1H NMR (CDCl3) 
δ (ppm): 3.22 (s, 3H), 4.03 (s, 3H), 7.07 (s, 1H), 7.08-7-13 (m, 3H), 7.18 (dd, 1H, J = 
8.6, 1.6 Hz), 7.27-7.32 (m, 2H), 7.65 (d, 1H, J = 8.4 Hz), 7.90 (d, 1H, J = 0.7 Hz), 10.32 
(bs, 1H). 
 
1-Hydroxy-6-(N-methyl-N-phenylsulfamoyl)-1H-indole-2-carboxylic acid (3.243) 
 
Methyl ester 3.248b (90.0 mg, 0.250 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2.5 mL) and treated with 0.8 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
24 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.243 (75.4 mg, 0.218 mmol, 87% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 3.15 (s, 3H), 7.08-7.15 (m, 4H), 7.27-7.34 (m, 3H), 7.56-
7.57 (m, 1H), 7.79 (d, 1H, J = 8.2 Hz). 13C NMR (DMSO-d6) δ (ppm): 30.69, 104.21, 
109.97, 118.31, 122.89, 123.53, 126.12 (2C), 127.08, 128.78 (2C), 130.01, 131.67, 
133.87, 141.14, 160.62. MS m/z 346 (M+, 17%), 330 (M+ –O, 14%), 240 (M+ –PhNMe, 
10%), 224 (M+ –O –PhNMe, 18%), 177 (M+ –PhNMe –SO2 +H, 51%), 106 (PhNMe·+, 
100%). 
 
 
 
Experimental section 
414 
 
3-Methyl-4-nitrobenzenesulfonic acid (3.250) 
 
Commercially available 4-amino-3-methylbenzenesulfonic acid 3.249 (1.00 g, 5.94 
mmol), acetic acid (24.3 mL), and 35% hydrogen peroxide (6.8 mL, 7.5 g, 77 mmol) 
were heated for 2 h with stirring at 75 °C. The sulfonic acid gradually dissolved to give 
a clear solution. Then, the reaction mxture was cooled to RT, sodium hydrogen 
carbonate was added and the solution was evaporated to a thick syrup. The crude 
product was purified by column chromatography over silica gel using CH2Cl2/MeOH 
8:2 with 0.01% acetic acid as the eluent, to yield the nitro-derivative 3.250 (836 mg, 
3.85 mmol, 72% yield). 1H NMR (DMSO-d6) δ (ppm): 2.52 (s, 3H), 7.59-7.67 (m, 2H), 
7.95 (d, 1H, J = 8.2 Hz). 
 
3-Methyl-4-nitrobenzene-1-sulfonyl chloride (3.251) 
 
Thionyl chloride (2.7 mL, .4.4 g, 37 mmol) and catalytic DMF (0.8 mL) were added 
to the sulfonic acid derivative 3.250 (710 mg, 3.27 mmol) and the reaction was kept 
under stirring at 100 °C for 3 h. Evaporation under vacuum of the organic solvent 
afforded a crude product 3.251 (5.10 g) which was immediately used for the next 
reaction without any purification. 
 
N,3-Dimethyl-4-nitro-N-phenylbenzenesulfonamide (3.252) 
CH3
NO2
S
OO
N
CH3  
A solution of 3.251 (5.10 g) in CH2Cl2 (5.2 mL) was added dropwise to N-
methylaniline (0.98 mL, 0.97 g, 9.0 mmol) and the reaction was kept under stirring at 
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RT for 1 h. The reaction mixture was acidified with 1N aqueous HCl, extracted several 
times with CH2Cl2 and the combined organic phase was dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
85:15 as the eluent, to yield the sulfonamidic derivative 3.252 (565 mg, 1.85 mmol, 2 
steps: 56% yield). 1H NMR (CDCl3) δ (ppm): 2.57 (s, 3H), 3.22 (s, 3H), 7.08-7.14 (m, 
2H), 7.30-7.37 (m, 3H), 7.45-7.53 (m, 2H), 7.97 (d, 1H, J = 8.2 Hz). 
 
Methyl 3-(5-(N-methyl-N-phenylsulfamoyl)-2-nitrophenyl)-2-oxopropanoate 
(3.253) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 277 mg, 6.92 
mmol) in 4.9 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.252 (530 mg, 1.73 
mmol) and dimethyl oxalate (1.02 g, 8.65 mmol) in 3.2 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
6 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.253 (378 mg, 0.964 mmol, 
56% yield). 1H NMR (CDCl3) δ (ppm): 3.22 (s, 3H), 3.96 (s, 3H), 4.50 (s, 2H), 7.06-
7.15 (m, 2H), 7.29-7.39 (m, 3H), 7.44 (d, 1H, J = 2.0 Hz), 7.68 (dd, 1H, J = 8.6, 2.0 
Hz), 8.21 (d, 1H, J = 8.4 Hz); signals imputable to the enol form (~ 16%) δ (ppm): 3.26 
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(s, 3H), 6.72 (d, 1H, exchangeable, J = 1.6 Hz), 6.83 (d, 1H, J = 1.3 Hz), 7.44-7.50 (m, 
1H), 7.89 (d, 1H, J = 8.4 Hz), 8.53 (d, 1H, J = 2.2 Hz). 
 
Methyl 1-hydroxy-5-(N-methyl-N-phenylsulfamoyl)-1H-indole-2-carboxylate 
(3.254) 
N
OH
COOMe
S
OO
N
CH3
 
Triethylamine (0.20 mL, 0.13 g, 1.3 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (86.3 mg, 0.382 mmol) and PhSH (0.10 mL, 0.13 g, 1.2 mmol) in 
acetonitrile (2 mL) at room temperature to generate a yellow precipitate over a period of 
5 min. Then, 3.253 (100 mg, 0.255 mmol) was transferred to the suspension and stirred 
at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 1:1 as the eluent, to give the N-hydroxyindole 3.254 
(45.4 mg, 0.126 mmol, 49% yield). 1H NMR (CDCl3) δ (ppm): 3.18 (s, 3H), 4.03 (s, 
3H), 7.05-7.14 (m, 4H), 7.23-7.31 (m, 2H), 7.42 (dd, 1H, J = 8.9, 1.6 Hz), 7.55 (dd, 1H, 
J = 8.9, 0.8 Hz), 7.95 (t, 1H, J = 0.8 Hz), 10.51 (bs, 1H). 
 
1-Hydroxy-5-(N-methyl-N-phenylsulfamoyl)-1H-indole-2-carboxylic acid (3.244) 
 
Methyl ester 3.254 (35.0 mg, 0.0971 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.9 mL) and treated with 0.3 mL of 2N aqueous solution of LiOH. The 
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reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 1 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.244 (33.3 mg, 0.0961 mmol, 99% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 3.20 (s, 3H), 7.10-7.15 (m, 2H), 7.26-7.33 (m, 4H), 7.42 
(dd, 1H, J = 8.9, 1.7 Hz), 7.63 (dt, 1H, J = 9.0, 0.8 Hz), 7.99 (dd, 1H, J = 1.6, 0.7 Hz). 
13C NMR (acetone-d6) δ (ppm): 38.47, 107.39, 110.63, 121.26, 124.52, 124.74, 127.25 
(2C), 127.73, 128.64, 129.46 (2C), 129.93, 137.65, 142.91, 161.54. HPLC, tR = 8.9 min. 
 
N-Butyl-4-methyl-3-nitro-N-phenylbenzenesulfonamide (3.262) 
 
A solution of commercially available 4-methyl-3-nitrobenzenesulfonylchloride 
3.245 (600 mg, 2.55 mmol) in CH2Cl2 (4.4 mL) was added dropwise to N-methylaniline 
(1.22 mL, 1.14 g, 7.64 mmol) and the reaction was kept under stirring at RT for 16 h. 
The reaction mixture was acidified with 1N aqueous HCl, extracted several times with 
CH2Cl2 and the combined organic phase was dried over anhydrous sodium sulphate. 
Evaporation under vacuum of the organic solvent afforded a crude product 
corresponding to the sulfonamidic derivative 3.262 (748 mg, 2.15 mmol, 84% yield). 1H 
NMR (CDCl3) δ (ppm): 0.87 (t, 3H, J = 6.8 Hz), 1.25-1.42 (m, 4H), 2.67 (s, 3H), 3.56 
(t, 2H, J = 6.6 Hz), 7.02-7.07 (m, 2H), 7.30-7.35 (m, 3H), 7.43 (d, 1H, J = 8.1 Hz), 7.63 
(dd, 1H, J = 8.1, 1.8 Hz), 8.17 (d, 1H, J = 1.8 Hz). 
 
Methyl 3-(4-(N-butyl-N-phenylsulfamoyl)-2-nitrophenyl)-2-oxopropanoate (3.263) 
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A stirred suspension of sodium hydride (60% dispersion in mineral oil, 230 mg, 5.75 
mmol) in 3.4 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.262 (500 mg, 1.44 
mmol) and dimethyl oxalate (848 mg, 7.18 mmol) in 2.5 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
24 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.263 (476 mg, 1.10 mmol, 
76% yield). 1H NMR (CDCl3) δ (ppm): 0.87 (t, 3H, J = 6.8 Hz), 1.29-1.39 (m, 4H), 3.57 
(t, 2H, J = 6.6 Hz), 3.97 (s, 3H), 4.62 (s, 2H), 7.03-7.09 (m, 2H), 7.31-7.36 (m, 3H), 
7.41 (d, 1H, J = 8.6 Hz), 7.72 (dd, 1H, J = 8.6, 1.8 Hz), 8.36 (s, 1H); signals imputable 
to the enol form (~ 48%) δ (ppm): 3.96 (s, 3H), 6.91 (s, 1H), 7.76 (dd, 1H, J = 8.1, 1.8 
Hz), 8.05 (d, 1H, J = 2.0 Hz), 8.38 (d, 1H, J = 8.4 Hz). 
 
Methyl 6-(N-butyl-N-phenylsulfamoyl)-1-hydroxy-1H-indole-2-carboxylate (3.264) 
S
O
N
O
N
COOMe
OH
 
Triethylamine (0.32 mL, 0.23 g, 2.3 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (103 mg, 0.457 mmol) and PhSH (0.21 mL, 0.23 g, 2.1 mmol) in 
acetonitrile (3.6 mL) at room temperature to generate a yellow precipitate over a period 
of 5 min. Then, 3.263 (200 mg, 0.457 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
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toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 6:4 as the eluent, to give the N-hydroxyindole 3.264 
(45.4 mg, 0.113 mmol, 25% yield). 1H NMR (CDCl3) δ (ppm): 0.85 (t, 3H, J = 7.0 Hz), 
1.36-1.39 (m, 4H), 3.57 (t, 2H, J = 6.7 Hz), 4.02 (s, 3H), 7.02-7.07 (m, 3H), 7.22 (d, 1H, 
J = 1.1 Hz), 7.27-7.31 (m, 3H), 7.66 (d, 1H, J = 8.6 Hz), 7.90 (d, 1H, J = 0.8 Hz), 10.30 
(bs, 1H). 
 
6-(N-Butyl-N-phenylsulfamoyl)-1-hydroxy-1H-indole-2-carboxylic acid (3.255) 
 
Methyl ester 3.264 (26.0 mg, 0.0647 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.7 mL) and treated with 0.2 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
16 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.255 (21.6 mg, 0.0556 mmol, 86% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 0.86 (t, 3H, J = 7.0 Hz), 1.35-1.42 (m, 4H), 3.66 (t, 2H, J = 
6.4 Hz), 7.08-7.13 (m, 2H), 7.22 (d, 1H, J = 0.7 Hz), 7.28-7.37 (m, 4H), 7.77 (s, 1H), 
7.83 (d, 1H, J = 8.6 Hz). 13C NMR (acetone-d6) δ (ppm): 13.84, 20.15, 50.71, 105.91, 
110.99, 119.82, 123.74, 124.80, 128.44, 129.62, 129.86, 135.30, 135.78, 140.24, 
161.28. HPLC, tR = 10.1 min. 
 
N,4-Dimethyl-3-nitro-N-p-tolylbenzenesulfonamide (3.265a) 
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A solution of commercially available 4-methyl-3-nitrobenzenesulfonylchloride 
3.245 (1.12 g, 4.76 mmol) in CH2Cl2 (8 mL) was added dropwise to N-methyl-p-
toluidine (1.78 mL, 1.70 g, 14.0 mmol) and the reaction was kept under stirring at RT 
for 2 h. The reaction mixture was acidified with 1N aqueous HCl, extracted several 
times with CH2Cl2 and the combined organic phase was dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
7:3 as the eluent, to yield the sulfonamidic derivative 3.265a (1.52 g, 4.74 mmol, 99% 
yield). 1H NMR (CDCl3) δ (ppm): 2.35 (s, 3H), 2.67 (s, 3H), 3.19 (s, 3H), 6.96 
(AA’XX’, 2H, JAX = 8.4 Hz, JAA’/XX’ = 2.2 Hz), 7.13 (d, 2H, J = 8.1 Hz), 7.44 (d, 1H, J = 
8.2 Hz), 7.60 (dd, 1H, J = 9.0, 1.8 Hz), 8.15 (d, 1H, J = 1.8 Hz). 
 
Methyl 3-(4-(N-methyl-N-p-tolylsulfamoyl)-2-nitrophenyl)-2-oxopropanoate 
(3.266a) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 320 mg, 8.00 
mmol) in 6 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.265a (640 mg, 2.00 
mmol) and dimethyl oxalate (1.18 g, 10.0 mmol) in 4 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
24 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.266a (406 mg, 0.999 
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mmol, 50% yield). 1H NMR (CDCl3) δ (ppm): 2.35 (s, 3H), 3.21 (s, 3H), 3.97 (s, 3H), 4 
62 (s, 2H), 6.98 (d, 2H, J = 8.4 Hz), 7.13 (d, 2H, J = 8.4 Hz), 7.69 (dd, 1H, J = 8.4, 1.8 
Hz), 8.04 (d, 1H, J = 1.8 Hz), 8.38 (d, 1H, J = 8.4 Hz). 
 
Methyl 1-hydroxy-6-(N-methyl-N-p-tolylsulfamoyl)-1H-indole-2-carboxylate 
(3.267a) 
S
O
N
CH3
O
N
COOMe
OH
H3C  
To a solution containing the ketoester 3.266a (102 mg, 0.251 mmol) in 15 mL of 
MeOH, was added lead powder (448 mg, 2.16 mmol) and 0.5 mL of HCO2HNEt3. The 
mixture was stirred at 55 °C for 6 h, cooled to RT, and filtered over a pad of Celite. The 
solvent was removed under reduced pressure and the residue purified by column 
chromatography over silica gel using CHCl3/MeOH 98:2 as the eluent, to give the N-
hydroxyindole 3.267a (75.2 mg, 0.201 mmol, 80% yield). 1H NMR (CDCl3) δ (ppm): 
2.32 (s, 3H), 3.17 (s, 3H), 4.01 (s, 3H), 6.96 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 2.2 
Hz), 7.05 (d, 1H, J = 0.7 Hz), 7.07 (d, 2H, J = 8.6 Hz), 7.17 (dd, 1H, J = 8.6, 1.6 Hz), 
7.63 (d, 1H, J = 8.6 Hz), 7.89 (t, 1H, J = 0.7 Hz), 10.13 (bs, 1H). 
 
1-Hydroxy-6-(N-methyl-N-p-tolylsulfamoyl)-1H-indole-2-carboxylic acid (3.256) 
S
O
N
CH3
O
N
COOH
OH
H3C  
Methyl ester 3.267a (75.0 mg, 0.200 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2 mL) and treated with 0.6 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
the complete consumption of the starting material, the reaction mixture was 
concentrated, diluted with water and washed with Et2O. Then, the aqueous phase was 
treated with 1N aqueous HCl and extracted several times with EtOAc. The combined 
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ethyl acetate organic phase was dried over anhydrous sodium sulphate and evaporated 
to afford the desired N-hydroxyindol-carboxylic acid product 3.256 (67.8 mg, 0.188 
mmol, 94% yield) without any further purification. 1H NMR (CDCl3) δ (ppm): 2.31 (s, 
3H), 3.21 (s, 3H), 7.02 (AA´XX´, 2H, JAX = 8.6 Hz, JAA´/XX’ = 2.1 Hz), 7.08-7.18 (m, 
2H), 7.23 (d, 1H, J = 1.0 Hz), 7.24 (dd, 1H, J = 8.4, 1.6 Hz), 7.78 (dt, 1H, J = 1.8, 0.8 
Hz), 7.83 (dd, 1H, J = 8.4, 0.8 Hz). 13C NMR (CDCl3) δ (ppm): 20.97, 38.67, 105.88, 
111.21, 120.01, 123.648, 124.91, 127.22, 130.06, 134.06, 135.25, 137.67, 140.14, 
161.27. MS m/z 359 (M+ –H). 
 
N,4-Dimethyl-3-nitro-N-(4-(trifluoromethyl)phenyl)benzenesulfonamide (3.265b) 
 
To a solution of 4-trifluoromethyl-N-methylaniline (0.40 mL, 0.50 g, 2.9 mmol) in 
dry CH2Cl2 (10 mL), pyridine (0.35 mL, 0.34 g, 4.3 mmol) and catalytic DMAP (15.0 
mg) were added, then the resulting mixture was cooled to 0 °C. Subsequently, 
commercially available 4-methyl-3-nitrobenzenesulfonylchloride 3.245 (807 mg, 3.43 
mmol) in CH2Cl2 (10 mL) was added dropwise and the reaction was kept under stirring 
at RT overnight. The reaction mixture was acidified with 1N aqueous HCl, extracted 
several times with CH2Cl2 and the combined organic phase was dried over anhydrous 
sodium sulphate. Evaporation under vacuum of the organic solvent afforded a crude 
product which was purified by column chromatography over silica gel using n-
hexane/EtOAc 93:7 as the eluent, to yield the sulfonamidic derivative 3.265b (1.19 g, 
3.18 mmol, >99% yield). 1H NMR (CDCl3) δ (ppm): 2.68 (s, 3H), 3.24 (s, 3H), 7.24-
7.30 (m, 2H), 743-7.64 (m, 4H), 8.19 (d, 1H, J = 1.5 Hz). 
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Methyl 3-(4-(N-methyl-N-(4-(trifluoromethyl)phenyl)sulfamoyl)-2-nitrophenyl)-2-
oxopropanoate (3.266b) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 320 mg, 8.00 
mmol) in 6 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.265b (748 mg, 2.00 
mmol) and dimethyl oxalate (1.18 g, 10.0 mmol) in 4 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
24 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
7:3 as the eluent, to yield the nitroaryl-ketoester derivative 3.266b (405 mg, 0.880 
mmol, 44% yield). 1H NMR (CDCl3) δ (ppm): 3.27 (s, 3H), 3.96 (s, 3H), 4 63 (s, 2H), 
7.25-7.32 (m, 2H), 7.44 (d, 1H, J = 8.1 Hz), 7.59-7.65 (m, 2H), 7.69 (dd, 1H, J = 7,9, 
1.8 Hz), 8.37 (d, 1H, J = 1.5 Hz); signals imputable to the enol form (~ 49%) δ (ppm): 
3.26 (s, 3H), 3.98 (s, 3H), 6.90 (bs, 1H, exchangeable), 6.97 (d, 1H, J = 1.3 Hz), 8.07 (d, 
1H, J = 2.0 Hz), 8.40 (d, 1H, J = 8.4 Hz). 
 
Methyl 1-hydroxy-6-(N-methyl-N-(4-(trifluoromethyl)phenyl)sulfamoyl)-1H-
indole-2-carboxylate (3.267b) 
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To a solution containing the ketoester 3.266b (275 mg, 0.598 mmol) in 4.1 mL of 
MeOH, was added lead powder (1.10 g, 5.31 mmol) and 1.1 mL of HCO2HNEt3. The 
mixture was stirred at 55 °C for 12 h, cooled to RT, and filtered over a pad of Celite. 
The solvent was removed under reduced pressure and the residue purified by column 
chromatography over silica gel using n-hexane/EtOAc 75:25 as the eluent, to give the 
N-hydroxyindole 3.267b (182 mg, 0.425 mmol, 71% yield). 1H NMR (CDCl3) δ (ppm): 
3.23 (s, 3H), 4.03 (s, 3H), 7.07 (d, 1H, J = 0.9 Hz), 7.13 (dd, 1H, J = 8.6, 1.6 Hz), 7.24-
7.29 (m, 2H), 7.53-7.59 (m, 2H), 7.66 (dd, 1H, J = 8.6, 0.7 Hz), 7.91 (dt, 1H, J = 1.5, 
0.8 Hz), 10.36 (bs, 1H). 
 
1-Hydroxy-6-(N-methyl-N-(4-(trifluoromethyl)phenyl)sulfamoyl)-1H-indole-2-
carboxylic acid (3.257) 
 
Methyl ester 3.267b (85.0 mg, 0.198 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1 mL) and treated with 0.6 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 3 
h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.257 (75.0 mg, 0.181 mmol, 91% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 3.29 (s, 3H), 7.20 (dd, 1H, J = 8.4, 1.8 Hz), 7.21 (d, 1H, J = 
1.8 Hz), 7.40-7.50 (m, 2H), 7.65-7.74 (m, 2H), 7.78-7.86 (m, 2H). 13C NMR (acetone-
d6) δ (ppm): 38.12, 105.71, 111.18, 119.61, 123.96, 125.16, 126.62 (q, 2C, J = 3.7 Hz), 
127.13 (2C), 127.75, 128.66 (q, J = 33.0 Hz), 130.20, 132.38 (q, J = 269.8 Hz), 133.39, 
146.30, 161.38. MS m/z 415 (M+H+ , 5%), 239 (CF3PhN(Me)SO2 +H+, 20%), 177 (M 
+H+ –CF3PhN(Me)SO2, 100%). 
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N-(4-Fluorophenyl)-N,4-dimethyl-3-nitrobenzenesulfonamide (3.265c) 
 
To a solution of 4-fluoromethyl-N-methylaniline (0.32 mL, 0.33 g, 2.7 mmol) in dry 
CH2Cl2 (10 mL), pyridine (0.32 mL, 0.32 g, 4.0 mmol) and catalytic DMAP (15.0 mg) 
were added, then the resulting mixture was cooled to 0 °C. Subsequently, commercially 
available 4-methyl-3-nitrobenzenesulfonylchloride 3.245 (695 mg, 2.94 mmol) in 
CH2Cl2 (10 mL) was added dropwise and the reaction was kept under stirring at RT 
overnight. The reaction mixture was acidified with 1N aqueous HCl, extracted several 
times with CH2Cl2 and the combined organic phase was dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
7:3 as the eluent, to yield the sulfonamidic derivative 3.265c (836 mg, 2.58 mmol, 97% 
yield). 1H NMR (CDCl3) δ (ppm): 2.68 (s, 3H), 3.20 (s, 3H), 6.96-7.12 (m, 4H), 7.45 (d, 
1H, J = 8.1 Hz), 7.59 (dd, 1H, J = 8.1, 1.8 Hz), 8.17 (d, 1H, J = 1.8 Hz). 
 
Methyl 3-(4-(N-(4-fluorophenyl)-N-methylsulfamoyl)-2-nitrophenyl)-2-
oxopropanoate (3.266c) 
S NO2
COOMe
ON
O O
CH3
F  
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 320 mg, 8.00 
mmol) in 6 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.265c (648 mg, 2.00 
mmol) and dimethyl oxalate (1.18 g, 10.0 mmol) in 4 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT. 
Once the disappearance of the precursor was verified by TLC, the reaction mixture was 
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slowly poured in an ice-water mixture; the water phase was acidified with 1N aqueous 
HCl and extracted several times with EtOAc. The combined organic phase was washed 
with saturated NaHCO3 solution and brine, then dried over anhydrous sodium sulphate. 
Evaporation under vacuum of the organic solvent afforded a crude product which was 
purified by column chromatography over silica gel using n-hexane/EtOAc 7:3 as the 
eluent, to yield the nitroaryl-ketoester derivative 3.266c (512 mg, 1.25 mmol, 62% 
yield). 1H NMR (CDCl3) δ (ppm): 3.23 (s, 3H), 3.96 (s, 3H), 4.63 (s, 2H), 6.94-7.12 (m, 
4H), 7.44 (d, 1H, J = 8.1 Hz), 7.72 (dd, 1H, J = 8.1, 1.8 Hz), 8.35 (d, 1H, J = 1.8 Hz); 
signals imputable to the enol form (~ 30%) δ (ppm): 3.21 (s, 3H), 3.98 (s, 3H), 6.90 (s, 
1H), 8.05 (d, 1H, J = 1.8 Hz), 8.40 (d, 1H, J = 8.4 Hz). 
 
Methyl 6-(N-(4-fluorophenyl)-N-methylsulfamoyl)-1-hydroxy-1H-indole-2-
carboxylate (3.267c) 
 
To a solution containing the ketoester 3.266c (150 mg, 0.366 mmol) in 4 mL of 
MeOH, was added lead powder (1.00 g, 4.83 mmol) and 1 mL of HCO2HNEt3. The 
mixture was stirred at 55 °C for 12 h, cooled to RT, and filtered over a pad of Celite. 
The solvent was removed under reduced pressure and the residue purified by column 
chromatography over silica gel using n-hexane/EtOAc 1:1 as the eluent, to give the N-
hydroxyindole 3.267c (100 mg, 0.264 mmol, 72% yield). 1H NMR (CDCl3) δ (ppm): 
3.15 (s, 3H), 3.98 (s, 3H), 6.89-7.87 (m, 5H), 7.13 (dd, 1H, J = 8.5, 1.6 Hz), 7.62 (d, 1H, 
J = 8.4 Hz), 7.83 (s, 1H), 10.20 (bs, 1H). 
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6-(N-(4-Fluorophenyl)-N-methylsulfamoyl)-1-hydroxy-1H-indole-2-carboxylic acid 
(3.258) 
 
Methyl ester 3.267c (80.0 mg, 0.211 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2.4 mL) and treated with 0.7 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
12 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.258 (76.0 mg, 0.209 mmol, 99% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 3.22 (s, 3H), 7.04-7.19 (m, 4H), 7.22 (d, 1H, J = 0.9 Hz), 
7.23 (dd, 1H, J = 8.4, 1.6 Hz), 7.75 (dt, 1H, J = 1.6, 0.8 Hz), 7.84 (dd, 1H, J = 8.6, 0.8 
Hz). 13C NMR (acetone-d6) δ (ppm). 38.71, 105.95, 111.25, 116.19 (d, 2C, J = 22.9 Hz), 
119.95, 123.78, 125.05, 129.48 (d, 2C, J = 9.2 Hz), 130.08, 133.55, 135.32, 138.89 (d, J 
= 3.7 Hz), 161.16, 162.13 (d, J = 244.4 Hz). 
 
N-(4-Chlorophenyl)-N,4-dimethyl-3-nitrobenzenesulfonamide (3.265d) 
 
To a solution of 4-chloro-N-methylaniline (0.35 mL, 0.40 g, 2.9 mmol) in dry 
CH2Cl2 (10 mL), pyridine (0.35 mL, 0.34 g, 4.3 mmol) and catalytic DMAP (15.0 mg) 
were added, then the resulting mixture was cooled to 0 °C. Subsequently, commercially 
available 4-methyl-3-nitrobenzenesulfonylchloride 3.245 (807 mg, 3.43 mmol) in 
CH2Cl2 (10 mL) was added dropwise and the reaction was kept under stirring at RT 
overnight. The reaction mixture was acidified with 1N aqueous HCl, extracted several 
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times with CH2Cl2 and the combined organic phase was dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
8:2 as the eluent, to yield the sulfonamidic derivative 3.265d (1.17 g, 3.43 mmol, >99% 
yield). 1H NMR (CDCl3) δ (ppm): 2.68 (s, 3H), 3.20 (s, 3H), 7.05 (AA´XX´, 2H, JAX = 
8.8 Hz, JAA´/XX’ = 2.6 Hz), 7.31 (AA´XX´, 2H, JAX = 9.0 Hz, JAA´/XX’ = 2.6 Hz), 7.45 (d, 
1H, J = 8.1 Hz), 7.57 (dd, 1H, J = 8.1, 1.8 Hz), 8.19 (d, 1H, J = 1.8 Hz). 
 
Methyl 3-(4-(N-(4-chlorophenyl)-N-methylsulfamoyl)-2-nitrophenyl)-2-
oxopropanoate (3.266d) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 320 mg, 8.00 
mmol) in 6 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.265d (682 mg, 2.00 
mmol) and dimethyl oxalate (1.18 g, 10.0 mmol) in 4 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT. 
Once the disappearance of the precursor was verified by TLC, the reaction mixture was 
slowly poured in an ice-water mixture; the water phase was acidified with 1N aqueous 
HCl and extracted several times with EtOAc. The combined organic phase was washed 
with saturated NaHCO3 solution and brine, then dried over anhydrous sodium sulphate. 
Evaporation under vacuum of the organic solvent afforded a crude product which was 
purified by column chromatography over silica gel using n-hexane/EtOAc 6:4 as the 
eluent, to yield the nitroaryl-ketoester derivative 3.266d (126 mg, 0.295 mmol, 15% 
yield). 1H NMR (CDCl3) δ (ppm): 3.21 (s, 3H), 3.95 (s, 3H), 4.62 (s, 2H), 7.02-7.09 (m, 
2H), 7.26-7.33 (m, 2H), 7.44 (d, 1H, J = 7.9 Hz), 7.68 (dd, 1H, J = 8.0, 1.7 Hz), 8.34 (d, 
1H, J = 1.8 Hz); signals imputable to the enol form (~ 24%) δ (ppm): 3.20 (s, 3H), 3.97 
(s, 3H), 6.89 (s, 1H), 8.38 (d, 1H, J = 8.6 Hz). 
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Methyl 6-(N-(4-chlorophenyl)-N-methylsulfamoyl)-1-hydroxy-1H-indole-2-
carboxylate (3.267d) 
 
To a solution containing the ketoester 3.266d (120 mg, 0.281 mmol) in 1.5 mL of 
MeOH, was added lead powder (300 mg, 1.45 mmol) and 0.3 mL of HCO2HNEt3. The 
mixture was stirred at 55 °C for 12 h, cooled to RT, and filtered over a pad of Celite. 
The solvent was removed under reduced pressure and the residue purified by column 
chromatography over silica gel using n-hexane/EtOAc 6:4 as the eluent, to give the N-
hydroxyindole 3.267d (85.0 mg, 0.215 mmol, 77% yield). 1H NMR (CDCl3) δ (ppm): 
3.17 (s, 3H), 4.02 (s, 3H), 6.95-7.07 (m, 3H), 7.14 (dd, 1H, J = 8.5, 1.7 Hz), 7.20-7.29 
(m, 2H), 7.65 (d, 1H, J = 8.4 Hz), 7.89 (s, 1H), 10.32 (bs, 1H). 
 
6-(N-(4-Chlorophenyl)-N-methylsulfamoyl)-1-hydroxy-1H-indole-2-carboxylic acid 
(3.259) 
 
Methyl ester 3.267d (50.0 mg, 0.127 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (2 mL) and treated with 0.4 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
complete consumption of the starting material, the reaction mixture was concentrated, 
diluted with water and washed with Et2O. Then, the aqueous phase was treated with 1N 
aqueous HCl and extracted several times with EtOAc. The combined ethyl acetate 
organic phase was dried over anhydrous sodium sulphate and evaporated to afford the 
desired N-hydroxyindol-carboxylic acid product 3.259 (44.0 mg, 0.116 mmol, 91% 
yield) without any further purification. 1H NMR (acetone-d6) δ (ppm): 3.22 (s, 3H), 
7.14-7.25 (m, 4H), 7.36 (AA´XX´, 2H, JAX = 9.0 Hz, JAA´/XX´ = 2.4 Hz), 7.77 (pseudo-t, 
1H, J = 0.8 Hz), 7.83 (dd, 1H, J = 8.4, 0.4 Hz). 13C NMR (acetone-d6) δ (ppm): 38.69, 
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105.99, 111.49, 120.08, 124.09, 125.16, 129.09, 129.82, 132.55, 133.17, 133.66, 
135.41, 141.86, 161.56. MS m/z 403 (M+Na+, 9%), 370 (M+Na+ –O –OH, 100%). 
 
N,N,4'-Trimethyl-3'-nitro-[1,1'-biphenyl]-4-sulfonamide (3.269) 
 
4-Bromo-N,N-dimethylbenzenesulfonamide 3.268 (664 mg, 2.51 mmol) was placed 
in a vial together with 4-methyl-3-nitrobenzeneboronic acid 3.127 (500 mg, 2.77 
mmol), sodium carbonate (798 mg, 7.53 mmol), Pd(OAc)2 (2.3 mg, 0.010 mmol), 
tetrabutylammonium bromide (809 mg, 2.51 mmol) and water (5 mL). The vial was 
sealed and heated under stirring at 150 °C in a microwave reactor for 5 min. The 
reaction mixture was then diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate and evaporated to 
afford a crude residue that was purified by column chromatography over silica gel using 
n-hexane/EtOAc 6:4 as the eluent, to give pure 3.269 (766 mg, 2.39 mmol, 95% yield). 
1H NMR (CDCl3) δ (ppm): 2.67 (s, 3H), 2.76 (s, 6H), 7.48 (d, 1H, J = 7.7 Hz), 7.74-
7.79 (m, 3H), 7.89 (AA’XX’, 2H, JAX = 8.4 Hz, JAA’/XX’ = 1.9 Hz), 8.23 (d, 1H, J = 1.8 
Hz). 
 
Methyl 3-(4'-(N,N-dimethylsulfamoyl)-3-nitro-[1,1'-biphenyl]-4-yl)-2-
oxopropanoate (3.273a) 
S
N
O O
H3C
CH3
COOMe
O
NO2
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 350 mg, 8.76 
mmol) in 6.2 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.269 (700 mg, 2.19 
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mmol) and dimethyl oxalate (1.29 g, 11.0 mmol) in 4.1 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
2 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
4:6 as the eluent, to yield the nitroaryl-ketoester derivative 3.273a (686 mg, 1.69 mmol, 
77% yield). 1H NMR CDCl3) δ (ppm): 2.76 (s, 6H), 3.96 (s, 3H), 4.61 (s, 2H), 7.46 (d, 
1H, J = 7.9 Hz), 7.76-7.93 (m, 5H), 8.42 (d, 1H, J = 1.6 Hz); signals imputable to the 
enol form (~ 36%) δ (ppm): 3.97 (s, 3H), 6.75 (d, 1H, exchangeable, J = 1.1 Hz), 6.97 
(d, 1H, J = 1.3 Hz), 8.16 (d, 1H, J = 2.0 Hz), 8.41 (d, 1H, J = 8.6 Hz). 
 
Methyl 6-(4-(N,N-dimethylsulfamoyl)phenyl)-1-hydroxy-1H-indole-2-carboxylate 
(3.274a) 
 
Triethylamine (0.30 mL, 0.25 g, 2.5 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (167 mg, 0.738 mmol) and PhSH (0.20 mL, 0.24 g, 2.2 mmol) in 
acetonitrile (3.8 mL) at room temperature to generate a yellow precipitate over a period 
of 5 min. Then, 3.273a (200 mg, 0.492 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 4:6 as the eluent, to give the N-hydroxyindole 3.274a 
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(73.2 mg, 0.196 mmol, 40% yield). 1H NMR (CDCl3) δ (ppm): 2.76 (s, 6H), 4.02 (s, 
3H), 7.07 (s, 1H), 7.40 (dd, 1H, J = 8.6, 1.5 Hz), 7.74 (d, 1H, J = 8.6 Hz), 7.77-7.79 (m, 
1H), 7.85 (s, 4H), 10.38 (bs, 1H). 
 
6-(4-(N,N-Dimethylsulfamoyl)phenyl)-1-hydroxy-1H-indole-2-carboxylic acid 
(3.260) 
 
Methyl ester 3.274a (45.0 mg, 0.120 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.2 mL) and treated with 0.36 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
overnight, the reaction mixture was concentrated, diluted with water and washed with 
Et2O. Then, the aqueous phase was treated with 1N aqueous HCl and extracted several 
times with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.260 (41.5 mg, 0.115 .mmol, 96% yield) without any further purification. 1H 
NMR (DMSO-d6) δ (ppm): 2.66 (s, 6H), 7.06 (d, 1H, J = 1.2 Hz), 7.51 (dd, 1H, J = 8.6, 
1.6 Hz), 7.76-7.85 (m, 4H), 8.02 (AA´XX´, 2H, JAX = 8.8 Hz, JAA´/XX´ = 1.4 Hz). 13C 
NMR (DMSO-d6) δ (ppm): 37.64 (2C), 104.40, 107.87, 119.84, 121.11, 122.95, 127.58 
(2C), 127.90, 128.21 (2C), 133.09, 134.88, 136.21, 144.87, 161.04. HPLC, tR = 8.5 min. 
 
4-Bromo-N-methyl-N-phenylbenzenesulfonamide (3.271) 
Br
S
O
N
H3C
O  
A solution of commercially available 4-bromobenzenesulfonylchloride 3.270 (600 
mg, 2.35 mmol) in CH2Cl2 (4.0 mL) was added dropwise to N-methylaniline (0.76 mL, 
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0.76 g, 7.0 mmol) and the reaction was kept under stirring at RT for 4 h. The reaction 
mixture was acidified with 1N aqueous HCl, extracted several times with CH2Cl2 and 
the combined organic phase was dried over anhydrous sodium sulphate. Evaporation 
under vacuum of the organic solvent afforded a crude product corresponding to the 
sulfonamidic derivative 3.271 (696 mg, 2.13 mmol, 91% yield). 1H NMR (CDCl3) δ 
(ppm): 3.18 (s, 3H), 7.07-7.11 (m, 2H), 7.27-7.35 (m, 3H), 7.39 (AA'XX', 2H, JAX = 8.4 
Hz, JAA’/XX’= 1.8 Hz), 7.60 (AA'XX', 2H, JAX = 8.2 Hz, JAA’/XX’= 1.8 Hz). 
 
N,4'-Dimethyl-3'-nitro-N-phenyl-[1,1'-biphenyl]-4-sulfonamide (3.272) 
 
A solution of Pd(OAc)2 (12.1 mg, 0.0540 mmol) and triphenylphosphine (70.8 mg, 
0.270 mmol) in absolute ethanol (4.0 mL) and anhydrous toluene (4.0 mL) was stirred 
at RT under nitrogen for 10 min. After that period, compound 3.271 (586 mg, 1.80 
mmol), 4.0 mL of 2M aqueous Na2CO3, and 4-methyl-3-nitrobenzeneboronic acid 3.127 
(520 mg, 2.88 mmol) were sequentially added. The resulting mixture was heated at 100 
°C in a sealed vial under nitrogen overnight. After being cooled to RT, the mixture was 
diluted with water and extracted with EtOAc. The combined organic phase were dried 
and concentrated. The crude product was purified by flash chromatography (n-hexane/ 
EtOAc 8:2) to yield 3.272 (442 mg, 1.16 mmol, 64% yield). 1H NMR (CDCl3) δ (ppm): 
2.66 (s, 3H), 3.22 (s, 3H), 7.11-7.16 (m, 2H), 7.27-7.35 (m, 3H), 7.46 (d, 1H, J = 7.9 
Hz), 7.66 (d, 4H, J = 1.6 Hz), 7.74 (dd, 1H, J = 7.9, 1.8 Hz), 8.22 (d, 1H, J = 1.8 Hz). 
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Methyl 3-(4'-(N-methyl-N-phenylsulfamoyl)-3-nitro-[1,1'-biphenyl]-4-yl)-2-
oxopropanoate (3.273b) 
S
N
O O
H3C
COOMe
O
NO2
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 141 mg, 3.53 
mmol) in 1.9 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.272 (337 mg, 0.883 
mmol) and dimethyl oxalate (522 mg, 4.42 mmol) in 1.6 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
3 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
1:1 as the eluent, to yield the nitroaryl-ketoester derivative 3.273b (358 mg, 0.764 
mmol, 86% yield). 1H NMR (CDCl3) δ (ppm): 3.23 (s, 3H), 3.96 (s, 3H), 4.61 (s, 2H), 
7.10-7.16 (m, 2H), 7.29-7.34 (m, 3H), 7.45 (d, 1H, J = 7.9 Hz), 7.68 (d, 4H, J = 2.0), 
7.86 (dd, 1H, J = 7.9, 2.0 Hz), 8.42 (d, 1H, J = 1.8 Hz); signals imputable to the enol 
form (~ 29%) δ (ppm): 3.97 (s, 3H), 6.76 (d, 1H, exchangeable, J = 1.5 Hz), 6.97 (s, 
1H), 7.84 (dd, 1H, J = 8.4, 2.0 Hz), 8.15 (d, 1H, J = 1.6 Hz). 
 
 
 
 
 
Chapter 4 
435 
 
Methyl 1-hydroxy-6-(4-(N-methyl-N-phenylsulfamoyl)phenyl)-1H-indole-2-
carboxylate (3.274b) 
 
Triethylamine (0.23 mL, 0.17 g, 1.7 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (112 mg, 0.498 mmol) and PhSH (0.15 mL, 0.16 g, 1.5 mmol) in 
acetonitrile (2.6 mL) at room temperature to generate a yellow precipitate over a period 
of 5 min. Then, 3.273b (150 mg, 0.320 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 6:4 as the eluent, to give the N-hydroxyindole 3.274b 
(82.7 mg, 0.189 mmol, 59% yield). 1H NMR (CDCl3) δ (ppm): 3.23 (s, 3H), 4.02 (s, 
3H), 7.07 (d, 1H, J = 1.1 Hz), 7.15 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’= 1.9 Hz), 7.28-
7.33 (m, 3H), 7.39 (dd, 1H, J = 8.6, 1.6 Hz), 7.62 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’= 
1.9 Hz), 7.70-7.78 (m, 4H).  
 
1-Hydroxy-6-(4-(N-methyl-N-phenylsulfamoyl)phenyl)-1H-indole-2-carboxylic 
acid (3.261) 
 
Methyl ester 3.274b (72.0 mg, 0.165 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (1.7 mL) and treated with 0.50 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 4 
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h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.261 (61.8 mg, 0.146 mmol, 89% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 3.25 (s, 3H), 7.16-7.22 (m, 3H), 7.30-7.39 (m, 3H), 7.52 
(dd, 1H, J = 8.3, 1.6 Hz), 7.64 (AA´XX´, 2H, JAX = 8.4 Hz, JAA´/XX´ = 1.9 Hz), 7.81 (d, 
1H, J = 8.6 Hz), 7.85-7.87 (m, 1H), 7.95 (AA´XX´, 2H, JAX = 8.4 Hz, JAA´/XX´ = 1.8 Hz). 
13C NMR (acetone-d6) δ (ppm): 38.67, 106.02, 109.04, 121.28, 122.72, 124.01, 127.42 
(2C), 127.98, 128.35 (2C), 129.26 (2C), 129.68 (2C), 136.67, 137.23, 137.25, 142.89, 
146.68, 162.21. 
 
N-(3-Chlorophenyl)-N,4-dimethyl-3-nitrobenzenesulfonamide (3.277a) 
CH3
NO2S
O
N
CH3
O
Cl
 
3-Chloro-N-methylaniline (0.47 mL; 0.55 g, 3.9 mmol) and anhydrous NaHCO3 
(1.94 g) were ground together into fine powder, and 4-methyl-3-
nitrobenzenesulfonylchloride 3.245 (915 mg, 3.88 mmol) was added under vigorous 
stirring at room temperature. The progress of reaction was monitored by TLC until the 
conversion of amine was completed. After 30 min., the reaction mixture was diluted 
with water, acidified with 1N aqueous HCl, extracted several times with Et2O and the 
combined organic phase was dried over anhydrous sodium sulphate. Evaporation under 
vacuum of the organic solvent afforded a crude product corresponding to the 
sulfonamidic derivative 3.277a (995 mg, 2.92 mmol, 75% yield). 1H NMR (CDCl3) δ 
(ppm): 2.68 (s, 3H), 3.20 (s, 3H), 7.00-7.06 (m, 1H), 7.11-7.13 (m, 1H), 7.26-7.30 (m, 
2H), 7.47 (d, 1H, J = 8.1 Hz), 7.60 (dd, 1H, J = 8.1, 1.8 Hz), 8.17 (d, 1H, J = 1.8 Hz). 
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Methyl 3-(4-(N-(3-chlorophenyl)-N-methylsulfamoyl)-2-nitrophenyl)-2-
oxopropanoate (3.278a) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 282 mg, 7.04 
mmol) in 4.2 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.277a (600 mg, 1.76 
mmol) and dimethyl oxalate (1.04 g, 8.80 mmol) in 3.1 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
slowly warmed to room temperature. The mixture was then left under stirring at RT for 
24 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 solution and brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
1:1 as the eluent, to yield the nitroaryl-ketoester derivative 3.278a (321 mg, 0.752 
mmol, 43% yield). 1H NMR (CDCl3) δ (ppm): 3.23 (s, 3H), 3.96 (s, 3H), 4.63 (s, 2H), 
7.14-7.16 (m, 1H), 7.27-7.31 (m, 3H), 7.45 (d, 1H, J = 8.1 Hz), 7.72 (dd, 1H, J = 7.8, 
1.7 Hz), 8.36 (d, 1H, J = 1.8 Hz); signals imputable to the enol form (~ 33%) δ (ppm): 
3.22 (s, 3H), 3.98 (s, 3H), 6.91 (s, 1H), 7.69 (dd, 1H, J = 8.1, 1.9 Hz), 8.05 (d, 1H, J = 
1.8 Hz), 8.40 (d, 1H, J = 8.5 Hz). 
 
Methyl 6-(N-(3-chlorophenyl)-N-methylsulfamoyl)-1-hydroxy-1H-indole-2-
carboxylate (3.279a) 
S
O
N
CH3
O
N
COOMe
OH
Cl
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Triethylamine (0.28 mL, 0.20 g, 2.0 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (135 mg, 0.597 mmol) and PhSH (0.18 mL, 0.20 g, 1.8 mmol) in 
acetonitrile (3.1 mL) at room temperature to generate a yellow precipitate over a period 
of 5 min. Then, 3.278a (170 mg, 0.398 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 1:1 as the eluent, to give the N-hydroxyindole 3.279a 
(73.1 mg, 0.185 mmol, 47% yield). 1H NMR (CDCl3) δ (ppm): 3.19 (s, 3H), 4.03 (s, 
3H), 7.01-7.13 (m, 2H), 7.08 (d, 1H, J = 0.9 Hz), 7.17 (dd, 1H, J = 8.6, 1.6 Hz), 7.21-
7.27 (m, 2H), 7.67 (dd, 1H, J = 8.5, 0.6 Hz), 7.92 (t, 1H, J = 0.7 Hz), 10.37 (bs, 1H). 
 
6-(N-(3-Chlorophenyl)-N-methylsulfamoyl)-1-hydroxy-1H-indole-2-carboxylic acid 
(3.275) 
 
Methyl ester 3.279a (31.7 mg, 0.0803 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.80 mL) and treated with 2.4 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
18 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.275 (22.0 mg, 0.578 mmol, 72% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 3.26 (s, 3H), 7.10-7.16 (m, 1H), 7.22 (dd, 1H, J = 8.4, 1.6 
Hz), 7.23 (d, 1H, J = 0.9 Hz), 7.25-7.28 (m, 1H), 7.32-7.36 (m, 2H), 7.79-7.81 (m, 1H), 
7.84 (dd, 1H, J = 8.9, 0.6 Hz). 13C NMR (acetone-d6) δ (ppm): 38.34, 105.20, 111.25, 
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119.61, 123.76, 125.10, 125.34, 127.27, 127.74, 130.22, 130.88, 133.24, 134.37, 
134.74, 144.17, 161.85. 
 
N-(2-Chlorophenyl)-N,4-dimethyl-3-nitrobenzenesulfonamide (3.277b) 
 
To a solution of 4-chloro-N-methylaniline (0.43 mL, 0.50 g, 3.5 mmol) in dry 
CH2Cl2 (6.0 mL), pyridine (0.43 mL, 0.42 g, 5.3 mmol) and catalytic DMAP (15.0 mg) 
were added, then the resulting mixture was cooled to 0 °C. Subsequently, commercially 
available 4-methyl-3-nitrobenzenesulfonylchloride 3.245 (1.00 g, 4.24 mmol) in CH2Cl2 
(19 mL) was added dropwise and the reaction was kept under stirring at RT for 72 h. 
The reaction mixture was acidified with 1N aqueous HCl, extracted several times with 
CH2Cl2 and the combined organic phase was dried over anhydrous sodium sulphate. 
Evaporation under vacuum of the organic solvent afforded a crude product which was 
purified by column chromatography over silica gel using n-hexane/EtOAc 2:8 as the 
eluent, to yield the sulfonamidic derivative 3.277b (528 mg, 1.55 mmol, 37% yield). 1H 
NMR (CDCl3) δ (ppm): 2.69 (s, 3H), 3.27 (s, 3H), 7.27-7.43 (m, 4H), 7.49 (d, 1H, J = 
8.4 Hz), 7.85 (dd, 1H, J = 8.1, 1.8 Hz), 8.35 (d, 1H, J = 2.0 Hz). 
 
Methyl 3-(4-(N-(2-chlorophenyl)-N-methylsulfamoyl)-2-nitrophenyl)-2-
oxopropanoate (3.278b) 
 
A stirred suspension of sodium hydride (60% dispersion in mineral oil, 245 mg, 6.12 
mmol) in 3.3 mL of anhydrous DMF cooled to –15 °C under nitrogen was treated 
dropwise with a solution containing the nitrotoluene precursor 3.277b (521 mg, 1.53 
mmol) and dimethyl oxalate (903 mg, 7.65 mmol) in 2.7 mL of anhydrous DMF. The 
mixture was left under stirring at the same temperature for 10 minutes and then it was 
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slowly warmed to room temperature. The mixture was then left under stirring at RT for 
24 h. Once the disappearance of the precursor was verified by TLC, the reaction mixture 
was slowly poured in an ice-water mixture; the water phase was acidified with 1N 
aqueous HCl and extracted several times with EtOAc. The combined organic phase was 
washed with saturated NaHCO3 and solution brine, then dried over anhydrous sodium 
sulphate. Evaporation under vacuum of the organic solvent afforded a crude product 
which was purified by column chromatography over silica gel using n-hexane/EtOAc 
65:35 as the eluent, to yield the nitroaryl-ketoester derivative 3.278b (281 mg, 0.658 
mmol, 43% yield). 1H NMR (CDCl3) δ (ppm): 3.29 (s, 3H), 3.96 (s, 3H), 4.64 (s, 2H), 
7.27-7.48 (m, 4H), 7.97 (dd, 1H, J = 8.1, 1.8 Hz), 8.20 (d, 1H, J = 8.8 Hz), 8.53 (d, 1H, 
J = 1.6 Hz); signals imputable to the enol form (~ 30%) δ (ppm): 3.32 (s, 3H), 3.98 (s, 
3H), 6.94 (s, 1H), 8.08 (dd, 1H, J = 8.1, 1.8 Hz), 8.44 (d, 1H, J = 8.4 Hz), 8.60 (d, 1H, J 
= 1.5 Hz). 
 
Methyl 6-(N-(2-chlorophenyl)-N-methylsulfamoyl)-1-hydroxy-1H-indole-2-
carboxylate (3.279b) 
S
O
N
CH3
O
N
COOMe
OH
Cl
 
Triethylamine (0.14 mL, 0.10 g, 1.0 mmol) was added dropwise to a stirred solution 
of SnCl2·2H2O (45.7 mg, 0.203 mmol) and PhSH (0.09 mL, 0.1 g, 0.9 mmol) in 
acetonitrile (1.6 mL) at room temperature to generate a yellow precipitate over a period 
of 5 min. Then, 3.278b (86.5 mg, 0.203 mmol) was transferred to the suspension and 
stirred at room temperature for 5 more min. After complete consumption of the starting 
material, the mixture was diluted with water and repeatedly extracted with EtOAc. The 
combined organic phase was dried over anhydrous sodium sulphate, diluted with 
toluene and a catalytic amount of p-toluensulfonic acid was added. Then it was 
evaporated to afford a crude residue that was purified by column chromatography over 
silica gel using n-hexane/EtOAc 6:4 as the eluent, to give the N-hydroxyindole 3.279b 
(12.1 mg, 0.0306 mmol, 15% yield). 1H NMR (CDCl3) δ (ppm): 3.24 (s, 3H), 4.03 (s, 
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3H), 7.09 (d, 1H, J = 0.9 Hz), 7.19-7.32 (m, 3H), 7.37-7.44 (m, 1H), 7.47 (dd, 1H, J = 
8.6, 1.6 Hz), 7.73 (dd, 1H, J = 8.6, 0.7 Hz), 8.07 (dt, 1H, J = 1.8, 0.8 Hz), 10.37 (bs, 
1H). 
 
6-(N-(2-Chlorophenyl)-N-methylsulfamoyl)-1-hydroxy-1H-indole-2-carboxylic acid 
(3.276) 
 
Methyl ester 3.279b (12.0 mg, 0.0304 mmol) was dissolved in a 1:1 mixture of 
THF/methanol (0.3 mL) and treated with 0.09 mL of 2N aqueous solution of LiOH. The 
reaction was kept under stirring in the dark at RT and it was monitored by TLC. After 
24 h, the reaction mixture was concentrated, diluted with water and washed with Et2O. 
Then, the aqueous phase was treated with 1N aqueous HCl and extracted several times 
with EtOAc. The combined ethyl acetate organic phase was dried over anhydrous 
sodium sulphate and evaporated to afford the desired N-hydroxyindol-carboxylic acid 
product 3.276 (10.2 mg, 0.0268 mmol, 88% yield) without any further purification. 1H 
NMR (acetone-d6) δ (ppm): 3.24 (s, 3H), 7.11-7.16 (m, 1H), 7.26 (d, 1H, J = 0.9 Hz), 
7.31 (td, 1H, J = 7.4 1.8 Hz), 7.39 (td, 1H, J = 7.3, 1.8 Hz), 7.50 (dd, 1H, J = 8.4, 1.6 
Hz), 7.51-7.55 (m, 1H), 7.91 (dd, 1H, J = 8.6, 0.7 Hz), 7.95 (dt, 1H, J = 1.6, 0.8 Hz), 
10.80 (bs, 1H). 13C NMR (acetone-d6) δ (ppm): 38.78, 105.99, 111.16, 119.95, 124.05, 
125.01, 128.56, 130.55, 131.33 (2C), 135.10, 135.43, 136.16, 138.21, 139.74, 161.19. 
MS m/z 380 (M+, 20%), 268 (M+ –C6H5Cl), 240 (M+ –oClPhNMe). HPLC, tR = 9.4 min. 
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